annual report new ambition patient shareholder people major progress journey significant corporate change gsk year track separate create new lead company opportunity impact human health scale deliver compelling performance shareholder gsk haleon gsk unite science talent technology haleon global leader focus ahead disease prioritise consumer health clear purpose innovation vaccine specialty medicine deliver well everyday health humanity maximise increase opportunity prevent focus strategy deliver sustainable abovemarket treat disease growth attractive return shareholders step change growth strong prospect growth expect sale growth adjust exceptional portfolio categoryleading brand operate profit growth attractive global footprint competitive capability compound basis compelling strategy outperform grow rd focus science immune system billion plus sector relevant human genetic advanced technology annual organic sale growth medium term positively impact health billion sustainable moderate margin expansion high cash people year conversion lead esg performance maintain attractive growth profile capacity invest deliver shareholder return set new purpose growth commitment set strategy capability growth rd catalyst investor update june ambition consumer healthcare capital market detail gskcom day february detail gskcom content strategic report board committee information financial statement business model board architecture note financial statement performance summary board activity financial statement chair statement board progress glaxosmithkline plc prepare ceo statement board approach continuous uk gaap financial performance engagement longterm priority boardle purpose culture investor information culture board performance quarterly trend key performance indicator board committee report fiveyear record external environment section statement product development pipeline innovation director report product competition performance intellectual property trust remuneration report principal risk uncertaintie consumer healthcare chair annual statement share capital share price stakeholder engagement annual report remuneration dividend risk management remuneration policy summary financial calendar group financial review remuneration policy report annual general meeting tax information shareholder corporate governance financial statement shareholder service contact board gsk leadership team director statement law regulation chair governance statement responsibility group company board role responsibilitie independent auditor report glossary term cautionary statement inside cover document cautionary statement forwardlooke statement nonifrs measure use number adjust noninternational financial reporting standard ifrs measure report performance business total report result represent group overall performance ifrs adjust result nonifrs measure consider addition substitute superior information present accordance ifrs adjust result nonifrs measure define page reconciliation near ifrs measure page gsk annual report strategic report governance remuneration financial statement investor information business model prepare new future continue help improve health hundred million people world discover develop manufacture innovative medicine vaccine consumer healthcare product develop deliver medicine vaccine consumer central success people expert science healthcare product impact human health scale technology manufacturing regulation intellectual property operation span value chain identify researching commercialisation collaborate worldleading develop testing groundbreake discovery expert form strategic partnership complement regulatory approval manufacturing commercialisation exist capability value create future great contribution improve health aim modern employer develop people people world include deliver offer broad range benefit include preventative billion medicine million vaccine billion healthcare service help attract retain good consumer healthcare product look ahead gsk people clear ambition positively impact health employ people country work billion people year directly supplier pay billion create value shareholder invest business corporation tax significant provide shareholder return pay dividend business employmentrelate taxis penny share new commitment growth step change performance year deliver strategic transformation prioritise innovation performance trust recent year transform gsk improve performance deliver invest effectively performance strengthen capability prepare business people execute competitively new future prioritise innovation ability launch new product successfully grow sale performance trust entire company exist portfolio key commercial success drive multiyear programme improve rd productivity year base year expect gsk commercial execution group structure capital allocation deliver highly attractive growth sale adjust underpinned new culture ambition operate profit accountability respectively compound basis innovation critical improve health create trust underpin maintain financial value total rd expenditure acknowledge leadership environmental social billion aer robust governance esg issue demonstrate sectorleading latestage rd pipeline asset potential position dow jones sustainability index long good class continue believe rapid standing leadership access medicine index convergence science technology biopharmaceutical remain deeply committed addressing issue provide significant opportunity rd matter sustainability company include pricing continue focus science immune system human access global health environment inclusion genetic use advanced technology diversity work integrity care include adjuvant sale performance summary strong commercial execution drive growth pharmaceutical vaccine consumer healthcare exclude divestmentsbrand review billion group turnover stable aer cer pharmaceuticals billion aer cer new specialty medicine billion aer cer vaccine billion aer cer covid solution sale billion consumer healthcare billion aer stable cer exclude brand divestedunder review cost discipline support delivery adjust eps growth total eps p aer cer adjust eps p aer cer contribution growth covid solution aer cer total operating profit billion aer cer adjust operate profit billion aer cer dividend p continued momentum rd delivery strengthen pipeline major product approval phase iii start vaccine medicine pivotal trial strong pipeline vaccine medicine offer potential good firstinclass opportunity patient deal execute secure access novel clinical programme include immunooncology immunoneurology flu plus technology expand capability human genetic artificial intelligencemachine learn aiml track create new lead company demerger mid new gsk investor update june set new purpose growth commitment rd catalyst detail gskcom consumer healthcare capital market day february highlight strategic priority key growth driver detail financial information detail gskcom lead esg performance st pharmaceutical industry dow jones sustainability index st access medicine index gold recognition sps sustainability yearbook cdp climate change gsk annual report gsk annual report strategic report governance remuneration financial statement investor information chair statement significant progress demerge gsk lead competitive company mid gsk deliver programme fundamental strategic considerable advance distinctive transformation emma start ceo year ago approach rd base science immune system design tackle root cause company longterm human genetic advanced technology chief underperformance include shareholder return scientific officer cso hal barron tony wood transition role cso august carefully board pleased emmas leadership consider succession plan build significant saw progress clear priority set enable progress tony world lead improve pipeline rd productivity sharpen chemist impressive track record medicine commercial execution cost discipline tackle development year career uk groups structure capital allocation priority underpin shift culture progress started reflect share price performance board build significant progress period management recognise sustain long term believe firmly track demerge gsk depend consistent performance delivery worldclass company mid focus strengthen competitiveness pharmaceutical vaccine focus consumer healthcare target sustain performance delivery performance inyear board maintain clear focus oversight company strategy plan board remain focused ensure gsk fundamental separate propose subject shareholder approval continue enhance ensure company fully happen mid competitive point split investor update june purpose strategy covid pandemic continue mean highly new gsk set clear performance target dynamic operating environment board please sale operating profit margin growth begin company exceed earning share guidance set communicate achieve represent start year achieve overdelivery quartile performance sector similar stretching ambition business include excellent commercial execution set consumer health business key market therapy area show ability compete grow market share board please course management deliver target commercial performance patient impact set clear remuneration tie enhance xevudy lead monoclonal antibody covid shareholder value link executive develop partnership vir biotechnology remuneration reward outperformance detail proposal lay later report saving programme announce early deliver chance shareholder vote agm result gsk cost base competitive versus peer capital allocation priority clear invest addition new gsk board fully focus rd pipeline new product launch deliver return company operate clear agenda esg shareholders environmental social governance leadership gsk strong tradition build area include maximise access medicine world ensure progress matter prioritychair statement continue shareholder engagement board transition close separation continue period considerable transition board assess skill capability experience gsk board management maintain significant engagement need pure biopharma business delight shareholder clear vast majority welcome anne beal board anne bring extensive support strategy direction company take healthcare experience doctor entrepreneur combine clear distraction sustain delivery passion patient advocacy january dr harry hal message hear board c dietz join board hal worldleading expert accountability foremost act interest human genetic professor genetic medicine johns shareholders hopkins university school medicine confident appointment continue input hal key strategy separation consumer barron august nonexecutive board director healthcare broad base support scientific credential gsk board shareholder direct ownership outstanding business strong industry demerger course gsk board fiduciary duty remain open consider alternative proposal want opportunity thank lynn elsenhans demerger create superior value shareholder step separation consumer proposal receive date health business mid lynn outstanding contribution board development current final stage create strategy year include notably chair exceptional company m delighted designate corporate responsibility committee increasingly appointment sir dave lewis lead board brian centre board work miss mcnamara ceo strongly believe new company board offer attractive profile prospective investor reflect growth outlook set capital market day finally like thank employee partner february shareholder customer support commitment year look forward promise exciting gsk sir jonathan symonds chair gsk annual report gsk annual report strategic report governance remuneration financial statement investor information ceo statement end strongly enter good momentum go landmark year company please report gsk deliver course priority contribute solution strong operational performance pipeline progress covid pandemic successfully develop new time complete multiyear programme monoclonal antibody treatment xevudy partner vir far reach transformation tackle longstanding issue biotechnology medicine prove effective impacting company success multiple variant include omicron secure rapid regulatory approval worldwide adjuvant ready deliver significant corporate partnership stand ready supply new vaccine change gsk year create new exceptional data read broadly increase investment company ambitious target growth clear mrna capability major new platform validate purpose positively impact health live billion pandemic people role vaccine widely appreciated performance provide momentum understand world right opportunity group sale billion cer gsk protect people deliver growth broad range product meaningfully help patient range vaccine remain significant different disease area include respiratory immuno progress see rd inflammation oncology hiv protect people viruse year outstanding leadership hal barron like shingles meningitis prevent hospitalisation cso august hand responsibility tony wood death covid help improve oral health key partner hal tony outstanding reduce pain treat everyday ailment scientist deep expertise science datum new strong operational performance enable increase technology perfectly place capture investment rd billion realise earning value opportunity gsk rd approach share excess expectation year addition delight hal remain gsk generate billion free cash flow support nonexecutive board director investment dividend pence share year new purpose new ambition improvement commercial execution demerger consumer healthcare establish cost base strengthen portfolio new gsk purely focus biopharmaceutical year pipeline mean momentum deliver step announce new purpose new growth ambition change growth start new company accelerate innovation gsk new purpose unite science talent technology continue believe rapid convergence science ahead disease prioritise technology biopharmaceutical provide significant innovation vaccine specialty medicine maximise opportunity gsk rd continue focus opportunity prevent treat disease aim science immune system human genetic positively impact health billion people use advanced technology approach deliver year deliver strong sustainable return improvement rd pipeline shareholder company outstanding people thrive month report regulatory approval new medicine include firstever longacte set ambitious fiveyear sale operate injectable prep treatment option hiv start profit compound growth target phase iii clinical trial currently asset respectively aim deliver pivotal clinical study time report billion annual sale sale exist late conclude deal external partner secure stage pipeline asset contribution include access novel clinical programme oncology neurology earlystage asset future business development hiv innovative technology notably target represent new level ambition gsk expansion capability human genetic deliver topquartile sector performance functional genomic use artificial intelligence embed commitment deeply company achievement spearhead strengthen pipeline include incentive programme drive focus action vaccine medicine clinical development potential bestinclassceo statement continue culture performance support succeed haleon new worldleading consumer strongly believe gsk company people health company thrive create right culture deliver haleon compelling prospect completely dedicated new purpose performance aspiration priority consumer health worldclass portfolio category team focus gsk place lead brand offer attractive proposition bring deep people ambitious patient accountable impact human understanding trust science deliver right thing well everyday health humanity world leader new standalone company offer prospective enormous responsibility inspire support investor highly attractive financial profile abovemarket people succeed continue look way invest sale growth sustainable margin expansion high cash people growth development help generation balance work personal life include strong focus management skill train support mental fantastic leadership team lead ceo designate health wellbee health safety brian mcnamara board lead sir dave lewis work gsk bring wealth international consumer sector experience year place additional new programme creation haleon reflect successful delivery series support priority commit develop progressive strategic move take year true approach inclusion equity altogether estimate acquisition integration diversity good progress new business target divestment close billion aspirational target female ethnically diverse value create business representation senior role take step time shareholder access value invest ensure clinical trial representative patient believe strong highly successful growth aim help orientate business capable deliver sustainable performance return esg leader operate responsibly core gsk aim continue landmark year deliver sectorleading esg performance recognise pandemic shone spotlight like late ranking dow jones sustainability index difference industry society access medicine index antimicrobial resistance people scientist factory team supply expert benchmark reflect progress core esg work healthcare professional thousand area environment access global health inclusion rise challenge ensure patient diversity product governance ethic clear people part world continue receive product longterm goal ambition complacent need deeply inspiring reflect deep want commitment people work gsk people set carbon netzero nature positive goal serve recognise increase need importance provide people reason gsk haleon investors stakeholder evidence tangible successful year come want thank esg performance develop new measure achieve momentum deliver report validate party audit team excite optimistic future share investor later year hope landmark year gsk commit demonstrate commitment bestinclass esg rely excited achieve performance transparent reporting emma walmsley chief executive officer gsk annual report gsk annual report strategic report governance remuneration financial statement investor information financial performance operate profit operating performance total operating profit million compare turnover million primarily reflect unfavourable comparison net profit disposal q horlick growth growth consumer brand resultant sale share cer hindustan unilever partly offset low major pharmaceutical restructuring cost low remeasurement charge vaccine contingent consideration liability unwind consumer healthcare fair market value uplift inventory arise completion group turnover consumer healthcare joint venture pfizer adjust operate profit million low financial result aer high cer turnover increase cer adjust operate margin growth cer percentage point low aer percentage point high turnover cer basis increase adjust total operating profit operating profit primarily reflect benefit incremental total earning share p pandemic sale sale growth pharmaceutical tight adjust operate profit control ongoing cost favourable legal settlement adjust earning share p benefit continue restructure business net cash operating activity offset low sale vaccine high supply chain free cash flow cost vaccine consumer healthcare divestment consumer healthcare increase investment rd turnover vaccine pharmaceutical strong commercial execution drive growth pharmaceutical vaccine consumer healthcare earning share exclude brand divestedunder review total eps p compare p group turnover million year stable aer primarily reflect unfavourable comparison cer sale covid solution sale xevurdy benefit net profit disposal horlick related pandemic adjuvant contribute approximately percentage transaction partly offset credit million taxation point growth year result revaluation defer tax asset low major restructuring cost low remeasurement pharmaceutical turnover year million charge contingent consideration liability adjust aer cer sale xevudy monoclonal ep p compare p antibody treatment covid million contribute aer cer cer increase adjust approximately percentage point total pharmaceutical operating profit primarily reflect incremental pandemic sale growth sale increase pharmaceutical tight cost control vaccine turnover million year favourable legal settlement low interest cost partly aer cer primarily drive pandemic offset low sale vaccine high supply chain cost adjuvant sale partially offset low demand routine vaccine increase rd investment high effective adult vaccination covid vaccination programme tax rate deployment disease circulation region vaccine cash flow turnover exclude pandemic vaccine decrease aer cer million net cash inflow operating activity year million million decrease consumer healthcare turnover million primarily reflect adverse exchange impact increase trade aer remain stable cer reflect dilution receivables adverse timing return rebate rar divestment give completion portfolio rationalisation increase separation cost partly offset improve adjusted end q sale exclude brand divestedunder operating profit cer reduce tax payment include tax review decrease aer increase cer reflect disposal underlie strength brand portfolio category continue growth ecommercefinancial performance continue total adjust result total report result represent group overall directly comparable similarly describe performance measure company gsk use number adjust nonifrs measure gsk encourage investor analyst rely report performance business adjust result single financial measure review gsk annual report nonifrs measure consider addition include financial statement note entirety substitute superior information present gsk undertaking number boardapprove major accordance ifrs adjust result define restructure programme response significant change nonifrs measure define group trading environment overall strategy follow gsk believe adjust result consider material acquisition cost cash noncash total result provide investor analyst programme provide individual element stakeholder helpful complementary information approve meet accounting recognition criterion understand well financial performance position result charge incur number year group period period allow group follow initiation major restructure programme performance easily compare majority peer company measure management planning reporting purpose divestment intangible intangible significant total asset asset major transaction legal separation adjust adjust item result amortisation impairment restructure relate item cost result turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost share aftertax profit associate joint venture loss disposal interest associates profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share p p p p p p p p intangible asset amortisation impairment divestment significant legal item amortisation intangible asset exclude computer software proceed cost disposal associate product capitalise development cost impairment intangible business significant settlement income significant legal asset exclude computer software goodwill charge net insurance recovery expense settlement litigation government investigation major restructuring operating income royalty income item major restructuring cost include impairment tangible include impact revaluation defer tax asset asset computer software specific board approve liability follow enactment increase headline programme structural significant scale rate uk corporation tax effective cost individual relate project exceed million include integration cost follow material acquisition separation cost additional cost establish consumer healthcare transactionrelate independent business admission list transactionrelated accounting adjustment relate demerger cost significant acquisition gsk annual report gsk annual report strategic report governance remuneration financial statement investor information financial performance continue adjust result growth turnover turnover cer turnover cost sale gross profit sell general administration research development royalty income operating profit net finance cost share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share p p increase adjust operating profit primarily reflect perform benefit incremental pandemic sale contribute cost sale approximately aer cer adjust operate profit growth adjust operating profit benefit sale adjust cost sale percentage turnover growth pharmaceutical include benefit prior period percentage point high aer percentage point rar adjustment tight control ongoing cost include high cer compare primarily reflect reduce promotional variable spending high pandemic sale xevudy high supply chain business result covid lockdown favourable cost vaccine result low demand high legal settlement compare increase legal cost inventory adjustment high commodity freight cost benefit continue restructure business consumer healthcare partly offset price benefit partly offset low sale vaccine primarily pharmaceutical include benefit prior period rar shingrix high supply chain cost vaccine consumer adjustment contribution restructure saving healthcare divestment consumer healthcare increase business favourable mix vaccine investment rd vaccine pharmaceutical sell general administration tax adjust sga cost percentage turnover tax adjust profit amount million represent percentage point low aer effective adjust tax rate percentage point low cer basis adjust sga cost decrease aer cer reflect tight control noncontrolle interest ongoing cost reduce variable spending allocation adjust earning noncontrolle interest business result covid lockdown amount million million continue benefit restructuring pharmaceutical reduction allocation primarily reflect reduce allocation consumer healthcare support function decrease viiv healthcare profit million million reflect favourable legal settlement compared partly offset high net profit group increase legal cost oneoff benefit entity noncontrolle interest allocation pension insurance partly offset oneoff consumer healthcare joint venture profit million benefit restructure postretirement benefit million partly offset increase investment launch hiv vaccine earning share adjust eps p compare p research development aer cer cer increase adjust adjust rd expenditure million operating profit primarily reflect incremental pandemic sale turnover high aer high cer sale increase pharmaceutical tight cost control operating profit favourable legal settlement low interest cost partly offset low sale vaccine primarily shingrix higher adjust operate profit million low supply chain cost vaccine increase rd investment aer high cer turnover increase high effective tax rate contribution growth cer adjust operate margin covid solution approximately aer cer percentage point low aer percentage point high cer basis longterm priority innovation performance trust realise ambition patient shareholder people deliver strong performance track successful demerger create new lead company innovation performance trust invest scientific technical deliver growth invest responsible company excellence develop launch effectively business commit use science pipeline new product develop people technology address health meet need patient execute competitively need product payer consumer affordable available modern employer objective objective objective deliver innovation sale excellent continue prioritise spending deliver continue deliver ontime infull supply commercial rd supply chain growth return investment product execution oncology hiv vaccine continue deliver twoyear programme improve manager capability motivate accelerate strengthen pipeline prepare gsk separation focus develop care people robust commercial input include new lead company continue deliver progress trust business development build strong diverse workforce commitment new lead company progress progress progress receive major approval strong commercial execution maintain sectorleading ranking apretude longacte hiv prevention pharmaceutical vaccine consumer esg indice include dow jones medicine jemperli endometrial cancer healthcare sustainability index access medicine xevudy covid pharmaceutical billion aer index antimicrobial resistance strong pipeline vaccine cer doubledigit growth benchmark medicine offer potential new specialty medicine aer maintain supply manufacture good firstinclass opportunity cer significant disruption patient pivotal trial vaccine billion aer cer pandemic deal execute secure access consumer healthcare aer stable progress deliver net zero novel clinical programme include cer aer cer exclude impact climate net positive impact iteo immunooncology alector divestmentsbrand review nature immunoneurology vir biotechnology track deliver separation plan roll new training programme flu plus technology expand mid develop manager support capability human genetic ai ml great manager lead care continue prioritise diversity good progress gender ethnicity target improve representation senior role recommend wide use rtss vaccine child region moderate high malaria transmission priority objective priority objective priority objective deliver innovation sale excellent deliver sale growth deliver lead esg performance commercial rd supply chain adjust operate profit effective risk management discipline execution compound basis year compliance accelerate strengthen pipeline continue prioritise spending deliver dedicated inhouse expertise growth return investment robust commercial input including deliver successful demerger mid optimise capital allocation business development culture creation new lead company embed culture ambitious patient accountable impact continue right thing track cultural change range indicator increasingly embed assessment hr process board receive regular update page principal risk risk management framework design support longterm priority page innovation sale define gsk annual report gsk annual report strategic report governance remuneration financial statement investor information culture culture power purpose ahead disease drive delivery strategy make gsk place outstanding people thrive past year focus embed know leader manager play crucial role culture anchor purpose performance ve bring culture life people continue great progress demonstrate strong engagement pride develop manager focus training support gsk contribute improve rd productivity great manager motivate team help performance commercial team supply focus matter support performance chain time impact covid development lead care pandemic drive team work dynamically individual measure effectiveness global deep connection purpose manager population annual feedback continue build refresh expertise senior leader gsk purpose unite science talent technology leader appoint ahead disease put people heart broad hr process include reward succession success deliver purpose help outstanding planning continue base assessment people thrive focus culture gsk place deliver ie cultural behaviour ambitious patient accountable impact right thing approach hybrid work performance choice anchor drive individual collective performance mean help people constantly strive thing create flexibility officebase people well fast focus matter work help mean set clear objective ensure accountability perform well base role team personal result give support space need circumstance pandemicrelate restriction begin ease succeed mean responsibly country officebase people care integrity people people change way work start discuss world count manager officebase worker measure progress range indicator approximately quarter people work look people experience gsk place week home continually look way work embody culture affect support people role type balance work performance engagement remain high settle personal life level boost early phase know strong culture need build pandemic change approach inside measure culture increasingly dynamic augment successful year bring people annual survey pulse survey quickly world represent role type identify area success area focus company business area region help accelerate culture respect people core give company ready excited continue opportunity build inclusive culture internally progress culture gsk force good improve inclusion diversity society deliver step change competitive growth build continue focus build inclusive culture successful company improve live people inclusion training people leader alongside world work evolve policy process practice consumer healthcare culture key performance indicator progress longterm priority use key performance indicator gsk leadership team glt board review track operating kpis internally key performance indicator kpi regularly update datum report externally commercial sensitivity people progress quarter decide people mean not publish datum operating kpis show nr bonus base relevant subset kpi report business performance use adjust nonifrs use reward executive performance measure include adjusted result free cash flow cer page growth rate describe page innovation innovation sale r pharmaceutical vaccine sale product launch year bn bn bn consumer healthcare sale product new market year total sale pipeline value progress r value product pipeline rd milestone achieve nr nr nr performance group turnover r flat aer cer bn bn bn profit r total operating profit aer cer bn bn bn adjusted operating profit aer cer bn bn bn total operate margin adjust operate margin free cash flow r bn bn bn market share market share relation competitor nr nr nr talent succession plan key role talented employee key role succession plan place nr nr nr trust employee feedback employee engagement score global employee survey supply service level percentage order deliver ontime infull nr nr nr corporate reputation reputation index stakeholder inform public measure globally market nr nr nr r link executive lti awards annual bonus page executive lti awards annual bonus base mix total sale growth adjust operate profit growth pipeline esg target page include product benefit significant lifecycle innovation comparative information reflect sale product meet definition nr report externally commercial sensitivity gsk annual report gsk annual report strategic report governance remuneration financial statement investor information external environment world change shaped major social economic trend continue influence covid pandemic contribution vaccine medicine healthcare clearly highlight year challenge remain respond dynamic environment working government regulator industry partner deliver innovation healthcare system demonstrate value patient payer reopen global economy drive outlook global healthcare market healthcare innovation prepandemic trend use medicine spending event give clear demonstration remain relatively constant high income country contribution industry world adoption new treatment offset patent lifecycle pandemic continue collaboration company competition generic biosimilar expect government regulator international organisation continue main driver medicine spending growth bring new vaccine medicine world record global medicine spending total trillion time regulatory process get fast company invest expect grow cagr reach rd deliver novel product expand manufacture trillion total market size exclude spending capacity rollout vaccine programme enable global covid vaccine market forecast grow economy reopen later year regulatory approval cagr year spend grant covid treatment gsk contribute european market expect increase billion global response agreement eu china expect increase uptake new original number government supply covid medicine grow billion spending therapeutic xevudy sotrovimab ongoing vaccination emerge market likely increase billion global development programme sanofi medicago sk spend vaccine predicted grow reach bioscience curevac billion time virus continue life forecast specialty medicine account world deal economic social impact nearly total expenditure highincome market pandemic bad prediction prolong economic remainder predominantly old traditional recession materialise global economic forecast therapy progressively lowercost time predict growth lead global therapy area oncology immunology uncertainty uniformity recovery forecast grow cagr respectively management debt inflationary trend similarly lift significant increase new continued economic social threat pose new treatment medicine use expect variant omicron global healthcare spend oncology treatment come market year expect rise compete funding demand frontline staff cost ongoing need pandemic position medical product catchup programme tackle grow performance suggest position waiting list government healthcare systems capitalise forecast growth specialty medicine evaluate cost new pharmaceutical innovation role increase investment key rd programme expand help address burden illness therapy area support new ongoing launch result sale growth drive strong uptake new medicine new specialty medicine grow cer record doubledigit sale growth immunoinflammation respiratory oncology result encourage demonstration strong progress strategic priority new medicine forefront exciting highvalue pipeline continue build prevention treatment disease imf world economic outlook recovery pandemic october iqvia global use medicine january iqvia global medicine spending usage trend outlook april external environment continue healthcare environment opportunity challenge medicine policy pricing access legislative effort address drug pricing equal access healthcare year pricing focal point attempt pass trillion social safety climate government equal access healthcare grow package build well act end year policy priority challenge bring covid vaccine drug pricing reform proposal provide direct equitably global population highlight dilemma negotiation federal government medicare industry manufacture distribute billion insurance programme industry price vaccine dose disproportionally go high costly drug disease cancer diabete income country people lowincome country supplier new price take effect receive dose government attempt measure seek address outofpocket expenditure balance immediate access respective population senior cap spending person year global health responsibility company raise price medicine inflation global initiative covax help part b medicare penalise inflation cap access vaccine disparity lead government apply private insurance market international organisation question intellectual property ip outofpocket measure improve affordability framework notably world trade organization senior industry concern take agreement traderelate aspect intellectual property package reduce patient choice limit access right trip waiver provision concern innovation future agreement reach exact move alter ip protection will not address term build well act year end extent problem destabilise innovation life science effect drug reform package remain unclear turn threaten future collaboration like one important create vaccine treatment european pharmaceutical reform tackle pandemic europe continue considerable scrutiny need demonstrate value innovation public drug pricing grow trend centralised private healthcare payer grow expenditure procurement vaccine medicine widerange review pharmaceutical heavily scrutinise renew call eu pharmaceutical legislation begin eus transparency price setting pharmaceutical strategy strategy base pillar significant moderation pharmaceutical expenditure cover access competitiveness innovation crisis decade major market survey iqvia preparedness strong eu voice world review medicine expenditure represent total healthcare look improve regulatory procedure spending remain relatively flat reliance vulnerability supply medicine pharmaceutical increase year european commission centralise continue genericisation medicine therapeutic procurement covid vaccine behalf member class include cancer increase use biosimilar state conclude joint procurement agreement continually improve affordability access purchase monoclonal antibodie outlook continue challenge demand datum realworld evidence support continue reimbursement europe country implement new product likely increase work payer reform range regulatory pathway cost containment design innovative solution manage risk china government commit accelerate patient uncertainty access health insurance cover innovative medicine china complete update national reimbursement drug likely great emphasis health resilience list nrdl add new highvalue medicine role preventative care play improve future access nrdl result price health outcome health protection intervention include reduction average immunisation represent significant value term return investment estimate pound spend uk position aim bring new medicine vaccine consumer healthcare product patient world matter live industryleade track record world economic forum zero covid vaccine billion show continue rank access year january medicine index work ensure medicine world datum coronavirus vaccination january specialised maintain commitment iqvia drug expenditure dynamic october access make product widely available abpi economic societal impact vaccination responsible price sustainable business hr build well act th congress pharmaexeccom china nrdl readout january gsk annual report gsk annual report strategic report governance remuneration financial statement investor information external environment continue get balance right responsible pricing region major regulatory initiative sustainable business fundamental innovation announce include uk china europe performance trust priority set price negotiation industry food drug medicine mature market use valuebase approach administration fda prescription drug user fee act balance reward innovation access affordability pdufa vii conclude potential regulatory innovation aim provide truly differentiate innovative covered result commitment letter move product offer effective health outcome patient legislative process eu industry continue payer product deliver value prepare european commission revision general pharmaceutical legislation industry work pricing esg performance report uks medicine healthcare product regulatory agency mhra establish new enhance partnership regulatory environment regulator outside eu follow brexit significant regulatory challenge implementation grow flexibility cooperation northern ireland protocol industry continue engage despite obstacle pose pandemic regulator uk eu agency resolve industry continue prioritise supply essential vaccine medicine accelerate position development new product new regulatory approach gsk closely monitor engage relevant facilitate innovation particularly digital healthcare appropriate improve regulation happen mainly cell gene therapie complex clinical trial big datum uk europe china japan realworld evidence example scientific innovation move scope regulator work close cooperation industry current regulation standard continue learn regulatory jurisdiction supranational experience covid working peer body international coalition medicine engage government create balanced regulatory authority potential permanent regulatory framework support discovery delivery adoption regulatory adaptation support development vaccine medicine develop emerge approval broad range new vaccine medicine technology technique opportunity simplify regulatory process global environment opportunity challenge advance science technology help respond change need grow demand healthcare create change age population increase global demand preventive demographic great patient control demand therapeutic health solution change way digital health healthcare deliver worldwide acceleration digital health telemedicine revolutionise delivery position healthcare year patient increasingly change demographic contribute rise demand manage healthcare home global digital health healthcare respond diverse portfolio market expect reach billion cagr span infectious disease hiv oncology immunology patient engage respiratory disease aim positively impact health healthcare company adopt patientcentric billion people year product approach focus patient outcome patient satisfaction line innovation priority investing pipeline user experience vaccine specialty medicine meet change prediction suggest global population grow billion healthcare need believe new technology enable billion despite pandemic early identification disease develop decrease life expectancy country precision medicine target treatment group number overyearold set double patient likely benefit vaccine technological people live city affluent innovation allow address unmet medical need live advanced age particularly true china age group experience world fastestever expansion middle class projection billion people middle class igital health global market report covid growth change research market march united nations world population prospect revise brooking china influence global middle class homi kharas meagan dooley october external environment continue climate change focus advance science technology recent political economic challenge slow exciting time medical discovery fuel progress un sustainable development goal genetic revolution decade combine need action remain urgent priority address expansion patientdriven healthcare datum advanced environmental issue extreme weather event new scientific technology like artificial intelligencemachine learn aiml datum climate change civic activism rapidly advanced advance functional genomic crispr gene case sustainable energy solution strong editing start redefine possible protection natural world biodiversity glasgow drug discovery allow researcher unravel mystery cop summit focal point international biology help pinpoint novel drug target high climate change solution lead glasgow climate pact probability success drive phenomenon include new emission pledge fulfil limit digitisation biology allow scientist explore human global warming degree preindustrial level biology way possible hold promise time cop plan set reduce treat disease previously reach require ai global use coal responsible annual co machine learn emission researcher regulator payer explore technology help improve clinical trial generate recognise good esg management well insight product effectiveness new societal expectation business continue increase combination product improve health business expect play address big challenge face society international rapid advance science technology fundamentally investment community respond context place change life science rd pandemic accelerate high value business actively manage esg risk vaccine innovation include mrna technology enable opportunity business see offer well bodys cell produce specific protein antigen foundation longterm sustainable growth good immune system prevent fight infectious disease environmental stewardship climate risk mitigation planning position priority investor forefront advance science technology position work create innovative solution kind healthcare trust essential deliver purpose create challenge longterm value shareholder society advanced technology platform central commitment support trust priority deeply rd approach expertise ai functional committed addressing issue matter include genomic dedicate global inhouse ai team pricing access global health environment machine learn unlock potential complex genetic inclusion diversity datum neverbeforeseen level speed precision good progress scale detail area retain sectorleading position dow jones vaccine use diverse platform technology sustainability index lead work improve global health adjuvant improve vaccine effectiveness mrna tackle antimicrobial resistance recognise technology heart pipeline differentiation access medicine foundation ranking collaboration partner team cut access medicine index amr benchmark edge field outside pharmaceutical vaccine recommend malaria vaccine wide use child help steer new science develop therapeutic page region moderate high malaria transmission detail launch new aspirational gender ethnic diversity target increase representation senior level alongside review recruitment process level sure responsible business reach attract diverse candidate societys expectation business remain high company strong progress climate nature goal sector face increase scrutiny social include largescale renewable energy investment environmental impact operation time major manufacturing site join coalition curb longterm socioeconomic trend continue drive trust deforestation invest rd cut greenhouse gas business organisation meet expectation emission meter dose inhaler engage benefit society economy environment company partner policymaker nonprofit organisation find new collaborative solution complex longterm issue climate change global health inequality lewis maslin thing need know glasgow climate pact world economic forum november ritchie h roser co emission fuel world datum access january gsk annual report gsk annual report strategic report governance remuneration financial statement investor information innovation innovation core continue strengthen pipeline vaccine medicine apply grow expertise partnership technology datum increase productivity rd year new launch regulatory approval important clinical study turn expertise transformational vaccine medicine patient pharmaceutical vaccine highlight strong pipeline vaccine medicine approval jemperli treatment endometrial potential bestinclass opportunity cancer certain solid tumour patient pivotal trial positive phase iii data daprodustat patient approval apretude longacte hiv anaemia chronic kidney disease preventative therapy deal execute secure access novel clinical xevudy sotrovimab monoclonal antibody treatment asset covid approve authorise conditional approximately target research temporary use uk eu genetically validate publish scientific research country show genetically validate target twice likely medicine innovation heart achieve purpose unite prioritise research vaccine medicine science talent technology ahead disease therapeutic area infectious disease hiv oncology discover develop new vaccine immunology include respiratory remain open medicine help patient largescale opportunity outside core area science align positive impact human health prevention strategic approach treatment disease pipeline consist potential vaccine medicine rd core innovation invest modulate immune system billion rd aer enhance move asset phase phase ii trial pipeline vaccine medicine work partnership business academia speed pace discovery currently vaccine medicine development development potential bestinclass productivity rd increase encourage team pursue bold research back ve double number asset phase iii clinical data science underpin clear accountability development cut overall cycle time streamlined rd governance allow development addition anticipate pace switch separate clinical milestone potential new vaccine development organisation vaccine medicine medicine identify key future growth driver include single combine organisation help sure apretude approve end invest programme big impact patient respiratory syncytial virus rsv vaccine candidate unlock scientific synergy prevention treatment old adult grow pace help difference approach rd people live instance blenrep belantamab mafodotin deliver transformational vaccine medicine rd treatment multiple myeloma gain regulatory approval approach focus science immune system year start pivotal study human genetic advanced technology artificial covid treatment sotrovimab achieve emergency use intelligence machine learn authorisation fda month partnership vir biotechnology begin april molecule preclinical phaseinnovation continue lead progress shingle vaccine shingrix approve wider ve major new vaccine medicine approve use market include canada put quartile industry expansion clinical trial programme zejula new great success rate indication breast lung cancer pivotal study compare industry contribution trelegy ellipta respiratory disease number launch billion dollar rd lung health continue evolve trelegy expand spend well peer median indicate use chronic obstructive pulmonary disease copd include asthma lifecycle innovation develop new treatment look innovation strategic partnership join force lifecycle exist vaccine medicine progress find new way help patient strategic partnership business development combine therapy join force commercial academic partner open increase number lifecycle project asset new avenue discovery advance development example new potential medicine announce benlysta treatment systemic lupus partnership collaboration provide erythematosus lupus nephritis access novel clinical asset include iteo immunooncology alector immunoneurology vir nucala anti il biologic approve biotechnology flu invest technology europe severe eosinophilic asthma expand capability human genetic artificial hypereosinophilic syndrome eosinophilic granulomatosis intelligencemachine learning aiml polyangitis chronic rhinosinusitis nasal polyp genetics genomics technology success rd rest find new gsk partner world good mind lead treatment getting well find institution area invest key combine genetic genomic advanced capability include london ai hub technology biomedical information aiml computing platform unlock new insight genetic clinical datum fulfil purpose ahead disease prioritise genetically validate target increase probability capability find new potential successfully deliver approve vaccine medicine combination exist therapy blenrep approximately target research genetically combination gamma secretase inhibitor validate publish scientific research show allow great patient benefit genetically validate target twice likely medicine able harness advance form right partnership genetic technology convert insight human genetics genomics genomic improve probability success rd collaboration consumer genetic research company andme yield novel research make well prediction help patient programme phase treatment decade see revolution genetic data cancer ve work uk biobank genomic ai machine learning help find pattern found join uks recent bioresource datum large scale far quickly future health additionally support new lead digitisation biology allow dataset feature diverse population gene well understand root cause disease health consortium east london black representation genetic research study andme late announce fiveyear collaboration university oxford focus neurodegenerative disease new institute leverage advanced technology build insight human genetic accelerate promising area drug discovery gsk annual report gsk annual report strategic report governance remuneration financial statement investor information innovation continue genomic partner include world preeminent extensive vaccine platform technology expert broad institute boston laboratory work vaccine platform technologies broad genomics research lgr establish portfolio industry enable select university california help find promise technology approach combination different genetically validate drug target investigate area platform technology develop new vaccine previously include genetic variation consequence think possible platform technology adjuvant function cell work pioneer crispr bioconjugation generalise modules membrane antigen technology lgr uncover new knowledge gmma adenovirus vector vaccine disease mechanism immunology oncology neurology range different pathogen allow tailor different programme work uk approach deliver success include mrna key focus biotech adrestia leverage new area call synthetic area development critical platform viability find novel drug target hard treat disease like technology major opportunity future vaccine frontotemporal dementia ftd investing significantly include fund phd studentship multiple university collaboration curevac building inhouse institute include crick institute university endtoend mrna development manufacturing capability adelaide australia university oxford stanford focus effort modify nonmodified university cambridge centre ai medicine mrna technology optimise high protein expression warwick university help sure sustained improve mrna potency tolerability talent pool right skill come year digitisation machine learning ai help speed aiml build scale speed vaccine research manufacturing process announce successful proof concept digital twin start new partnership king college approach vaccine manufacturing siemen ato london aiml understand patient respond digital twin use machine learn modelling provide cancer treatment disease progress new insight optimise development manufacturing technology tell role tumour genetic vaccine tumour microenvironment response therapie addition technology aid creation tool help well clinical decision personalise treatment nvidias cambridge supercomputer perform similar role immunooncology fuse different dataset build largescale model help determine good treatment patient large chip processor ai build silicon valley startup cerebra help construct largerscale genetic model learn dna help deconstruct gene operate different disease context infectious disease world face persistent threat infectious moved multiple vaccine candidate clinical disease claim life strain trial include meningitis abcwy second generation healthcare system half vaccine vaccine vaccine candidate klebsiella pneumoniae medicine pipeline address infectious disease cytomegalovirus cmv new strain varicella chickenpox late trial include proteinbase target new launch include adjuvante covid vaccine develop vaccine candidate rsv old adult gepotidacin collaboration company antibiotic treat uncomplicated urinary tract infection uuti potential bestinclass aim complete proof concept study new vaccine candidate successfully demonstrate proof concept ready registrational clinical trialsinnovation continue combine expertise vaccine medicine mean rsv uniquely position focus connection respiratory syncytial virus rsv common virus treatment prevention example include lead cause acute respiratory infection old adult covid working treatment rsv exacerbate underlying condition lead vaccine pneumonia cause hospitalisation death over year highincome country rsv respiratory condition effort remain major infectious disease vaccine develop rsv vaccine population risk rsv leading cause severe respiratory infection develop future respiratory medicine infant cause hospitalisation influenza hepatitis b antisense oligonucleotide vulnerable group vaccine technology development programme help prevent rsv consist candidate influenza develop vaccine vaccine advance test adult antibodie aged year use recombinant prefusion f close collaboration rd research area antigen combine adjuvant adjuvant help innovate area multiple tool key ingredient shingrix boost immune response require antimicrobial resistance amr pandemic help overcome challenge associate protect response draw crossover work old people anticipate phase iii data candidate vaccine pharmaceutical enhance ability vaccine half stop enrolment develop innovative solution meet patient need vaccination trial rsv maternal candidate vaccine february follow feedback independent datum shingle monitor committee idmc analysis well people develop shingles lifetime understand safety datum trial ongoing shingrix vaccine signal step change stop develop phase ii rsv paediatric prevent painful potentially illness candidate vaccine base adenovirus vector nonlive shingle vaccine combine specific subunit prefusion f antigen unlikely antigen adjuvant sustain immune response meet efficacy target currently investigate new continue expand access shingrix technology address important medical need launch new market australia singapore hong kong macau italy spain denmark finland austria meningitis uk switzerland follow early million people develop invasive meningococcal regulator canada australia hong kong disease imd year infant young child singapore extend indication vaccine adult adolescent particularly vulnerable early diagnosis year old increase risk shingrix shingle adequate treatment patient bacterial vaccine indicate expand use meningitis die hour symptom starting leave untreated meningitis fatal case achieve regulatory approval vaccine south cause brain damage hearing loss disability korea brazil switzerland taiwan include survivor increase risk population gain new recommendation vaccine italy spain australia switzerland leader imd protection million patient vaccinate bexsero meningitis b vaccine addition uss national comprehensive cancer network menveo meningitis acwy vaccine help nccn survivorship guideline update preferentially protect imd case recommend shingrix cancer survivor aged year old nccn guideline prevention gsk file submission fda fully liquid treatment cancerrelate infection update version menveo simplify administration shingrix recommendation autologous hematopoietic cell vaccine healthcare provider transplantation hct multiple myeloma lymphoma develop menabcwy pentavalent patient global initiative chronic obstructive lung vaccine mean vaccine disease gold guideline update recommend help protect major disease shingle vaccination protect shingles adult cause serogroup generation menabcwy vaccine copd age year old candidate phase iii clinical trial create combine technology develop exist bexsero menveo vaccine start phase iii trial second generation pentavalent candidate broad age indication strain gsk annual report gsk annual report strategic report governance remuneration financial statement investor information innovation continue covid follow positive phase ii datum vaccine collaboration globally million case covid sanofi begin phase iii trial parallel record outbreak emerge result death programme booster study december half million people partner announce positive preliminary result show single develop treatment vaccine booster dose adjuvante recombinant proteinbase covid vaccine candidate deliver consistently strong treatment harnessing monoclonal antibodie immune response primary vaccine receive alongside vaccine effective treatment critical support february announce intention submit patient community phase application regulatory approval vaccine pandemic covid patient high risk europe follow positive read out booster hospitalisation death risk factor old age primary phase iii trial vaccine candidate comorbiditie patient remain important access early effective treatment option include december report positive phase iii datum monoclonal antibody adjuvante plantbase vaccine develop medicago build positive phase ii result announce collaboration vir biotechnology begin early year base datum vaccine covifenz develop xevudy sotrovimab sarscov approve canada february monoclonal antibody work prevent virus enter infect healthy cell body vaccine adjuvant technology development half gsk vir announce result comet sk bioscience successful intend distribute ice phase iii trial investigate intravenous iv infusion vaccine globally covax facility gpb sotrovimab adult mild moderate covid high vaccine selfassembled nanoparticle vaccine target risk progression severe disease receptorbinde domain sarscov spike protein start phase iii trial august sotrovimab authorise emergency use brand xevudy grant marketing develop second generation mrna covid authorisation eu conditional provisional marketing vaccine candidate modify nonmodified rna authorisation great britain switzerland australia saudi vaccine technology collaboration curevac arabia approve japans special approval august november announce encourage emergency pathway temporary authorisation sotrovimab result range preclinical study grant country infectious disease sotrovimab bind specifically region spike protein diphtheria tetanus pertussis likely change increase potential europe healthcare provider boostrix remain effective variant emerge time datum combination tetanus diphtheria pertussis vaccine preclinical vitro study demonstrate sotrovimab additional vaccine shingrix retain activity test variant concern interest unadjuvante inactivated seasonal influenza vaccine date include delta omicron save patient multiple vaccination visit vir continue progress clinical healthcare efficient development programme sotrovimab explore chronic hepatitis b convenient method administration november million people suffer chronic hepatitis b receive positive result comettail trial year die decompensate investigate intramuscular m route administration cirrhosis liver cancer cause sotrovimab early treatment mildtomoderate covid highrisk nonhospitalise adult candidate vaccine currently phase iii target paediatric patient know great immunotherapy combine different technology include need effective prophylactic treatment likely come adjuvant shingrix rsv candidate immunocompromise people gsk vir vaccine old adult aim activate functional virus support clinical study specific population specific tcell bcell response restore immune competence hepatitis b virus hbv immune covid vaccine technology boost restoration lead functional cure chronic hepatitis b immune response define control virus eradicate work company covid vaccine body functional cure reduce risk proprietary adjuvant technology adjuvant longterm complication chronic hepatitis b infection liver vaccine effective boost extend bodys inflammation cancer expect proof concept datum immune response possible produce dose antigen enable production vaccine dose address global needsinnovation continued develop bepirovirsen hbv antisense clostridium difficile cause oligonucleotide potential firstinclass case hospital patient lead death functional cure chronic hbv design restore year progress phase firsttimein immune system natural ability eliminate infect liver human study candidate vaccine pathogen cell provide longterm control hbv phase iia klebsiella pneumoniae cause severe infection lung programme demonstrate bepirovirsen reduce bladder brain liver eye blood type hepatitis b surface antigen week treatment meningitis approve vaccine resistance anticipate datum ongoing phase iib programme treatment grow candidate vaccine develop limmatech start cytomegalovirus clinical development july succeed help cmv health risk baby infant prevent klebsiellaassociate infection people congenital cmv asymptomatic birth risk high risk include old people underlie longterm health problem include hear sight loss condition like diabetes kidney disease chronic liver disease delay development seizure cmv vaccine tetravalent bioconjugate include oantigen lead infectious cause birth defect target serogroup cause infection combine baby bear congenital cmv infection antigen proprietary adjuvant system longterm health problem show vaccine like shingrix help s currently approve vaccine work provide strong immune response people age change adjuvanted subunit vaccine enter include old adult phase iii trial shigella cause death year second lead cause diarrheal death globally rotavirus antibiotic antimicrobial resistance currently widely available license vaccine antimicrobial resistance amr urgent threat public protect shigella relate threat grow health undermine effectiveness antibiotic antimicrobial resistance significant issue currently contribute death year globally start phase trial quadrivalent shigella vaccine figure expect increase significantly action candidate base innovative gmma technology take focus organism high risk unique approach create bacterial vaccine replicate develop amr characterised center disease surface characteristic bacteria membrane control prevention cdc world health organization vesicle medicine develop new mechanism early science additional collaboration develop gepotidacin novel mechanism partnership infectious disease include work topoisomerase inhibitor uncomplicate urinary tract curevac mrna vaccine covid infection uuti gonorrhea partnership additional target include seasonal universal flu biomedical advanced research development authority building understand microbiome chronic barda time new oral antibiotic disease address infection year gepotidacin currently phase iii develop collaboration company generate scientific insight turn innovation vaccine target resistant pathogen microbiome engineering optimisation new therapy new scientific insight technology include adjuvant mrna bioconjugation generalise modules october expand collaboration viome membrane antigen gmma target pathogen create life science start investigate role significant health burden likely develop antibiotic microbiome chronic disease combine expertise resistance immunology viome mrna analysis ai platform new insight chronic disease cancer age vaccine clinical trial staphylococcus aureus clostridium difficile shigella klebsiella aim generate data pathogen cause programme major impact exacerbate chronic disease include autoimmune reduce case disease directly indirectly contribute inflammatory condition immunooncology help amr include rsv tuberculosis build predictive model tell target therapy build vaccine technology prevent staphylococcus aureus resistant antibiotic reverse chronic disease multiple drugresistant strain circulation methicillinresistant strain cause case eligo bioscience focus develop hospital patient estimate death way treat acne mean eligo crispr candidate vaccine prevent primary recur soft bacteriophage technology remove unwanted bacteria skin tissue infection pathogen enter phase ii leave beneficial bacteria intact gsk annual report gsk annual report strategic report governance remuneration financial statement investor information innovation continue hiv hiv urgent global health threat million new robust industryleade clinical trial programme case year include new case drive confidence twodrug regimen goal new case eu million dovato successful dolutegravirbase regimen people live hiv world case few reaction drug reduce exposure million people come subsaharan africa antiretroviral year efficacy safety datum dovato set bar high work hiv viiv healthcare world twodrug oral treatment regimen european specialist hiv pharmaceutical company majority treatment guideline include dovato recommend pfizer shionogi shareholder goal adult patient new therapy stably limit impact hiv people live treat prevent suppress patient need switch hiv therapy ultimately cure develop longacte medicine support people live hiv range potential dramatically change people experience give option alternative daily medicine work single medicine work people live hiv longacte therapy prevent hiv offer innovative choice help address evolve need replace daily medicine longacte portfolio approve antiretroviral medicine offer range regimen therapeutic option include tivicay triumeq contain dolutegravir aim offer innovative choice help address evolve need people live hiv despite incredible receive european marketing authorisation progress current oral hiv medicine people dispersible tablet formulation dolutegravir form live hiv face challenge take pill day tivicay treatment child week old transforming live people live hiv reduce kilogramme live hiv europe number day treatment regulatory submission fda ema approval year spare daily reminder live hiv new dispersible tablet formulation fix dose relieve pressure medicine combination abacavir dolutegravir lamivudine triumeq day low minimum weight child prescribe medicine january receive fda approval cabenuva firstever complete longacte injectable regimen hiv europe receive approval february rukobia offer people live hiv new approach fostemsavir firstinclass hiv attachment inhibitor care study cabenuva dose oncemonthly address unmet need heavily treatmentexperience effective threedrug oral regimen patient currently adult hiv not respond current antiretroviral day treatment exhaust option european approval follow approval fast receive approval dose month track fda breakthrough therapy early europe regiman approve combination prevent hiv longacte cabotegravir prep vocabria cabotegravir rekambys rilpivirine dosing prevent hiv essential reinforce month government goal reduce acquisition hiv launch innovative treatment regimen establish viiv healthcare industry leader develop longacting december fda approve viiv healthcare hiv medicine apretude longacte injectable preexposure prophylaxis prep option reduce risk sexually acquire give patient twodrug regimen option hiv integrase inhibitor gold standard hiv treatment study report show onceeverytwomonth medicine dolutegravir widely prescribe regimen superior daily pill effectiveness world million people live hiv time high man woman respectively oral currently hiv medicine take medicine prevent hiv acquisition dolutegravirbase regimen twodrug regimen oral therapy dovato juluca base dolutegravir show tolerate effective threedrug regimen allow people live hiv maintain viral suppression take few hiv drug lifetime h ivgovhivbasicsoverviewdataandtrendsglobalstatisticsinnovation continue increase ambition patient announce licensing agreement life pipeline include number medicine new sciences company halozyme recombinant human mechanism action combine hyaluronidase call ph ph inject integrase inhibitor cabotegravir create medicine subcutaneously create temporary expansion extend interval dose objective skin allow increase volume medicine deliver produce world selfadministere longacte add discomfort patient ability medicine people want medicine home large dose hope expand interval dose develop ultralongacte regimen dose open opportunity combine cabotegravir interval month long product pipeline create ultralongacte regimen treatment prevention hiv particular s potential year history success develop integrase use technology increase dose interval inhibitor hiv include dolutegravir cabotegravir cabotegravir prevention month long collaboration shareholder shionogi month year sign exclusive collaboration licence agreement shionogi thirdgeneration integrase ultimate goal remain find cure hiv inhibitor preclinical candidate call vh believe continue progress unique industryacademic partnership potential offer medicine long dose university north carolina chapel hill interval cabotegravir anchor future pipeline jointlyowne qura therapeutic expect start innovative longacting therapy hiv phase trial cure medicine oncology cancer second heart disease world continue dreamm trial understand big killer develop transformational cancer potential blenrep early line treatment medicine lifechange potential patient monotherapy combination standard novel therapy explore dose scheduling accelerate research area include synthetic modification example dreamm platform study lethality generation immunooncology agent draw investigate novel combination treatment expertise functional genomics science nirogacestat gamma secretase inhibitor gsi immune system partner isatuximab cd target monoclonal antibody oncology medicine jemperli dostarlimab approve patient mean market gynaecologic cancer therapie asset development numerous gynaecologic cancer common cancer preclinical target represent rapid progress affect woman nearly million woman approve medicine asset world diagnose gynaecologic cancer development advanced phase approval jemperli treat endometrial cancer blood cancer new case globally endometrial cancer cancer begin line multiple myeloma common blood cancer uterus patient limit treatment option cancer worldwide people develop year progress firstline therapy blenrep belantamab mafodotin treatment patient april jemperli dostarlimab receive accelerate relapse refractory multiple myeloma approval certain patient dmmr endometrial receive therapy therapy cancer conditional approval europe certain patient kind humanise antibody drug conjugate target dmmr msih endometrial cancer treat advanced protein bcell maturation antigen bcma recur endometrial cancer worsen despite blenrep receive regulatory approval previous treatment platinumbase chemotherapy jemperli europe follow pivotal dreamm trial activate immune system well attack cancer cell demonstrate deep durable response patient august jemperli receive accelerate approval advanced multiple myeloma launch patient dmmr solid tumour progress germany expand eu country despite early treatment mean jemperli available united kingdom hong kong patient confirm dmmr solid tumour satisfactory alternative treatment option gsk annual report gsk annual report strategic report governance remuneration financial statement investor information innovation continued investigate jemperli firstline treatment ignyteeso phase ii trial evaluate letecel patient combination chemotherapy patient advance synovial sarcoma myxoidround cell liposarcoma recur endometrial cancer ruby phase iii trial accelerate development path receive european evaluate combination zejula jemperli prime fda breakthrough status maintenance treatment focus develop generation cell treat ovarian cancer zejula therapy include approach technology woman diagnose ovarian enhance anticancer activity cancer collaboration lyell immunopharma treatment zejula niraparib oral oncedaily poly exploring way enhance tcell ability attack kill adpribose polymerase parp inhibitor monotherapy tumour cell engineering cell long maintenance treatment woman advance ovarian lasting potent collaborate cancer regardless biomarker status respond immatic biotechnology build capability cell therapy platinumbase chemotherapy receive approval solid tumour patient benefit kind firstline maintenance treatment eu treatment evaluate zejula pivotal trial assess activity early science collaboration multiple tumour type explore combination zejula therapeutic pivotal phase iii trial rd oncology invest new technology study zejula combination jemperli treatment partnership push boundary combat cancer firstline ovarian cancer important area immunooncology additionally functional genomics help identify new treatment target solid tumour synthetic lethality approach cancer treatment target genetic mutation cancer cell healthy cell explore zejula treatment lung breast cancer continue advance immunooncology currently conduct phase iii trial zejula lung immunooncology fastdevelope area search breast cancer new target important far patient respond certain immunooncology treatment phase iii lung cancer trial zeal investigate zejula firstline maintenance therapy patient advance work aim help immune system nonsmall cell lung cancer squamous nonsquamous recognise kill cancer cell effectively study histology receive platinumbase combination treatment jemperli enhance chemotherapy trial study efficacy safety antitumour activity utilise cd axis express zejula combination standard care treatment surface tcell natural killer cell include checkpoint cd tigit pvrig phase iii breast cancer trial zest explore efficacy safety zejula earlystage treatment trial use company access antibodie target circulate tumour dna technology time pivotal cd axis checkpoint gsk anticd breast cancer study offer potential detect tumour phase development monotherapy combine cell early molecular level identify woman high jemperli june partner iteo therapeutic risk recurrence mean therapy zejula start develop tigit antibody gska currently burden disease low create phase ib safety trial combination jemperli opportunity effectively slow stop cancer explore potential functional genomic progress synthetic lethality harness cell therapy internal work functional genomic identify cell therapy important avenue treat cancer target candidate research evaluation field address cell therapy programme solid synthetic lethality partner ideaya bioscience tumour combine strategy research clinical oncologyfocuse precision medicine company development supply chain address patient unmet explore mata inhibition tumour mtap deletion need common feature solid tumour study move phase develop new asset lead cell therapy asset development letetresgene expect clinic year autoleucel letecel gsk tcell receptor tcell therapy tcrt harness immune system develop personalise treatment extract patient tcell genetically modify express tcell receptor tcr target nyeso antigen find solid tumoursinnovation continue immunology include respiratory focus science immune system help november alector announce encourage new datum develop medicine immunemediate condition like open label infront phase ii trial datum lupus rheumatoid arthritis range inflammatory show consistent slow clinical progression patient disease year produce ftd treat al compare historical innovative medicine help million people match ftd subject group progranulin respiratory condition breathe easily gene mutation trend normalisation stabilisation diseaseassociate biomarker infront help lupus patient benlysta phase iii trial currently enrol ftd patient mutation benlysta belimumab biologic approve progranulin gene confirm phase ii data chronic autoimmune disease systemic lupus partnership bring alector immunoneurology erythematosus sle lupus nephritis ln kidney expertise rd focus science immune inflammation cause lupus monoclonal antibody system human genetic drug development target bly underlying cause sle ln reduce capability autoantibody level help control disease receive approval benlysta adult patient grow respiratory portfolio tackle active lupus nephritis market include brazil eosinophildriven disease eu member states japan receive broad portfolio respiratory medicine approval china indication follow approval industry continue grow use launch new inhaled therapy biologic nucala mepolizumab firstinclass monoclonal antibody move new way treat rheumatoid target interleukin il lead research arthritis eosinophildriven disease like asthma people worldwide suffer rheumatoid year inflammatory condition associate arthritis ra chronic inflammatory disease cause elevated level eosinophil type white blood cell pain joint swell inflammation lead acute occur range tissue organ chronic disability need great trial study nucala change live ra patient achieve remission despite use target people affect condition severe eosinophilic therapy currently available patient asthma sea hypereosinophilic syndrome s eosinophilic report daily pain debilitate granulomatosis polyangitis egpa chronic earlystage trial otilimab novel monoclonal antibody rhinosinusitis nasal polyps crwnp target il target gmcsf demonstrate rapid substantial nucala reduce number eosinophil excessive improvement pain move phase iii study number cause inflammation trial lead expect result pivotal study end important new approval nucala address unmet need positive pivotal trial result otilimab broad group patient new medicine ra decade fda approve nucala adult crswnp common chronic condition cause difficulty breathe find new disease target immunoneurology sleep interfere taste smell focus human genetic science immune approval nucala indicate eosinophil system give unique insight pinpoint potential target drive disease november receive approval patient neurodegenerative disease nucala europe crswnp s egpa july announce partnership alector january receive fda approval extend develop monoclonal antibodie al al marketing authorisation nucala include specific neurodegenerative disease include frontotemporal dementia paediatric presentation prefille safety syringe enable ftd amyotrophic lateral sclerosis al parkinson disease healthcare professional caregiver administer nucala alzheimer disease antibodie design raise home appropriate patient await european level progranulin regulate immune activity approval indication brain al pivotal phase iii trial people high risk develop ftd mutation progranulin gene phase ii trial patient al al development parkinson disease alzheimer disease phase ia trial healthy volunteer gsk annual report gsk annual report strategic report governance remuneration financial statement investor information innovation continue nucala phase iii trial determine help earlyphase portfolio patient copd high eosinophil count start phase ib trial exist il copd patient increase risk exacerbation monoclonal antibody atopic dermatitis phase trial additionally focus develop depemokimab novel monoclonal antibody target il multiple longacting antiinterleukin il monoclonal antibody sclerosis inform access genetic current phase iii programme assess safety efficacy database identify indication high severe asthma eosinophillic phenotype far result probability success reduce suppress eosinophil level long complete worldwide licence agreement period antiil monoclonal antibodie arrowhead pharmaceutical gsk arohsd mean treatment extended injection genetically validate investigational rna interference rnai month therapeutic currently phase iii development patient nonalcoholic steatohepatitis nash agreement cover medicine development commercialisation outside great china phase pipeline consist molecule target immune system celiac disease osteoarthritis pain neurodegenerative disease opportunity drive alongside balanced portfolio key therapy innovate patient primary biliary area lead science pursue cholangitis opportunity develop linerixibat ileal bile acid transporter ibat inhibitor treatment cholestatic pruritus transform treatment anaemia patient primary biliary cholangitis pbc condition million people suffer chronic kidney disease significant unmet need new worldwide estimate seven suffer pharmacologic therapy follow datum anaemia limited treatment option today glimmer phase iib trial initiate glisten daprodustat potential novel oral treatment dialysis phase iii trial glimmer study time andme nondialysis setting approve daprodustat bring help identify recruit enrol patient opt ease use oral treatment potential improve participate research glisten phase iii study current injectionbase standard care work effectively use andme database help match patient manage haemoglobin level pivotal trial allow assessment participant home technology homebase app track daprodustat base compelling human genetic nobel progress prizewinne science demonstrate cell sense adapt oxygen availability approve japan follow fda orphan drug designation linerixibat duvroq datum read positively receive positive decision orphan drug designation phase iii study independently meet primary efficacy european commission safety endpoint demonstrate daprodustat improve maintain patient target haemoglobin range show primary safety analysis intention totreat population similar rate major cardiovascular event compare injectionbase standard care esa therapy trial datum ascend programme support regulatory filing health authority worldwideinnovation continued pipeline overview asset development latestage phase iiiregistration bexsero infant vaccine xevudy sotrovimabvir covid covid medicago vaccine blenrep antibcma adc multiple myeloma covid sanofi vaccine jemperli pd antagonist l endometrial cancer covid sk bioscience vaccine letetresgeneautoleucel nyeso tcr ssmrcls menabcwy st gen vaccine zejula parp inhibitor ovarian lung breast cancer menveo liquid vaccine al antisortilin frontotemporal dementia mmr vaccine depemokimab la antiil antagonist asthma rotarix liquid vaccine nucala copd rsv maternal vaccine otilimab agmcsf inhibitor rheumatoid arthritis rsv old adult vaccine daprodustat hifphi anaemia chronic kidney disease gepotidacin bti inhibitor uuti gc linerixibat ibati cholestatic pruritus primary biliary cholangitis phase ii malaria fractional dose vaccine bepirovirsen hbv aso hbv aureus vaccine leucyl trna inhibitor tuberculosis shigella vaccine maturation inhibitor hiv therapeutic hbv vaccine broadly neutralise antibody hiv menabcwy nd gen vaccine cobolimab tim antagonist nsclc varicella new strain vaccine phase c difficile vaccine sting agonist cancer klebsiella pneumoniae vaccine nyesotgfbr tcr cancer sam covid model vaccine nyesocda tcr cancer sam rabies model vaccine lag antagonist cancer cmv vaccine mata inhibitor cancer bvlgsk ethionamide booster tuberculosis eos tigit antagonist cancer vir neutralise monoclonal antibody influenza cd antagonist cancer mtb inhibitor tuberculosis al antisortilin neurodegenerative disease crk inhibitor visceral leishmaniasis anticcl osteoarthritis pain proteasome inh visceral leishmaniasis tg inhibitor celiac disease fimh antagonist uuti antiil atopic dermatitis pik inhibitor viral copd exacerbation antiil multiple sclerosis vir covid arohsd sirna nonalcoholic steatohepatitis maturation inhibitor hiv trpv blocker diabetic macular edema cabotegravir mgml formulation hiv heart failure capsid protein inhibitor hiv advanced indication show asset inlicence alliance relationship phase iii trial patient progranulin nsclc nonsmall cell lung cancer uuti party gene mutation uncomplicate urinary tract infection additional indication investigation g sk exclusive option codevelop gc gonorrhea ss synovial sarcoma gsk contribute pandemic adjuvant post phase ii mrcls myxoidround cell liposarcoma phase iii trial enrolment vaccination stop february analysis well transition activity underway enable understand safety datum trial progression partner ongoe potentially registrational phase ii trial gsk annual report gsk annual report strategic report governance remuneration financial statement investor information performance strong financial performance drive class commercial execution strong uptake new product pharmaceutical highlight vaccine highlight total turnover billion aer cer total turnover billion aer cer sale new specialty pharmaceutical billion covid pandemic sale vaccine million aer cer include pandemic adjuvant sale million sale xevudy million reflect ongoing shingle shingrix sell country include fulfilment contract world market launch significantly meningitis increase market share bexsero strong commercial execution key growth product menveo include trelegy nucala exceed billion maintain market share key product despite sale time significant disruption covid well digital capability support effective excellent supply performance shingrix supply fully engagement healthcare professional high unconstrained productivity efficient supply chain accelerate digital transformation help drive datadriven decision manufacturing supply read read pharmaceutical performance oncology continue strong doubledigit sale growth pharmaceutical turnover year million sale zejula million aer cer aer cer impact ongoing low diagnosis rate covid pandemic particularly blenrep sale xevudy sotrovimab monoclonal antibody approve launch europe q treatment covid million contribute ongoing launch europe blenrep approximately percentage point pharmaceutical growth sale globally total million december year pivotal phase iii datum sotrovimab treat covid immunoinflammation sale million grow aer patient sell reserved million dose cer benlysta sales aer cer agreement eu dozen million benefit lupus nephritis launch country include uk japan australia canada japan h singapore uae sales establish pharmaceutical decrease aer hiv sales aer cer cer million million growth dovato juluca partly offset adapt covid pandemic tivicay triumeq broad portfolio include new product cabenuva longacte injectable treatment apretude covid pandemic continue affect healthcare longacte injectable hiv prevention rukobia system globally see interruption usual care highly treatment experience patient healthcare facility delay diagnosis subsequent treatment patient preexist medical maintain lead position respiratory amid high condition remain particularly vulnerable demand pandemic strong commercial execution respiratory sale aer cer amidst ongoing restriction access customer million sale trelegy nucala exceed continue perform strongly market area like billion year time approval launch oncology online digital tool maintain strong eosinophildriven disease indication nucala engagement healthcare professional continued increase uptake therapys home administration option meet need patient patient support boost performance trelegy ellipta market programme increase market share chronic obstructive pulmonary disease gain asthma aid approval japan late group financial review detailperformance continue drive growth decade transform interaction healthcare portfolio pharmaceutical innovative professional patient establish medicine lead global position essential maintain strong connection hcp respiratory disease hiv develop presence meet need patient specialty therapy area include oncology business pandemic accelerate use immunoinflammation broad portfolio supply innovative technology effective commercially highquality medicine make positive impact ve increase use virtual call hcp inform life million patient year expect clinical datum launch product pipeline specialty medicine key driver gsk growth help understand science product good use complement newly define general medicine business contain primary care run successful pilot good engage brand include trelegy anoro classic hcp coordinate way online traditional establish product support broad investment channel scale brand innovation rd market datale automatically orchestrate mix traditional digital promotion deploy hiv business position growth remain refine novel datum set commercial innovation leader anticipate continue growth analytic orchestration engine let tailor longacte injectable therapy cabenuva deliver plus hcp global data treatment hiv apretude hiv prevention look drive customer experience programme recognise multiple opportunity sustain growth externally win silver award international latestage asset excite early customer experience award help improve stage pipeline innovative longacte medicine competitiveness eu digital investment lead strengthen capability organisation immediate increase hcp attend webinar china reach time hcp wechat want well bright people specialty website medicine marketing medical team continue focus appoint right leader lead name new virtual meeting educational activity ve general manager country bring clinical experience customer global attract external people right expertise speaker programme follow feedback hcp compete oncology hire people tell like receive information peertopeer set commercial rd expert practitioner leadership position leadership change improve continue engage patient patient support interface commercial rd function early programme benlysta care programme commercial input select develop pipeline asset information guidance include text reminder help create last value benefit saving nurse support exclusive content optimise policy collaboration marketing help patient take benlysta treatment medical sale team sale force september d enrol patient effective competitive key market change time benlysta care sale incentive policy positive impact sale show help patient stick treatment team high engagement personal accountability patient engagement liaison pel team run internal audits achieve compromise patient education programme patient ethical standard engagement healthcare disease pel partner national professional hcp january introduce individual local patient advocacy group pag patient target sale representative drive disease awareness resource productive competitiveness conversation care provider datum predictive analytic deliver engage china yinchuan copd patient support programme china customer interaction monitor improve sale digital copd patient management programme enable performance market share big datum g internet thing iot ve work national healthcare commission nhc embe smart digital technology inhaler help doctor sure patient follow prescription gsk annual report gsk annual report strategic report governance remuneration financial statement investor information performance continue invest supply chain keep supply consistent dependable supply chain transformation continue line success rest maintain highquality reliable portfolio shift innovative specialty care product new way supply product patient consumer reduce work response pandemic agile resource total cost supply chain continue increase allocation prioritise return investment help productivity simplify supply network cost reduction saving set gsk leaner productive sale growth improve gross profit financially efficient margin invest facility people manufacture partnership strengthen internal external quality oversight continue help launch specialty medicine rapidly model modernise quality management system accelerate delivery portfolio new facility simplify way work improve deviation rate barnard castle uk site start manufacture medicine pharmaceutical supply chain continue quarter come year support industry quartile fda recall billion sale manufacturing majority key exist new regulatory inspection pharmaceutical site biopharmaceutical asset pipeline satisfactory invest million expansion generation safety performance critical success ve biopharma manufacturing facility upper merion pennsylvania take extra measure incident likely set open expand facility rockville strengthen safety culture include deploy life maryland begin commercial supply saving rule help employee understand apply streamlined supply chain help control cost allocate basic safety rule work launch operational safety capital effectively big share direct leadership programme strengthen safety monitor specialty medicine simplify network central system function complete divestment site pozna reliability supply improve median poland closure xochimilco mexico commercial performance ontime infull supply chain team collaborate initiative lower despite covid disruption apply cost good sell cog protect margin increase profit supply chain segmentation ve improve performance work include reduce active pharmaceutical ingredient invest technology like resilinc tool ai cost optimise capacity improve process work highlight emerge supply chain risk pilot digital twin supplier simplify portfolio ve reduce optimise planning increase operational efficiency brand sell year skus ve accelerate datum digital analytic dda adoption use enterprise system manage datum invest automation aiml improve efficiency document plan operation include value chain reduce variability supply chain demonstrate mapping supply chain planning cognitive supply chain track reach topquartile day inventory outstanding model low logistic cost dio free work capital expect digital investment year help improve plan productivity accuracy reduce inventory vaccine performance hepatitis vaccine sale aer cer vaccine turnover million year million adversely impact deprioritisation aer cer anticipate vaccine routine adult vaccination increase hepatitis b vaccine business face significant disruption give competition unfavourable cdc stockpile movement government prioritisation covid vaccination covidrelate travel restriction europe programme measure contain pandemic international result low demand routine adult vaccination include meningitis sale decrease aer cer million shingrix hepatitis vaccine vaccine turnover exclude drive primarily unrepeated international tender volume pandemic adjuvant sale decrease aer cer meningitis vaccines bexsero sale stable aer million grow cer million reflect increase market shingrix decrease aer cer million share menveo sales aer cer sale fall international sale grow europe million primarily drive cohort catchup drive germany launch uk spain italy vaccination high demand increase shingrix sell country include market market share launch group financial review detailperformance continue adapt covid pandemic plan launch new vaccine include pandemic continue dominate highly programme help prevent rsv vaccination transmissible variant emerge country world old adult significant medical commercial opportunity cycle stayathome order country access support goal draw strong covid vaccine available adult manufacturing capability scale global population child healthcare system adapt reach commercial execution significantly enable huge vaccination endeavour area focus attract retain repercussion aspect health provision include right people strategic area strengthen low priority vaccine disease covid capability include mrna focus pandemic mean approximately people access customer usual despite maintain digital capability market share key vaccine strategic country hold virtual meeting hcp attend event virtually continue build capability vaccine virtual provide educational support material vaccination day bring hcp bring close continue inform people importance immunisation customer share scientific discourse world disease awareness brand campaign lead expert vaccine new econgress meningitis shingle diphtheria tetanus pertussis dtp platform extend second edition event hcp country include china offer drive growth decade translation different language attract portfolio market vaccine broad registrant receive net promoter score industry include vaccine help protect hcp feedback score industry standard people worldwide range disease event play role help improve protect public life include meningitis shingles flu polio measle health vaccine sale efficacy level continue work philip pregnancy baby app partnership philip live country commercial term vaccine tend long lifecycle reach approximately million parent continue medicine generate significant revenue effective tool educate parent vaccine decade example engerix vaccine help prevent paediatric portfolio follow success launch hepatitis b virus infection available digital partnership fourth quarter focus year remain important portfolio adult time partnership san franciscobase november cdcs advisory committee nextdoor neighbourhood network immunization practice voted unanimously recommend household hepatitis b vaccination adult aged year global momentum vaccination vaccine expect large driver growth covid vaccination programme require country gsk high singledigit percentage sale growth population adapt learn believe cagr anticipate period aim positive longterm impact vaccination widely double revenue shingrix shingles vaccine particularly adult attitude vaccination shift fiveyear period double meningitis flu vaccine research people age year old sale decade help protect million people large vaccine market show disease increase positive attitude vaccination result pandemic gsk annual report gsk annual report strategic report governance remuneration financial statement investor information performance continue real opportunity healthcare system harness continue apply codevelopment model colleague momentum need vaccination remain rd manufacturing work handinhand scale strong commission publish report production effectively efficiently possible ongoing avalere health show adolescent adult example prepare accelerated launch miss million dose recommend rsv candidate investment wavre clinical vaccine january july compare commercial activity finding demonstrate routine immunisation great stride unlocking capacity get continue lag prepandemic level original exist asset good example avalere report follow cdcs analysis shingles vaccine shingrix improve yield miss vaccine dose call government public policy throughput supply chain reduction lead time group medium prioritise recovery vaccination mean fully unconstrained shingrix supply rate disease covid support growth aspiration supply performance meet covid commitment scale pandemic adjuvant production respond fluctuating continue strengthen manufacturing capability demand agility meant deliver adjuvant sure support growth vaccine portfolio agreement pandemic adjuvant sale important despite supply chain disruption cause pandemic contribution revenue covid strong year supply solution performance time ve continue accelerate digital proud fact strategic vaccine site transformation include investment manufacturing approve multiple regulatory agency include execution system production line site fda network manufacturing site switch paper batch record electronic system country produce deliver million dose deploy year benefit year continue inv network include operational efficiency leadtime reduction modernising automating fill packaging activity improvement compliance yield stability build mrna production capability add launch investment accelerate capacity pipeline product rsv datadriven decision manufacture supply example invest infrastructure need future data analytic technology improvement include robotic plan lyophilisation freeze dry unit site wavre automation material handling activity bot replace belgium support manufacturing capacity repetitive manual task automate visual inspection priority product innovation pipeline syringe vial aiml work supply chain reduce embed lean sigma tool technique endtoend lead time improve agility marketplace process system capability improve effectively manage demand uncertainty close way work cooperation shop floor delivery end customer allow betterinformed decision investment make manufacturing facility share datum free cash increase efficiency people help way example ensure competitive tender customer right mrna capability talent place investment help manufacture ready redesign supply chain reduce lead time support bright future vaccine make sure right inventory right place win marketplace multiyear effort use work capital effectivelytrust trust longterm priority trust build well perform value create shareholder people society trust priority cover work esg factor esg governance integral overall strategy approach esg help boardlevel corporate responsibility committee crc deliver sustainable performance longterm growth oversee progress commitment build trust stakeholder stakeholder address view expectation stakeholder engagement reduce risk operation glt senior management responsible delivery risk management help trust commitment report regularly crc positive social impact progress commitment esg area approach report big difference commitment help respond challenge opportunity industry broad section report highlight progress society external environment page trust commitment provide contribute un sustainable development goal detail reporting datum commitment esg especially goal ensure healthy life promote wellbee performance report report include un global age compact communication progress global reporting initiative index sustainability accounting standard board index gskcom contribution sdgs assurance statement social environmental datum g skcom esg performance report external benchmarking maintain acknowledge leadership esg continue key driver goal deliver health impact shareholder return detailed perform key esg rating frequently ask investor dow jones sustainability index djsi st cdp climate change b water b forest pharmaceutical industry group palm oil timber supplier engagement leader sp global sustainability award gold class sustainalytic low risk rating access medicine index atmi rank st atmi msci aa rating industry leader antimicrobial vigeo eiris rank nd pharmaceutical sector resistance benchmark ftsegood member ftsegood index gsk annual report gsk annual report strategic report governance remuneration financial statement investor information trust continue science technology address health need commitment progress new medical innovation see major approval medicine phase iii start vaccine develop differentiate medicine pipeline detail innovation section page highquality need medicine vaccine consumer healthcare product improve health global health commitment improve global health impact rd infectious disease improve global health impact access medicine vaccine recognise access medicine index rd infectious atmi rank number seven year year disease affect child inception young people low rtssase malaria vaccine vaccine show longterm clinical income country focus trial reduce malaria child recommend broad deployment vaccine reduce illness death child subsaharan africa region hiv malaria tb moderate high malaria transmission follow new datum show vaccine combination seasonal antimalarial lower clinical episode malaria hospital admission severe malaria death compare antimalarial december gavi announce decision provide funding procurement introduction vaccine routine child immunisation programme gavi eligible country good progress improve availability ageappropriate hiv treatment option child world generic dolutegravir dispersible tablet available key subsaharan african country year fda approval treatment work facilitate publicprivate partnership clinton health access initiative unitaid generic manufacturer mylan viatris group macleod shigella second big cause morbidity mortality diarrhoea worldwide rotavirus approve vaccine widely available late subject vaccinate quadrivalent shigella vaccine candidate firsttimeinhuman clinical phase iii study goal develop affordable vaccine give broad protection prevalent shigella serotype rich pipeline focus global health priority disease industry include medicine vaccine currently clinical development launch collaboration novartis project africa gradient support scientific research link genetic diversity patient response malaria tuberculosis drug african region health security take broad approach develop covid solution help world well apply science find covid innovation prepare future disease company sit pandemic preparedness partnership steering outbreak pandemic group convene uk government bring industry international potential tackle organisation expert advise g government speed response antimicrobial resistance future pandemic trinity challenge found member announce winner inaugural competition find innovative way well predict prevent outbreak disease data analytic winner include vaccineledger track vaccine manufacture patient blockchain technology commitment prevent antimicrobial resistance amr recognise access medicine foundation amr benchmark gsk industry leader consecutive time benchmark highlight particular diversity depth rd pipeline particularly amrrelevant vaccine detail progress commitment esg performance reporttrust continue make product affordable available commitment progress pricing develop market price new product reflect value deliver patient improve health million healthcare system wide society compare available alternative support people year make work meet future healthcare need offer patient support product available provide prescribe vaccine medicine lowincome uninsured underinsured medicare patient gsk viiv healthcare patient responsible price assistance program foundation sustainable business pricing low income country lic low middle income country lmic use innovative pricing structure extend product reach vaccine business tiere pricing model base world bank gross national income country classification file patent medicine enforce historic patent lowincome country lic product reach access strategy continue reach underserved people low income use access strategy reach country good progress target reach million underserved million people product access strategy strategy include people low income advanced market commitment provide vaccine low income country country product gavi partnership gavi include supply cervarix critical tool low income country address cervical cancer synflorix pneumococcal vaccine rotarix vaccine rotavirus common cause severe diarrhoeal disease child commitment supply rotarix humanitarian mechanism civil society organisation serve vaccination need refugee emergency situation build exist commitment humanitarian mechanism synflorix viiv healthcare voluntary licensing agreement generic manufacturer allow million people live hiv lics lmic access generic product contain dolutegravir end donate billion albendazole tablet include million support effort end lymphatic filariasis control intestinal worm schoolage child healthcare access number partnership ngos multilateral organisation improve partner improve disease disease prevention awareness access healthcare service prevention awareness programme reach million people year develop ambitious access healthcare service global health strategy gsk include set new target million people partnership save child increase emergency preparedness response capability invest datum analytic earlyaction protocol provide efficient timely healthcare crisis partnership save children amref health africa care international train frontline health worker reach million people prevention treatment infectious disease plus provide maternalchild healthcare vaccination hygiene sanitation nutrition viiv healthcare positive action programme aim explore way support peoplecentre communityle intervention help meet un target end aids programme reach approximately people fund grant country detail progress commitment esg performance report gsk annual report gsk annual report strategic report governance remuneration financial statement investor information trust continue modern employer commitment progress engage people early launch new allcompany survey focus purpose strategy achieve maintain engagement culture progress engagement remain high general competitive employee industry benchmark settle level extra boost early phase engagement score pandemic inclusion diversity aspiration woman hold vp svp role end accelerate progress woman hold role vp ftse woman inclusion diversity leader rank show ftse company base include aspirational target proportion woman board leadership position publish fifth annual uk gender pay gap report show continue outperform female ethnically national average diverse representation senior aspiration ethnically diverse leader role vp role end uk end representation december recognition disability show ethnically diverse leader vp role uk confident employer ethnically diverse leader role vp lgbt index progress support rigorous focus equal employment opportunity launch programme accelerate difference ethnic diversity support development ethnically diverse employee build strength address development gap individual group coach publish gsk ethnicity pay gap datum uk develop threeyear plan increase disability confidence roll workplace adjustment programme big market make available employee population far sign international labour organization global business disability network promote inclusion people disability workplace continue recognise global lgbt index include designate good place work lgbtq equality human right campaign foundation corporate equality index health wellbeing gsk leadership team continue oversee covid response include development health wellbeing engagement employee location continuously lead company monitor impact covid employee public health vaccination support employee health programme continue helping educate raise awareness wellbee personal public health vaccination programme available committed offer development vaccination minimal cost employee eligible dependent continue mental health training available employee manager complete launch confidential support available global employee assistance programme successfully pilot new wellbeing programme focus resilience strategy energy management continue implement global rollout run health safety training people cover identify measure reduce workplace risk reportable injury illness rate remain hour work fatality employee access internal development portal grow campus offer extensive development course video article range topic include decision make building change capability coach influence health wellbee people complete leadership business course datum employee gender include total employee board management provide nonfinancial information statement f detail progress commitment esg performance reporttrust continue responsible business commitment progress reliable supply priority sure highquality reliable supply product commit quality safety patient consumer continue high importance reliable supply product pandemic increase strain global supply chain patient consumer manage continuity supply page quality management system allow continuous improvement help high standard product quality safety external regulatory inspection manufacture site local operating company conduct virtually pandemic respond inspection finding matter minor run quality audits supplier audits clinical trial run behalf gsk assess quality safety find area improve create improvement plan track progress ethic value gsk complete training company expect operate ethical value rename mandatory employee code conduct training work gsk drive culture improve content focus risk compliance diversity create issue respond swiftly inclusive workplace employee contract worker complete train transparently inside outside gsk raise concern speak independent party speak reporting channel confidentially anonymously fear retaliation continue concern raise seriously review report identify need investigate formally investigation employee breach policy action change way report disciplinary datum expand scope include case initiate previous year employee concern raise additional employee concern raise prior year open case discipline employee initially concern raise previous year increase primarily drive late completion mandatory training leave voluntarily dismiss receive write warning case take action short write warning end case await investigation disciplinary decision undertake independent assessment approach manage human right help well understand continue improve manage priority human right area assessment show good understanding human right impact review address finding year come party act direct impact meet prioritie important manage relationship include way choose contract monitor thirdparty oversight tpo programme evaluate mitigate risk introduce engage thirdpartie provide good service gsk complete assessment portion party present great potential risk example interaction government official annual transfer value certain predefine limit run assessment high risk party risk area identify highrisk area party good service provider contract manufacturer external supplier distributor wholesaler evaluate tpo programme simplify upfront assessment broaden focus risk management thirdparty relationship user feedback finding ongoing monitor detail progress commitment esg performance report gsk annual report gsk annual report strategic report governance remuneration financial statement investor information trust continue responsible business continue commitment progress datum engagement simplify privacy notice easy access portal website privacy key mandatory work gsk annual training people complete help employee understand gsk responsible handling personal information right way patient panel insight advice building trust longterm relationship patient carer help develop medicine meet patient need ran panel disease area include cancer rheumatoid arthritis hepatitis b commitment datum transparency clinical study publish clinical study report summarie result list study datum share wwwvivliorg wwwclinicalstudydatarequestcom want clinical trial representative accessible possible reflect patient population disease include age race ethnicity sex gender past year endeavour improve patient diversity clinical trial implement training support personnel investigator site include awareness training conduct clinical trial serve community form global demographic diversity team coordinate learn epidemiology burden disease health equity relate age sex gender race ethnicity apply lesson planning trial environment climate net zero impact achieve ambitious net zero goal set target value chain carbon climate net positive footprint target accredit science base target initiative align impact nature oc pathway reduce operational carbon emission scope compare primarily increase use renewable energy september announce million investment uk manufacturing site secure renewable power generation include new wind turbine year power purchase agreement supply solar electricity irvine facility scotland solar energy oak hill facility new york late available data emission supplier logistic people product scope reduce reflect evolution product portfolio reduction business travel commuting result pandemic meter dose inhaler asthma copd account carbon footprint start rd programme find lowerimpact propellant reduce emission nature collaboration important strategy year join global pharmaceutical company launch energize programme collaboration kind use scale single industry global supply chain drive great use renewable electricity principal partner un global climate change conference cop glasgow champion need action climate nature protect health join health system task force sustainable market initiative drive collective action digital healthcare supply chain patient care pathway accelerate shift net zero climaterelate financial disclosure page energy carbon emission datum gsk carbon reduction pathway net zero find gskcom energy carbon emission datum provide climaterelate financial disclosure page f detail progress commitment esg performance reporttrust continue responsible business continue commitment progress environment involve develop standardised guidance measuring impact nature continue work science base target nature initiative taskforce naturerelate financial disclosure tnfd achieve net nature positive goal reduce environmental impact water material biodiversity investing protect restore nature reduce overall water use operation compare site high water stress region site good water steward line alliance water stewardship definition year join water resilience coalition wrc partnering develop approach water neutrality water stress region deliver water resilience project ground cape town site south africa network embark journey water neutrality work wrc local partner address share water challenge clear alien plant specie replant local flora create great resilience basin reduce waste site recover material circular route like reuse recycle consumer healthcare launch million recycleready toothpaste tube market pilot approach biodiversity stevenage site uk working partnership kew garden deliver increase biodiversity site aim measurable effective biodiversity plan place gsk site join publicprivate lower emission accelerate forest finance leaf coalition contribute highquality emission reduction support country protect tropical forest deforestation detail progress commitment esg performance report gsk annual report gsk annual report strategic report governance remuneration financial statement investor information consumer healthcare future standalone consumer healthcare business haleon track separate gsk mid new world leader focus consumer healthcare consumer healthcare firstmarket launch commit produce billion recyclable toothpaste new innovation tube total turnover billion aer cer significant investment onsite solar power goal exclude brand divestedunder review source electricity renewable source ecommerce represent total sale deliver billion consumer healthcare product announce growth ambition annual organic sale growth medium term sustainable moderate margin expansion high cash conversion sector relevant pass key milestone look ahead global consumer healthcare grow billionplus despite challenge ve face pandemic market event year underscore successfully complete integration pfizer consumer industry importance pandemic continue healthcare delay timing impact world mean consumer focus deliver synergy target complex health wellness manage integration impact multiple part business symptom proactively look wellbee include commercial manufacturing rd completion vitamin mineral supplement mark major milestone separation plan new consumer healthcare company haleon selfcare support healthcare ukbase list october announce burden healthcare system increase drive proposal new company headquarter locate age population rise middle class population weybridge newly build campus feature consumer healthcare sector particularly overthecounter otc innovation centre open end subject product play important role address challenge consultation planning approval ambition datum show spend otc medicine reflect ambitious sustainability target set healthcare system save amount billion annually set success grow business opportunity standalone consumer billion annual sale operating margin sale billion healthcare company operate margin worldleade consumer consumer healthcare sector role support broad healthcare business public health present significant opportunity standalone company focus consumer healthcare industryleade portfolio announce plan separate consumer world leader consumer healthcare hold leadership healthcare business ukliste company position category operate oral health demerger vitamin mineral supplement vms pain relief significant progress prepare respiratory health digestive health separation happen mid growth strategy base prioritise investment june confirm intention separate power brand number strategically demerger july brian mcnamara name important brand concentrate key country region ceodesignate new consumer healthcare company previously describe operating model design december sir dave lewis appoint drive performance brand chairman designate february lay strategic divestment low growth brand focus portfolio priority key growth driver detail financial information geographically number otc haleon future consumer healthcare vms market operate include priority business gskcom information market china therapeutic oral health segment nicholas hall db consumer healthcare otcvms database store ecommerce salesconsumer healthcare continue performance covid pandemic accelerate consumer consumer healthcare turnover year million shift great proactivity manage health decrease aer stable cer reflect dilution wellness research highlight consumer divestment give completion portfolio example take supplement rationalisation end q twoyear cagr prior year research uncover sale exclude brand divestedunder review grow overall centrum consumer favour solution despite adverse impact covid pandemic target multivitamin base insight launch tailor solution scientifically blend centrum sale exclude brand divestedunder review decrease number key market australia move aer increase cer reflect underlying strength multivitamin launch new centrum benefit range brand portfolio category continue multiingredient combination order cater consumer growth ecommerce overall sale benefit strong need mind body beauty include mind memory growth category exclude respiratory health rest renew immune defence recovery collagen negatively impact q historically low cold boost glow china successfully launch centrum flu season decrease cold flu sale result dual probiotic proposition specially design approximately drag fullyear growth appeal grow consumer trend gut health international sale exclude brand divestedunder review grow body selfdefence power continue high single digit cer basis double digit growth innovate new format expand centrum mini emerge market include india china middle east centrum gummie portfolio include launch centrum africa exclude brand divestedunder review sale grow organic multigummie innovation help evolve low single digit european sale stable cer brand single multivitamin pill bring number basis region particularly negatively impact personalise solution base trust science historically low cold flu season q inform clinical datum group financial review detail continue increase interest emergenc brand consumer continue look sciencebased innovation address unmet way support immune health research reveal consumer need consumer look botanical natural quality innovation continue driver growth order support wellness goal launch deliver major innovation base trusted science formulation combine natural goodness plant human understanding meet need consumer base botanical nutrient core emergenc world total deliver firstmarket launch new formula antioxidant b c vitamin electrolyte innovation brandmarket launch overall continue invest locally relevant innovation research show tooth sensitivity sufferer china key market launch contac multi searching trust longlaste solution address symptom innovation big otc launch sale cause pain treat symptom business china provide fast relief address key consumer need innovate develop multiple cold flu symptom contac multisymptom launch sensodyne repair protect deep repair comprise active ingredient single pill relieve market product scientifically prove seven cold flu symptom fever headache sneeze runny provide deep target repair dentine tubule nose limb pain sore throat nasal congestion hole tissue beneath tooth enamel source investment digital drive growth pain provide longlaste protection sensitivity pandemic see explosion digital commerce digital engagement position oral health expand gum health expert capture digital opportunity offer paradontax brand research show people globally suffer bleed gum ecommerce sale grow mid range versus sign gum disease parodontax active gum repair overall ecommerce represent total sale innovation clinically prove help reverse early sign see good growth key ecommerce market gum disease strengthens appeal brand include china consumer gum problem reinforce invest capability digital medium credential dental expert significant proportion total advertising spend digital medium allow efficient effective target consumer gsk annual report gsk annual report strategic report governance remuneration financial statement investor information consumer healthcare continue purpose culture guiding run responsible business serve hundred million world strong esg strategy performance critical brand significant effect everyday health expectation future standalone company integral future standalone company root purpose live purpose deliver well everyday health deliver well everyday health humanity guide humanity key pillar strategy esg choice increasingly important stakeholder success depend create right culture health world affect health people people consumer healthcare business clear not enjoy well everyday health world matter environment threat society increasingly unequal divide heighten economic inequality manifest culture start right thing act grow health inequality focus esg integrity nonnegotiable mean strategy tackle environmental social proud operate culture focus barrier everyday health behaviour environmental tackle carbon emission climate hunger desire drive change develop sustainable packaging well pace outperform trust ingredient sustainably source competition take step create healthy environment people matter prioritise live important thing challenge unnecessary social improve health inclusivity tackle bias human dedication discrimination prejudice hold people consumer customer serve equally important everyday health educating empower people dedication commitment well sustainable selfcare help create demand unmatched understand empathy healthy social environment people live build right culture start diverse workforce governance define strategy governance create inclusive environment colleague reflect increase stakeholder expectation support thrive believe inclusion diversity d lead appointment board lead sir dave lewis bring business success unleash enormous potential wealth international consumer sector experience people strengthen ability respond year stepchange action sustainability differ need patient consumer include significant investment onsite solar power commitment accelerate progress d remain goal source electricity renewable priority include work aspirational target source commit billion toothpaste tube female ethnically diverse representation senior role recyclable achieve palm oil derivative end accreditation otrivin action breathe clean project campaign help child learn air pollution identify good way minimise exposure scale education topic broad population high profile presence cop ahead standalone company continue work define social sustainability strategy governance reflect increase stakeholder expectationsstakeholder engagement engage building trust broad range stakeholder vital longterm success summarise key stakeholder engage issue matter respond enable board management understand stakeholder view include decision make section statement patient consumer matter patient consumer differentiate product innovation base patient consumer insight patient consumer enable develop need product well meet need access reliable supply highquality product engage price healthcare product particularly outofpocket expense advisory board diseasespecific patient panel patient advocacy leader summit provide patient insight strengthen pipeline innovative product engagement support patient group disclose gskcom maintain high standard product quality safety initiative empower patient involve medicine development continue valuebase approach pricing balance reward innovation access affordability market research include consumer sensory lab investor matter investor sustainable performance longterm shareholder value maintain regular constructive dialogue investor communicate strategy performance order promote understand rd strategy successfully develop investor confidence ensure continue access capital pipeline commitment strong management esg issue engage ongoing communication include agm quarterly result call inperson virtual roadshow detailed company information create new lead company demerger online onetoone meeting board member senior executive good financial performance transparent report institutional investor business rd update event key pipeline milestone biennial investor analyst perception study drive leadingedge esg performance culture ambition accountability responsibility healthcare professional medical expert matter hcp medical expert work healthcare professional hcp medical access product scientific information expert understand patient journey partner resolve responsible sale marketing practice unmet medical need sure product safety efficacy differentiate innovation safely effectively engage increase use digital channel deliver personalise scientific dialogue increase understand disease management effective share information hcp patient experience ensure attract retain good talent uphold responsible providing highquality balanced information vaccine sale marketing standard medicine hcp insight disease management patient experience collaborate clinical trial research inform development vaccine medicine rd partner academia matter rd partner academia find right partner identify accelerate potential vaccine partner scientific institution national health system medicine reach patient need academia industry partner help develop effective vaccine medicine meet unmet patient need push science technology far advance human health engage dissemination advancement scientific knowledge collaborate outstanding scientist academic institution accelerate discovery development new vaccine medicine license advanced technology potential vaccine medicine work worldleading expert biotechs research institutes biotechs university improve drug vaccine discovery increase productivity rd pipeline establish joint venture strengthen innovation improve efficiency collaborate broad range partner support rd focus science immune system human genetic advanced technology page support advancement scientific knowledge longstanding commitment sharing research gsk annual report gsk annual report strategic report governance remuneration financial statement investor information stakeholder engagement continue government regulator matter government regulator investment innovation life science work government regulator advocate policy encourage innovation promote efficient management scientific funding collaboration healthcare spend medicine pricing reimbursement engage public health threat covid antimicrobial resistance amr meeting regulatory body development process investment preventive health strengthen health system ensure highquality new product engage government health agency demonstrate value engage policy pricingreimbursement debate product patient economy phrma comment legislative proposal healthcare reform working government protect strengthen operate partnering industry government tackle amr environment life science innovation new medicine vaccine engage government include uk eu launch production procurement covid vaccine treatment participate international effort address global health threat pandemic ngo multilateral organisation matter ngos multilateral organisation access vaccine medicine work partner improve access healthcare service product advocate policy environment un sdgs target specific disease area successful deliver ambition universal health coverage future health system patient finance global health include covid solution engage work nongovernmental organisation ngos partner focus unique role global health partner develop research develop product address global health challenge product scientific expertise collaborate ngo generic manufacturer sustainably partner organisation complementary capability supply product low income country reach create sustainable model share risk include partner strengthen health system low income country partnership gavi support access vaccine low income drive progress global health priority country leverage community investment programme support scientific expertise deliver great impact patient supplier matter supplier prompt payment agree term work thousand supplier large small provide good service support deliver reliable supply understand gsk policy ensure compliance highquality safe product patient consumer opportunity innovate grow relationship engage regular direct engagement supplier ensure support engage supplier develop improvement plan track gsk strategy target progress identify area improvement engage supplier thirdparty oversight programme provide proactive support thirdparty ehs team conduct indepth audits country priority supplier locate participate forum pharmaceutical supply chain initiative consumer good forum improve supply chain sustainability people matter people purpose able difference involve listen people increase employee engagement drive business performance retain talented great line manager people feel understand value engage inclusive diverse workplace regular interactive broadcast event glt senior leader foster culture accountability ambition underpin facilitate dialogue collaboration internal integrity humanity communication platform work council employee forum launch new leadership programme help manager motivate employee resource group focus care develop team provide feedback manager global allcompany survey campaign programme support safety mental wellbee question enable worklife balance drive diversity inclusion activity support new aspirational targetsrisk management risk management internal control framework wellembedde mature continuously review overseen board identify evaluate manage risk rocc conduct annual risk review assess principal risk management internal control framework emerge risk company review support embed provide ability board evaluate extensive analysis external trend insight senior level oversee company manage principal emerge risk interview recommendation risk management line longterm objective companywide compliance board risk owner rocc share annual policy set requirement role responsibility review arc board assessment form management governance risk control basis follow year risk management focus support guidance essential element internal put risk management plan place control framework routinely evaluate framework improvement define enterprise risk plan include description risk context assessment risk appetite treat governance risk action business need line board oversee risk management system internal control framework mitigate risk enable establishe risk appetite support audit risk board committee assess effectiveness risk committee arc corporate responsibility committee management strategy year annual business crc science committee assess effectiveness risk report continue quarterly reporting risk rocc risk management strategy pertinent define remit board committee drive dynamic datadriven risk oversight compliance council rocc help discussion agile risk management strategy oversight arc crc oversee risk strategy report exist control measure implementation emerge address risk external insight outoftolerance key risk indicator tolerance align risk appetite include risk risk management compliance board group mitigation associate covid promote tone establish risk culture oversee effectiveness risk management risk management framework complement culture activity communicate information internal speak process ensure risk actively control business accountable delivering effectively identify mitigate provide reasonable objective line establish risk appetite assurance material misstatement mitigate potential loss arise ordinary course business enterprise risk owner responsible principal risk monitor important risk take action address oversight glt member risk owner report risk issue annual confirmation exercise check key risk mitigation rocc glt appropriate board manage action place address gap committee legal compliance support effort business advise business strategy activity risk control audit assurance provide assessment adequacy business continuity planning embed framework effectiveness framework principal risk include control respond problem risk plan business continuity planning consider current emerge risk critical process continue business operation event crisis risk assessment process consider likelihood impact risk timescale risk occur change risk consider current emerge risk affect ability achieve longterm objective emerge risk november annual risk review rocc agree threeyear horizon line viability principal risk remain largely unchanged statement define risk way need know evolution privacy data ethic privacy non likely materialise impact promotional engagement scientific patient engagement d evaluate additional investigation transformation separation separation additionally require classify principal risk risk agree environmental sustainability manage management compliance board level esg area focus identify new organisation identify emerge risk ongoing basis emerge risk geopolitical tension healthcare reform rocc discuss emerge risk meeting scan evaluate classified risk horizon year identify external trend principal risk opportunitie andor emerge risk monitor table follow page show current principal business activity internal environment new emerge risk respective trend assessment mitigation change risk activity year order significance risk definition potential impact context mitigate viability statement risk associate activity principal risk uncertainty covid arc report page internal control framework gsk annual report gsk annual report strategic report governance remuneration financial statement investor information risk management continue principal risk summary risk trend assessment mitigation activity patient safety macro risk level stable remain challenge public awareness drug safety increase follow medium coverage safety efficacy covid vaccine therapie misinformation negative characterisation industry fuel vaccine hesitancy highly publicise information security threat datum breach require consider securely collect safety information external source gsk risk exposure stable portfolio evolve great focus advanced therapy medicinal product require specialised pharmacovigilance need carefully balance resource execute routine pharmacovigilance manage change initiative include separation consumer healthcare business accelerate pace drug development simplification safety process product quality macro risk increase follow covid regulator resume multiple onsite inspection check product quality expectation meet continue focus datum governance datum integrity requirement evaluation product presence nitrosamine gsk risk exposure increase need respond heighten inspectorate presence launch inspection readiness programme ensure preparedness continue invest technology digital platform strengthen control good datum management practice governance control strategy deploy timely nitrosamine evaluation mitigation require focus diligence gsk undergo significant organisational change financial external environment remain challenge political uncertainty propose increase control obligation director auditor increase threat cyber attack information security fraud reporting increase environmental disclosure requirement gsk risk exposure remain stable ongoing focus resilience personnel test internal control framework implement optimal risk mitigation transformational programme technology centralise process risk control assessment maintain effective tax treasury strategy continually strengthen control framework collaborate external body standard set antibribery macro risk level bribery corruption remain unchanged continued corruption ongoing impact pandemic government people business rigorous antibribery abac corruption standard aid improve technology continue enforcement focus party intermediary gsk risk exposure unchanged continuously improve anti bribery corruption programme ensure appropriate control training capability building awareness raise strong monitoring use data analytic commercial covid consequence continue impact macro level competitive pressure increase practice therapy area market segment future innovation require successful launch key medicine product vaccination rate impact accessibility political issue government remain focused initiative drive medicine vaccine cost consumer gsk risk exposure level remain stable mature robust control environment continue evolve commercial practice competitively invest new technology support virtual customer engagement maintain proportionate control training monitor employee engage healthcare organisation professional train senior business leader deliver performance manage risk non macro environment nonpromotional activity scientific engagement hcp promotional patient stable continue characterise complex dynamic disease area treatment engagement increase patientcentric focus increase diversity engagement platform continue increase virtual engagement pandemic gsk risk exposure remain stable digital practice continue develop modernise apply internal principle policy design mitigate risk rapidly evolve environment internal network foster collaboration good practice share identification emerge risk associate nonpromotional activity conduct compliance gsk value policy local law regulationsrisk management continue principal risk summary continue risk trend assessment mitigation activity privacy macro risk continue increase priority gsk market uk eu china india institute new privacy law court ruling invalidate establish international datum transfer mechanism international company rely increase trend datum sovereignty initially target tech company affect healthcare company ability drive medical innovation effectively operate internationally gsk risk exposure increase impact unstable privacy regulatory environment prevent standardise privacy framework globally scale change necessary prepare creation new datadriven company research macro risk level unchanged need continually assess rd context practice future ambition benchmark evolve global regulation quality standard particularly vital expectation change countryspecific requirement human genetic resource administration china schrems ii gsk risk exposure unchanged law regulation continually evolve regulation change accountable rd function develop action plan include risk impact assessment determine internal control framework need change meet new requirement rd regularly scan external environment membership professional organisation consortium attendance industry agencysponsore meeting review publicly post regulatorylegal report environment macro risk level unchanged covid protocol embed way health working site staffing move essential worker staffing mean safety able resume consistent management oversight onsite global support eh senior leader subject matter expert audit team gsk risk exposure level consistent work practice relate covid control measure organisational change continue factor place continue focus safety leadership training embed life save rule adhere ehs standard environmental macro risk level continue increase investor regulator stakeholder expect sustainability company understand actively reduce environmental footprint operation value chain mitigate impact climate change operation supply chain gsk risk exposure unchanged set ambitious new environmental sustainability goal end establish enterprise transformation programme address climate water waste biodiversity operation increase scope depth task force climaterelate financial disclosure tcfd analysis continue monitor trend physical reputational regulatory risk climate change impact information macro risk level continue rise large multinational increase digital footprint threat security hacker sophisticated risk identify increase pandemic level continue ongoing threat time government tighten regulatory framework expect enforcement increase gsk risk exposure increase target pharmaceutical vaccine intellectual property thirdparty service availability intensify response cyber security programme continue improve control increase cyber threat intelligence capability protect critical information system include operational technology network supply macro risk level remain high ongoing impact pandemic product supply continuity continue potential increase protectionism brexit uncertainty covid issue management team actively manage supply risk mitigation ongoing basis gsk risk exposure stabilise procurement task force crossfunctional group procurement supply chain accountable identification management potential bottleneck supply component transformation macro risk level unchanged remain challenge set new company highly separation competitive external labour market gsk risk exposure level remain unchanged transformation separation project progress plan employee engagement remain priority gsk annual report gsk annual report strategic report governance remuneration financial statement investor information risk management continue climaterelate financial disclosure gsk climaterelate disclosure consistent programme steering team coordinate recommendation recommend disclosure task sustainability programme associate workstream force climaterelate financial disclosure tcfd oversight monitoring performance progress compliance requirement lr r uk list rule enabler deliver sustainability programme gsk report climaterelate financial disclosure capital allocations board cab include accordance tcfd recommendation cfo group financial controller review climate purpose building trust connect relate capital expenditure annual plan strategic financial disclosure climate change capital allocation process expand disclosure undertake detailed finance sustainability network include leader review gsk manufacture operation inhaler finance sustainability procurement focus portfolio large contributor gsk current key financial enabler deliver sustainability carbon footprint portfolio medicine vaccine programme consumer product gsk carbon reduction pathway net zero find gskcom strategy risk management continue evolve future climaterelate disclosure methodology assumption build climate risk assessment external disclose longterm risk climate supply chain change value chain key product account approximately revenue expand governance assessment focus risk manufacture environmental sustainability include climate change operation develop threeyear plan assess principal risk gsk board embed climaterelate analysis significant area overall accountability management gsk business principal risk support glt climate scenario base internationally boardlevel corporate responsibility committee crc recognise datum set oversee environmental sustainability principal risk businessasusual bau assume little mitigation progress environmental target nonexecutive lead c warming director lynn elsenhans chair crc report lowcarbon future assume global temperature risk oversight compliance council rocc increase limit c rapid help crc oversee risk strategy change legislation technology address quarterly reporting refer detail board board committees architecture enterprise risk plan carry scenario analyse risk opportunity prioritise regis simard president pharmaceutical supply chain physical transitional risk opportunity accord glt member management responsibility environmental likelihood magnitude potential impact sustainability include climate change responsible gsk manufacturing operation staff governance oversight risk opportunity ensure effective framework place identify risk opportunity analyse potential manage risk opportunity business impact profit classify low million unit deliver commitment medium million million high million net zero impact climate net positive impact nature consider climaterelated issue time horizon refer detailed risk management plan strategic capital planning process shortterm establish specialised team gsk work month mediumterm year longterm deliver environmental strategy embe year focus climate risk business usual include material risk identify fall short medium term gsk sustainability council chair regis simard include leader business unit global test resilience gsk climaterelate strategy function include manufacture rd procurement take consideration different scenario risks facility management ethic compliance finance opportunity identify result continue play key role deliver environmental strategy improve management climaterelate risk council support dedicated programme steering opportunity team run global sustainability team provide specialist expertise advice business httpswwwgskcommediagskcarbonglidepathpdf scenario base ippc representative concentration pathway iea world energy outlook new policy scenario current policy scenario sustainable development scenario datum set wwf wri water stress flood risk modellingrisk management continue risk management internal control framework establish specific dedicated environmental sustainability enterprise environmental sustainability include appointment risk management plan place detail dedicate senior leader environmental sustainability risk management risk management plan ensure governance process place effective cover expectation gsk address impact performance reduce carbon emission energy environment environment increase impact water utilisation waste continue deliver operational resilience access energy water manage mature programme enhance natural resource product include ecodesign consideration product anticipate cost increase regulatory change package environmental taxis summary gsk risk opportunity potential physical risk profit impact description scenario risk management timeframe metric target increase level bau perform water stewardship risk low site achieve good water stress low assessment manufacturing site achieve water water stewardship reduce carbon identify site current long stewardship availability water network currently area highwater year site water use operation risk operation reduce overall gsk use freshwater develop plan site water use site main source water neutral partner operation supplier site water manufacture organisation address share medicine vaccine water challenge currently pilot achieve water water neutral consumer health approach cape town site work neutrality product partner include wwf water operation resilience coalition water availability key supplier restrict factory tcfd process help develop water stress production watch list additional site potentially region operation longterm threat monitor change interrupt risk level update site water risk assessment appropriately increase frequency bau perform risk assessment low site site extreme weather low manufacturing operation business response event cause carbon business continuity plan place long continuity extreme disruption review annually respond impact year plan weather event extreme weather event include adopt business extreme weather appropriate mitigation plan continuity plan event flood storm etc tcfd process help identify result shortterm watch list site place interruption flood risk expect increase time manufacturing risk flooding remain operation low gsk wellestablishe loss prevention risk engineering programme identify range risk impact site flood risk exist take action mitigate risk increase number bau gsk operation country low scope net zero hot day experience hot temperature periodically carbon emission c result control temperature long emission operation reduce productivity humidity inside building year ehs control framework site conduct risk extreme heat net zero assessment hot day include result heat stress emission adaptation outside work affect staff value chain define alliance water stewardship gsk annual report gsk annual report strategic report governance remuneration financial statement investor information risk management continue potential transitional risk profit impact description scenario risk manage timeframe metric target regulation bau start rd programme find medium scope net zero governing use low lowerimpact propellant reduce carbon emission high global warming carbon emission meter dose inhaler emission operation potential gwp long substance year portfolio dry powder net zero update uk inhaler product use propellant emission eu impact risk value chain lead monitor evolve regulation increase cost governing use fluorinate gas restriction use review assessment future declaration high gwp propellant hfaa meter dose inhaler mdi product uncertainty low carbon transition renewable low scope net zero future regulatory electricity start carbon emission policy response investigate option renewable heat long emission operation address climate technology reduce carbon emission year change country energy world sale fleet aim transition electric develop include vehicle reduce scope carbon pricing carbon emission anticipate shadow carbon pricing embed carbon pricing capital investment process operational carbon tonne drive conversation emission come decision carbon emission level force organisation region medium long term increase operating cost potential profit impact opportunity scenario opportunity manage timeframe metric target cop bau reduce scope carbon low scope net zero november low carbon emission turn reduce scope carbon emission footprint customer supplier long emission value chain country year start new ecodesign programme total waste world commit reduce impact product non zero operational provide low carbon packaging circular waste waste include healthcare system eliminate gsk certify publish carbon lead singleuse plastic footprint portfolio respiratory inhaler increase demand launch carbon neutral low carbon vaccine inhaler uk enable healthcare medicine provider patient informed choice environmental impact reduction start rd programme find product lowerimpact propellant reduce packaging emission meter dose inhaler waste reduction supply chain risk management continue metric target detail progress make achieve commitment net zero impact climate climate target find additional net positive impact nature value chain background climate nature target additional detail target carbon reduction glidepath progress make approach adopt contribute goal available gskcom meet target find esg performance science base target initiative validate near report public response cdp climate term carbon target align c pathway deliver water forest questionnaire goal act priority impact area work order align approach climate nature stakeholder value chain include supplier target remuneration executive director customer work external partner senior executive introduce esg target world business council sustainable development measure initially short longterm remuneration un water resilience coalition incentive plan include set measure short longterm performance participant nature net positive climate net zero ambition detail remuneration report page energy carbon emission carbon emission carbon emission tonne coe scope emission energy scope emission scope emission marketbase scope emission available report uk scope emission energy scope emission energysale revenue tonne coem scope emission energyfte tonne co efte total energy gwh uk energy gwh carbon emission calculate accord greenhouse gas protocol corporate accounting reporting standard revise edition gsk use marketbase scope emission reporting purpose report scope emission category esg performance report ask external assurance provider dnv provide limited assurance isae energy scope select scope carbon emission datum methodology report measurement provide esg performance report kpi definition gsk ask dnv provide limited assurance isae energy scope select scope carbon emission water waste wastewater data methodology report measurement provide esg performance report kpi definition page refer emission sale force vehicle propellant emission release manufacture inhaler onsite waste wastewater treatment refrigerant gas loss collect publish scope datum category recent scope datum available process compile datum complete publish datum available include esg performance report gsk annual report gsk annual report strategic report governance remuneration financial statement investor information risk management continue viability statement accordance provision revision metric subject sensitivity analysis code gsk assess prospect group involve flex number main assumption underlie long period month require go forecast individually combination concern provision director confirm mitigate action realistically take avoid reasonable expectation gsk continue operate reduce impact occurrence underlie risk meet liability fall year future separation consumer healthcare joint venture director assessment reference gsk pfizer approve board shareholder likely current position prospect strategy board risk occur period cover viability assessment appetite gsk principal risk manage director consider ability group detailed page strategic report continue current form ie scenario board review internal control risk management demerger procee threeyear period end policy approve governance structure code december viability new gsk conduct appraise approve major financing demerger proceed plan investment licensing decision evaluate monitor follow hypothetical downside scenario performance prospect gsk focus evaluate largely improve longterm financial performance delivery company business strategy scenario business performance risk include key align innovation performance trust priority performance risk include low sale new product great adverse impact generic competition board review gsk strategy make significant capital competitive launch gsk product investment decision longterm time horizon base possible supply manufacturing challenge multiyear assessment return capital performance company business unit market scenario external macroeconomic risk scenario opportunity pharmaceutical vaccine consumer reflect incremental risk business drive outside sector approach align gsk model achieve factor intense competition increase pricing balanced growth invest highquality innovative pressure europe potential product patient consumer healthcare provider impact material negative change macroeconomic internal external parameter healthcare environment increasingly unpredictable long time horizon gsk scenario principal risk scenario include severe focus detailed bottomup plan threeyear cycle assessment potential loss impact principal risk plan review annually director approve relate patient safety product quality supply chain continuity business forecast show expect financial impact environmental sustainability antibribery director believe threeyear assessment period corruption consequent regulatory action fine viability statement appropriate align fundamentally threaten operation risk group establish business planning process manage mitigating activity describe page balance longterm nature investment pharmaceutical vaccine consumer sector scenario option exercise scenario evaluate assessment period analysis nearterm additional funding requirement assume early potential business performance realistically visible exercise outstanding option hold partner plan stress test series robust operational hiv business principal risk downside scenario board scenario demerger consumer healthcare joint review risk include potential risk associate venture ch final scenario focus impact ch ongoing covid pandemic consider demerger early q downside assessment plan stress test downside scenario scenario apply new gsk cash flow plan assume year challenge healthcare industry continue uncertainty relate threeyear review make certain assumption impact covid pandemic adult vaccination normal level capital recycling likely occur consider continue pressure pricing pharmaceutical gsk additional financing facility require assume premature loss exclusivity key product respective level funding flexibility headroom period gsk expect volume demand product result stress testing certain combination increase particularly shingrix healthcare system hypothetical scenario increase funding expect return normal follow disruption demand gsk require mitigate change government prioritisation covid vaccination group funding strategy light liquidity programme ongoing measure contain pandemic available group base analysis director downside scenario consider gsk cash flow reasonable expectation sustainability dividend fund strategy insurance provision severe stress test group demerger recovery key financial ratio period able continue operation meet liability fall threeyear period assessmentrisk management continue risk associate covid potential impact covid pandemic gsk continue remain confident underlying demand trading performance principal risk vaccine encourage rate assess mitigation plan place covid vaccination booster administer anticipate pandemic impact group performance country provide support healthcare system primarily demand vaccine reflect prioritisation eventual return normal continue dynamic covid vaccination programme government situation future severity duration impact unknown include social distancing rule result covid point include potential impact trading result clinical affect customer ability willingness access vaccination trial supply continuity employee situation service region change time assurance covid pandemic material adverse impact future result group nonfinancial information statement follow align nonfinancial reporting requirement contain section cb company act description business model human right policy diligence outcomes value create ethic value summary principal risk datum engagement principal risk uncertaintie social matter party viability statement global health audit risk committee report health security anticorruption bribery affordability availability ethic value nonfinancial key performance report investigate concern indicator employee antibribery corruption key performance indicator employee engagement diversity environmental matter policy wellbee development carbon water waste public policy code gender pay gap climaterelate financial disclosure standard available gskcom ethic value board diversity employee gender male female total board management employee senior manager define company act strategic report director report regulation gsk annual report group financial review section report framework approach tax financial performance adjust item cash generation conversion financial position resource treasury policy critical accounting policy gsk annual report strategic report governance remuneration financial statement investor informationgroup financial review report framework total adjust result cost ordinary course small scale restructuring group financial review discuss operate legal charge expense retain total financial performance group cash flow financial adjust result position resource result year adjust result include benefit major restructuring compare primarily result precede year programme exclude significant cost amortisation intangible asset computer software total result capitalise development cost significant legal major total report result represent group overall restructure transaction item performance regard complete picture group financial gsk use number adjust nonifrs measure performance present total result report performance business adjust result exclusion adjust item result adjusted nonifrs measure consider addition earning materially high low total earning substitute superior information present particular significant impairment restructure accordance ifrs adjust result define charge legal cost exclude adjusted earning nonifrs measure define high total earning gsk believe adjust result consider gsk undertake number major restructure total result provide investor analyst programme response significant change group stakeholder helpful complementary information trading environment overall strategy follow material understand well financial performance position acquisition cost cash noncash group period period allow group programme provide individual element performance easily compare majority approve meet accounting recognition criterion peer company measure result charge incur number year management planning reporting purpose follow initiation major restructure programme directly comparable similarly describe measure significant legal charge expense arise company settlement litigation government investigation gsk encourage investor analyst rely normal course materially large single financial measure review gsk annual report regularly occur individual matter include certain include financial statement note entirety major legacy matter adjust result reconciliation total adjust result provide adjusted result exclude follow item total result information key adjust item tax effect item set year set page amortisation intangible asset exclude computer software capitalise development cost gsk provide earning guidance investor community basis adjust result line peer company impairment intangible asset exclude computer expectation investor community support easy software goodwill comparison group performance peer gsk major restructuring cost include impairment able guidance total result reliably tangible asset computer software specific forecast certain material element total result board approve programme structural particularly future fair value movement contingent significant scale cost individual relate consideration option give rise project exceed million include integration cost significant adjustment drive external factor follow material acquisition currency movement capital market transactionrelate accounting adjustment relate significant acquisition proceed cost disposal associate product business significant settlement income significant legal charge net insurance recovery expense settlement litigation government investigation operate income royalty income item include impact revaluation defer tax asset liability follow enactment increase headline rate uk corporation tax effective separation cost include cost establish consumer healthcare independent business admission list demerger cost gsk annual report group financial review continue gsk annual report strategic report governance remuneration financial statement investor information reporting framework continue historical record adjust item reconciliation total adjust operating profit year summarise follow total operating profit intangible asset amortisation intangible asset impairment major restructuring transactionrelate item divestment significant legal item separation cost tax reform adjust operate profit analysis impact transactionrelated item operating profit year follow novartis consumer healthcare joint venture option contingent consideration shionogiviiv healthcare jv include shionogi preferential dividend viiv healthcare option pfizer preferential dividend contingent consideration novartis vaccine business release fair value uplift acquire pfizer inventory adjustment transactionrelate item reconciliation total adjusted result set page explanation adjust item report noncontrolle interest viiv healthcare acquisitionrelate arrangement trading profit allocation consideration acquisition shionogis interest shionogiviiv healthcare joint venture shionogi viiv healthcare subsidiary group receive equity stake viiv healthcare viiv operating result turnover operate profit profit tax healthcare agree pay additional future cash include group income statement consideration shionogi contingent future sale portion earning allocate noncontrolle performance product develop joint interest own shareholder line venture dolutegravir cabotegravir ifrs business respective equity shareholding pfizer shionogi combination gsk require provide estimate shareholder include gsk entitle fair value contingent consideration time preferential dividend determine performance acquisition require update liability late certain product shareholder contribute estimate fair value subsequent period end relative performance product change time liability contingent consideration recognise proportion overall earning allocate shareholder balance sheet date acquisition million change particular increase proportion sale subsequent remeasurement reflect dolutegravir cabotegravircontaine product operating incomeexpense adjust item favourable impact proportion preferential dividend income statement period allocate gsk adjust item allocate shareholder base equity interest gsk entitle cash payment settle contingent consideration approximately total earning shionogi viiv healthcare quarter base adjusted earning viiv healthcare actual sale performance income relevant remeasurement liabilitie preferential dividend product previous quarter payment reduce allocate pfizer shionogi include balance sheet liability record income operating incomeexpense statement cash payment shionogi viiv healthcare million liability require record fair value estimate future payment significant timing difference charge record total income statement reflect movement fair value liability actual cash payment settle liabilitygroup financial review continue report framework continue cash payment reflect cash flow statement q gsk notify shionogi partly operate cash flow partly investing irrevocably give right accordingly recognise activity tax relief payment reflect liability option group balance sheet group adjust item tax charge q initial value million q payment relate original estimate fair shionogi irrevocably agree waive option value contingent consideration acquisition result gsk derecognise liability option shionogiviiv healthcare joint venture million group balance sheet directly equity value report investing activity cash flow statement liability million derecognise payment relate increase gsk option shionogis shareholde liability acquisition report operate cash viiv healthcare original agreement flow exercisable sixmonth window commencing movement contingent consideration payable shionogi gsk irrevocably agree waive follow exercise window sixmonth window remain option fair value value accounting purpose contingent consideration begin year remeasurement income statement settlement gilead sciences inc gilead cash payment operate cash flow february viiv healthcare reach agreement cash payment invest activity gilead settle global patent infringement litigation relate contingent consideration end year commercialisation gilead biktarvy term global settlement licensing agreement gilead contingent consideration payable posttax basis upfront payment billion viiv healthcare shionogi december million december receive february addition gilead million expect pay year pay royalty future sale biktarvy exit right respect bictegravir component future bictegravircontaine product sell royalty pfizer request ipo viiv healthcare time payable gilead viiv healthcare february gsk consent ipo offer expiry viiv healthcare patent complete month pfizer require gsk october gileads obligation pay acquire shareholde original agreement gsk royalty extend period regulatory paediatric unconditional right long subsequent exclusivity award settlement result distribution shareholder withhold consent remeasurement exist liability contingent exercise pfizer option result accordance consideration pfizer option year end ifrs gsk recognise liability option balance sheet q gsk notify impact settlement gilead contingent pfizer irrevocably give right accordingly consideration liability ccl increase million recognise liability option group balance posttax basis q obligation viiv sheet q initial value million healthcare pay future cash consideration shionogi consistent revise treatment end q share upfront future sale performance gsk recognise liability future preferential biktarvy product contain bictegravir include dividend anticipate payable pfizer shionogi impact settlement december liability group balance sheet discount stand million posttax basis closing balance liability related pfizer shareholding follow pfizer right require gsk acquire shareholding viiv healthcare certain circumstance time option liability record group balance pfizer option sheet current liability measure gross pfizer preferential dividend redemption basis derive internal valuation viiv healthcare business original agreement shionogi impact settlement pfizer option liability request gsk acquire shareholding viiv healthcare increase million include sixmonth window commence remeasurement december gsk unconditional right long explanation post balance sheet subsequent distribution shareholder withhold event impact consent exercise shionogi option result gsk recognise liability option balance sheet gsk annual report group financial review continue gsk annual report strategic report governance remuneration financial statement investor information reporting framework continue free cash flow year compound annual growth rate free cash flow define net cash inflow operating cagr define compound annual growth rate activity capital expenditure property plant show annualise average rate proforma revenue growth equipment intangible asset contingent consideration give year assume growth take place payment net finance cost dividend pay non exponentially compound rate consumer healthcare control interest plus proceed sale property year revenue cagr present show plant equipment intangible asset dividend annualise average rate proforma revenue growth receive joint venture associate management planning reporting purpose discussion presentation investment analyst covid solution rating agency free cash flow growth calculate covid solution include sale pandemic adjuvant report basis reconciliation net cash inflow covid solution include vaccine manufacture operation free cash flow set xevudy associate cost include reinvestment rd categorisation cer aer growth management believe helpful investor order illustrate underlie performance group provide clarity result group show practice discuss result term constant exchange contribution growth covid solution rate cer growth represent growth calculate exchange rate determine result overseas general medicine company sterling remain unchanged general medicine usually prescribe primary comparative period cer represent growth care community setting general healthcare practitioner constant exchange rate aer represent growth gsk include medicine inhale respiratory actual exchange rate dermatology antibiotic disease return capital employ specialty medicine return capital employ calculated total profit specialty medicine typically prescription medicine taxation percentage average net asset year treat complex rare chronic condition gsk comprise medicine infectious disease hiv oncology net debt immunology respiratory note net debt calculation net debtgroup financial review continue approach tax business make major contribution public purse seek maintain open constructive relationship tax contribution include direct taxis tax authority worldwide meeting regularly discuss tax corporate income tax indirect taxis vat affair real time business update possible custom duty taxis employment monitor government debate tax policy key taxis property taxis important jurisdiction understand share inform company explain approach tax help inform point view potential future change tax law dialogue tax tax policy relevant provide pragmatic constructive supportive effort ensure company business input tax policy maker directly appropriately transparent tax affair industry trade body advocate reform support economic manage tax strategy set growth job creation need patient detail public policy section website key stakeholder support exchange countrybycountry reporting group corporate tax charge million cbcr datum tax authority validate million profit tax million exist information hold taxpayer support ability million represent effective tax rate ensure multinational group pay right tax cash tax payment right place million year million addition taxis pay profit pay duty levy transactional global healthcare company substantial business employment taxis employment presence country world pay significant tax include corporate adjust tax rate income tax business taxis tax associate rate benefit closure open issue tax employee collect significant tax authority jurisdiction follow separation behalf government supply chain include consumer business subject material change employee product mix material change tax regulation law country operate group average subject taxation supply chain effective adjust tax rate medium term expect worldwide nature operation mean crossborder supply route necessary ensure supply medicine numerous country result conflict claim tax group total tax rate authority profit tax individual country low adjust tax rate mainly enactment lead double taxation profit tax increase uk corporate income tax rate country result increase value balance sheet tax asset magnitude gsk report credit profit recognise territory reference activity adjust item obscure key performed value generate ensure trend group performance period profit recognise jurisdiction align activity undertake line current oecd guideline oecd eu continue develop new policy base transfer pricing policy arm length principle lead substantially increase tax compliance support transfer price economic analysis report burden case oecds project address tax challenge digitalisation fundamentally change engage artificial tax arrangement international corporate tax landscape tax business commercial substance seek avoid tax profile multinational company include gsk use tax haven transaction fully reallocate country tax right large disclose tax authority zerotolerance approach profitable multinational ii set new minimum global tax evasion facilitation tax evasion corporate tax rate project achieve political tax risk country operate manage consensus plan effective implementation robust internal policy process train compliance detailed rule discussion programme board director audit risk possible accurately forecast impact committee responsible approve tax policy gsk stage risk management arrangement wide internal detail corporate tax charge year control framework set note gsk annual report group financial review continue gsk annual report strategic report governance remuneration financial statement investor information financial performance group turnover bn total result group set bn aer growth cer growth growth turnover turnover cer turnover cost sale sell general administration research development royalty income operating expensesincome operating profit net finance cost total operating profit bn share aftertax profit associate bn aer growth cer growth joint venture loss disposal interest associates profit taxation taxation profit taxation year profit attributable shareholder earning share p p earning ad adjust operating profit bn adjust result group set reconciliation total result adjust result bn aer growth cer growth set growth turnover turnover cer turnover cost sale sell general administration research development gsk use number adjust nonifrs measure report royalty performance business adjust result income nonifrs measure consider addition adjust substitute superior information present operating accordance ifrs adjust result nonifrs profit measure define page adjust profit attributable shareholder adjust earning share p p group financial review continue financial performance continue pharmaceutical group turnover pharmaceutical turnover year million group turnover business aer cer sales xevudy monoclonal antibody treatment covid million contribute growth growth cer approximately percentage point pharmaceutical growth pharmaceutical hiv sale aer cer vaccine million growth dovato juluca partly offset tivicay consumer healthcare triumeq respiratory sale aer cer million growth trelegy nucala oncology corporate immunoinflammation therapy area continue unallocated turnover strong doubledigit sale growth sale establish pharmaceutical decrease aer cer million group turnover geographic region sale grow aer cer include sale growth growth cer xevudy contribute approximately percentage point total growth continue strong performance trelegy nucala europe benlysta dovato drive growth new specialty product region establish product stable international aer grow cer reflect strong demand establish respiratory product covid environment group turnover million year stable aer certain supply challenge face generic competitor cer sale covid solution contribute product plus benefit favourable prior period rar approximately percentage point growth year adjustment europe sale decrease aer cer decrease pharmaceutical establish pharmaceutical portfolio impact generic competition include seretide duodart volibris turnover bn low antibiotic demand divestment cephalosporin product start fourth quarter decrease bn aer growth cer growth partly offset strong growth trelegy benlysta oncology product dovato double year sale xevudy totalling million contribute group turnover approximately percentage point total growth international sale decrease aer grew cer decrease establish pharmaceutical reflect impact covid suppress antibiotic market increase generic competition half year offset strong growth respiratory dovato tivicay tender sale xevudy add approximately percentage point international total growth pharmaceutical turnover revise growth growth cer respiratory hiv immunoinflammation oncology pandemic new specialty establish pharmaceutical g sk review presentation pharmaceutical product january move sale arnuity ellipta incruse ellipta relvarbreo ellipta respiratory therapeutic area establish pharmaceutical therapeutic area comparative information revise consistent basis gsk annual report group financial review continue gsk annual report strategic report governance remuneration financial statement investor information financial performance continue respiratory immunoinflammation total respiratory sale aer cer immunoinflammation sale million grow aer sale trelegy nucala exceed billion year cer benlysta sales aer cer time international respiratory sale grow aer million benefit lupus nephritis launch cer include nucala aer cer japan h trelegy aer cer include impact trelegy asthma launch japan q europe oncology respiratory grow aer cer double digit cer sale zejula parp inhibitor treatment ovarian cancer growth trelegy nucala respiratory grow million aer cer impact aer cer drive continue strong performance ongoing low diagnosis rate covid pandemic trelegy nucala particularly sale include million sale nucala million year grow million europe aer cer consistent strong growth blenrep treatment patient relapse refractory region sales aer cer multiple myeloma approve launch million international sale million grow aer europe q ongoing launch europe cer europe sales million grow aer blenrep sale globally total million cer pandemic sale trelegy sale aer cer million drive growth region sale continue grow sale xevudy million year reflect strongly include benefit asthma indication approve ongoing fulfilment contract world launch q sale aer cer significantly report sale million europe sale grow aer cer international international record sale million europe trelegy asthma approve japan q million sale grow aer cer million establish pharmaceutical hiv sale establish pharmaceutical year hiv sale million decrease aer million aer cer growth cer year triumeq sale establish respiratory product decrease aer million aer cer tivicay sales cer million include impact generic million aer cer mature portfolio competition xyzal japan advairseretide globally result percentage point cer sale decrease decrease partially offset approximately new hiv product juluca dovato rukobia cabenuva percentage point impact growth favourable prior period deliver sale million represent total rar adjustment hiv portfolio sale drug regimen remainder establish pharmaceutical portfolio juluca dovato million million decrease aer cer million low respectively combine growth aer cer demand antibiotic covid pandemic period rukobia sale million cabenuva long act divestment gsk cephalosporin product start injectable record million sale year fourth quarter impact government mandate total sale million decrease change increase use generic market include france aer growth cer new hiv product deliver japan china sale million include dovato million growth aer cer juluca million growth aer cer rukobia million cabenuva million combine tivicay triumeq sale million decline aer cer europe total sale million decrease aer growth cer new hiv product deliver sale million include dovato sale million double aer cer juluca million growth aer cer combined tivicay triumeq sale million decline aer cer international continue grow strongly total sale million growth aer cer driven tivicay tender business new hiv productsgroup financial review continue financial performance continue influenza vaccine fluarixflulaval sale decrease aer cer million result unfavourable prior period rar movement turnover bn partially offset high volume strong bn aer growth cer growth southern hemisphere demand international shingle group turnover shingrix decrease aer cer million primarily drive low demand international routine adult vaccination covid vaccination programme deployment disease circulation europe sale growth drive germany launch uk spain italy shingrix sell country include market launch establish vaccine vaccine turnover hepatitis vaccine sale aer cer million adversely impact deprioritisation routine growth growth cer adult vaccination increase hepatitis b vaccine competition meningitis unfavourable cdc stockpile movement influenza covid relate travel restriction europe international shingles sale dtpacontaine vaccine infanrix pediarix establish vaccine boostrix decrease aer grew cer infanrix pediarix sale decrease aer cer million pandemic vaccine reflect low tender volume europe international change recommendation dose schedule germany partly offset increase demand boostrix vaccine turnover year decrease aer grow sale grow aer cer million largely drive cer million primarily drive pandemic demand recovery tender volume international adjuvant sale partially offset low demand routine adult high demand share vaccination covid vaccination programme deployment disease circulation region result rotarix sale aer cer lower shingrix hepatitis vaccine sale unfavourable million reflect demand recovery international prior period rar adjustment reduce overall vaccine growth synflorix sale decrease aer cer approximately percentage point particularly fluarix million primarily low tender demand emerge flulaval shingrix impact product growth market decrease decrease respectively mmrv vaccine sale stable aer grow cer vaccine turnover exclude pandemic vaccine decrease million largely drive high demand international aer cer million pandemic vaccine meningitis pandemic vaccine sale million include million meningitis sale decrease aer cer million pandemic adjuvant sale canadian drive primarily unrepeated international tender volume government meningitis vaccine bexsero sale stable aer grow cer million reflect increase market share menveo sales aer cer million primarily drive cohort catchup vaccination high demand increase market share gsk annual report group financial review continue gsk annual report strategic report governance remuneration financial statement investor information financial performance continue oral health consumer healthcare oral health sale decrease aer grow cer million sensodyne deliver high single digit growth turnover bn reflect underlie brand strength continue innovation aer growth cer growth strong growth key market include china india bn japan gum health deliver broad base high single digit growth key market denture care grow low single group turnover digit drive partly return growth q pain relief pain relief sale increase aer cer million panadol benefit seasonal demand quarter grow double digit voltaren grow midsingle digit offset expect shortterm decrease second half year introduction private label competition early excedrin deliver growth consumer healthcare turnover versus prior year decrease reflect supply improvement growth growth cer vitamin mineral supplement oral health pain relief vitamin mineral supplement sale stable aer vitamin mineral supplement grow cer million building significant cer growth centrum grow midteen percent respiratory health drive successful innovation improve supply capacity digestive health continue consumer focus health wellness caltrate grow midsingle digit emergenc decrease brand divestedunder review highsingle digit reflect particularly challenging comparator unprecedented demand early stage pandemic growth growth cer respiratory health respiratory health sale decrease aer cer europe million q cold flu sale rebound international strongly level europe slightly level year cold flu consumer healthcare turnover year million product midsingle digit h rebound decrease aer stable cer reflect dilution insufficient offset considerable decrease divestment give completion portfolio quarter result historically low demand rationalisation end q twoyear cagr cold flu product effectively halve global market sale exclude brand divest review grow overall period allergy product grow midsingle digit despite adverse impact covid pandemic digestive health sale exclude brand divestedunder review decrease aer increase cer reflect underlying strength digestive health brand sale decrease aer brand portfolio category continue grow cer million digestive health brand growth ecommerce overall sale benefit strong highsingle digit particularly strong growth growth category exclude respiratory health tum eno skin health smoker health brand negatively impact q historically low cold midsingle digit offset partly decrease small flu season decrease cold flu sale result nonstrategic brand approximately drag year growth international sale exclude brand divestedunder review grow high single digit cer basis double digit growth emerge market include india china middle east africa exclude brand divestedunder review sale grow low single digit european sale stable cer basis region particularly negatively impact historically low cold flu season q group financial review continue financial performance continue cost sale research development growth growth growth growth cer cer total cost sale total research development adjust cost sale adjust research development total cost sale percentage turnover total rd expenditure million turnover percentage point low aer percentage point aer cer including increase impairment low cer term compare primarily partly offset decrease major restructuring charge reflect low writedown number manufacture site adjust rd expenditure million unwind fair market value uplift turnover high aer high cer inventory arise completion consumer healthcare pharmaceutical rd expenditure million joint venture pfizer turnover stable aer cer primarily drive exclude adjust item adjust cost increase investment specialty portfolio include sale percentage turnover percentage early stage research project efficiency saving continue point high aer percentage point high cer implementation rd programme compare primarily reflect high pandemic pharmaceutical vaccine separation sale xevudy high supply chain cost vaccine preparation restructure programme result low demand high inventory adjustment growth specialty portfolio primarily high commodity freight cost consumer drive programme covid treatment xevudy healthcare partly offset price benefit pharmaceutical otilimab otilimab programme include benefit prior period rar adjustment rheumatoid arthritis bepirovirsen hbv antisense contribution restructure saving oligonucleotide depemokimab antiil asthma business favourable mix vaccine partly offset reduce spend daprodustat sell general administration completion programme oncology continued investment reflect commitment synthetic lethality growth growth cer blenrep bintrafusp alfa total selling general accelerate closeout cost programme administration largely offset reduction spend feladilimab adjusted sell general follow decision terminate programme april administration rd expenditure vaccine million total sga cost percentage turnover turnover aer cer reflect increase percentage point low aer percentage point investment clinical programme meningitis rsv low cer compare include increase investment mrna platform partly offset efficiency separation cost partly offset low restructuring charge saving implementation development exclude adjust item adjust sga cost programme variable spending result covid percentage turnover percentage point lockdown rd expenditure consumer healthcare low aer percentage point low million cer basis adjust sga cost decrease aer cer reflect tight control ongoing cost royalty income reduce variable spending business royalty income million million result covid lockdown continue benefit aer cer primarily drive high sale restructuring pharmaceutical consumer healthcare gardasil support function decrease reflect favourable legal settlement compare increase legal cost oneoff benefit pension insurance partly offset oneoff benefit restructure postretirement benefit partly offset increase investment launch hiv vaccines gsk annual report group financial review continue gsk annual report strategic report governance remuneration financial statement investor information financial performance continue operating incomeexpense contingent consideration cash payment net operating expense million shionogi company reduce balance sheet liability million income primarily reflect accounting charge record income statement million million arise total contingent consideration cash payment remeasurement contingent consideration liability amount million million include related acquisition shionogiviiv cash payment shionogi million healthcare joint venture novartis vaccine million business liability pfizer option pfizer shionogi preferential dividend viiv healthcare adjust operate profit business include remeasurement charge million pharmaceutical operating profit million million contingent consideration liability aer cer turnover increase cer shionogi result unwind discount operate margin percentage point high million charge million primarily aer percentage point high cer adjustment sale forecast settlement gilead basis primarily reflect price benefit pharmaceutical partly offset number asset include benefit prior period rar adjustment disposal include disposal royalty right reduce supply chain cost tight control ongoing cost cabozantinib disposal cephalosporin business short term benefit change way work favourable disposal number consumer healthcare brand fair legal settlement compare increase legal cost value uplift investment include net profit continue benefit restructuring partly disposal horlick consumer healthcare brand offset support launch hiv increase investment million partly offset related loss sale rd share hindustan unilever million vaccine operate profit million aer operating profit cer turnover increase cer operating margin percentage point low aer total operating profit million compare percentage point low cer basis million primarily reflect unfavourable primarily drive high supply chain cost result comparison net profit disposal q horlick high inventory adjustment low demand consumer brand resultant sale share high rd spend support key strategic priority hindustan unilever partly offset low major increase sga investment support business growth partly restructure cost low remeasurement charge offset high royalty income pandemic adjuvant contingent consideration liability unwind beneficial mix fair market value uplift inventory arise completion consumer healthcare joint venture pfizer consumer healthcare operate profit million aer cer stable turnover cer operate exclude adjust item adjust operate margin percentage point high aer profit million low aer percentage point high cer basis high cer turnover increase cer adjust primarily reflect sale growth continue brand price operate margin percentage point low increase favourable mix synergy delivery pfizer aer percentage point high cer basis joint venture integration tight cost control partially offset impact divestment percentage point increase increase adjust operating profit primarily reflect advertising promotion investment increase commodity benefit incremental pandemic sale xevudy adjuvant freight cost investment manufacturing site contribute approximately aer cer adjust operate profit growth adjust operating profit benefit sale growth pharmaceutical include benefit prior period rar adjustment tight control ongoing cost include reduce promotional variable spending business result covid lockdown favourable legal settlement compare increase legal cost benefit continue restructure business partly offset low sale vaccine primarily shingrix high supply chain cost vaccine consumer healthcare divestment consumer healthcare increase investment rd vaccine pharmaceuticalsgroup financial review continue financial performance continue net finance cost charge million represent effective tax rate total result reflect different finance income tax effect adjust item include credit interest income million result revaluation defer tax fair value movement asset follow enactment increase headline rate uk corporation tax effective april reflect disposal horlick consumer brand finance expense subsequent disposal share receive hindustan unilever interest expense tax adjust profit amount million unwind discount provision represent effective adjust tax rate remeasurement fair value movement finance expense lease liability issue relate taxation describe note taxation finance expense annual report group continue believe adequate provision liability likely arise total net finance cost million compare period open agree tax authority million adjust net finance cost ultimate liability matter vary amount million compare million provide dependent outcome agreement decrease primarily result reduce interest expense relevant tax authority lower debt level favourable movement foreign exchange rate premium pay early repayment noncontrolle interest refinance bond debt reduce interest tax allocation total earning noncontrolle interest partly offset low interest income overseas cash post amount million million increase closing divestment horlick consumer primarily increase allocation consumer healthcare nutrition product india number healthcare joint venture profit million country million increase allocation viiv healthcare profit million million include reduce share tax profit associate joint credit remeasurement contingent consideration liability venture allocation adjust earning noncontrolle interest share tax profit associate joint venture amount million million million million reduction allocation primarily reflect reduce allocation viiv healthcare profit million million loss disposal interest associate partly offset high net profit group net loss disposal interest associate entity noncontrolle interest allocation consumer million primarily drive loss disposal healthcare joint venture profit million interest associate innoviva inc million profit tax earning share take account net finance cost share profit total eps p compare p associate loss disposal interest associate profit primarily reflect unfavourable comparison net taxation million compare profit disposal q horlick consumer million brand partly offset related loss sale share hindustan unilever partly offset credit million taxation taxation result revaluation defer tax asset follow enactment increase headline rate uk corporation tax effective april low major restructuring cost low remeasurement charge uk current year charge contingent consideration liability rest world current year charge charge respect prior period adjust eps p compare p total current taxation aer cer cer increase total defer taxation adjust operating profit primarily reflect incremental taxation total profit pandemic sale sale increase pharmaceutical tight cost control favourable legal settlement low interest cost partly offset low sale vaccine primarily shingrix high supply chain cost vaccine increase rd investment high effective tax rate contribution growth covid solution approximately aer cer gsk annual report group financial review continue gsk annual report strategic report governance remuneration financial statement investor information financial performance continue dividend reflect factor new gsk expect sale board declare interim dividend result total grow cer adjust operate profit dividend year penny line dividend declare grow cer compare note financial statement dividend include future benefit royalty income settlement license agreement gilead sciences inc gilead dividend policy announce february june new gsk investor update gsk set june gsk announce expect new gsk progressive dividend policy implement deliver sale growth adjust operate profit growth dividend policy total expect cash distribution respectively cagr constant respective dividend payout ratio new gsk new exchange rate year period consumer healthcare remain unchanged base year financial outlook exclude contribution covid relate revenue new gsk gsk expect declare p share dividend payable expect improve adjust operate margin mid current group half comprise penny share cash generate new gsk penny share represent consumer operation expect exceed billion healthcare half whilst group new gsk aim deliver sale billion second half new gsk continue expect declare constant exchange rate p share dividend previously communicate new gsk expect declare dividend penny share medium term outlook provide consumer healthcare capital market day schedule february time formal criterion treat consumer healthcare follow separation dividend policy new consumer discontinue operation satisfy currently healthcare company responsibility board expect q gsk continue present director expected guide cent consumer healthcare business continue operation payout ratio basis expect secondhalf consolidate business reporting purpose dividend new consumer healthcare company equivalent demerger complete payout penny share subject board decision intrayear phase dividend payment base known bind agreement government expect distribution share second half year expect covid solution contribute similar sale adjust highlight gsk investor update level substantially reduce profit contribution june reflect total number share circa increase proportion low margin xevudy sale billion share new consumer healthcare company expect reduce new gsk adjust operate profit growth expect issue demerger june include covid solution year planning assumption investor update reflect continue discuss opportunity gsk share issue time circa billion share government aggregate represent year basis equivalent group dividend p share dividend payable consumer healthcare receivable shareholder remain invest consumer healthcare postseparation appropriate record date guidance outlook expect continue deliver strategic priority plan increase target investment rd build invest line momentum key growth driver deliver demerger consumer healthcare business midyear assume global economy healthcare system approach normality year progress expect sale specialty medicine grow approximately cer sale general medicine slight decrease primarily reflect increase genericisation establish respiratory product vaccine sale expect grow low teen percentage cer year government prioritisation covid vaccination programme ongoing measure contain pandemic expect result continue disruption adult immunisation impact weight half shingrix despite potential shortterm pandemic disruption continue expect strong doubledigit growth record annual sale base strong demand exist market geographical expansiongroup financial review continue adjust item divestment intangible intangible significant adjust result reconciliation total asset asset major transaction legal separation adjust result amortisation impairment restructure relate item cost result december turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost loss disposal interest associate share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share p p p p p p p p weight average number share million divestment intangible intangible significant adjust result reconciliation total asset asset major transaction legal separation adjust result amortisation impairment restructure relate item cost result december turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share p p p p p p p p weight average number share million gsk annual report group financial review continue gsk annual report strategic report governance remuneration financial statement investor information adjust item continue major restructure integration total cash payment million pharmaceutical sector highly regulate million million million relate manufacturing operation supply chain long life separation preparation restructure programme cycle business mean restructure programme million million relate consumer particularly involve rationalisation closure healthcare joint venture integration programme million manufacturing rd site likely year million major restructuring complete programme include settlement certain charge accrue previous quarter million million major restructuring cost relate specific exist combined restructure integration programme boardapprove major restructuring programme exclude adjusted result major restructure analysis major restructuring charge business programme include integration cost follow material follow acquisition structural significant scale cost individual relate project exceed million ordinary course smallerscale restructuring pharmaceutical cost retain total adjust result vaccine consumer healthcare total major restructuring charge incur million million analyse follow corporate central function total major restructuring charge non non cash cash total cash cash total analysis major restructuring charge income major statement line follow restructure programme incl tesaro cost sale consumer sell general administration healthcare joint venture integration research development programme operating incomeexpense separation total major restructuring charge preparation restructuring benefit year restructure programme programme billion benefit separation preparation combine restructure programme billion benefit restructure consumer healthcare joint venture integration billion integration benefit restructure programme programme billion major restructuring programme include tesaro cash charge million separation preparation cost billion end cash cost programme primarily arise restructure billion noncash cost billion administrative central manufacturing function deliver annual saving billion end commercial pharmaceutical rd function noncash rate saving fully reinveste charge million primarily reflect writedown asset help fund target increase rd commercial support administrative location rd site new product programme substantially complete cash charge million consumer healthcare gsk cease external reporting total cost joint venture programme primarily relate severance benefit major restructure programme integration cost noncash credit combine onwards restructure integration programme primarily reflect completion consumer healthcare joint venture write disposal site pfizer realise substantial cost synergy largely deliver expect total annual cost saving billion cash cost expect billion noncash charge expect billion plus additional capital expenditure billion cost saving intend reinveste business support innovation growth opportunitiesgroup financial review continue adjust item continue group initiate q twoyear separation million charge relate contingent preparation programme prepare separation gsk consideration shionogiviiv healthcare joint company new gsk biopharma company venture represent increase valuation rd approach focus science relate immune contingent consideration shionogi result system use genetic new technology new unwind discount million charge leader consumer healthcare programme aim million primarily adjustment sale forecast settlement gilead update exchange rate drive common approach rd improve capital assumption million charge relate viiv allocation healthcare option pfizer preferential dividend align improve capability efficiency global represent increase valuation option support function support new gsk result settlement gilead offset low cash optimise supply chain product portfolio update exchange rate assumption include divestment noncore asset viiv healthcare contingent consideration liability fair strategic review prescription dermatology underway value ifrs potential impact covid prepare consumer healthcare operate standalone pandemic remain uncertain december company assume significant impact longterm value liability position remain programme continue target delivery billion review liability update future annual saving billion total quarter information impact pandemic cost estimate billion billion expect available explanation accounting cash cost proceed divestment largely noncontrolle interest viiv healthcare set cover cash cost programme transactionrelated adjustment divestment significant legal charge item transactionrelated adjustment result net charge divestment item include gain number million million include net asset disposal include disposal royalty right million accounting charge remeasurement cabozantinib disposal cephalosporin business contingent consideration liability relate acquisition disposal number consumer healthcare brand fair value shionogiviiv healthcare joint venture gain investment certain adjust item novartis vaccine business liability pfizer include impact enactment increase option pfizer shionogi preferential dividend viiv headline rate uk corporate tax discuss healthcare consumer healthcare brand disposal programme chargecredit complete deliver net proceed billion contingent consideration shionogiviiv net loss disposal interest associate healthcare joint venture include shionogi million primarily drive loss disposal interest preferential dividend associate innoviva inc charge million viiv healthcare option pfizer preferential million record significant legal matter arise dividend period significant legal cash payment million contingent consideration novartis million include divestment significant vaccine business legal item defer tax credit million release fair value uplift acquire pfizer inventory arise transfer intellectual property group adjustment quarter defer tax credit arise total transactionrelated charge difference group value market value asset transfer separation cost q group start report additional cost prepare establishment consumer healthcare business independent entity separation cost total separation cost incur million million include million relate transaction cost include preparatory admission cost cost relate achieve list total separation cost estimate million exclude transaction cost gsk annual report group financial review continue gsk annual report strategic report governance remuneration financial statement investor information cash generation conversion summary consolidate cash flow statement set reconciliation net cash inflow operating activity free cash flow reconciliation net cash inflow operating activity close equivalent ifrs measure free cash flow net cash inflow operating activity show net cash inflowoutflow investing activity net cash outflow financing activity increase cash bank overdraft net cash inflow operating activity cash bank overdraft begin year purchase property plant equipment increase cash bank overdraft purchase intangible asset exchange adjustment proceed sale property plant equipment cash bank overdraft end year proceed disposal intangible asset interest pay cash bank overdraft end year comprise interest receive cash cash equivalent dividend associate joint venture overdraft contingent consideration pay report investing activity contribution noncontrolle interest capital expenditure financial investment distribution noncontrolle interest cash payment tangible intangible fix asset free cash flow amount million million disposal realise million million future cash flow cash payment acquire equity investment amount long term expect future cash generate million million primarily relate operation sufficient fund operating debt vir biotechnology sale equity investment realise servicing cost normal level capital expenditure obligation million million exist licensing agreement expenditure arise restructure programme routine outflow include free cash flow tax pension contribution dividend subject free cash flow cash generate group principal risk uncertainty discuss page meet obligation contingent consideration time time additional demand interest tax dividend pay noncontrolle interest finance acquisition include potentially acquire capital expenditure property plant equipment increase ownership interest viiv healthcare business intangible asset minority shareholder hold option access multiple source liquidity short longterm capital market financial institution need addition free cash inflow cash flow operation total cash payment shionogi relation viiv healthcare contingent consideration liability year investment appraisal capital allocation million million million strong framework capital allocation include recognise cash flow operating activity board govern allocation capital million recognise contingent consideration pay business utilise consistent cash return invest invest cash flow payment deductible capital croic methodology prioritise investment tax purpose group effectively compare return business allocate capital consider impact ep credit profile relevantgroup financial review continue financial position resource property plant equipment business sciencebase technologyintensive highly asset regulate governmental authority allocate significant noncurrent asset financial resource renewal maintenance property plant equipment property plant equipment minimise risk interruption right use asset production ensure compliance regulatory standard goodwill number process use hazardous material intangible asset total cost property plant equipment investment associate joint venture december million net book value investment million land building represent defer tax asset million plant equipment million asset derivative financial instrument construction million invest million noncurrent asset new property plant equipment mainly related total noncurrent asset large number project renewal improvement current asset expansion facility worldwide site support new inventory product development launch improve efficiency exist supply chain property mainly hold current tax recoverable freehold new investment finance liquid resource trade receivable december contractual commitment derivative financial instrument future capital expenditure million believe liquid investment property plant facility adequate current need cash cash equivalent asset hold sale observe stringent procedure use specialist skill total current asset manage environmental risk activity environmental total asset issue date operation modify discontinue report environment page liability note financial statement legal current liability proceeding shortterm borrowing contingent consideration liability right use asset trade payable right use asset amount million december derivative financial instrument compare million january current tax payable decrease year reflect impact depreciation shortterm provision disposal million million respectively partly total current liability offset addition million noncurrent liability goodwill longterm borrowing corporation tax payable goodwill decrease million december million defer tax liability pension postemployment benefit intangible asset provision derivative financial instrument intangible asset include cost intangible acquire party computer software net book value contingent consideration liability intangible asset december noncurrent liabilitie million million increase primarily total noncurrent liability reflect addition net disposal write off total liability million offset amortisation impairment loss net net asset reversal year million total equity gsk annual report group financial review continue gsk annual report strategic report governance remuneration financial statement investor information financial position resource continue investment associate joint venture provision hold investment associate joint venture carry deferred tax provision shortterm carry value december million noncurrent provision million december million group sell million provision yearend share innoviva inc innoviva follow include million million relate legal divestment group hold investment associate dispute million million relate joint venture list entity note major restructuring programme provision financial statement investment associate legal dispute indemnify disposal liability joint venture employee relate liability cost restructure programme extent balance sheet date legal investment constructive obligation exist reliably hold investment carry value estimate december million million high value investment hold december pension postemployment benefit curevac ag book value december account pension postemployment million million vir biotechnology arrangement accordance ias net deficit book value million million million million pension arrangement investment include equity stake company million million unfunded research collaboration provide postemployment liability note financial access biotechnology development potential interest statement pension postemployment benefit interest company arise business divestment noncurrent liability derivative financial instrument asset noncurrent liability amount million hold current derivative financial asset fair value december million million million noncurrent derivative financial asset hold fair value million contingent consideration liability million majority financial instrument relate contingent consideration amount million foreign exchange contract designate december million designate accounting hedge million million represent estimate present value amount payable shionogi relate inventory viiv healthcare million million inventory million decrease million represent estimate present value contingent consideration payable novartis relate vaccine acquisition trade receivables liability shionogi include million respect trade receivables million increase preferential dividend liability preferential dividend million pfizer december nil million explanation accounting non defer tax asset control interest viiv healthcare set defer tax asset amount million total contingent consideration payable posttax million december basis december million million expect pay year consideration derivative financial instrument liability payable expect pay number year hold current noncurrent derivative financial liability result total estimate liability discount fair value million million primarily present value posttax basis posttax discount rate relate foreign exchange contract designate designate accounting hedge impact settlement gilead contingent consideration liability ccl increase million trade payable posttax basis q obligation viiv healthcare pay future cash consideration shionogi december trade payable share upfront future sale performance million compare million biktarvy product contain bictegravir include december increase primarily reflect impact impact settlement december liability high customer return rebate accrual higher discount stand million accrual relate collaboration note posttax basis financial statement trade payable shionogiviiv healthcare contingent consideration liability discount novartis vaccine contingent consideration liability discount partly partly group financial review continue financial position resource continue maturity profile bond debt equivalent gbp bonds eur bond usd bond net debt cash liquid investment billion billion hold centrally december analysis cash gross debt effect hedge cash cash equivalent liquid investment follow borrowing repayable year borrowing repayable year net debt cash liquid investment gross debt fix december net debt billion compare float billion december comprise gross debt noninterest bear billion cash liquid divestment billion net debt net debt reduce billion free cash flow billion proceed investment include billion movement net debt proceed innoviva disposal billion net favourable exchange impact translation nonsterle denominate debt exchange financing item partly offset dividend pay shareholder billion net debt begin year additional investment billion decreaseincrease cash bank overdraft decreaseincrease liquid investment december gsk shortterm borrowing increase longterm loan include overdrafts lease liability repayable net repayment shortterm loan month billion billion repayable repayment lease liability subsequent year exchange movement december gsk cash liquid investment movement hold follow net debt end year bank balance deposit treasury treasury repo money market fund liquidity fund cash cash equivalent liquid investment government security gsk annual report group financial review continue gsk annual report strategic report governance remuneration financial statement investor information financial position resource continue interest rate benchmark reform total equity interest rate benchmark reform amendment ifrs ias december total equity increase ifrs ifrs ifrs phase phase ii million december million issue iasb september august summary movement equity set adopt uk endorsement board january phase amendment modify specific hedge accounting requirement allow hedge accounting continue affect total equity beginning year hedge period uncertainty hedge total comprehensive income year item hedge instrument affect current interest dividend shareholder rate benchmark amend result ongoing ordinary share issue interest rate benchmark reform phase ii provide change noncontrolle interest financial instrument measure amortise cost transaction noncontrolle interest measurement change basis determine sharebase incentive plan contractual cash flow require interest rate benchmark tax sharebase incentive plan reform reflect adjust effective interest contribution noncontrolle interest rate immediate gain loss recognise distribution noncontrolle interest group closely monitor market output total equity end year industry work group manage transition new benchmark interest rate include share purchase announcement libor regulator include december gsk hold million share financial conduct authority fca commodity treasury share million share cost future trading commission transition away million million libor include gbp libor usd libor deduct retain earning euribor sterle overnight index average rate ordinary share repurchase period january sonia secure overnight financing rate sofr february company expect euro shortterm rate str respectively ordinary share repurchase remainder december group directly expose interest rate benchmark reform hold interest rate treasury share transfer employee derivative float rate debt reference libor share ownership plan esop trust share hold group transition material derivative float rate trust satisfy future exercise option award debt new index instrument reference group share option award scheme libor mature december proportion share hold trust respect award rule scheme require gsk satisfy exercise market purchase issue new share share hold trust match option award grant december esop trust hold million million gsk share future exercise share option share award carry value million million deduct reserve market value share million million february million share transfer esop trust trust hold million share exercise share option share rewardsgroup financial review continue financial position resource continue contractual obligation commitment reach agreement trustee financial commitment summarise note uk pension scheme additional contribution financial statement commitment assist eliminate pension deficit identify december actuarial funding valuation table follow table set contractual obligation include commitment exclude normal ongoing commitment december fall annual funding requirement uk approximately payment million information pension obligation total yr yrs yrs yrs note financial statement pension postemployment benefit loan interest loan contingent liability lease obligation contingent liability set note financial future finance charge statement contingent liability intangible asset follow table set contingent liability comprise property plant equipment performance guarantee letter credit item arise investment normal course business expect purchase commitment expire pension total total yr yrs yrs yrs commitment respect loan future interest payable guarantee loan disclose take account effect contingent liability derivative total enter number research collaboration normal course business provide develop new compound pharmaceutical company indemnification guarantee respect business disposal term arrangement include upfront fee legal dispute subsequently arise equity investment loan commitment fund specify provision outflow resource consider level research addition agree probable reliable estimate likely payment future milestone achieve outcome dispute include note agreement relate compound early financial statement provision stage development potential obligation provide outcome tax legal dispute milestone payment continue number year outflow resource consider probable compound successfully development reliable estimate outflow december process generally close product marketing dispute provision approval great probability success amount possible reliable estimate show intangible asset represent maximum potential outflow fund require settle pay milestone achieve dispute possibility outflow decrease commitment result reduction remote outstanding loan commitment ultimate liability matter vary significantly amount provide dependent negotiation relevant tax authority outcome litigation proceeding relevant discuss principal risk uncertainty page note financial statement legal proceeding gsk annual report group financial review continue gsk annual report strategic report governance remuneration financial statement investor information treasury policy report sterling pay dividend sterling cash interest rate risk management flow role treasury monitor manage gsk objective minimise effective net interest cost group external internal funding requirement financial balance mix debt fix float interest rate risk support strategic objective gsk operate time policy interest rate risk management limit global basis primarily subsidiary company net float rate debt specific cap review manage capital ensure subsidiary able agree annually board operate go concern optimise return shareholder appropriate balance debt foreign exchange risk management equity treasury activity govern policy approve objective minimise exposure overseas operate annually board director recently subsidiarie transaction risk match local currency october treasury management group tmg income local currency cost possible foreign meeting chair chief financial officer take place currency transaction exposure arise external internal regular basis review treasury activity member trade flow selectively hedge gsk internal trading receive management information relate activity transaction match centrally manage intercompany payment term reduce foreign currency risk treasury operation possible manage cash surplus borrow objective gsk treasury activity minimise requirement subsidiary company centrally forward posttax net cost financial operation reduce volatility contract hedge future repayment originate order benefit earning cash flow gsk use variety currency financial instrument finance operation derivative order reduce foreign currency translation exposure financial instrument manage market risk seek denominate borrowing currency operation derivative principally comprise foreign exchange principal asset cash flow primarily forward contract swap swap denominate dollar euro sterling borrowing liquid asset currency require group purpose interest rate swap borrowing swap currency require manage exposure financial risk change interest borrowing denominate swap foreign rate currency match investment overseas group asset treat hedge relevant asset forward derivative exclusively hedge purpose relation contract major currency reduce exposure underlie business activity trading group investment overseas group asset tmg speculative instrument review ratio borrowing asset major currency regularly capital management gsk financial strategy implement group commodity risk management financial architecture support gsk strategic priority objective minimise income statement volatility arise regularly review board manage capital fluctuation commodity price practical cost structure group appropriate mix debt effective tmg authorise approve equity continue manage financial policy credit execution certain financial derivative hedge commodity profile particularly target shortterm credit rating price exposure p maintain single longterm rating consistent target counterparty risk management gsk longterm credit rating standard poor set global counterparty limit bank stable outlook moodys investor service moodys investment counterpartie base longterm credit rating stable outlook shortterm credit rating moodys standard poor usage limit p standard poor moodys respectively actively monitor breach limit report cfo immediately liquidity risk management addition relationship bank credit rating gsk policy borrow centrally order meet anticipate review regularly change rating occur funding requirement cash flow forecast funding change investment level authority limit requirement monitor tmg regular basis appropriate banking counterparty limit review strategy diversify liquidity source range facility annually maintain broad access financial market day sweep cash number global subsidiary central treasury account liquidity management purposesgroup financial review continue critical accounting policy group consolidated financial statement medicaid programme stateadministere prepared accordance international accounting standard programme provide assistance certain poor conformity requirement company act vulnerable patient medicaid drug rebate international financial reporting standard ifrs program establish reduce state federal issue international accounting standard board iasb expenditure prescription drug patient protection affordable care act law require estimate assumption participate provide rebate state accrual affect amount asset liability revenue expense medicaid rebate calculate base specific report financial statement actual amount term relevant regulation patient protection result differ estimate affordable care act critical accounting policy relate follow area cash discount offer customer encourage turnover prompt payment accrue time taxation note invoicing adjust subsequently reflect actual experience legal dispute note record accrual estimate sale return apply contingent liability note historical experience customer return amount pension postemployment benefit note invoice marketrelate information information judgement estimate stock level wholesaler anticipate price increase area give note financial statement critical competitor activity accounting judgement key source estimation reconciliation gross turnover net turnover uncertainty pharmaceutical business follow turnover margin margin margin respect turnover accounting policy large business pharmaceutical market gross turnover complex arrangement rebate discount marketdriven allowance follow briefly describe nature segment arrangement existence pharmaceuticals business government mandate arrangement certain indirect customer state programme customer able buy product cash discount wholesaler reduce price chargeback represent customer return difference invoice price wholesaler prior year adjustment indirect customer contractual discount price item accrual estimate chargeback calculate base total deduction term agreement historical experience net turnover product growth rate customer rebate offer key manage care marketdriven segment consist primarily manage care group purchasing organisation direct indirect medicare plan negotiate contract pricing customer arrangement require customer honour rebate chargeback mandate segment achieve certain performance target relate value consist primarily medicaid federal government product purchase formulary status predetermine market programme receive governmentmandate pricing share relative competitor accrual customer rebate chargeback rebate estimate base specific term agreement historical experience product growth rate gsk annual report group financial review continue gsk annual report strategic report governance remuneration financial statement investor information critical accounting policy continue decrease deduction government mandate involved significant legal proceeding state programme gross turnover net turnover respect possible meaningfully assess reconciliation primarily reflect low rebate chargeback outcome result probable outflow respiratory product advair particular quantify reliably estimate liability result ultimate resolution proceeding case year advair account appropriate disclosure case include pharmaceutical turnover approximately annual report provision total deduction rebate return position change time respiratory portfolio include establish assurance loss result outcome respiratory product account approximately legal proceeding exceed material total deduction year provision report group financial balance sheet accrual rebate discount allowance statement return pharmaceutical vaccine like pharmaceutical company face business manage combined basis december complex product liability antitrust patent litigation total accrual amount million investigation operation conduct million governmental regulatory agency year monthly process operate monitor inventory level general counsel group head group legal wholesaler abnormal movement process use function senior vice president head global gross sale volume prescription volume base party litigation group responsible litigation datum source information receive key wholesaler government investigation routinely brief chief executive aim maintain inventory consistent level officer chief financial officer board director year year base pattern consumption significant litigation pende group basis pharmaceutical vaccine inventory governmental investigation group level wholesaler distribution channel meeting appropriate detail status significant december estimate litigation government investigation review matter approximately week turnover calculation use number claim notify information party information accuracy totally potential claim notify assessment validity verify believe sufficiently reliable claim progress settle claim recent settlement purpose level potential reimbursement insurer meeting include assessment legal dispute sufficient information available able respect accounting policy legal dispute reliable estimate potential outcome dispute follow briefly describe process external counsel assist litigation determine level provision necessary matter investigation assist briefing accordance requirement ias provision board senior management follow discussion contingent liability contingent asset provide matter possible reliable estimate anticipate settlement cost outflow resource provision require consider probable reliable estimate level provision legal dispute review likely outcome dispute legal expense adjust appropriate matter discuss arise claim group note financial statement legal proceeding strategic report strategic report approve board director february iain mackay chief financial officer february corporate governance section board gsk leadership team chair governance statement board role responsibilitie board committee information board architecture board activity board progress board approach continuous engagement boardle purpose culture board performance board committee reports section statement director report ggsskk aannnnuuaall rreeppoorrtt gsk annual report strategic report governance remuneration financial statement investor information board board composition board diversity international experience composition gender executive male global nonexecutive female europe tenure nonexecutive ethnicity emap year ethnically diverse year white year year information sir jonathan symonds cbe skill experience nonexecutive chair jon extensive international financial life science governance experience jon serve independent nonexecutive director hsbc holdings plc april deputy age group chairman august retirement board february previously nationality british chairman hsbc bank plc chief financial officer novartis ag partner managing director goldman appoint september sachs chief financial officer astrazeneca plc partner kpmg governance experience include role nonexecutive director chair audit committees diageo plc qinetiq group plc n nonexecutive chair proteus digital health inc jon fellow institute charter accountant england wale external appointment nonexecutive director rubius therapeutics inc nonexecutive director genomics england limited previously serve chairman member european round table industry senior advisor chatham house dame emma walmsley skill experience chief executive officer prior appointment gsk ceo emma ceo gsk consumer healthcare joint venture gsk novartis creation march emma join gsk loreal age work year variety role paris london new york shanghai emma previously nationality british nonexecutive director diageo plc appoint january emma hold classic modern language oxford university chief executive officer external appointment april independent director microsoft inc iain mackay skill experience chief financial officer prior join gsk iain group finance director hsbc holdings plc position hold year charter accountant iain live work asia europe hsbc general age electric schlumberger dowell price waterhouse iain previously trustee british heart nationality british foundation chair audit risk committee appoint january iain hold business study account hold honorary doctorate aberdeen university chief financial officer scotland april iain member institute chartered accountant scotland external appointment member court university aberdeen chair remuneration committee member group chair stakeholder communication reporting committee dr hal barron skill experience chief scientific officer prior join gsk hal president rd calico llc california life company alphabetfunde company use advanced technology increase understand lifespan biology prior hal president rd executive vice president head global product development chief medical officer roche responsible age product combine portfolio roche genentech genentech senior vice nationality american president development chief medical officer hal nonexecutive director chair science appoint january technology committee juno therapeutics inc march acquire celgene chief scientific officer corporation hal previously serve nonexecutive board director grail inc advisory board president rd april member verily life sciences llc announce january tony wood succeed hal cso head rd effect august date hal transition nonindependent nonexecutive director additional responsibility support rd external appointment nonexecutive director altos labs inc associate adjunct professor epidemiology biostatistics university california san francisco key committee chair n nomination corporate governance audit risk r remuneration science c corporate responsibilitythe board continue charles bancroft skill experience independent nonexecutive charlie wealth financial management experience global biopharma director charlie retire successful career bristol myers squibb bms march hold number leadership role commercial strategy finance begin career bms hold position age increase responsibility finance organisation commercial operational responsibility latin nationality american america middle east africa canada japan pacific rim country appoint chief appoint financial officer chief financial officer executive vice president global business operation executive vice president head integration strategy business development n charlie successfully steer bms period strategic transformation include recent billion acquisition celgene charlie serve member board colgatepalmolive company march external appointment board member kodiaksciences inc board member biovector inc advisory board member drexel university lebow college business board determine charlie recent relevant financial experience agree appropriate qualification background audit committee financial expert manvinder singh vindi banga skill experience senior independent nonexecutive vindi year commercial experience track record deliver outstanding performance highly competitive global consumerfocuse business director prior join gsk vindi spend year unilever plc role senior position age president global foods home personal care business member unilever nationality british executive board vindi sit prime minister indias council trade industry appoint september board governor indian institute management iim ahmedabad vindi senior independent nonexecutive recipient padma bhushan india high civilian honour vindi nonexecutive director director confederation british industry cbi thomson reuters corp chairman supervisory board mauser group chairman kalle gmbh director high ridge brands llc member indo uk ceo n r forum senior independent director mark spencer group plc external appointments partner clayton dubilier rice nonexecutive director economist newspaper limited member holdingham international advisory board board member international chamber commerce united kingdom member governing board indian school business hyderabad member global leadership council sad business school oxford chair board trustees marie curie chairman uk government investment dr anne beal skill experience independent nonexecutive anne bring extensive healthcare experience board physician entrepreneur combine passion patient advocacy recognise health policy expert development global national director programme improve healthcare access patient group ensure voice patient age reflect research programme nationality american prior current role anne spend year harvard medical school massachusetts general hospital appoint instructor paediatric hold leadership role commonwealth fund aetna foundation anne previously deputy executive director chief engagement officer c patientcentere outcomes research institute chief patient officer global head patient solution sanofi external appointment founder ceo absolutejoi skincare board member academyhealth board member prolacta bioscience dame vivienne cox skill experience independent nonexecutive vivienne wide experience business gain energy natural resource publishing sector deep understand regulatory organisation government director workforce vivienne work bp plc year britain continental europe post include executive vice engagement director president chief executive bps gas power renewable business alternative energy unit age vivienne previously nonexecutive director bg group plc rio tinto plc senior independent nationality british director pearson plc chairman supervisory board vallourec lead independent director appoint july uk governments department international development vivienne dame commander order british empire dbe uk new year honour list service sustainability diversity inclusion business r c external appointment chair designate victrex plc nonexecutive director stena ab advisory board member african leadership institute vice president energy institute advisory board member montrose associate investment advisor qantx ventures chair rosalind franklin institute vice chair sad business school oxford member global leadership council patron hospice st francis key committee chair n nomination corporate governance audit risk r remuneration science c corporate responsibility gsk annual report gsk annual report strategic report governance remuneration financial statement investor information board continue dr harry hal c dietz skill experience independent nonexecutive hal bring extensive experience field human genetic central gsk approach rd president american society human genetic recognise world lead director scientific authority genetic disorder know marfan syndrome bring experience development novel medical expert therapie role founder scientific adviser blade therapeutic biopharmaceutical age company focus diseasemodifye treatment fibrotic neurodegenerative disease total hal author original publication peerreviewe journal career nationality american appoint january physician scientist dedicate entire career care study individual heritable connective tissue disorder primary perturbation extracellular matrix homeostasis function lab identify gene condition use model system elucidate disease mechanism hal receive multiple prestigious award include curt stern award american society human genetics colonel harland sanders lifetime achievement award medical genetics taubman prize excellence translational medical science harrington prize american society clinical investigation harrington discovery institute pasarow award cardiovascular research inbevbaillet latour health prize country belgium research achievement award american heart association inductee american society clinical investigation american association advancement science association american physicians national academy medicine national academy sciences external appointment victor mckusick professor paediatric medicine molecular biology genetics department genetic medicine johns hopkins university school medicine investigator howard hughes medical institute founder scientific advisor blade therapeutic consultant chair scientific advisory board aytu biopharma independent chair gsk human genetic scientific advisory board lynn elsenhans skill experience independent nonexecutive lynn wealth experience run global business significant knowledge global market gsk operate director lynn serve chair president chief executive officer sunoco inc prior join age sunoco president chief executive officer lynn work royal dutch shell join nationality american hold number senior role include executive vice president global appoint july manufacturing lynn previously nonexecutive director tee great houston flowserve corporation texas medical center trustee unite way great c n houston external appointment nonexecutive director chair governance corporate responsibility committee baker hughe company board director chair audit committee saudi aramco advisory board member johns hopkins university whiting school engineering member audit committee leadership network dr laurie glimcher skill experience independent nonexecutive laurie bring scientific public health expertise board deliberation wealth global publicly list pharmaceutical business experience director scientific medical expert addition number senior leadership position hold harvard medical school harvard school public health laurie serve stephen suzanne weiss dean professor medicine age weill cornell medical college attend physician new york presbyterian hospitalweill nationality american cornell medical center laurie step board bristolmyer squibb bms appoint september serve year board laurie previously nonexecutive director water corporation cofounder chair scientific advisory board quentis therapeutics inc external appointment professor medicine harvard medical school ceo president attend physician danafarber cancer institute member national academy sciences national academy medicine member scientific steering committee parker institute cancer immunotherapy independent director analog devices inc director member executive committee breakthrough cancer member scientific advisory board repare therapeutics inc abpro therapeutic kaleido biosciences inc biocentury inc stand cancer judy lewent joined board april retired board key committee chair n nomination corporate governance audit risk r remuneration science c corporate responsibilitythe board continue dr jesse goodman skill experience independent nonexecutive jesse bring scientific public health expertise board deliberation wealth experience span science medicine vaccine regulation public health prove record addressing press director scientific public health need academic federal sector medical expert jesse previously serve senior leadership position food drug administration fda include age recently fda chief scientist previously deputy commissioner science public health nationality american director center biologics evaluation research cber appoint january jesse play leadership role develop fda regulatory science medical countermeasure initiative work collaboratively industry academia government global public health regulatory c partner prepare respond major public health threat include emerge infectious disease disaster terrorism lead fdas response west nile virus hn influenza pandemic serve senior leadership team white house medical countermeasure review jesse previously member scientific advisory committee regulatory legal working group coalition epidemic preparedness innovation cepi external appointment professor medicine attend physician infectious disease georgetown university direct georgetown university center medical product access safety stewardship compass board member president united states pharmacopeia usp board member scientific counselor infectious disease center disease control prevention cdc board member intellia therapeutics inc member national academy medicine board member adaptive phage therapeutics inc urs rohner skill experience independent nonexecutive urs broad business bank legal background extensive senior level experience multinational company director urs serve chairman number board recently credit suisse group age april prior join credit suisse urs serve chairman executive board ceo nationality swiss prosieben prosiebensat media ag follow number year private practice major law appoint january firm switzerland admit bar canton zurich switzerland state new york r n external appointment member international advisory board investcorp chair vega cyber associates ag key committee chair n nomination corporate governance audit risk r remuneration science c corporate responsibility gsk annual report gsk annual report strategic report governance remuneration financial statement investor information gsk leadership team skill experience dr hal barron hal join gsk gsk leadership team glt board biography page chief scientific officer president rd roger connor roger join glt appoint president gsk vaccine addition president vaccine global health leadership vaccine business lead gsk global health organisation responsible gsk global procurement organisation roger member board gavi vaccine alliance chair international federation pharmaceutical manufacturer association ifpma ceo vaccines committee previously president global manufacturing supply vice president office ceo corporate strategy roger join gsk astrazeneca roger hold degree mechanical manufacturing engineering queen university belfast masters manufacturing leadership cambridge university chartered accountant diana conrad diana appoint chief people officer member glt april chief people officer previously senior vice president hr pharmaceuticals rd play key strategic role leader rd people culture agenda support transformation diana join gsk canadas hr team hold role increase responsibility senior vice president hr consumer healthcare prior join gsk hold hr role company include ge capital gennum corporation zenon environmental laboratories diana honour bachelor art mcmaster university canada james ford james join glt appoint senior vice president group general svp group general counsel counsel legal compliance join gsk serve general counsel consumer healthcare general counsel global pharmaceutical vice president corporate legal compliance legal act head global ethic compliance prior gsk james solicitor clifford chance dla hold law degree university east anglia diploma competition law king college qualified solicitor england wales attorney new york state bar james base london practise law live singapore hong kong james cochair usbase civil justice reform group director european general counsel association sally jackson sally join glt march senior vice president global communications ceo svp global communication office lead communication government affair function globally ceo chief staff prior sally senior vice president office ceo cfo ceo office previously serve head investor relation join gsk sally hold degree natural science university cambridge iain mackay iain join gsk glt board biography page chief financial officer brian mcnamara brian ceo gsk consumer healthcare ceo designate new consumer healthcare ceo gsk consumer healthcare company haleon join gsk head europe america consumer healthcare lead successful joint venture gsk novartis recently pfizer previously head novartis otc division brian begin career pg brian board member consumer good forum chairman board member global selfcare federation gscf earn undergraduate degree electrical engineering union college new york mba finance university cincinnati n august hal barron transition current role nonexecutive director tony wood join glt chief scientific officergsk leadership team continue skill experience luke miel luke join gsk glt chief commercial officer responsible chief commercial officer commercial portfolio medicine vaccine luke cochair portfolio investment board hal previously work astrazeneca executive vice president european business prior executive vice president global product portfolio strategy global medical affair corporate affair head asia roche base shanghai singapore prior hold role increase seniority roche sanofiaventis europe asia luke hold bachelor science degree biology flinder university adelaide mba macquarie university sydney shobie ramakrishnan shobie join glt appoint chief digital technology officer chief digital technology officer join gsk deep broad experience biotech hitech company recently lead digital technology gsk global commercial organisation transform company capability digital data analytic play pivotal role establish agile commercial operating model join gsk shobie hold senior technology leadership role organisation include astrazeneca salesforce genentech roche board member remediant advisory board pistoia alliance shobie hold bachelor degree electronic engineering vellore institute technology university madras india david redfern david join glt chief strategy officer responsible corporate development chief strategy officer strategic planning previously senior vice president northern europe responsibility gsk pharmaceutical business region senior vice president central eastern europe join gsk david appoint chairman board viiv healthcare limited nonexecutive director aspen pharmacare holdings limited board bachelor science degree bristol university chartered accountant regis simard regis join glt president pharmaceutical supply chain president pharmaceutical responsible manufacturing supply gsk pharmaceutical product lead quality environment health safety sustainability corporate level regis join supply chain gsk site director france rise senior vice president global pharmaceutical manufacture current role previously hold senior position sony konica minolta tyco healthcare member board viiv healthcare mechanical engineer hold mba phil thomson phil join glt appoint president global affairs president global affair responsibility group strategic approach stakeholder engagement reputation policy development previously phil senior vice president communication government affairs phil chair whitehall industry group board member chinabritain business council earn degree english history russian study durham university emma walmsley emma join gsk glt board biography page chief executive officer deborah waterhouse deborah appoint glt january chief executive officer viiv ceo viiv healthcare healthcare april deborah join gsk prior viiv senior vice president primary care gsk business strong track record performance specialty primary care deborah lead hiv business uk head hiv centre excellence pharma europe hold role general manager australia new zealand senior vice president central eastern europe deborah nonexecutive director schroders plc hold degree economic history english literature liverpool university nick hirons member glt senior vice president global ethic compliance july karenann terrell member glt chief digital technology officer december gsk annual report gsk annual report strategic report governance remuneration financial statement investor information chair governance statement board priority governance delivery october vindi banga sid attend meeting year significant change member investor forum share progress gsk highly dynamic operating environment prepare creation new gsk pure biopharma progress formation independent company separation ch business include company middle support discussion plan timing create board separation consumer healthcare ch creation new continue oversight biopharma ch business gsk stage oversight work december annual governance meeting board ensure clarity board colleague please share specific management gsk strategy execution investor prioritie focus oversight key priority focus articulate ambition progress presentation slide transform gsk complete biopharma meetings available website information business investor update iu june urs rohner chair remuneration committee ch business end february ambition consult extensively new compensation proposal provide foundation enhance performance biopharma business statement seek summarise management highly transparent way track progress governance work undertaken board committees final stage ensure company exceptionally busy year compensation system reinforce performance culture board maintain continue build esg seek embed reward delivery leadership benefit company shareholder iu ambition compensation system stakeholder ch determine new board current board accountability priority focus work focus create good platform ch business demerge grow sustainably ahead start year follow annual evaluation board category year come mechanism reconfirm priority separation ch valuebased process time remain objective act good interest company board regard good longterm interest shareholder shareholder sustained value creation heart agenda important board operate align board agenda strategy performance high standard corporate governance support pipeline priority oversee delivery gsk transformation separation ch board continue focus work ensure management performance succession key priority take important decision necessary assess delivery progress hold accountable use iu target provide foundation enhance shareholder key stakeholder performance management board significantly step ensure separation ch valuebased process engagement shareholder hold meeting range investor nearly explicit board priority mean company share register prime importance able maximise time focus meeting board clear understanding view strengthen fundamental gsk company performance strategy board support value creation concentrated oversight effectiveness oversight transformation separation commercial execution cost base capital allocation pipeline process share shareholder perspective board culture ensure delivery transformation gsk continue improve alignment clarity help underpin increase agility way board operate board combination chair committee meet time seek improve ability respond quickly adapt event occur whilst continue deliver plan chair committee comprise sid committee chair authorise necessary engage decision urgent matter arise schedule board meeting agile important improve sustain competitiveness despite challenge environment continue compete deliver patient shareholderschair governance statement continue set strategy board challenge propose complete work board wellpositione new ambition target biopharma business consider unsolicited conditional nonbinding proposal agreed publish iu new growth receive acquire ch business exercise fiduciary outlook ambition seek clear step change duty proposal consider reject board performance expect new gsk board good interest shareholder oversee hold management account delivery fundamentally undervalue business public ambition future prospect board confident haleon deliver sustain organic annual sale growth range board adopt process maximising value cer medium term gsk shareholder consider creation ch independent list company haleon focus carefully consider good present worldleading ensure business wellpositione grow sustainably ch business management team shareholder ahead category year come highly analyst prospective investor ch capital market skilled management team lead day february management continue good progress target separate ch business middle year create publicly list worldleading consumer health company board attention direct oversee smooth execution demerger current board accountability board transformation separation priority focus mandate separate unlock maximise longterm shareholder value remain objective act well devolve committee architecture december interest company shareholder nomination corporate governance commitment drive sustained value mandate gsk board design transition haleon board creation management team formation board agenda align strategy performance pipeline prioritie science management performance mandate pipeline progress board strategic collaboration key succession assess delivery priority science innovation investor update target provide foundation enhance performance corporate responsibility management mandate gsk trust priority responsible sustainable business separation consumer healthcare create haleon valuebased process audit risk continuous engagement mandate financial reporting risk control plus public shareholder document deliver separation remuneration mandate alignment gsk remuneration investor update target haleon remuneration policy separation impact gsk annual report gsk annual report strategic report governance remuneration financial statement investor information chair governance statement continued board committee mandate committee recommend appointment sir dave board committee pivotal lewis haleon chair designate december support board activity set extensive search process follow appointment later report like highlight key brian mcnamara haleon ceo designate july sir dave contribution discharge mandate allocate responsible building haleon board mr year mcnamara please introduce management team investor ch capital markets day february transformation separation committee deal fundamental separation technical requirement science committee continue focus pipeline good release maximise longterm shareholder progress strategic collaboration key priority value consider good separate ch science innovation business principal value achieve corporate responsibility committee focus oversight option capital structure require company key aspect trust priority main area focus competitive distribute share haleon safety culture inclusion diversity charitable shareholder exchange haleon list give community involvement esg performance comprehensive programme work new gsk development esg framework support independent adviser process independent ch company haleon execution phase give remain work remuneration committee revisit remuneration plan clear oversight devolve relevant policy focus reinforce fundamental change committee appropriate fulfil mandate performance culture support delivery iu committee decommission ambition esg priorities biopharma company audit risk committee particular consider committee chair consult extensively financial implication separation include shareholder policy subject bind progressive dividend policy adopt vote year agm preparation demerger document shareholder detail board committee work consider approve separation ch business set follow page oversee establishment chs financial control look forward connect annual general meeting year update time nomination corporate governance committee transformation gsk progress ch demerger oversee key board appointment transition thank continued support company pure biopharma business include succession plan especially cso subsequent appointment dr tony wood cso designate sir jonathan symonds appointment dr anne beal dr hal dietz board chair independent nonexecutive director february board ask committee opportunity reevaluate determine optimal biopharma board composition include skill diversity capability experience separation middle year expect member current gsk board join haleon board ensure new haleon board continuity history knowledge experience board haleon board establish early yearsboard role responsibilitie leadership independent oversight rigorous challenge chair nonexecutive director jonathan symond provide strong independent element board lead manage business board constructively support challenge management provide direction focus scrutinise performance meeting agree ensure clear structure effective operation deliverable board committee shape proposal strategy offer specialist advice maintain dialogue shareholder management governance company letter appointment set term set board agenda ensure sufficient time condition directorship allocate promote effective debate support sound devote time necessary proper decision make performance duty ensure board receive accurate timely clear expect attend meeting require information independence statement meet continuously nonexecutive director discuss individual contribution performance board consider nonexecutive director train development need identify page independent share peer feedback provide assess provision financial board evaluation process report council frc uk corporate governance meet regularly nonexecutive director code code review continue independence independently executive director commitment lynn elsenhans serve board year describe chair role description available gskcom independence commitment vindi banga dame vivienne cox dr jesse goodman urs chief executive officer rohner serve board emma walmsley year course subject responsible management group rigorous review business ne role description available gskcom develop group strategic direction consideration approval board senior independent director implement agree strategy vindi banga support member glt act sound board chair trust maintain continual active dialogue intermediary director shareholder respect company performance nonexecutive director lead chief executive officer role description available gskcom annual review chair performance take account view executive director discuss result chair effectiveness review chair lead search appointment process make recommendation board new chair act additional point contact shareholder maintain understand issue concern major shareholder briefing company secretary investor relation senior independent nonexecutive director role description available gskcom company secretary secretary board board committees victoria whyte supports board committee chair annual agenda planning ensure information available board member timely fashion support chair designing deliver board induction coordinate continue business awareness training requirement nonexecutive director undertake internal board committee evaluation request chair advise director board practice procedure corporate governance matter chair group disclosure committee operate boardapprove appointment policy reflect board external appointment requirement current code point contact shareholder corporate governance matter gsk annual report gsk annual report strategic report governance remuneration financial statement investor information board committee information board establish follow committees board committee board committee role membership comprise report science support board understand key strategic dr jesse goodman chair theme company rd strategy base dr hal dietz january external transaction perform indepth dr laurie glimcher review underlie scientific assumption charles bancroft board technical assurance undertake indepth february risk oversight rdrelate risk judy lewent corporate responsibility consider gsk trust priority oversight progress lynn elsenhans chair associate trust commitment reflect dr anne beal important issue responsible sustainable dame vivienne cox business growth oversight view interest dr jesse goodman internal external stakeholder review issue potential impact gsk business reputation transformation advise assist board transformation sir jonathan symonds chair separation separation company oversee associate risk charles bancroft devolve committee separate group biopharma consumer vindi banga architecture disband healthcare company dame vivienne cox december lynn elsenhans urs rohner judy lewent nomination review structure size composition board sir jonathan symonds chair corporate governance appointment member board committee charles bancroft appointment corporate officer make vindi banga recommendation board appropriate plan lynn elsenhans assess orderly succession executive nonexecutive urs rohner director review management succession plan judy lewent ensure adequacy responsible reporting board oversee monitor corporate governance arrangement make recommendation board ensure company standard arrangement consistent exist corporate governance standard emerge good practice review company conflict interest audit risk review financial reporting process integrity charle bancroft chair march company financial statement external internal audit vindi banga process system internal control identification dr anne beal july management risk company process lynn elsenhans monitor compliance law regulation ethical dr laurie glimcher code practice judy lewent chair march initiate audit tender selection appointment member external auditor set remuneration exercise oversight work remuneration set company remuneration policy regard urs rohner chair gsk workforce remuneration gsk able recruit vindi banga retain motivate executive dame vivienne cox remuneration policy regularly review ensure consistent company scale scope operation support business strategy growth plan align wide workforce help drive creation shareholder value chair ceo responsible evaluating make recommendation board remuneration nonexecutive directors board committee write term reference approve board review annually ensure comply late legal regulatory requirement reflect good practice development current term reference board committee available gskcom number committee meeting hold committee member attendance describe detail committee member skill experience include biography board page accordance frc code board determine charles bancroft recent relevant financial experience agree appropriate qualification background audit committee financial expert define sarbanesoxley act determine independent mean security exchange act amendedboard architecture corporate governance framework design improve effectiveness board support gsk leadership team glt continue evolve support delivery strategy priority alignment board architecture board agenda support demerger illustrate gsk internal control risk management arrangement describe page integral corporate governance framework board chief science committee corporate responsibility audit risk committee executive committee officer r ead read read gsk nomination corporate remuneration committee transformation leadership governance committee separation committee team r ead read read role membership board committee attendance schedule board committee meeting nomination corporate corporate transformation board governance audit risk remuneration science responsibility separation total number schedule meeting member attend attend attend attend attend attend attend sir jonathan symonds emma walmsley iain mackay dr hal barron charle bancroft vindi banga dr anne beal dame vivienne cox lynn elsenhans dr laurie glimcher dr jesse goodman urs rohner judy lewent number adhoc meeting charles bancroft dr anne beal judy lewent number bracket denote number meeting individual eligible attend dr beal joined board corporate responsibility committee audit risk committee july charles bancroft join science nomination corporate governance committee judy lewent retired board follow agm addition adhoc meeting include table chair committee establish end meet occasion consider item business transformation separation committee devolve committee architecture disband december board please report compliance provision frc code exception code provision require alignment pension rate executive director available local workforce january current executive director role pension rate align wide workforce local replicate pension arrangement new executive director appoint gsk transition set annual report addition provision require base salary pensionable pension arrangement employee allow basic salary bonus pensionable follow dr barron transition nonexecutive director effect august requirement meet board please report consistently apply principle frc code set page remuneration report copy code available frc website wwwfrcorguk gsk annual report gsk annual report strategic report governance remuneration financial statement investor information board activity board discharge responsibility annual programme meeting paper presentation give board committee focus oversight strengthen fundamental element business growthbase performance ambition transformation separation gsk create worldleading company esg leadership priority pursuit company strategy information help board facilitate effective decision make input aid board oversight awareness business performance routine good governance practice operate company detail selection principal decision take board committee interest relevant stakeholder take account arrive decision set page item business consider critical gsk longterm success achievement key priority highlight area focus board oversight fundamental commercial execution cost base capital allocation pipeline culture include strengthen gsk receive regular progress update provide input company vaccine mrna strategy plan fundamental receive discuss commercial strategy performance report pharmaceutical vaccine viiv healthcare business review approve objective ambition company patient announce investor update june approve gsk progressive new dividend policy approve board priority approve business development transaction strategic partnership party include vir biotechnology curevac iteo alector receive update rd strategy progress company pipeline receive quarterly report ceo cfo cso scrutinise group financial performance set company new purpose simplify culture oversight project collaboration party develop vaccine treatment covid review risk impact covid group business performance approve term global settlement licensing agreement gilead separation board preparation demerger valuebased process include consumer regularly discuss scrutinise transformation plan consumer healthcare business healthcare receive discuss commercial strategy performance report consumer healthcare business discuss plan consumer healthcare separation haleon annual board glt strategy day approve appointment haleon chair ceo designate plan haleon board composition reviewing reject unsolicited proposal consumer healthcare business new gsk board oversight creation gsk pure biopharma business deliver step change performance include regularly discuss scrutinise transformation plan new gsk discuss plan company separation new gsk pure biopharma company annual board glt strategy day review approve objective ambition company patient announce investor update receiving update rd strategy progress company pipeline succession plan new gsk board include approval appointment new nonexecutive director corporate responsibility committee chair successor new nonexecutive director designate scientific medical expert maintain board oversight trust esg agenda include esg leadership approve trust section annual report approve task force climaterelate financial disclosure annual report delegate specific responsibility corporate responsibility committee oversight human right company operation regular board focus routine programme good governance activity include governance review quarterly financial result dividend proposal earning guidance investor material result announcement oversight receive report external auditor approve annual report form f set annual budget plan forwardlooke threeyear forecast conduct annual review board enterprise risk responsibility framework enterprisewide risk consider observation agree action board external evaluation review continue evolve board governance architecture evaluate ceo performance set objective review annual talent succession plan receive report board committee workforce engagement director discuss employee pulse survey result receive report corporate governance regulatory development company secretary report approve company modern slavery statement gender pay gap positioning review stakeholder perception researchboard progress board committee highly focused key priority ensure gsk fundamental continue enhance board member decision make significant matter include consideration interest gsk key stakeholder decision potentially affect paper consider board committee seek highlight relevant stakeholder impact perspective matter positive negative select example principal decision take board board consider relevant stakeholder perspective describe stakeholder group progress area principal decision boardcommittee regard stakeholder interest section duty consider commercial china committee review gsk china implementation stakeholder execution audit risk committee healthcare professional hcp speaker hcp medical expert recommend incremental change engagement sale force incentive sfi policy employee investor commercial model china change date note tangible improvement government regulator board approval observe people customer engagement patient consumer detail available context committee consider duty incremental change hcp engagement sfi longterm result workforce programme china include plan business relationship increase number citylevel healthcare reputation organisation hcos increase reach improvement hcp coverage country enable innovative specialty care product ultimately reach patient continue safeguard key stakeholder interest include patient committee review risk assessment training approach propose implementation control new potential hco recommend change cost base transformation programme board agree acceleration stakeholder board conclude oversight programme generate additional saving investor patient saving invest rd pipeline potential benefit employee transformation programme patient deliver shareholder return duty achieve cost base competitive longterm business peer performance workforce business relationship capital allocation dividend policy change board support audit risk stakeholder committee carefully consider matter investor patient board review approve conclude progressive dividend policy people implementation new progressive dividend policy consideration duty director dutie implementation examine importance predictable return longterm result workforce particularly uncertain time business relationship detail available deliberation board carefully balanced reputation fairness impact tradeoff reduce shareholder dividend importance set new gsk right capital structure resource invest grow improve shareholder return long term ultimately board determine set progressive dividend policy way support investment need deliver growth unlock shareholder value develop strong pipeline innovative product capable transforming live patient pipeline business development science committee board review stakeholder collaboration business development opportunity year patient employee deal lead conclude transaction include investor science committee consider collaboration iteo therapeutic enable duty scientific merit generation immuneoncology combination longterm result workforce opportunity prior board expansion collaboration vir business relationships review approval biotechnology advance new therapeutic detail available influenza respiratory virus collaboration alector codevelop anti body neurodegenerative disease deal consider context potential help gsk deliver transformational medicine patient gsk annual report gsk annual report strategic report governance remuneration financial statement investor information board progress continue stakeholder group section progress area principal decision boardcommittee regard stakeholder interest duty consider new growth investor update board draw comprehensive investor feedback stakeholder ambition board approve june investor key stakeholder research outreach patient consumer people update iu objective ambition help inform shape agree ambition share investor government focus gsk growth outlook iu event new gsk patient regulator nongovernmental maximise shareholder value shareholder impact health organisation multilateral creation include billion people year audit organisation risk committee review proposal duty competitive growth margin outlook detail stakeholder interest longterm business performance take account remuneration committee workforce business competitive sustainable return incorporate key iu ambition update relationship community value creation remuneration policy gsk environment reputation new ambition shareholder describe remuneration policy review fairness shareholder society principal decision detail available separation rejection unsolicite proposal complete foundational work board stakeholder consumer ch business wellpositione consider unsolicited patient consumer people healthcare conditional nonbinding proposal receive investor government board ensure ch acquire ch business regulator nongovernmental business wellpositione sustainably grow ahead proposal reject organisation multilateral category year come good interest shareholder organisation highly skilled management fundamentally undervalue business duty team lead future prospect longterm business performance workforce business confident ch relationship community business sustainably deliver environment reputation organic sale growth range fairness shareholder cer medium term demerger ch board support transformation stakeholder separation committee consider good way patient consumer people board approve release maximum shareholder value investor government retention stake company set firm foundation able regulator nongovernmental consumer healthcare company effectively serve patient customer organisation multilateral haleon post demerger respectively organisation haleon opening capital structure include appropriate capital duty structure require company longterm business performance competitive distribute share haleon workforce business separation ch create gsk shareholder retain stake relationship community haleon mid haleon exchanges haleon environment reputation detail available list fairness shareholder remuneration remuneration policy review prior develop new remuneration stakeholder policy new policy behalf people investor patient remuneration committee approve remuneration committee remuneration consumer government new remuneration policy committee chair chair regulator proxy adviser measure biopharma company subject bind consider investor feedback key duty shareholder vote ambition set iu event engage longterm result workforce annual general meeting major investor proxy adviser community environment incorporate new long propose change reputation shortterm incentive include consult corporate responsibility sale adjust operate profit committee gsk esg commitment growth measure align iu trust priority ambition listen view esg expert outline esg measure reflect esg leadership principal decision company work regard concern view stakeholder linkage esg remuneration incentive meet chief people officer hr lead area business hear view remuneration arrangement gsk wide workforce pay alignment opportunity new gsk consult investor proxy adviser new policy proposal follow engagement committee carefully consider feedback finalising design new policy detail available page board progress continue stakeholder group section progress area principal decision boardcommittee regard stakeholder interest duty consider esg leadership lead esg expert view esg expert stakeholder insight gsk provide overview esg investor investor patient employee follow wideranging expectation government regulator nongovernmental organisation comprehensive briefing debate describe major trend esg causal multilateral organisation recognise esg expert driver corporate responsibility duty cover gsk sector specific issue committee agree programme longterm result business include culture net zero intangible action improve relationship community esg communication ir share development esg link environment reputation engagement remuneration fairness shareholder provide evidence committee consider positive negative metric datum investor historical stakeholder perception company culture gsk focus purpose mission culture transform company new environmental sustainability goal proactively target announce previous year longterm investor base company approach enhance strengthen alignment remuneration increase availability incentive delivery esg ambition board committee chair help expert insight consider strengthen understand development remuneration committee committee approach work esg remuneration measure explain detail available remuneration report new gsk board succession planning committee consider optimal future stakeholder composition new gsk board future patient consumer people nomination corporate governance committee agree appropriately reflect stakeholder interest investor board wish constitute duty set key guide principle new gsk board diverse broad sense longterm business performance workforce optimal board skill matrix appropriate operational depth business relationship life science value chain general support development reputation commercial perspective roadmap future appointment medium term help deliver experience major customer market state ambition patient shareholder need skill insight member detail available continue ensure company leadership position esg settle significant gilead dolutegravir global decision settle global litigation stakeholder litigation settlement take careful consideration context investor patient government bring certainty investor support regulator board approve term global settlement license additional investment business future duty agreement gilead benefit patient investor longterm result business detail available relationship reputation upfront payment billion viiv healthcare pay royalty future sale biktarvy respect bictegravir component bictegravircontaine product sell gsk annual report gsk annual report strategic report governance remuneration financial statement investor information board approach continuous engagement engage main stakeholder group include board learn stakeholder view patient shareholder consumer customer employee engagement feedback event quarterly company summarise page investor result call annual general meeting employee strategic report survey report workforce engagement board consider interest stakeholder director report expert present board discussion decision make set committee meeting particular investor update chair sid meet investor forum section statement section member provide additional source investor feedback reference annual report opportunity gain wide stakeholder view principal decision board committee provide annual strategy meet glt page annual budget planning process stakeholder rightly high expectation review specific aspect company policy dynamic operating environment present challenge strategy opportunity board aim sure remain addition board member encourage meet individually commercially successful balanced align meeting employee shareholder key stakeholder stakeholder expectation uphold reputation induction ongoing basis maintain licence operate building trust board encourage report board experience engage stakeholder ensure identifie relevant material respond expectation effectively influence importance different stakeholder group vary depend matter consider certain people stakeholder interest conflict meaning board need balanced judgement wellestablishe strong engagement mechanism stakeholder engagement feedback help identify colleague describe page emerge issue enable board decision key governance channel help communicate context relevant important people think boardroom principal board committees glt undertake feedback global small target engagement board behalf accordance pulse employee survey remit mean build detailed understanding work workforce engagement director dame action plan areor impact stakeholder vivienne cox regularly gather explain colleague insight share board appropriate view board outline particular board receive substantial chair nonexecutive director regularly information stakeholder perspective work meet people group report corporate responsibility committee discuss board covid restriction permit year page please meet employee person board member regularly receive individually small group continue meet virtually ceos board report chair workforce engagement director corporate specific external stakeholder report provide responsibility committee chair designate meet leader strategic insight base analysis key development employee resource group erg example achievement risk impact reputation continue dialogue progress inclusion perception external stakeholder diversity agenda issue matter monthly investor relation report summarise investor erg member employee perception significant year change people regular corporate governance litigation regulatory future ready transformation programme intensify update increase anticipation demerger consumer healthcare shape gsk ahead pulse survey small group employee mean board glt check sentiment quickly frequently provide valuable insight impact major initiative event communicationsboard approach continuous engagement continue year board glt spend time listen postevent survey good progress session leader small group employee explain new gsk building confidence positive frontline role company help well sentiment employee feel board understand future build people confidence gsk acutely aware pandemic increase fatigue testing listening feedback new reduce resilience people reinforce purpose strategy culture emma hold importance prioritise care people small group session workforce glt cumulatively provide support need successful board hold session specifically focus new gsk monitor employee engagement provide rich feedback help shape internal quarterly monitoring employee take communication achieve record engagement level support absent leave employee join live event company board please glt chose recognise employee week thank pay award recognition resilience strong delivery extraordinary circumstance workforce engagement director year workforce engagement director engagement programme highlight time appreciate chance meet different joined site director site quality leader meet people company listen carefully comprise group employee recently view perspective year engagement appoint role meet attend continue virtual long induction programme undertake take pleased prevent people session discuss impact new culture open transparent discussion role stress importance ensure continuous improvement site purpose strategy culture midpoint meet hr leader establish programme visit start impressed energy commitment conscious year significant change separation clear focus people transformation programme restructure group culture leadership capability key support advance separation launch continued environment people thrive additionally naturally important new simplified hr system operating model uncertainty people keen use ensure quality support people role understand impact change organisation additionally separation get ahead session ambitious close raise question mind people receive twoday digital event bring future shape new gsk consumer healthcare employee world objective share business new list company particular want think progress launch new company understand work board glt exchange idea opportunity lie ahead define new purpose strategy embe new simplify finally spend time group high potential commercial culture discuss annual report employee great china intercontinental region experience complete virtual development programme probably consistent message hear year discuss key learning importance value people attach work company develop resilience building trust strong sense purpose clear strategy additionally meet employee group share people meet supportive new culture thought observation leader board appreciate simplicity clarity bring nonattributable basis valuable aspect continue jon chair engage ongoing basis view perspective diversity employee resource group erg specifically factor board glt discussion decision impact announcement company public make aspiration improve ethnicity gender representation workforce leadership position overall dame vivienne cox response positive continue encourage workforce engagement director board glt intensify effort support february promote diverse talent gsk annual report gsk annual report strategic report governance remuneration financial statement investor information board approach continuous engagement continue shareholder annual governance meeting year event virtual institutional shareholder key board seeks directly engage private retail investment industry body proxy advisory firm chair institutional shareholder way include regular join senior independent director workforce communication annual general meeting annual engagement director committee chair gsk external governance meeting work investor audit partner relation team chair sir jonathan symonds share investor priority focus board company secretary victoria whyte committee progress include year ceo emma walmsley cfo iain continue focus strengthen fundamental mackay give quarterly result presentation institutional business maintain esg leadership strong oversight investor analyst medium webcast teleconference progress separation create worldleading regularly join cso chief consumer healthcare company new growth outlook commercial officer ceo viiv healthcare president global ambition set gsk deliver stepchange vaccine ceo gsk consumer healthcare performance available provide detailed insight area remuneration committee chair share detail responsibility committee review executive remuneration arrangement regular meeting emma iain ongoing gsk ahead separation include update gsk active dialogue institutional shareholder policy focus reinforce delivery public performance plan objective ceo hold performance ambition set iu june individual meeting major shareholder host delivery public esg commitment submit group meeting actual potential major shareholder bind shareholder vote agm cfo hold individual meeting group meeting workforce engagement director discuss programme chair maintain active dialogue engagement gather help board shareholder include fund portfolio manager understand people perspective new purpose see governance professional strategy new simplify culture ch demerger chair hold meeting range investor meeting receive shareholder feedback nearly company share register enable share subsequently rest board current understand investor view insight perspective company cover investor annual general meeting board succession planning arrangement capacity restriction public gathering light covid chair nominations corporate governance committee situation time shareholder unable physically chair ceo rest board particular focus attend agm hold register office brentford communicate plan demerger priority seek provide live electronic shareholder future ambitions gsk biopharma access agm shareholder possible business extensive outreach june ceo aim promote similar type meaningful engagement member glt host virtual investor update board occur conventional agm provide clear view strategy gsk outlook pleasingly shareholder join meet electronically growth ambition watch listen update chair ceo ask question vote propose resolution october investor forumhoste event december approve shareholder majority range annual governance meeting chair provide update board committee align work drive demerger establish key governance intend agm hold workstream support deliver focus gsk future sofitel london heathrow hotel use hybrid format biopharma business allow shareholder flexibility attend ask question vote person electronically detail investor material event available gskcom boardle purpose culture board role promote gsk sustainable success clearly identify make progress drive longterm growth shareholder value need change board glt stakeholder strategic report page change track measure culture change demonstrate work achieve goal insight measure frequently corporate governance report page explain responsive make information easy access governance arrangement support oversight help drive progress shortterm significant strategic transformation separate business change longterm detail new ambition patient shareholder work board brief propose new mission support renew company culture strategy culture haleon culture focus board responsible set group overall behaviour purpose culture fundamental conducting business high standard promote longterm success unlocking protect maximise value matter shareholder human year emma walmsley ceo board describe detail work change culture guide launch formally haleon chair ceo designate purpose value culture move work capital market day february effectively longterm strategic priority board support gsk new culture appoint innovation performance trust board see momentum promote right people uphold incentivising ambition new business right behaviour strong governance control thorough unique opportunity unify people purpose process train develop employee strategy culture board recognise tone drive new purpose unite science talent technology company culture board glt role model ahead disease clear ambition lead example word action behaviour meaningful impact human health create set template people like people member well sustainable return want board follow key training awareness environment allow outstanding people thrive module board get ahead mean prevent disease live value expectation explore value treat mean innovate combine ideas expectation culture apply capability knowhow inside outside gsk focus operation way work rd deliver new vaccine medicine science immune system human genetic advance antibribery corruption technology make deep commitment inclusion diversity stakeholder operate responsibly detail new single definition culture essential plan embed new simplified culture invest reward people page board remain committed get ahead issue ambitious patient deliver matter well matter sustainability company price fast access environment strong diversity inclusion accountable impact clear ownership progress area set page support succeed strategic report esg performance report available gskcom right thing work integrity care understand people count code conduct embody value board review refreshe regularly available gskcom board discussion year focus new purpose culture centre corporate standard employee policy align value include longstanding speak rationale change system enable people raise matter confidentially review employee engagement feedback anonymously fear reprisal board trialling change audit risk committee review speak report provide step board glt need legal compliance team speak channel change real people report manage independent party case investigate legal compliance gsk annual report gsk annual report strategic report governance remuneration financial statement investor information board performance board evaluate performance board agree update priority year ahead committee year facilitate externally encapsulate action identify stage year external evaluation facilitate evaluation process addition agree use annual jan hall business advisory company strategy meeting board glt autumn reset recalibrate board future new gsk board committee evaluation process composite key assessment korn ferry board committee conduct interview board director elicit review board committee involve questionnaire view ideal future composition board director complete committee member committee provide advance information peer company consider operate effectively enhance performance board composition committee input follow improvement point agree discussion conversation board director cover range topic include corporate responsibility continue bring direct external stakeholder perspective committee key challenge opportunity gsk discussion provoke quality debate respect year eg science china area management company trust priority strength support audit risk continue balance committee work culture gsk current issue long term perspective skill experience prioritise recruit new committee continue seek focus nonexecutive director board imperative material enhance oversight desirable attribute consider strategic remuneration bring external perspective opportunity lie ahead change remuneration practice trend committee working board committee obtain attention ensure remain contemporary think external input nomination corporate governance focus delivery finding form basis transition plan transition plan create optimal composition optimal composition new gsk board nomination new gsk board corporate governance committee report explain science continue support cso leadership result work take forward team whilst provide perspective opinion rd step follow annual board glt strategy meeting work nonexecutive director form group discuss thought day discussion agree key insight chair priority debate board sid seek feedback director day conclusion reach incorporate board performance board chair unanimous view prioritie action finally nonexecutive director board function effectively complete short questionnaire performance continually strengthen chair provide excellent board committee year response leadership important eventful year board collate summarise consider board culture inclusive purposeful focus important issue strategy performance talent progress board evaluation progress conclusion board evaluation review set area focus progressachievement consideration continue give stop unnecessary board priority agree adhere structure board discussion task free time focus priority precondition key priority key driver examine performance transaction create shareholder value prime importance remain key focus consideration give make good use board increase use breakout session focus bring different time virtual meeting incorporate opportunity unstructured perspective particular issue october facilitate great person discussion possible interaction despite ongoing covid restriction board committee annual strategy meeting hold dual site uk chair lead meet uk ukeuropeanbased director ceo lead meet usbased director addition specific time set aside glt member meet board member set objective agenda discussion greatly appreciate welcome opportunity connect science committee look deepen understanding board science committee meeting agenda design rd resource allocate facilitate deeply dive line board agree key priority desire enhance root cause analysis enhance approach foundation global safety review undertaken incident issue occur ensure avoid future group approach improve performanceboard committee report inclusion diversity d committee continue corporate responsibility committee assess progress gsk d strategy commitment report include particular implementation change hr process monitor arrangement need support delivery aspirational diversity target announce lynn elsenhans year annual report committee consider key corporate responsibility committee requirement strengthen succession planning please present report sixth arrangement diverse talent application final chair corporate responsibility committee broad concept equity workplace evolve committee d strategy d incredibly important culture gsk committee review support role committee comprehensive annual d training awareness session committee oversee gsk trust priority undertaken board people company progress trust commitment charitable give gsk tremendous reflect important area responsible sustainable longstanding commitment charitable give community business growth trust priority cover management work involvement committee review exist approach esg factor integral gsk overall strategy gsk compare peer consider committee oversight view interest leverage approach align gsk core purpose strategy internal external stakeholder review issue culture encourage impact measure term seriously impact gsk business reputation contribution commitment announce investor update june positively impact health billion committee continue oversee people year progress trust commitment regular report esg performance new gsk committee review glt member senior manager management plan area esg focus new gsk gsk approach manage risk opportunity outline investor company june working associated esg factor help create value audit risk remuneration committee shareholder society committee review management proposal specific metric measure progress area management understand key issue stakeholder recommendation creation single esg performance perspective listen directly key independent expert rating assessment kpi gsk demerger voice review approach risk management governance principal risk relevant area expertise oversight arrangement measure report esg responsibility product quality nonpromotional performance committee please support engagement supply continuity environmental sustainability change help retain develop gsk esg health safety leadership position key activity consumer healthcare ch preparation demerger committee review discuss ch safety culture committee review progress management progress develop distinctive delivery global safety improvement plan gsk holistic responsible business esg framework business develop comprehensive farreache support purpose strategy culture list external evaluation safety culture reviewing action company focus key responsible business issue embed sustain plan safety improvement new company committee scrutinise future committee encourage strong focus framework propose target include environmental sustainability target incorporate education training build capability key insight expectation gather investor analyst ensure clear accountability leader safety external stakeholder heighten awareness application gsk stakeholder insight benchmarke simplify culture right thing integrity care people count committee pay close attention evolve view expectation companys broad range key stakeholder receive regular report stakeholder insight meet ensure consider issue bear gsk reputation delivery responsible business agenda employee insight feedback discuss relation progression company modern employer agenda gsk annual report gsk annual report strategic report governance remuneration financial statement investor information board committee report continue keep desire continually bring external science committee report perspective committee room committee benefit direct engagement insight dr jesse goodman expectation sector company specifically science committee area firstly receive expert insight investor please present fifth report science view esg trend expectation outcomes committees committee activity report secondly gather expert view rise expectation government investor key activity business understand human right impact risk committee inception continued committee monitor investor expectation esg refine focus provide great value board report disclosure ongoing basis gsk continue deliberation particular committee focus align good practice report accordance ensure validity key scientific assumption sustainability accounting standard board esg drive company rd strategy provide performance report task force climaterelate technical assurance particularly relation potential financial disclosure transaction addition committee monitor company esg performance index relation peer pipeline progress respect particularly pleased gsk rank start year committee closely review dow jones sustainability index pharmaceutical objective biopharma business include industry group improve carbon cdp rating b relate pipeline progression deliver pipeline help rate sustainalytic patient heart gsk committee pharmaceutical sub group external monitor progression closely term strategy benchmark help evidence gsk acknowledge leadership performance committee hold number discussion esg continue key driver goal dr hal barron cso rd leader deliver health impact shareholder return year encourage progress approach separation committee aim separation announce rds strategy committee continue scrutinise monitor progress deliver strong pipeline asset potential gsk material trust topic relevant enterprise risk bring transformational vaccine medicine patient company demerge focus oversight gsk notable approval year include embed new approach esg performance jemperli dostarlimab treatment endometrial measurement cancer common female reproductive cancer major milestone gsk oncology pipeline corporate responsibility committee chair succession potential transform live woman previously delight welcome dr anne beal bring limited treatment option extensive healthcare experience board committee physician public health expert cabenuva cabotegravir rilpivirine longacte anne work smooth injectable treatment hiv cabenuva potential transition handover succeed committee transform hiv care patient reduce treatment dose chair conclusion agm continue day year addition apretude receive serve committee member provide continuity fda approval december longacte support retire step board injectable option hiv prevention conclusion demerger later year november company announce positive phase iii privilege serve member board chair datum daprodustat potential new oral treatment patient committee help shape oversee particular anaemia chronic kidney disease development embed framework focus set commitment support company trust priority covid approach responsible business listen carefully pipeline covid solution xevudy view stakeholder help inform positive sotrovimab monoclonal antibody develop collaboration step take reinforce position leader vir biotechnology approve europe receive esg emergency use authorisation treatment patient covid study xevudy retain lynn elsenhans activity omicron variant term vaccine gsk corporate responsibility committee chair announce positive phase iii result plantbase february covid vaccine candidate develop medicago vaccine covifenz approve canada february february announce intention seek regulatory authorisation covid vaccine develop sanofi base datum booster phase iii efficacy trialsour board committee report continue february report collaboration enhance rd governance curevac jointly develop generation mrna vaccine committee particularly impress covid potential address emerge variant development rd governance dr barron appoint vaccine pharma rd scientific deepdive fully unite single organisation enable innovation remain key priority gsk rd effective term efficiency committee continue meet cso share technical scientific expertise talente rd leadership undertake deepdive benefit governance enhancement exciting complex area science strategic apparent improvement cycle time importance gsk include clinical development probability success immunology pivotal study oncology focus synthetic lethality half year ago management set new approach rd dr barron leadership pipeline vaccine mrna strategy stand advanced notably science immune system key pillar rd committee emphasise need continue momentum strategy leverage develop novel therapeutic separation potentially revolutionise drug discovery development gsk partnership andme provide board committee change company exclusive insight field represents welcome dr hal dietz committee january enormous opportunity rd build strong exist experience field human genetic add portfolio committee please immunology significant value committee discussion embed gsk rd include appointment mean committee oncology vaccine viiv infectious disease round area expertise require evaluate gsk strategy pipeline potential business development target business development judy lewent left committee retirement addition oversight company organic rd board agm charles bancroft joined innovation committee continue review potential committee february follow business development transaction committee receive appointment dr dietz regular preview potential business development opportunity explore undertake indepth technical committee participate cso succession planning review transaction prior presentation board fully supportive tony wood appointment transaction add new programme aim pleased dr barron join committee august differentiate gsk pipeline competitor support transition nonexecutive director organic development company dr jesse goodman key transaction review committee science committee chair year include february iteos collaboration iteo codevelop antitigit monoclonal antibody collaboration gsk position produce nextgeneration immunooncology therapy especially target cd axis alector collaboration develop potential firstinclass monoclonal antibodies range neurodegenerative disease include parkinson disease alzheimer disease arrowhead pharmaceutical exclusive licence agreement arrowhead pharmaceutical gsk develop commercialise arrowhead investigational rnai therapeutic develop treatment patient chronic liver disease halozyme therapeutic global collaboration license agreement viiv healthcare halozyme grant exclusive access halozyme enhanze drug delivery technology enable development ultra longacte medicine hiv shionogi exclusive license agreement viiv healthcare shionogi develop thirdgeneration hiv integrase inhibitor potential use ultra longacte hiv regimen gsk annual report gsk annual report strategic report governance remuneration financial statement investor information board committee report continue nomination corporate governance cpo ceo cso dr wood establish transition plan approve committee ensure committee report smooth transition necessary jonathan symond january board activate succession plan nomination corporate governance committee follow dr barron decision accept position ceo cochair altos lab august dr wood please present report chair key partner dr barron deliver gsk rd nomination corporate governance committee approach wide experience expertise committee science datum new technology perfectly place build dr barron outstanding progress deliver value key activity pipeline board agree appoint dr committee play important role deliver key tony wood cso designate succeed dr barron priority transform gsk separate ch business cso member glt august committee meet time year report set detail background find work company announcement issue january key priority status available gskcom succession plan cso cso succession candidate committee recommend cso rd leadership team identify subsequently appoint cso designate transition plan dr barron appoint nonindependent nonexecutive director member science committee appoint chair corporate dr anne beal join board responsibility committee succeed effect august initially threeyear term lynn elsenhans support cso transition process appoint scientific medical expert dr hal dietz join board corporate responsibility committee chair sme january report describe search lynns successor design target gsk board composition target gsk board composition chair corporate responsibility committee crc recruit high calibre nonexecutive agree search new result dr anne beals appointment board complete new gsk biopharma board nonexecutive director anne bring extensive healthcare experience gsk progress physician entrepreneur combine passion patient appoint haleon ceo assemble brian mcnamara appoint advocacy detail experience rationale appropriately season management haleon ceo designate july appointment include company announcement team haleon management team announce december april available gskcom transition process underway enable anne succeed lynn crc appoint chair haleon support sir dave lewis appoint chair close agm despite serve composition haleon board haleon chair designate year lynns experience ceo sit december selection board mean continue demonstrate remain haleon board characteristic independence expect board progress carry role board shaping gsk board future scientific medical expert sme please confirm search sme management succession planning successfully conclude continued finetune committee nonexecutive director present selection criterion process evolve considered continuously assess succession plan management follow executive director ensure appropriate succession plan diverse pipeline potential successor outlook future direction rd innovation place treatment management human health give importance cso leadership experience people leadership management scale rd committee collaboration ceo academic industry set appropriate cso intensify planning identify interested deep understanding breadth potential cso succession candidate committee scientific therapeutic area particularly immunology support chief people officer cpo science genomics genetics perspectives committee committee follow comprehensive process ability harness digital technology include artificial making recommendation describe intelligence enhance research development replicate assess succession candidate new medicine committee science committee review diverse able deliver complex science broad audience highly long list internal external potential successor candidate collaborative willingness engage proactively short list candidate compile topic immediate realm expertise interview science committee member chair ceo cpo cso committee join non executive director review final candidate follow extensive process nonexecutive director agree identify dr tony wood cso successorour board committee report continue committee please recommend appointment committee review brian propose leadership team dr hal dietz board effect january haleon particular propose cfo chief people dr dietz bring extensive experience field human officer announce december follow genetic central gsk approach rd extensive internal external search role add strength science committee board shortlist candidate interview relevant panel discussion detail hal experience rationale nonexecutive director agree role criterion appointment include company announcement committee approve final appointee haleon october available gskcom management team introduce investor ch capital market day february transition new gsk board haleon chair committee follow search process planning structure new gsk board select haleon chair search focus candidate independent biopharma company committee follow knowledge experience commitment commission korn ferry meet board member significant list board experience understand gather view optimal board design future investor analyst bank regulator government detail process give skill matrix develop map current board member high degree financial acuman successful business skill capabilitie succession planning need track record create shareholder value grow board discuss nonexecutive director business key capability refine final target strong emphasis coaching skill ability create skill matrix agreed committee agree brief highperformance environment initiate search new nonexecutive director appoint board month deep experience consumer face business high committee follow search process recruit degree customercentricity international experience role long list candidate role preferably china consider strong strategic skill track record innovative thinking coaching development haleon board appointment respect high credibility committee appoint subcommittee comprise stakeholder include investor capital market participant chair vindi banga dame vivienne cox dr beal regulator government mr rohner progress haleon board appointment report progress schedule committee meeting high integrity strong value drive strong final decision reach committee sense purpose nonexecutive director invite participate understand role chair ftse haleon ceo cfo committee conduct possession humility subdue ego strong extensive global search selection process appoint emotional commitment passion ch business haleon ceo cfo designate work follow commit diversity form resilient open committee search process particular ceo role profile mind strong judgement natural team builder contain key selection criterion responsibilitie successful candidate need fulfil especially committee agree sir dave lewis highly demerger emphasise importance experience respected global business leader consumer establish new haleon board deliver growth good retail suitable candidate lead strategy drive significant shareholder value haleon board note time selection require relentless focus innovation promote high deem meet independence requirement performance inclusive culture whilst operate code committee recommendation subsequently exact standard corporate governance endorse board detail sir dave experience rationale appointment include follow interview board member internal company announcement december external candidate board please endorse available gskcom committee recommendation appoint brian mcnamara haleon ceo designate board note particular brian sir dave progress search high calibre non strong track record success building ch business executive director build haleon board ensure considerable experience fmcg consumer health continuity expect nonexecutive member mean uniquely suit right choice gsk board transfer haleon board completion unlock growth potential haleon independent list demerger company ch joint venture partner company detail brians experience pfizer right appoint nonexecutive rationale appointment include company director new haleon board announce publicly announcement july available gskcom later year demerger arrangement gsk annual report gsk annual report strategic report governance remuneration financial statement investor information board committee report continue way working committee work number executive search firm committee seeks follow good practice provide additional consultancy service appointment recommend agree criterion role company outline appropriate interview panel consider korn ferry general recruitment executive search comprehensive diverse long list candidate shortlist assessment service coach hrrelate service candidate interview assess choose egon zehnder executive search assessment coaching criterion diligence undertaken committee service specific senior executive make final recommendation executive search firm appoint accordance company procurement heidrick struggle executive search service policy base expertise relative role spencer stuart executive search assessment service committee agree search firm signatorie voluntary code conduct executive committee review potential conflict interest search firm gender diversity good practice judge appropriate safeguard engage conflict board committee chair glt membership change year date report committee approve follow change membership board committee glt director membership appointment date retirement date charle bancroft chair audit risk committee chair march member nomination corporate governance science committee february step science committee dr hal dietz join committee dr anne beal member corporate responsibility audit risk committee july dr hal dietz member science committee january judy lewent chair audit risk committee chair march member audit risk nomination corporate governance remuneration science transformation separation committee lynn elsenhans chair corporate responsibility committee member audit risk corporate responsibility nomination corporate ch governance committees demerger dr anne beal chair corporate responsibility committee shobie ramakrishnan chief digital technology officer member glt december board composition tenure diversity commit diversity boardroom board seek balance composition tenure gsk commit equal opportunity employee committee refresh time level organisation board management enable board benefit experience long seek encourage diverse inclusive culture serve director fresh perspective insight company effective board need range balance new appointee nonexecutive director draw skill experience knowledge ethnicity gender social wide range industry background include economic background independence individual pharmaceutical industry rd vaccine consumer prepare challenge work product healthcare medical research academia collaboratively mix need complement insurance financial service collectively diversity personal attribute include character intellect wealth experience complex organisation global judgement honesty courage reach board member experience longercycle industry great assistance understand sectorour board committee report continue board glt diversity target transformation separation committee responsible develop measurable committee report objective monitor progress achievement assist implementation board diversity policy jonathan symond include gender ethnic diversity progress transformation separation committee target set consistency diversity metric january show line gender please present second final report chair diversity submission ftse woman leader review transformation separation committee committee review give fulfil purpose mandate committee establish charge progress achieve principal function diversity objective status performance board position exceed exercise oversight future ready transformation hold woman objective programme particularly delivery target cost saving glt position meet objective separation company infrastructure prior hold woman delivery team move project design implementation combine glt exceed direct report position hold objective consider optimal form separation woman include implication separation board director exceed director appropriate listing location haleon ethnically diverse objective committee please future ready committee particularly intent increase gender transformation programme complete schedule especially ethnically diverse representation board end exceed cost saving identify glt develop pipeline direct report derive programme glt ethnically diverse background committee undertake programme work committee supportive new gender diversity target understand consider key fundamental separation review publish late february include technical requirement consider woman board please good unlock release maximise longterm shareholder year board gender representation target value work support guidance advice comfortably exceed normally board position external expert appropriate committee begin hold woman transitional period consider separate principal value company separate ch business demerge achieve option available discussion committee working transition target board profile progress capital structure require result new biopharma company result composition company competitive independent entity diversity board transition inevitably follow decision demerge ch business subject fluctuation look forward confirm completion important determine distribute share haleon work year report report progress shareholder exchange haleon list review increase gender diversity target committee consider retain stake representation woman ethnically diverse leader haleon big stake retain cover diversity gsk global intensive detailed programme work workforce progress inclusion diversity committee address major question commitment include gender ethnicity illustrate impact stakeholder report board esg performance report gskcom accordingly conclusion recommendation process execution phase oversight sir jonathan symonds remain work appropriately rest nomination corporate governance committee chair specialist board committee devolve february appropriate review oversee directly board fulfil mandate agree committee decommission like thank board colleague commitment diligence support committee work respect sir jonathan symonds transformation separation committee chair february gsk annual report gsk annual report strategic report governance remuneration financial statement investor information board committee report continue audit risk committee report process system fundamental appropriate financial reporting charle bancroft control manage risk position audit risk committee respect company main accounting reporting system centralise global instance sap pleased present report chair wellestablishe finance model audit risk committee committee centralise transactional controller activity embed joined committee succeed judy gsk regional hub free inmarket finance lewent chair march comprehensive people focus core business operation decision transition draw business background make committee continue exercise regular oversight include year serve cfo major monitoring activity critical financial system pharmaceutical company bristol myers squibb integrity financial statement include annual view people process system report quarterly result announcement endure key importantly culture critical foundation successfully focus committee join board manage financial reporting audit compliance risk committee impress clarity rigour time serve committee observation process committee position generally board member confident gsk aim clear transparent financial disclosure control score highly area like gsk financial reporting share initial impression key aspect previous committee chair highlight report culture people year continue ensure company financial gsk strong compliance culture consistent tone report control framework remain robust engagement regularly consider require fundamental change important emphasise committee discussion zero despite ongoing impact covid company way tolerance approach unethical behaviour risk work addition external auditor regularly test management internal control framework mature financial system control challenge management embed organisation demonstrate page report result committee include area annual report enable committee deficiency external auditor identify progress evaluate oversee gsk manage principal remediation issue discuss evaluated emerge risk key activity committee routinely exercise oversight key decision usual busy year improvement compliance culture committee work regular programme gsk underpin great people right skill activity make important decision support set corporate governance framework require board progression key priority include good people quality decision right thing review support board committee chair unfettere access senior incremental change companys commercial leadership key member team regularly model china year meet individually key committee attendee management include cfo general company new growth ambition counsel chief compliance officer head audit share investor update june assurance group financial controller company progressive dividend policy secretary external auditor additionally committee matter consider outcome report member opportunity speak end page meet external auditor management present crucially ability speak key preparation demerger member management private session require committee key ch governance delivery workstream increasingly review technical aspect delivery demerger committee specifically accountable reviewing recommend board approval key transaction document relate mattersour board committee report continue board ultimately responsible decision principal risk assign risk owner draw demerge respect time final term senior management accountable manage hisher demerger recommendation transaction principal risk oversight glt member include set shareholder publication gsk shareholder implement risk mitigation plan risk owner report circular committee role scrutinise document quarterly respective risk management approach prior board review process progress rocc appropriate board committee committee board continue intensify compliance function assist rocc rmcbs half year formal point separation approach compliance responsible advance enterprisewide risk management develop riskbase ethically sound committee assist ch management working practice actively promote ethical behaviour establish robust internal control risk management enable employee operate line value framework ready separation overarch principle comply applicable law regulation replicate gsk current internal governance control finance system necessary adapt exist audit assurance aa function provide independent framework process committee please assurance senior management board ch business currently advanced set effectiveness risk management groupwide line governance process organisation manage agree assurance plan help senior management process business usual environment q board meet oversight advisory responsibility fulfil gsk strategic objective build trust internal control framework patient stakeholder aa dual reporting line board recognise obligation present fair balanced cfo committee understandable assessment gsk current position committee receive regular report business unit prospect reflect responsibility accountable principal risk owner compliance aa area evaluate approve effectiveness gsk internal significant risk group relate internal control control include financial operational compliance report assess internal control environment control risk management process principal risk area include enhancement strengthen ensure reliability financial reporting control follow consideration report compliance law regulation internal committee report annually board effectiveness control framework comprehensive enterprisewide risk gsk internal control management model support board continuous authority delegate committee identification evaluation management group board conduct robust assessment group principal principal risk require frc code framework risk assessment line frc design manage risk achieve business code include consideration nature extent risk objective board willing achieve gsk strategic objective fitforpurpose framework complement corporate board committee oversee effectiveness value culture expectation speak process internal control environment risk management ensure risk associate business activity process group year actively effectively control line agree risk approval date annual report appetite believe gsk framework provide reasonable review group risk management approach absolute assurance material misstatement loss discuss risk management section strategic board mandate group risk oversight compliance report page council rocc senior leader assist committee management principal risk explain principal oversee risk management internal control activity risk uncertainty page group provide business framework risk viability discuss group risk management section management upward escalation significant risk risk strategic report management compliance board rmcbs group promote tone establish risk culture ensure effective oversight internal control risk management process gsk annual report gsk annual report strategic report governance remuneration financial statement investor information board committee report continue significant issue relate financial statement consider gsk quarterly financial result announcement financial result annual report committee review significant issue management judgement determine result review management paper set key area risk action take quantify effect relevant issue judgement management appropriate accounting require address issue financial statement significant issue consider relation financial statement year end december set follow table summary financial outcomes appropriate committee external auditor discuss significant issue address committee year area particular audit focus describe independent auditor report page significant issue consider committee relation financial statement issue address committee go concern basis preparation committee consider outcome management halfyearly year end review current financial statement forecast net debt position financing facility option available group committee consider management review current longerterm impact covid pandemic outbreak pandemic year end follow consideration assessment include stress testing viability scenario sources liquidity funding forecast estimate committee confirm application go concern basis preparation financial statement continue appropriate revenue recognition include return committee review management approach time recognition revenue accrual rebate rar accrual customer return rebate pharmaceutical vaccine accrual return rebate billion december committee review basis accrual concurred management judgement amount involved full description process operate pharmaceutical vaccine business determine level accrual necessary set critical accounting policy provision legal matter include committee receive detailed report actual potential litigation internal external legal investigation group counsel number detail update investigation group commercial practice commercial practice management outlined level provision correspond disclosure consider necessary respect potential adverse litigation outcome area possible determine provision necessary december provision legal matter billion set note financial statement provision provision uncertain tax position committee consider current tax dispute area potential risk concur management judgement level tax contingency require december tax payable liability billion include provision uncertain tax position recognise group balance sheet impairment intangible asset committee review management process review testing goodwill intangible asset potential impairment committee accept management judgement intangible asset require writing result impairment million note financial statement intangible asset detail valuation contingent consideration committee consider management judgement necessary increase liability pay relation viiv healthcare contingent consideration result increase sale forecast unwind discount update exchange rate assumption cash payment approximately billion year december group balance sheet include contingent consideration liability billion relation viiv healthcare settlement gilead result remeasurement exist liability contingent consideration year end include closing balance viiv healthcare option committee review agree accounting pfizer option concur management judgement valuation option billion december settlement gilead result remeasurement pfizer option year end include close balanceour board committee report continue auditor reappointment committee chair regularly meet independently external auditor audit partner committee meet auditor end meeting discuss progress appropriate external auditor appointment review feedback note area tender december improvement implement audit team transition year committee satisfy shareholder approval current auditor effectiveness auditor external audit process audit annual report f year end december audit tender require regulation auditor independence qualification objectivity expertise contractual similar obligation restrict resource group choice external auditor committee consider committee agree recommend company comply mandatory reappointment deloitte board forthcome agm audit process audit committee responsibility provision make recommendation committee free competition market authority statutory audit influence party service order effectiveness quality external audit process nonaudit services committee commit ensure gsk receive management operate presumption highquality effective external audit evaluate deloitte accountancy firm provide nonaudit services gsk performance prior make recommendation external auditor skill experience reappointment early committee review suitable supplier nonaudit support effectiveness performance criterion auditrelate matter tax service agree management beginning good interest company line gsk detailed criterion judging effectiveness deloitte nonaudit services policy committee ensure external auditor base audit approach auditor objectivity independence safeguard strategy highquality independent audit effective partnership review preapprove external auditor provision value money override responsibility deliver service company policy complie frc smooth thorough efficientlyexecuted audit revise ethical standard sarbanesoxley act available gskcom undertaking review committee observe follow core policy feature consider engage external auditor nonaudit service overall quality audit gsk nonaudit services policy key feature independence deloitte process nonaudit service competitive tender financial service provider line deloitte exhibit appropriate level challenge group procurement process skill experience scepticism work external auditor suitable supplier deloitte length tenure take account safeguard adequate safeguard establish objectivity assess independence objectivity independence group audit threaten recently appoint gsk auditor committee compromise consider effectively assume role auditor fee cap total fee payable nonaudit services committee consider feedback external exceed annual audit fee special audit survey committee member financial circumstance clear advantage auditor undertake additional work management team corporate business unit level survey cover prohibition gsk policy include whitelist permit nonaudit service line relevant regulation service effectiveness auditor challenge list prohibit integrity deloitte preapproval nonaudit service require preapproval set table ensure service approve consistent transparency report management gsk nonaudit policy permissible service process committee ensure service fall scope service permit preapproved committee represent clarity auditor communication way working delegation authority preapproval alignment audit group investment value preapprover system application product sap committee chair cfo quality audit team leadership group financial controller skill experience audit team designate group financial controller fee pay company auditor associate set overleaf detail given note financial statement operate profit gsk annual report gsk annual report strategic report governance remuneration financial statement investor information board committee report continue fair balanced understandable assessment audit service comparison need annual report fair balanced understandable key compliance requirement company financial statement ensure gsk annual report meet requirement wellestablished document process govern coordination review groupwide contribution publication run parallel process follow external auditor committee receive summary management approach gsk annual report ensure meet requirement frcs code enable committee board confirm gsk annual report fair balanced understandable provide necessary information shareholder assess company position audit assurance service service include tax regulatory compliance treasuryrelate performance business model strategy service service relate consumer healthcare demerger preparation code conduct report line note financial statement provide detail fee payable number wellestablishe policy include company auditor code conduct available gskcom detail confidential speak line report year fee audit relate assurance investigate unlawful conduct service million increase million compare increase work associate charles bancroft deloitte report accountant role prepare audit risk committee chair demerger consumer healthcare business include february audit fee respect gsk pension scheme million fee audit relate assurance service represent annual audit service fee exclude demerger work fee audit relate assurance service represent annual audit fee committee consider hire deloitte undertake report accountant role demerger good interest shareholder deloitte possess type expertise experience size international scope require handle major demerger scale complexity company benefit specifically deloitte indepth knowledge understand ch business process compliance environment management time devote educate firm company business operation instead spend deliver demerger creation haleon committee consider level nonaudit service incur annual review deloitte independence set satisfied auditor continue independent exercise objectivity section statement company director require law promote success allow build trust fully understand potential organisation benefit shareholder impact decision make stakeholder wide stakeholder include employee supplier engagement gsk main stakeholder group include community patient shareholder consumer customer employee level organisation summarise statement align requirement set page strategic report section section cza company act act indicate year director company governance architecture process address matter set section f summarise page corporate governance act perform duty avoid duplication report summary explore board consider incorporate information area annual report relevant matter make principal decision contribute board consider statement focus risk delivery gsk longterm priority innovation opportunity strategically important gsk performance trust consistent group size complexity information issue factor stakeholder board consider relevant complying section f act find location outline board regard follow matter longterm result b workforce c business relationships likely consequence decision interest group employee importance develop group business longterm relationship supplier customer strategic report strategic report business model strategic report business model culture business model chair statement modern employer external environment ceo statement stakeholder engagement stakeholder engagement key performance indicator innovation corporate governance report risk management performance board activity viability statement reliable supply board progress work party board approach continuous corporate governance report risk management engagement chair governance statement boardle purpose culture corporate governance report board activity audit risk committee report board activity board progress nomination corporate governance board progress board approach continuous committee report board approach continuous engagement engagement boardle purpose culture remuneration report audit risk committee report audit risk committee report remuneration committee chair corporate responsibility committee report statement director pay wider set gskcom gender pay gap report community environment e reputation f fairness shareholder impact group operation desire maintain reputation high aim act fairly member community environment standard business conduct group strategic report strategic report corporate governance report trust section include culture chair governance statement environment trust board approach continuous environment health safety ethic value engagement environmental sustainability risk human right transformation separation committee climaterelate financial disclosure reporting investigate concern report antibribery corruption risk page investor information corporate governance report nonfinancial information statement corporate responsibility committee report approach tax corporate governance report gskcom corporate responsibility committee esg performance report report gskcom modern slavery statement gsk annual report gsk annual report strategic report governance remuneration financial statement investor information director report director power determine uk legislation nomination corporate governance committee article association contain rule review register potential conflict authorisation appointment replacement director provide register conflict january committee report director appoint ordinary resolution board conflict appropriately member resolution board provide authorise process authorisation continue appoint board director retire annual operate effectively committee recommend general meeting follow appointment approval register conflict board subsequently approve describe note article provide director require seek financial statement relate party transaction reelection annually annual general meeting end financial year director person closely accordance frc code associate material interest contract director cease director significance group company bankrupt article prohibit director voting resolution cease director virtue company act concern appointment term termination article appointment suffer mental physical ill health board resolve independent advice shall cease director company agree procedure director miss director meeting continuous period independent legal andor financial advice company month permission board resolve expense deem necessary shall cease director indemnification director prohibit director law qualify party indemnity provision define resign offer resign board accept offer company act force benefit director require resign board director hold office approval signature annual report director conflict interest director duty company act change control essential contract avoid situation direct contract arrangement indirect conflict interest possible conflict individually fundamental ability business company article provide general power board operate effectively company party material authorise conflict agreement effect altered terminate board review new potential actual conflict change control follow takeover bid record company secretary director count agreement director provide compensation quorum authorisation actual loss office employment result takeover potential conflict nomination corporate governance provision company share plan cause committee review register conflict annual basis option award grant plan vest board subsequently approve takeover continue basis director responsible detail termination provision executive director inform company secretary new actual service contract give version company potential conflict arise change remuneration policy available wwwgskcom circumstance affect authorisation previously give investor section provide authorisation director absolve statutory duty promote success company actual conflict arise postauthorisation board choose exclude director receipt relevant information participation debate suspend director board resort require director resigndirector report continue follow information incorporate director content director report report purpose uk company act location annual report director report glaxosmithkline plc year end interest capitalise financial statement december comprise note publication unaudite financial information group financial review director report detail longterm incentive scheme remuneration report waiver emolument director applicable section page waiver future emolument director applicable corporate governance report non preemptive issue equity cash applicable employee engagement non preemptive issue equity cash applicable director statement responsibility unliste major subsidiary undertake investor information parent company participation place applicable strategic report set matter require list subsidiary disclose director report consider provision service control applicable strategic importance shareholder shareholder waiver dividend financial statement strategic report note shareholder waiver future dividend financial statement section page note risk management objective policy agreement control shareholder applicable director report likely future development company draw present accordance research development activity reliance english company law liabilitie business relationship director connection report shall subject diversity limitation restriction provide law provision information consultation employee approve board director february carbon emission sign behalf section statement sir jonathan symonds chair february gsk annual report gsk annual report strategic report governance remuneration financial statement investor information remuneration section committee chair annual statement annual report remuneration remuneration policy summary remuneration policy report gsk annual report strategic report governance remuneration financial statement investor informationremuneration report committee chair annual statement dear shareholder vest lti award performance share plan psp award vest preagreed measure behalf remuneration committee committee award rd new product performance adjust pleased present remuneration report free cash flow relative tsr equally include annual statement explain committee work weight performance measure year year annual report remuneration december rd new product update remuneration policy report explain measure vest reflect delivery strengthen change propose align compensation arrangement pipeline successful commercialisation newly new gsk detail propose operate policy launch product continue strong focus cash year management generation result delivery adjust free cash flow measure disappointingly review ipt outcome company relative tsr performance year like set decision take committee result award lapse course context overall performance vested share defer year innovation term innovation significant base salary follow review executive director progress strengthen rd biopharma performance committee agree receive pipeline comprise vaccine specialty medicine annual increase line increase exciting new development hiv covid provide wide workforce uk solutions committee agree award dr barron increase performance overall year strong sale august reflect creation rd performance strategic progress gsk see group new organisation bring scientist sale growth cer drive growth governance pharmaceutical vaccine ensure pharmaceutical vaccine consumer healthcare focus invest matter exclude brand divestedunder review total earning group decline cer reflect profit disposal detail horlick business achieve adjusted bonus award relation eps growth include covid solution cer accordance remuneration policy determine ahead update guidance pipeline remain outcome committee carefully consider robust continue progress pharma vaccine executive director performance deem necessary trust company continue build esg leadership exercise discretion address anomaly position year rank performance outcome review include assessment access medicine index eighth time row gsk performance relevant measure wide pharmaceutical industry group dow context especially company culture trust priority jones sustainability index receive gold recognition sps gsk access covid government support job sustainability yearbook cdp climate change retention scheme dividend policy maintain year company deliver remuneration outcome upgrade financial guidance year performance delivery result high total remuneration respect emma walmsley ceo dr hal barron gsk remuneration policy cso iain mackay cfo like set committee seek update increase variable performance relate pay remuneration policy time annual bonus achievement adjust group pbit past year see period significant financial measure addition cfos remuneration increase transformation gsk result reflect vest psp award join evident seek fundamentally address long stand company issue prolong total shareholder return key decision committee follow performance committee agree essential bonus outcome ceo cfo cso review remuneration policy ahead usual threeyear cycle define biopharma business new approach determine reference performance remuneration agree financial measure adjust group pbit committee assessment individual performance financial performance result bonus payment financial target committee assessment executive performance personal objective set start year set committee believe bonus outcome appropriately reflect overall underlie performance achieve detail provide gsk annual report gsk annual report strategic report governance remuneration financial statement investor information policy review seek ensure remuneration support increase alignment shareholder arrangement reward delivery bold new propose bonus earn excess salary performance ambition key focus investor update ie maximum current remuneration policy iu ambition year deliver sale growth salary propose maximum deliver cagr adjust operate profit growth fully share defer year half bonus earn cagr ambition exclude salary continue defer share contribution early stage asset future business year mean event management development covid solution significantly performance iu ambition significantly change performance pay curve end focus exceed increase maximum bonus earn expectation delivery go forward achievement base salary deliver cash ambition deliver quartile performance balance defer gsk share year sector develop new remuneration policy engage follow comprehensive review committee conclude extensively shareholder gain view feedback main policy framework remain fit purpose give committee grateful result drive long term performance consistent year adjustment approach quantum clarity year short term improvement main aim change performance measurement feature final annual bonus plan support deliver determine propose policy please process allow key imperative develop remuneration structure work company shareholder enter new phase careful consideration committee conclude business post demerger change require operation annual bonus important note achieve new maximum annual raise target performance level align delivery sale growth adjust operate profit growth iu ambition require percentage point reduce reward previously available low respective target acknowledge performance target performance expect frequent occurrence achieve change financial bonus measure adjust group committee believe appropriately reward pbit sale growth adjust operate profit growth give additional value deliver investor line key iu ambition patient people strengthen focus strategic operational measure event annual bonus financial measure executive director stretch personal achieve committee consider appropriateness objective align quantifiable iu ambition reflect measure pay personal area accountability reinforce term competitiveness ceo emma walmsley culture trust priority maximum opportunity earn result deliver give fundamental esg dna success exceptional performance require reach overall important recognise specific performance compensation package quartile versus condition incentivise incremental year year global pharmaceutical comparator group assume improvement public ambition peer group achieve target bonus group include company list uk europe significantly reduce pay opportunity target performance committee agree post demerger ftse company new gsk important incentivise reward truly exceptional pursue ambitious growth strategy focus purely performance occasion achieve reinforce biopharmaceutical compete talent highly step change performance culture result key policy competitive global pharmaceutical biopharmaceutical change annual bonus propose sector remuneration level significantly exceed see uk propose change annual bonus current bonus maximum salary pay design strike pragmatic balance cash share defer year shareholder expectation uk list business maintain commercial imperative duty committee change propose additional opportunity ensure company secure retain good talent material outperformance iu ambition additional propose annual bonus opportunity salary mean maximum potential annual award exceptional outperformance underpin bonus opportunity salary delivery significant growth shareholder value additional element achieve public remuneration arrangement enhance annual ambition sale growth bonus opportunity remain overwhelmingly weight adjust operating profit growth significantly exceed delivery longterm performance committee bring significant shareholder value confident change annual bonus good longterm interest company shareholdersremuneration policy implementation target set year new gsk require adjustment follow demerger board annual bonus lti performance measure committee believe proposal represent propose implement change annual bonus right approach appropriately focus reward executive lti measure go forward align iu deliver public ambition secure strong performance ambition trust priority metric great stakeholder linkage long shortterm measure ensure focus line line growth salary critical achieving iu ambition committee agree follow review performance ensure sharp focus strategic priority executive director receive salary include pipeline culture esg increase align provide wide workforce respective geography annual bonus measure annual total sale growth follow company announcement january annual adjust operating profit growth dr hal barron transition cso nonindependent strategic operational esg human capital nonexecutive director july committee management inclusion diversity d determine give dr barron agree remain director treat good leaver receive lti measure relative tsr total sale exist salary july prorate bonus growth year adjust operate profit growth retain exist longterm incentive award year pipeline progress esg vest subject performance prorate basis environment composite scorecard august receive fee nonexecutive committee agree key stretch strategic director subject shareholder approval operational objective executive director annum respect additional responsibility focus particularly individual area accountability undertake gsk rd underpin delivery fundamental strategy support recoupment ultimate financial success example ceo cso clear pipeline delivery objective allegation notify group february executive objective require demonstration respect dr moncef slaoui executive director culture trust priority committee ensure company committee exercise discretion measure quantifiable suitably stretch align apply claw provision recoupment policy delivery public ambition provide disclosure respect past stock incentive receive dr slaoui performance objective reassure december dr slaoui agree return group shareholder stretch form cash recoupment policy corporate responsibility committee support consumer healthcare demerger committee key consideration design make strong progress separation development adoption align approach key company new gsk haleon new list consumer esg commitment fundamental operate healthcare company mid new haleon board introduce esg measure initially short engage shareholder propose remuneration longterm plan reward delivery external ambition arrangement new company trust priority specifically respect human capital management d nature net positive climate agm net zero ambition finally like opportunity thank shareholder input engagement remuneration policy choose focus element human capital review help shape new policy present report management annual bonus esg measure consultation please able engage reinforce delivery public d target access approximately company shareholder register medicine measure consider agree welcome shareholder feedback report ahead give success area suitably agm look forward receive support new stretching target d important business remuneration policy annual report remuneration imperative suitably stretch target set annual general meeting warrant additional reward urs rohner remuneration committee chair february gsk annual report gsk annual report strategic report governance remuneration financial statement investor information glance total remuneration following show composition total remuneration pay executive director office december respect emma walmsley iain mackay dr hal barron usm usm usm usm usm usm usm fix pay salary benefit pension performance pay annual bonus ltis earn respect year performance period end december pay performance annual bonus financial performance lti outcome performance period end december overall vest maximum target relative rd new target tsr product threshold target adjust group pbit performance achieve vested adjust maximum performance target lapse free cash flow executive director shareholding audit align interest executive director share ownership vs sor multiple base salary shareholder require build maintain significant holding share gsk time executive emma walmsley x x director require continue satisfy share ownership requirement sor hold iain mackay x x sor month leave gsk sor month leave gsk dr hal barron x x executive director glt sor salary x x x x x sor december shareholding ceo executive director appoint effect january gsk leadership team member glance key change strong link short longterm performance annual bonus lti performance measure directly target payout annual bonus salary align investor update iu ambition align iu ambition ie increase deliver core ambition measure complementary design ensure inyear performance deliver longterm sustain result reward incremental exceptional performance opportunity deliver fully share defer annual bonus lti performance calibration year align shareholder experience toughen mean reduced reward target performance maximum reward exceptional annual bonus lti measure alignment performance iu ambition cascade glt wide organisation maximum annual bonus opportunity increase salary salary enable recognition exceptional outperformance achieve incentive measure align strategy ab lti performance measure alignment strategy weighting weighting relative total alignment shareholder participant reward strong ab lti shareholder return shareholder return total sale growth line growth deliver iu ambition sale growth ab lti adjust operate line growth deliver iu ambition ab lti profit growth profit growth pipeline increase emphasis innovation reward acceleration ab lti strengthen pipeline esg ambition focus key esg ambition include human capital management ab lti d priority nature net positive climate net zero ambition strategic focus key area individual accountability underpin delivery ab operational strategy public ambition key ab annual bonus lti longterm incentive executive director remuneration emma walmsley iain mackay fix remuneration salary pension reduce align wide workforce january salary annual bonus maximum opportunity half bonus pay share salary defer year incremental exceptional performance additional salary pay share defer year lti salary share ownership requirement salary dr hal barron transition nonexecutive director effect august gsk annual report gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration total remuneration audit fix pay pay performance annual bonus vested lti awards maximum opportunity vest psp award salary measure measure adjust group pbit rd new product total benefit individual objective afcf remuneration year deferral relative tsr b pension gsk share read page read page read read total remuneration audit emma walmsley iain mackay dr hal barron fix pay salary benefit pension total fix pay pay performance annual bonus vest lti award psp total pay performance total remuneration note detail mandatory bonus deferral defer annual bonus plan dabp set f rom august dr barron base salary increase reflect creation rd organisation bring scientist governance pharmaceutical vaccine focus invest matter group psp value base closing share price february closing ad price vested amount executive director attributable share price appreciation performance period ceo cfo cso committee exercise discretion relation vest award share price change committee specific circumstance line state principle apply clawbackmalus determine appropriate follow consideration committee recovery sum pay clawback reduction outstanding award vest level malus apply respect current executive directorsannual report remuneration continue total remuneration audit continue follow section provide detail element total remuneration include committee implement approve remuneration policy year fix pay audit salary table provide analysis total benefit gross table set base salary executive tax receive executive director director year compare increase benefit benefit uk workforce change base salary emma walmsley effective date benefit available employee emma walmsley business relate service iain mackay january business travel dr hal barron benefit dr hal barron august total benefit uk employee april iain mackay b ase salary increase august reflect creation benefit available employee rd organisation bring scientist governance business relate service pharmaceutical vaccine focus invest matter group business travel detail salary level provide benefit total benefit benefit dr hal barron uk remuneration reporting regulation require company benefit available employee add executive director total benefit calculation business relate service item deem tax authority taxable business travel benefit accommodation whilst business travel comprise benefit employee benefit line policy total benefit employee vary location role note business relate service provide employee assist b usiness relate service tax regulation deem taxable benefit enable carry role tax authority uk andor mackays benefit increase year year mainly deem taxable benefit individual membership global business organisation support work cfo business expense company meet recognise uk hm revenue customs deem taxable benefit incur tax arise item ncrease travel cost compare follow change covid show gross tax split area restriction neoff refund accommodation cost relate prior year business travel include travel cost executive director appropriate spousepartner associate accompany executive director gsk business deem taxable benefit executive director accommodation whilst business travel benefit gsk annual report gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue fix pay audit continued pension detail change pension policy future policy table implementation addition committee previously determine current future uk executive director pension arrangement align wide uk workforce appropriate january executive director member pension arrangement emma walmsley pension contribution base salary matching contribution salary cash iain mackay supplement base salary lieu pension salary excess dr hal barron cso member k plan open employee executive supplemental saving plan essp saving scheme open executive accrue benefit k plan limit receive base salary contribution k essp equivalent total base salary bonus net bonus defer dabp addition line wide workforce january combine contribution rate k essp plan core contribution plus match total base salary bonus net bonus defer dabp member define contribution plan emma walmsley iain mackay eligible receive matching award salary accordance term plan emma walmsley iain mackay receive cash payment lieu pension base salary excess line gsk define contribution pension plan rate follow table show breakdown pension value set pension remuneration figure calculate accordance methodology set large mediumsize company group account report amendment regulation remuneration regulation emma walmsley iain mackay dr hal barron pension remuneration value uk define contribution define benefit employer cash contribution total pension remuneration value detail pension value dr hal barron set table pension figure disclose dr hal barron member style define benefit plan accordance paragraph eii schedule remuneration regulation table show accrued benefit ie annual pension accrue date accordance remuneration regulation pension remuneration calculate increase accrue benefit adjust inflation multiply reflect fact benefit receive number year normal retirement age cash balance pension plan age additional benefit retire early accrue pension pension remuneration december december value dr hal barron pension value fund unfunded total annual report remuneration continue pay performance audit annual bonus individual annual bonus adjust group pbit objective performance target performance measure weighting follow weight adjusted group pbit performance position performance measure executive director target outcome target adjust group pbit individual objective threshold maximum performance target set target respectively adjust group pbit target outcome purpose annual bonus calculation differ adjust group pbit disclose annual report primarily target outcome number calculate apply gsk budget exchange rate actual exchange rate follow table show actual bonus earn compare bonus opportunity bonus opportunity bonus outcome financial individual total total target maximum performance objective bonus bonus bonus salary salary base salary salary salary salary emma walmsley iain mackay dr hal barron detail mandatory deferral executive director defer annual bonus plan annual bonus earn set table provide detail delivery adjust group pbit financial performance overall encourage performance exceed update guidance despite uncertainty covid pandemic deliver fullyear report group sale billion stable aer cer strong commercial execution drive cer growth pharmaceutical vaccine consumer healthcare exclude brand divestedunder review include covid solution sale billion adjust group pbit million target drive high sale effective cost control outcome adjusted exclude commercial benefit covid solution adjust eps p aer cer ahead guidance include covid solution delivery drive high sale effective cost control gsk annual report gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue pay performance audit continue follow table summarise performance scorecard individual objective agree committee executive director addition contribution financial performance individual objective achievement emma walmsley committee determine ceo clearly exceed meet individual objective highly successful year focus acceleration gsk longterm ipt priority company exceed financial target gsk track separation unlock potential new growth company landmark year company strengthen pipeline continue progress strengthen advance pharmaceutical vaccine pipeline potential new build gsk reputation medicine vaccine candidate development innovation covid solution focusse prevention treatment include xevudy sotrovimab launch treatment positive datum omicron drive growth return deliver ep ahead initial update guidance sale growth drive commercial execution excellence investment pharmaceutical sale billion vaccine billion consumer healthcare billion demonstrate continue transform specialty medicine commercial capability effectiveness key market commercial execution exceptional supply chain reliability continue covid disruption continue network strengthen excellence simplification deliver separation demerger milestone track programme milestone new ambition set new gsk deliver step change growth performance health impact scale demonstrate strong sustained lead esg performance delivery global health environment inclusion diversity environmental social commitment maintain sectorleading ranking key esg index progress deliver climate governance esg credential nature commitment build trust future delivery demonstrate strong culture culture talent deliver success new company strong progress build strong diverse leadership workforce senior female representation track gender race ethnicity aspiration continue development succession planning leadership team role internal candidate appoint chief scientific officer designate chief digital technology officer iain mackay committee determined cfo successfully meet individual objective demonstrate financial strong financial leadership key role delivery investor update set competitive growth profile new gsk leadership deliver year report group sale billion stable aer cer demonstrate financial adjust eps p aer cer ahead update guidance delivery support cost discipline oversight cost discipline initial saving scale transformation programme deliver separation separation preparation track include corporate finance capital market readiness programme milestone demonstrate strong culture strong oversight finance tech transformation include appointment new head investor relation leadership chief digital technology officer dr hal barron committee determine cso successfully meet individual objective strengthen pipeline continue rd momentum rd delivery strengthen pipeline pipeline progress target exceed build gsk reputation approval phase iii starts phase ii start potential new medicine vaccine candidate innovation development business development augment pipeline include vir iteos alector halozyme drive growth return continue progress improve rd productivity success rate include achieve fda emergency use investment authorisation xevudy month deal signing vir preclinical phase medicine prove effective multiple covid variant include omicron creation rd organisation bring scientist governance pharmaceutical vaccine focus invest matter demonstrate strong culture continue focus talent key role rd new talent key role external hire robust leadership succession planning include appointment new global head vaccine rd global head oncology development malus clawback policy detail exist policy malus clawback resolve legally permissible disclose refer company remuneration policy report unduly prejudice company annual report available gskcom shareholder committee review disclose line disclosure guideline committee recoupment committee exercise malus clawback exercise instance clawback disclosure matter subject detail recoupment committee public report misconduct fully annual report remuneration continue pay performance audit continued policy detail exist policy recruitment remuneration loss office termination payment refer remuneration policy report page annual report available gskcom change loss office policy propose remuneration policy value earn longterm incentive ltis follow table set performance achieve target set company lti plan include update performance outstanding award line committee agree principle measure applicable lti awards actual performance target review adjustment appropriate ensure vest outcome reflect genuine underlie business performance result deliver line culture trust business priority psp award performance period end december committee review performance psp award grant executive director target set adjust free cash flow afcf target revise line disclosure annual report restate account revise phase future ready programme restructure cash payment separation cost revise timing divestment base detailed programme separation planning undertake result target increase billion billion psp value base closing share price february closing ad price vested amount executive director attributable share price appreciation performance period ceo cfo cso committee exercise discretion relation vest award share price change performance achieve year december vest level set table outcome vest level performance measure relative weighting performance target outcome maximum award rd new product rd new product sale performance measure aggregate threeyear sale new bn performance product launch threeyear performance period precede rd year ie target vest maximum bn bn bn threshold bn adjust free line company agree principle afcf figure include adjustment bn cash flow number material distort item include legal settlement exchange rate performance movement special pension contribution rd original revise target target vest maximum bn bn bn bn bn bn threshold bn bn revise target adjust annual report note relative tsr rank th tsr ranking comparator group vest performance maximum st nd rd rd th th threshold median th th sr comparator group astrazeneca bristolmyers squibb eli lilly gsk johnson johnson merck co novartis pfizer roche holding sanofi vest schedule base deliver vest median performance comparator group company median fall company total vest respect award gsk annual report gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue pay performance audit continue update performance ongoing lti awards committee review performance psp award grant executive director follow chart provide estimate vest level take account performance december actual vest level determine base performance threeyear performance period indication regard prediction final vest level afcf threshold associate vest scale psp award adjust net overall impact increase billion billion award increase billion billion award adjustment account follow item revise phase future ready programme restructure cash payment base detailed programme planning undertake revise dividend noncontrolle interest viiv shionogi pfizer change target set innovation sale previously name rd new product relative tsr performance measure award psp award psp award rank rd rank rd bn threshold bn threshold maximum commercially commercially commercially commercially median bn sensitive sensitive median bn sensitive sensitive threshold relative adjust free innovation pivotal trial major relative adjust free innovation pivotal trial major tsr cash flow sale start regulatory tsr cash flow sale start regulatory approval approval milestone milestone estimate vest level estimate lapsing level pipeline progress pipeline progress threshold performance award vest respect performance measure individual lti award level appear annual report set lti awards historical vest lti plan vest year adjust free rd new business lapse total vested grant relative tsr cash flow product diversification lti awards dabp award respect deferral bonus psp award show table dabp award psp awards total bonus number face value award level number face value defer share award base salary share award emma walmsley share share iain mackay share share dr hal barron ad ad face value dabp award calculate base share price ad price closing price february day grant nilcost option uk executive director restrict share executive director performance condition attach dabp award reflect mandatory year deferral respect annual bonus earn face value psp award calculate base share price ad price closing price february day grant conditional share base performance measure outline performance period psp award january december awards vest maximum threshold performanceannual report remuneration continue director pay wider set internal context set executive pay important committee good understand wide workforce pay end annual basis meet human resource business leader global support function pharmaceutical viiv healthcare vaccine consumer healthcare understand perspective pay gsk remuneration package wide workforce year annual meeting hold pleased discuss progress group human capital management d agenda attract retain diverse talent lie heart company fundamental commitment equity employment reward practice meeting cover current reward environment employee enterprise notable global competitive challenge face company competitive pressure inhigh demand skill business action take attract retain key talent area handle different pay level group different geography include company experience particular pay challenge currently anticipate experience future mitigatory step take address preparation competitive reward strategy programme consumer company implementation demerger progress company publicly disclose gender ethnically diverse leader aspiration discuss countrybase review clear guidance tool support provide market ensure pay equity finally dame vivienne cox workforce engagement director member committee ensure employee view perspective pay reward reflect committee discussion urs rohner remuneration committee chair remuneration structure employee element wide workforce pay comparison executive director glt pay salary market competitiveness salary company executive director glt ordinarily assess local market level competitiveness follow performance review increase base salary role measure external market line average wide employee internal peer keep regular review population change scope individual role responsibility experience pension company seek provide appropriate pension executive director glt eligible benefit package align competitive receive benefit broadly line policy benefit market practice country employee vary location company operate employee base pension arrangement structure accordance executive director glt member expect retire current future uk executive director pension arrangement align wide uk workforce january annual exception sale force participate executive director glt participate plan bonus separate arrangement wide workforce participate base assessment combination stretching plan base performance business financial business personal objective financial measure measure consumer executive director require defer healthcare structure reflect priority glt bonus earn share specific business area adss appropriate year plan design reward employee collective clawback andor malus provision apply contribution business achievement separate mechanism place recognise outstanding individual performance address underperformance lti plan employee senior vice president svp vice executive director glt grant annual president vp level participate psp psp award performance target executive director glt period performance target period executive director require hold vested clawback andor malus provision apply award additional twoyear period svp vp employee director clawback andor malus provision apply manager glt receive annual share value executive director glt receive share plan award restrict share value plan award follow appointment gsk annual report gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue director pay wide set continue ceo pay ratio supplementaladditional ratio lower upper gsk ceo pay ratio likely vary potentially significantly quartile median quartile time drive largely ceo variable pay outcome financial year methodology p p p line reward principle ceo large portion pay base performance individual p p option p mean depend gsk performance ratio increase decrease significantly committee pay ratio calculate actual earning believe senior executive significant ceo uk employees ceo total single figure proportion pay directly link performance remuneration light provide supplemental ratio detailed report lti compensation exclude believe total remuneration uk fulltime equivalent employee provide additional view ltis form substantial company december calculate line percentage ceo total remuneration highly single figure methodology employer pension variable dependent business performance ceo contribution employee define benefit pension total remuneration exclude lti compensation cost complexity calculation instead future service rate agree recent actuarial funding financial year methodology p p p valuation employee reflect actual earning receive exclude option business expense produce percentile calculation option remuneration regulation business expense exclude reimburse total remuneration vest longterm incentive award employee sufficiently substantial value historic ceo remuneration significantly impact ratio emma walmsley gsk continue choose option robust statistically accurate way company total remuneration calculate ratio option available annual bonus award maximum remuneration regulation increase pay ratio vest lti awards maximum high level bonus receive compare sir andrew witty reflect high business individual performance set table base salary total pay total remuneration benefit percentile annual bonus award maximum vest lti awards maximum p p p emma walmsley total remuneration include pay period january salary march ceo total sir andrew witty receive prorata payment lieu variable bonus opportunity accordance remuneration policy pay benefit psp dabp awards sir andrew witty grant vest april accordance term executive financial recoupment policy committee believe median pay ratio consistent company pay reward progression policy base salarie employee include executive director set reference range factor include market practice experience performance roleannual report remuneration continue director pay wide set continue percentage change remuneration director percentage change percentage change salaryfee benefit bonus salaryfee benefit bonus uk employee executive director emma walmsley iain mackay dr hal barron nonexecutive director sir jonathan symonds charle bancroft vindi banga dr anne beal dame vivienne cox lynn elsenhans dr laurie glimcher dr jesse goodman urs rohner judy lewent uk employee population consider relevant comparison closely reflect economic environment encounter majority executive director percentage change calculate base total remuneration table executive director total fee table nonexecutive director information salary benefit executive director find information annual bonus executive director find fee nonexecutive director include fee receive cash form share ad term nonexecutive director share allocation plan charle bancroft dr anne beal appoint board respectively judy lewent retired board relative importance spend pay participant company share save plan save table show total employee pay group dividend month year end period pay shareholder option buy gsk share discount share change price start saving contract participant share reward plan contribute month purchase total employee pay gsk share company match dividend pay year detail figure table reflect payment year impact movement exchange dilution limit rate set page dividend award plan incorporate dilution declare respect million limit consistent guideline publish investment million increase association limit roll tenyear period total employee pay base employee average plan roll tenyear period executive number people employ share plan grant senior executive estimate dilution exist award year share repurchase company december follow allemployee share plan uk executive director participate hmrc approve gsk employee share plan allemployee share plan wide uk workforce ie share save share reward plan executive share plan actual limit gsk annual report gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue director pay wide set continue external context comparator group pay relative tsr performance graph committee pay comparator group follow graph set performance company consider executive pay global pharmaceutical relative ftse index pharmaceutical comparator group measure relative tsr performance comparator group tenyear period performance primary group executive december index select comparison director follow purpose reflect primary index gsk constituent industry operate european crossindustry comparator group emma walmsley roche holding ag linde deutsche telekom iain mackay novartis sanofi kere lvmh astrazeneca heineken anheuserbusch inbev diageo basf unilever siemens vinci sap christian dior adida loreal inditex bayer novo nordisk bat safran airbus volkswagen reckitt benckiser global pharmaceutical comparator group dr hal barron france sanofi abbvie switzerland amgen novartis bristolmyer squibb roche holdings eli lilly johnson johnson uk merck co astrazeneca pfizer gsk total return gsk pharma peer ftse total return index total return index bbvie amgen include remuneration benchmarking include relative tsr comparator group index comprise astrazeneca bristolmyers squibb eli lilly johnson johnson merck co novartis pfizer roche holding sanofi ceo total remuneration positioning review ceo remuneration committee reference pay global pharmaceutical group european global crossindustry pharmaceutical group group low quartile median upper emma walmsley median quartile current position remuneration include salary expect value incentive base committee agree benchmarke methodologyannual report remuneration continue implementation remuneration policy fix pay pay performance salary annual bonus committee consider average increase annual bonus plan redesign well align award employee level executive director iu ambition trust priority detail propose uk consideration performance change annual bonus plan refer agree appropriate award increase line glance propose remuneration wide workforce ceo cfo cso ensure policy report page competitiveness remuneration maintain bonus opportunity salary base salary change exceptional target maximum performance wide workforce emma walmsley emma walmsley iain mackay iain mackay dr hal barron dr hal barron exceptional performance additional salary fully pay share base average increase budget employee level glt deferred year uk weight performance measure dr barron transition nonexecutive director effect august adjust strategic benefit total sale operate operational esg inclusion significant change provision benefit propose growth profit growth measure diversity emma walmsley detail policy relation benefit refer propose new remuneration policy iain mackay report dr hal barron pension reduce payout target performance table provide overview pension compare current policy propose increase arrangement ongoing executive director payout opportunity target performance incentivise exceptional outperformance excess iu committee previously commit reduce exist ambition trust priority goal uk executive director pension align wide uk workforce january increase importance trust business priority esg commitment lead propose inclusion new ukbased usbased executive director pension diversity human capital management measure annual align appropriate wide workforce bonus base progress aspirational appointment target gender ethnically diverse representation senior pension contribution role emma walmsley base salary matching contribution iain mackay salary accordance term inevitably target link directly financial strategic plan open employee base plan commercially sensitive committee salary lieu pension salary excess consider appropriate disclose annual bonus target dr hal barron base salary contribution k year result competitive harm detail essp equivalent total base salary bonus performance target usual disclose net bonus defer dabp addition retrospective basis annual report line wide workforce january combine contribution rate k defer annual bonus plan dabp award essp plan core contribution plus match total base salary bonus net table provide detail mandatory deferral bonus defer dabp dabp annual bonus payment associate award grant share award dr barron transition nonexecutive director effect august performance condition hold year regardless continue employment total bonus defer dabp award share share ad emma walmsley iain mackay dr hal barron gsk annual report gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue implementation remuneration policy continue performance share plan psp award performance table provide detail award grant relative tsr continue measure gsk psp global pharmaceutical comparator group total sale growth adjust operate profit growth salary share emma walmsley measure recognise importance commercial iain mackay ambition iu committee set target align ambition dr barron receive psp award give transition nonexecutive director august trust business priority propose new esg environment measure base lti performance measure trust priority goal nature net positive proposing change measure weight climate net zero impact lti award well align iu ambition target esg environment measure grant trust priority detail refer base series nature goal relate water remuneration policy report new propose waste material reduction biodiversity impact climate lti measure weight goal incorporate scope emission reduction target carbon offset industrialisation green ventolin lti measure measure weight innovation pipeline progress shareholding versus share ownership requirement performance relative tsr sor audit total sale growth adjust operate profit growth align interest executive director trust esg environment shareholder require build maintain significant holding share gsk time executive composite scorecard incorporate scope target assessment performance metric determined line world resource director require continue satisfy share instituteworld business council sustainable development ghg protocol ownership requirement sor hold sor methodology accounting reporting emission footprint month leave gsk innovation sor month leave gsk pipeline progress measure seek reward acceleration strengthen pipeline base equally value holding salary sor weight element key asset indication measure salary february december threeyear performance period emma walmsley point allocate successful asset submeasure iain mackay base forecast commercial value peak year sale dr hal barron end performance period share subject performance condition exclude submeasures award vest follow executive director sor calculation end pivotal trial start performance period vest share include focuses mainly phase iii registrational trial start director sor extent performance include phase ii start eg oncology condition meet value holding calculate posttax basis performance level point payout threshold nil dr hal barron ad contribute sor include threshold investment gsk k plan essp emma walmsley dr barron currently exceed sor iain mackay join board early currently maximum work satisfy sor company process place ensure major regulatory approval executive director sor continue satisfied performance level point payout leave gsk include monitor nominee account threshold nil executive director agree term sor threshold include service contract maximum pipeline progress measure commercially sensitive time grant end performance period provide disclosure achievedannual report remuneration continue remuneration governance committee role membership subject election subsequent annual reelection detail available incorporate subject mutual agreement expect serve reference report chair ceo chief people year year appointment line officer head reward group financial controller provision code subject annual company secretary assisted committee year reelection adviser committee committee focus pricewaterhousecooper llp pwc independent remuneration policy adviser committee appoint committee set broad structure remuneration policy initial period year commercial tender determine remuneration executive director exercise conclude company prior expiry chair corporate officer initial period committee review quality item discuss service pwc provide result agree extend propose remuneration policy pwcs term end allow remuneration impact major group restructuring ch market review undertake summer demerger follow commercial tender appropriate prior engagement shareholder consideration feedback presenting recommendation committee adviser salary review support january pwc member committee periodically review consider remuneration remuneration consultant group voluntarily environment executive director glt approve annual operate code conduct relation executive adjustment necessary regard performance remuneration consulting uk code conduct remuneration wide workforce find wwwremunerationconsultantsgroupcom item discuss review remuneration environment wide employee trend year addition provide consultancy service executive director glt benchmarking competitiveness committee pwc provide consulting assurance gsk comparator group service company line protocol agree set glt company secretary salary review recommendation committee chair pwc provide advice committee satisfied advice objective executive director salary review recommendation independent pwc provide independent commentary annual bonus matter consideration committee update committee responsible set specific performance market practice legislative requirement review measure annual bonus assessment performance potential conflict interest judge item discuss appropriate safeguard conflict pwcs fee ceo executive director glt bonus recommendation advice year charge fix ceo executive director bonus objective time material basis willis tower watson provide additional market datum committee lti plan committee responsible approve lti plan rule change shareholder vote remuneration matter grant assessment performance vest lti award vote executive director glt include interim award total vote total vote total vote withhold cast billion million item discuss remuneration report lti performance outcome vest lti awards glt agm remuneration policy confirmation lti grant glt agm governance area focus committee adhere robust remuneration governance service contract letter appointment framework ensure alignment internal action external table set date executive director reportingcompliance requirement service contract available review company item discuss register office gskcom executive director remuneration consideration committee programme service contract contain month notice period review term reference date contract effective date expiry date committee evaluation annual review emma walmsley remuneration report iain mackay na confirmation group budget remuneration purpose agm remuneration report feedback external dr hal barron remuneration environment performance target disclosure dr barron transition nonexecutive director letter appointment incentive plan effect august remuneration report disclosure include ceo pay ratio nonexecutive director ne letter appointment annual governance meeting key committee message available view company register office committee chair consultation employee representative ne expect serve board end set pay wide workforce pay practice agm follow anniversary appointment gsk annual report gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue nonexecutive director fee chair nonexecutive director nonexecutive director fee company aim provide chair non nonexecutive director fee apply executive director fee competitive set table pay company equivalent size complexity annum subject limit contain article association standard annual fee supplemental fee chair fee chair audit risk committee chair pay fee annum senior independent director take gsk share chair fee review scientific medical expert appointment review annually chair remuneration corporate responsibility science committee conclude remain appropriate workforce engagement director nonexecutive director undertake intercontinental meet travel meeting implementation nonexecutive director policy nonexecutive director standard supplemental fee increase effect january follow review subject shareholder approval agree authorise payment fee january science committee member annum pay respect additional responsibility undertake behalf gsk support rd reflect time commitment responsibility expect increase fee payable nonexecutive director new policy period total fee audit audit table set value fee benefit receive nonexecutive director form cash share ad detail nonexecutive director share allocation plan set nonexecutive director fee pay currency sterling convert average exchange rate review time time average exchange rate update nonexecutive director fee convert dollar exchange rate benefit comprise gross cash value travel subsistence cost incur normal course business relation attendance board committee meeting overseasbase director include travel meeting uk nonexecutive director fix fee fix fee emolument audit cash sharesad benefit total pay cash sharesad benefit total pay sir jonathan symonds vindi banga charles bancroft dr anne beal dame vivienne cox lynn elsenhans dr laurie glimcher dr jesse goodman urs rohner judy lewent r etired board annual report remuneration continue director interest share audit executive director interest share interest executive director company office person closely associate pca show table december unvested share plan interest beneficial subject total director interest interest subject performance performance february december sharesad sharesad option sharesad share emma walmsley iain mackay ad dr hal barron total director interest include beneficial interest unvested share plan interest subject performance balance february include sharesad award performance share plan psp defer annual bonus plan dabp vested february sell satisfy tax liability vest amount executive director shareholding versus sor outline b eneficial interest include sharesad hold executive director pcas emma walmsley include share purchase glaxosmithkline share reward plan iain mackay currently participate share reward plan employee dr hal barron eligible participate share reward plan open uk employee dr barron beneficial interest include ad notional ad hold way investment gsk k plan executive supplemental saving plan essp detail dr barron membership plan find u nveste sharesad subject performance represent psp sharesad vest subject additional twoyear hold period emma walmsley dr barron unvested ad subject performance dr barron represent bonus deferral describe note unvested option subject performance represent bonus deferral dabp award nilcost option describe note unvested sharesad subject performance represent unvested psp award vest unexercised option director hold vested unexercised option abp table show bonus deferral subsequent reinvestment dividend dabp amount represent gross sharesad balance prior sale sharesad satisfy tax liability vest deferred annual bonus plan bonus deferral february december january shares emma walmsley iain mackay ad dr hal barron uk employee bonus deferral dabp grant nilcost option emma walmsley iain mackay follow table set detail nilcost option exercise number share date market price gain exercise dabp date grant option exercise grant price exercise emma walmsley deferral award respect nilcost option award dabp bonus defer executive director record remuneration annual bonus total remuneration table respect number share option include initial award reinveste dividend accrue date exercise gsk annual report gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue director interest share audit continued nonexecutive director interest share interest nonexecutive director company office person closely associate pca show table share allocation plan nonexecutive director total director interest number sharesad beneficial dividend elect december interest reinveste december allocate february december year end year january share sir jonathan symond vindi banga dame vivienne cox urs rohner ad charle bancroft dr anne beal dr hal dietz lynn elsenhans dr laurie glimcher dr jesse goodman judy lewent otal director interest include beneficial interest sharesad receive fee nonexecutive director share allocation plan dividend receive sharesad plan year january convert sharesad january beneficial interest include sharesad hold nonexecutive director pcas haresad allocate year nonexecutive director share allocation plan cover quarter allocation period october december change timing allocation sharesad allocate include dividend reinveste year j udy lewent retire board time hold ad nonexecutive director share allocation plan release term plan hold subject uk income tax director senior management information provide compensation interest director senior management group group purpose group define executive nonexecutive director member glt company secretary financial year follow table set aggregate remuneration group period serve capacity remuneration total compensation pay aggregate increase accrue pension benefit net inflation aggregate payment define contribution scheme member group award share ad company lti plan set table align interest senior management shareholder executive director glt member require build maintain significant holding share gsk time glt member require hold share equivalent multiple time base salary continue satisfy share ownership requirement minimum month leave gsk award dividend reinvestment award award share ad share ad performance share plan defer investment award share value plan n otional share ad executive director eligible receive defer investment award participate share value planannual report remuneration continue director senior management continue february group pcas follow interest share ad company interest award lti plan describe note financial statement employee share scheme interest february share ad own unexercised option defer annual bonus plan performance share plan defer investment award share value plan n otional share e xecutive director eligible receive defer investment award participate share value plan fee respect executive director external appointment ceo emma walmsley independent nonexecutive director microsoft corporation receive deliver cash stock option microsoft corporation defer compensation plan nonemployee director cso dr hal barron nonexecutive director grail inc private company august earn fee payment past director audit simon dingemans leave board voluntary leaver vest dabp award govern remuneration policy prevailing time mr dingemans leave board table reflect value defer bonus accrue dividend point release number date vest share vest dabp february payment loss office audit loss office payment remuneration policy continue reflect provision uk corporate governance code code clarity simplicity remuneration arrangement executive director set clear simple way remuneration policy prior finalise remuneration policy committee consult extensively shareholder ensure transparency clarity implementation fix remuneration element salary benefit pension closely align wide workforce arrangement pay performance plan annual bonus longterm incentive reward delivery financial strategic esg objective short longterm risk line code operate deferral postvesting holding period addition malus clawback provision committee retain discretion adjust award outcome zero appropriate consider payout determine appropriately reflect overall position performance company predictability proportionality remuneration policy define maximum limit total annual bonus longterm incentive opportunity payout element link fulfilment performance condition support company publicly state ambition implementation maximum reward short longterm plan achievable material outperformance state ambition alignment culture gsk purpose value strategy directly reflect performance condition set annual bonus longterm incentive particular introduce esg measure short longterm plan give external ambition trust priority nature net positive climate net zero ambition share ownership requirement strengthen focus strategic aim ensure alignment interest experience shareholder employment remuneration policy operate intended term company performance quantum gsk annual report gsk annual report strategic report governance remuneration financial statement investor information remuneration policy summary remuneration policy review current remuneration policy policy approve create longterm shareholder value shareholder annual general meeting drive success company benefit receive vote favour shareholder shareholder patient people key stakeholder ask approve new policy annual general meeting intend apply year addition change policy ensure implementation support delivery business strategy committee consider policy define whilst deliver clear understandable appropriately biopharma business new approach remuneration competitive package attract retain motivate executive decisionmaking process committee follow talent determination review implementation propose new policy set committee chair statement page committee develop new policy executive nonexecutive director context oversight wide workforce pay consult directly employee committee review policy sought ensure new policy consult large shareholder continue respect propose change take shareholder align company business priority culture wide feedback account finalise new policy workforce pay policy emerge good practice table provide overview main change support bold performance ambition announce propose respect new policy policy investor june company key esg commitment shareholder ask approve set page remuneration element propose change policy rationale change pension description policy update reflect commitment give reflect pension arrangement current uk remuneration report pension executive director align new arrangement executive director executive director arrangement january align new contribution rate update executive director january reference update reflect late contribution rate wide workforce come effect january annual bonus maximum bonus opportunity executive director additional opportunity salary target performance introduce annual bonus bonus payout salary appropriately focus reward executive bonus equivalent salary deliver exceed public ambition executive director require defer secure strong performance bonus earn share ad appropriate stakeholder year portion bonus earn excess additional opportunity salary defer defer ensure alignment basis shareholder interest nonexecutive authority seek nonexecutive director appropriately remunerate nonexecutive director fee member science committee director work remunerate annum undertake additional responsibility behalf gsk support rd current requirement nonexecutive director company choose replace chair invest net basic fee current investment requirement share ad company retain minimum ownership requirement company choose replace chair continue maintain meaningful nonexecutive director minimum prudent level investment align non share ad ownership requirement executive director interest times gross annual standard fee shareholder retirement board share ad previously ability replace current investment acquire investment fee continue requirement facilitate great flexibility hold arrangement operation arrangement deliver release follow retirement board share ad count expect minimum ownership requirement remuneration policy report subject shareholder approval gsk annual general meeting remuneration policy remuneration element outline table future policy table salary provide core reward role set level appropriate secure retain high calibre change individual need deliver group strategic priority operation opportunity individual role experience performance independently formal maximum limit ordinarily salary increase source datum relevant comparator group consider broadly line average increase wider determine salary level gsk workforce salary increase typically effect quarter increase higher reflect change year scope individual role responsibility experience salary adjustment reflect wide market condition salary normally pay currency executive geography individual operate director home country detail current salary level set annual report remuneration performance measure overall performance individual key consideration determine salary increase benefit level set recruit retain high calibre individual execute business strategy change operation executive director base outside uk executive director eligible receive benefit line require travel uk fulfil responsibility policy employee vary location role attend board meeting subject tax include limited car allowance healthcare business travel expense uk life assurancedeath service provide provision accommodation uk reality individual pension arrangement personal financial advice represent business expense tax treatment require contractual postretirement benefit line policy travel accommodation expense include employee executive director eligible benefit business context tax liability receive overseas relocation allowance international cover company grossedup basis transferrelate benefit require executive director benefit provision tailor reflect market practice uk eligible participate allemployee share geography executive director base scheme eg share save share reward plan different policy apply current future executive subject term director base different country employee opportunity order recognise high business travel requirement formal maximum limit benefit cost fluctuate role executive director entitle car travel depend change provider cost individual exceptionally accompany spousepartn circumstance business trip benefit include expense incur ordinary course business deem taxable detail current benefit cost set annual benefit individual report remuneration performance measure gsk annual report gsk annual report strategic report governance remuneration financial statement investor information remuneration policy report continue future policy table continue pension pension arrangement provide competitive level retirement income change pension arrangement provide competitive level retirement new executive director uk receive date income appointment base salary contribution define contribution plan operation match contribution subject pension arrangement structure accordance relevant cap line implementation principle plan operate country individual likely member plan retire individual choose member base salary cash payment lieu pension pension plan cash lieu relevant pension contribution portion relevant cap contribution pay instead executive director uk entitle join define contribution pension plan base salary cash payment lieu pension receive cash payment lieu pension contribution contribution individual member gsk legacy define benefit plan define contribution plan alternative supplemental cash balance pension plan provide annual pension plan arrangement subsequently appoint contribution base salary total base salary board remain member plan bonus net bonus defer dabp gsk k plan essp core contribution opportunity salary bonus match contribution policy current executive director salary bonus uk january current executive director base salary contribution define contribution plan role pension arrangement align match contribution subject new executive director arrangement follow relevant cap line implementation principle new executive director receive date member plan appointment base salary cash payment lieu pension gsk k plan essp core contribution contribution portion relevant cap salary bonus match contribution salary bonus base salary cash payment lieu pension global contribution eligible appropriate equivalent arrangement excess january current uk director usuk arrangement role pension arrangement align new performance measure executive director arrangement follow n event change plan operate similar treatment provide successor arrangement introduce market l ess bonus defer dabp offset equal contribution k essp move pension plan line wide workforce january annual bonus incentivise recognise execution business strategy annual basis reward change achievement stretch annual financial strategic operational measure operation committee adjust formulaic vest outcome financial operational business target set start ensure overall outcome reflect underlying year committee bonus level determine business performance vest period clawback andor committee base performance target malus provision apply describe strategic operational measure set start opportunity year committee performance maximum bonus opportunity executive director measure assess committee salary target performance bonus executive director require defer bonus earn payout financial measure nil target share ad appropriate year performance bonus payout salary equivalent salary defer portion excess defer deferred bonus share eligible dividend equivalent date vest remuneration policy report continue future policy table continue performance measure base combination financial target individual reason majority annual bonus opportunity strategic esg performance objective majority base formal review performance stretch bonus assess financial measure financial target remainder bonus subject weight different measure determine assessment individual performance key strategic year accord business priority detail include operational measure align company measure financial year provide key objective financial year andor assessment annual report remuneration performance esg target selection annual bonus measure annual bonus financial target set reference annual bonus design drive achievement internal budget external consensus target gsk annual financial strategic operational measure performance incentivise recognise delivery long term business priority financial growth share plan psp increase shareholder value compare pharmaceutical company addition provide alignment shareholder interest retention element encourage longterm change shareholding discourage excessive risk take operation opportunity conditional award annually vest dependent normal maximum award limit grant achievement performance condition year psp individual year set table subject additional twoyear hold period psp target set reference internal budget external salary consensus target ceo award eligible dividend equivalent date cfo vest release executive director committee adjust formulaic vest outcome performance measure ensure overall outcome reflect base combination financial share price relate underlie business performance vest period strategic esg performance condition align clawback andor malus provision apply describe company strategic plan measure award vest threshold performance detail include performance target attach psp respect year weighting target psp award provide annual report remuneration selection longterm incentive measure major adjustment calculation performance committee select performance measure focus measure disclose shareholder vest executive director longterm remuneration delivery audit risk committee chair member gsk key strategic priority long term addition member remuneration committee provide input set robust target committee implement number audit risk committee review group safeguard ensure target meet sustainable way performance oversight risk factor relevant performance reflect genuine achievement target remuneration decision represent delivery value shareholder detail rationale performance measure performance measure impact acquisition select calculate set annual divestment quantify adjust event report remuneration share ownership requirement change align interest executive director minimum executive director require maintain shareholder require build maintain share ownership requirement end significant holding share gsk time year follow retirement company requirement executive director follow end second year salary ceo executive director gsk annual report gsk annual report strategic report governance remuneration financial statement investor information remuneration policy report continue future policy table continue clawback malus change event trigger event ie significant misconduct respect financial year remuneration committee way violation regulation law significant gsk policy disclose recoupment committee code conduct material misstatement result exercise clawback malus disclosure reputational damage company matter subject public report ability claw year annual defer misconduct fully resolve legally bonus vest unvested ltis addition permissible disclose respect psp award participant unduly prejudice company shareholder subject investigation vest award additionally continuity responsibility delay outcome investigation initiation adverse event emergence separate recoupment committee establish problem adverse event take account investigate relevant claim misconduct recoupment assess annual bonus award lti vest level committee exercise authority wide employee base year problem identify future period comprise senior executive relevant oversight remuneration committee recoupment committee appropriate experience include senior vice president appropriate adjustment individual annual bonus chief compliance officer senior vice president grant vest level lti awards reflect group general counsel legal compliance approach recruitment remuneration change committee determine remuneration package new internal appointment entitlement exist executive director casebycase basis depend remuneration element continue include pension role market operate entitlement outstanding award experience total remuneration level set reference case internal appointment require relevant pay comparator group appropriate executive director contractual term include allow future development role termination provision expect new executive director participate committee mindful sensitivity relate short longterm incentive plan basis recruitment package particular buy exist director exceptional circumstance right relate previous employment seek committee reserve flexibility set incentive limit minimise arrangement certain new executive director additional circumstance enable recruitment exceptional talent exist limit committee determine arrangement good interest company shareholder committee retain flexibility recognition high arrangement possible likeforlike basis level variable pay gsk global pharmaceutical forfeit remuneration term arrangement competitor committee use flexibility vary depend plan arrangement consider good interest company place previous employer form investor cash share subject performance pension arrangement external recruit executive condition explanation provide payment director set remuneration policy table compensation previous remuneration forfeit remuneration arrangement newly appoint benefit provide line policy exist executive director disclose soon practicable executive director appointment require meet business need relocation support provide line company policy remuneration policy report continue future policy table continue loss office payment policy change company policy fix term contract notice period termination employ company generally contract new appointment expire line executive director calendar month applicable policy retirement age ability impose month noncompete period nonsolicitation restriction executive director contract exist executive director expire consider important company ability date show protect group intellectual property staff light committee believe appropriate provide mitigation contract termination employment event executive director employment company terminate follow policy payment apply element remuneration loss office payment policy termination termination notice month annual salary payable termination company prorate notice period work payment termination payment respect notice period extend contract expiry date bonus element normally include termination payment term contract seek balance commercial imperative good practice redundancy termination notice uk statutory redundancy pay apply general severance policy apply retirement death illhealth injury disability termination payment lti award psp award govern plan rule approve shareholder follow provision normally apply termination notice unvested awards lapse redundancy retirement death illhealth injury disability reason generally award continue vest original timescale subject performance prorate time event change control psp award vest take account performance date normally take account proportion performance period elapse alternatively award exchange new award annual bonus termination notice individual individual serve notice termination date fall december bonus forfeit termination notice company redundancy retirement death illhealth injury disability termination date fall financial year eligible prorate ontarget bonus employ december bonus payable base actual result mandatorily dabp defer bonus award respect mandatorily defer bonus amount govern plan rule approve shareholder defer follow provision normally apply bonus termination gross misconduct generally unvested awards lapse dabp reason generally award vest original vest date event change control awards vest exchange new award pension pension scheme contribution individual company pension scheme benefit accrual generally cease termination date accordance pension scheme rule access pension scheme benefit govern pension scheme rule country legislation benefit generally benefit continue apply termination date committee payment connection exist legal obligation respect claim related cessation employment include fee outplacement assistance legal andor professional advice termination notice company retirement executive line policy applicable senior executive eligible future date receive continue medical dental insurance terminationretirement termination mutual agreement certain circumstance good interest company board manage proactively succession planning development senior talent pipeline circumstance board agree executive departure mutual agreement order apply committee need satisfied executive demonstrate performance line expectation require contribute orderly succession case executive director treat good leaver purpose gsk longterm incentive plan termination date fall financial year eligible prorate ontarget bonus employ december bonus payable base actual result gsk annual report gsk annual report strategic report governance remuneration financial statement investor information remuneration policy report continue loss office payment policy continue committee anticipate exercise discretion executive director leave company provide psp dabp plan rule respect committee carry assessment individual termination payment manner benefit performance conduct time role executive director unforeseen determined individual performance conduct circumstance good interest company contrary legitimate expectation company shareholder necessary exercise committee reserve right apply appropriate mechanism discretion explanation provide clawback reduction lapse outstanding incentive award malus ensure termination payment good interest company shareholder difference remuneration policy executive director employee set remuneration executive director employee directly consult respect committee consider company strategic priority remuneration policy urs rohner committee chair prevail market condition global talent competitive meet senior hr representative business environment comparison remuneration review employee feedback dame vivienne cox executive company similar size complexity independent nonexecutive director engage employee international reach position relativity pay topic include remuneration role employment condition broad gsk workforce workforce engagement director board member engage employee board meeting particular committee consider range base encourage share view company management salary rise workforce part gsk remuneration executive director employ consider relevant comparison population reflect wide organisation align performance closely economic environment encounter reward system innovation performance trust individual prioritie culture anchor purpose performance performance system evaluate employee principle apply remuneration policy need senior executive director employee people disincentivise unethical working practice remuneration offer executive director clawback mechanism allow recover performance policy strong emphasis performancerelate pay relate pay offer employee group salary benefit include pension tailor local market annual bonus plan apply wide employee population base business performance combination performancerelate restricted share plan apply wide employee population allemployee share plan available employee uk include hm revenue customs approve uk share save share reward plan remuneration policy report continue scenario future total remuneration chart opposite provide illustration future total remuneration executive director respect emma walmsley remuneration opportunity grant propose remuneration policy range potential outcome provide executive director underlie assumption set scenario base salary benefit figure ie base actual amount receive pension emma walmsley iain mackay base salary amount show value psp award base relevant multiple include amount respect dividend reinveste factor change share price vest period fix expect maximum maximum share price describe increase fix include base salary pension benefit exclude pay iain mackay performance ie annual bonus pay psp award vest expect include fix pay annual bonus assume target performance achieve psp award amount reflect vest level maximum fix expect maximum maximum share price assume annual bonus payable increase maximum level ie award psp vest fix pay annual bonus psp share price increase maximum share price increase element maximum assume increase share price gsk annual report gsk annual report strategic report governance remuneration financial statement investor information remuneration policy report continue nonexecutive director remuneration policy nonexecutive director fee change element purpose link strategy operation chair fee provide inclusive flat rate formal maximum fee review annually set reference fee competitive review chair performance independently source market datum pay company committee responsible evaluating make recommendation board equivalent size fee payable chair chair participate discussion respect fee complexity subject limit contain gsk article association basic fee formal maximum chair fee review annually set reference independently source datum chair ceo responsible evaluating make recommendation board fee payable company nonexecutive director fee payment alignment shareholder fee pay cash nonexecutive director include chair require invest total net fee share ad company company choose replace ownership requirement hold share ad aggregate value time gross annual standard fee retirement board current investment requirement replace ownership requirement share ad previously acquire investment fee continue hold arrangement deliver release follow retirement board share ad count minimum ownership requirement supplemental compensate nonexecutive additional fee senior independent director committee chair science medical expert fee director workforce engagement director role intercontinental travel chair take additional company authority pay additional fee equivalent committee chair board responsibility supplement nonexecutive director company require significant additional time undertake intercontinental commitment exceptional unforeseen circumstance travel company authority pay additional fee nonexecutive director exclude chair member science committee undertake additional responsibility behalf gsk support rd benefit facilitate execution travel subsistence cost nonexecutive director incur normal course business responsibility dutie relation meeting board committee matter gskhoste event overseas require role base nonexecutive director include travel meeting uk event necessary business purpose whilst normal practice nonexecutive director accompany spouse partner meeting event cost associate meet company instance deem taxable treat benefit nonexecutive director approach recruitment remuneration change follow policy principle apply role chair nonexecutive director nonexecutive director seek ensure alignment fee level new nonexecutive director set shareholder requirement invest company basis exist nonexecutive director share ad company subject local law regulation event nonexecutive director different role chair responsibility appoint fee level benchmarke fee set level competitive pay set reference comparable role company company equivalent size complexity fee equivalent size complexity pay partly share loss office change chair nonexecutive director entitle receive payment respect fee loss office retire step board remuneration policy report continue operation scope remuneration policy remuneration policy policy set page ii policy come effect provide term annual report intend policy payment consistent shareholderapprove gsk executive nonexecutive director operate remuneration policy force time agree period year date approval company iii time relevant individual director annual general meeting company opinion committee payment committee write policy principally relation consideration individual director remuneration arrangement executive director whilst company purpose payment include take account possible recruitment replacement committee satisfy awards variable remuneration additional executive director operation relation award share ad term policy committee intend policy operate payment agree time award grant period set entirety performance share plan psp award subject consideration seek change policy period term psp plan rule award believe appropriate longterm grant committee adjust amend award success company consultation shareholder accordance provision plan rule includes seek shareholder approval general meeting make adjustment reflect oneoff corporate event committee reserve right remuneration change company capital structure payment andor payment loss office include committee minor amendment policy exercise discretion available connection regulatory exchange control tax administrative purpose payment notwithstanding line account change legislation obtain policy term payment agree shareholder approval amendment agm date company shareholderapprove director remuneration policy come statement consideration shareholder view effect committee engage regular dialogue shareholder hold annual meeting gsk large investor discuss feedback remuneration policy practice governance matter basis preparation annual report remuneration prepare annual report remuneration approve accordance company act large board director sign behalf mediumsize company group account report amendment regulation regulation accordance regulation follow part urs rohner annual report remuneration subject audit total remuneration committee chair remuneration figure executive director include february details element remuneration salary benefit pension annual bonus longterm incentive awards nonexecutive director fee emolument receive year director interest share include interest gsk share plan payment past director payment loss office share ownership requirement holding opinion thereon express remain section annual report remuneration subject audit page refer audit section gsk annual report gsk annual report strategic report governance remuneration financial statement investor information financial statement section director statement responsibilitie independent auditor report financial statement note financial statement financial statement glaxosmithkline plc prepare uk gaap gsk annual report strategic report governance remuneration financial statement investor informationdirector statement responsibilitie director responsible prepare annual report director responsible keep adequate accounting remuneration report group parent company record sufficient explain company financial statement accordance applicable law transaction disclose reasonable accuracy time regulation financial position group enable ensure group financial statement remuneration uk company law require director prepare financial report comply company act article statement financial year director require ias regulation responsible safeguarding prepare group consolidated financial statement asset group take reasonable step accordance international accounting standard prevention detection fraud irregularity conformity requirement company act international financial reporting standard ifrs group financial statement year end issue international accounting standard board iasb december comprise principal statement director elect prepare parent company support note set financial statement financial statement accordance united kingdom page report parent company accounting standard applicable law united kingdom financial statement year end december generally accept accounting practice company law comprise balance sheet statement change director approve financial statement equity year end december support satisfied true fair view state note set page affair group profit loss period responsibilitie auditor relation financial prepare financial statement director statement set independent auditor report require page select suitable accounting policy apply financial statement year end december consistently include annual report publish print form available website director judgement accounting estimate responsible maintenance integrity annual reasonable prudent report website accordance uk legislation state group financial statement comply govern preparation dissemination financial ifrs issue iasb conformity statement access website available outside requirement company act uk comparable legislation different state regard parent company financial statement current director name function applicable uk accounting standard list corporate governance section annual follow subject material departure disclose report confirm good knowledge explain parent company financial statement group financial statement prepare prepare financial statement go concern basis accordance ifrs issue iasb inappropriate presume group conformity requirement company act parent company continue business true fair view asset liability financial position profit group strategic report risk section annual report represent management report include fair review development performance business position company group take description principal risk uncertainty face gsk annual report gsk annual report strategic report governance remuneration financial statement investor information director statement responsibility continue disclosure information auditor uk corporate governance code director office date annual report board consider glaxosmithkline plc apply confirm principle comply provision uk corporate governance code maintain financial report far aware relevant audit council describe corporate governance section information company auditor unaware page board consider take step ought annual report take fair balanced take director aware understandable provide information necessary relevant audit information establish company shareholder assess group position performance auditor aware information business model strategy confirmation give interpret require financial conduct authority list rule accordance provision section auditor consider director statement company act compliance relation point uk corporate governance code specify review go concern basis page contain information performance annual report group financial position cash flow net debt position annual report year end december borrowing facility information include treasury comprising report director remuneration risk management policy exposure market credit risk report financial statement additional information hedging activity give note financial investor approve board director statement financial instrument relate disclosure sign behalf assess principal risk matter consider connection viability statement sir jonathan symond director consider appropriate adopt go concern chairman basis accounting prepare financial statement february internal control board audit risk committee review assessment risk internal control framework operate gsk consider effectiveness system internal control operation group year cover annual report date approval board director detail review internal control set governance report independent auditor report members glaxosmithkline plc report audit financial statement opinion basis opinion opinion conduct audit accordance international standard audit uk isas uk applicable law financial statement glaxosmithkline plc parent responsibility standard company subsidiary group true describe auditor responsibility audit fair view state group parent financial statement section report company affair december group profit year end independent group parent company accordance ethical requirement relevant group financial statement properly prepare audit financial statement uk include accordance united kingdom adopt international financial reporting council frc ethical standard accounting standard international financial reporting apply list public interest entity fulfil standard ifrss issue international accounting ethical responsibility accordance standard board iasb requirement confirm provide parent company financial statement properly nonaudit service prohibit frc ethical standard prepared accordance united kingdom generally group parent company note audit risk accept accounting practice include frs reduced committee report corporate governance section disclosure framework annual report financial statement prepare accordance believe audit evidence obtain requirement company act sufficient appropriate provide basis opinion audit financial statement comprise audit scope execution group structure approach audit reflect consolidated balance sheet december group organise ensure audit consolidated income statement year end effective risk focus audit approach consolidate statement comprehensive income summarise follow area enable obtain year end evidence require form opinion group consolidate statement change equity year parent company financial statement end risk assessment audit planning group level consolidated cash flow statement year end central control common system group enable structure audit centrally use note financial statement include datum analytic tool allow detailed understanding accounting principle policy flow transaction enable focus risk assessment design target audit testing procedure parent company risk assessment procedure consider balance sheet december factor impact global pandemic climate change account balance disclosure company statement change equity year end practice appoint partner group audit team note l financial statement include lead global audit business unit accounting principle policy pharmaceutical vaccine consumer healthcare addition partner responsible component legal financial reporting framework apply entity audits country global business unit preparation group financial statement applicable law partner meet regularly senior business unit management united kingdom adopt international accounting standard understand strategy performance matter ifrss issue iasb financial reporting arise year impact framework apply preparation financial reporting addition hold regular meeting parent company financial statement applicable law member internal audit internal legal counsel united kingdom accounting standard include frs global ethic compliance team understand reduce disclosure framework united kingdom generally work review report enhance risk accept accounting practice assessment audit work perform global share service centre significant group operational process cover financial reporting undertake share service centre group audit team include senior individual responsible global process coordinate audit work share service centre gsk annual report gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue inscope group audit ensure develop good impact climate change audit understand endtoend process support climate change potential impact group material account balance class transaction number way set strategic report page disclosure group financial statement annual report note evaluate effectiveness internal control financial financial statement group set environmental reporting process consider goal paris climate accord net zero impact implication remainder audit work climate net positive impact nature audit work execute component level individual planning audit consider potential legal entity follow component subject impact climate change group business audit procedure assessment financial statement effectiveness internal control financial reporting seek understand group identification australia belgium canada china france germany italy assessment potential impact climate change japan spain switzerland united kingdom united risks influence group strategy implication state group audit team active dialogue financial statement audit component audit team responsible audit work direction group assessment focus impact supervision group audit team include frequent extreme weather condition water scarcity change determine work plan perform political landscape medium focus accordance overall group audit strategy propensity cause change consumer market requirement group audit instruction behaviour volatility cost availability material component restriction overseas travel resource impact future financial performance visit component year consistent prior asset valuation year satisfy oversight supervision consultation climate change specialist appropriate perform remote review audit work paper videoconferencing technology conduct detailed risk assessment procedure increase frequency length review inscope balance transaction determine risk depend significance risk component material misstatement financial statement apply continue attend planning clearance meeting expect impact climate change understand component business audit procedure undertake group level challenge appropriateness group assessment parent company addition perform potential impact climate change impact audit work group parent company financial financial statement include area statement include limited consolidation intangible asset describe section report group result preparation financial assessment impact climate change statement certain disclosure director challenge group assessment go concern remuneration report litigation provision exposure include consider potential impact future addition entity level oversight control relevant performance availability finance financial reporting component legal entity engage provide assurance annual revenue great total group revenue accuracy climate change disclosure set page include audit scope component legal annual report audit procedure entity cover audit scope subject require read consider disclosure analytical procedure confirm conclusion consider materially inconsistent significant risk material misstatement financial statement knowledge obtain audit aggregate financial information identify material inconsistency result internal control testing approach test procedure effectiveness internal control financial reporting inscope entity entity level control application materiality group level common system allow relevant define materiality magnitude misstatement control test centrally component financial statement make probable economic able place reliance control plan decision reasonably knowledgeable person efficient notwithstanding control change influence use materiality planning deficiency disclose key audit matter section scope audit work evaluate result report mitigate control exist allow work continue reliance control plan audit scope address group revenue group profit tax group total assetsindependent auditor report continue report audit financial statement continue base professional judgement determine agree audit risk committee materiality financial statement follow report committee audit difference excess million million difference parent company group financial statement financial statement threshold view warrant reporting materiality million million qualitative ground report audit risk million million committee disclosure matter identify basis determine benchmark materiality assess overall presentation financial statement determine materiality consider determined materiality metric investor total asset benchmark conclusion relate go concern reader financial statement cap particular consider group materiality audit financial statement conclude statutory profit tax adjust materiality represent director use go concern basis accounting profit tax revenue net total asset preparation financial statement appropriate cash flow operation professional judgement evaluation director assessment group determine materiality parent company ability continue adopt go concern million basis accounting include metric enquiry group director management statutory profit tax assumption go concern model include adjusted profit tax potential impact climate change revenue net cash inflow evaluate group exist access source operating activity financing include undrawn commit bank facility reconciliation statutory reading analyst report industry datum external profit tax adjust profit tax detail adjust information determine provide corroborative item section strategic report contradictory evidence relation assumption compare forecast sale recent historical financial rationale give importance parent company information metric investor hold group benchmark reader financial statement investment test underlying datum generate prepare forecast apply conclude statutory profit profitoriente scenario determine adequate tax primary strength benchmark adjust profit balance sheet key support assumption underlie forecast tax revenue net cash measure financial evaluate group disclosure go concern inflow operating activity health important support benchmark shareholder requirement ias component materiality primary concern base work perform identify allocate inscope parent company material uncertainty relate event condition component range payment million million dividend individually collectively cast significant doubt benchmark total group parent company ability continue go range materiality allocate asset concern period month component audit appropriate metric prior year group financial financial statement authorise issue statement relation reporting group apply million million uk corporate governance code material set performance materiality level low materiality add draw attention relation director statement reduce probability aggregate uncorrected financial statement director consider undetected misstatement exceed materiality appropriate adopt go concern basis account financial statement group parent company responsibility responsibilitie director performance materiality set group parent respect go concern describe relevant section materiality respectively audit report determine performance materiality consider factor include risk assessment include assessment group overall control environment consider appropriate rely control number business process past experience audit indicate low number correct uncorrected misstatement identify prior period gsk annual report gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue key audit matter key audit matter matter professional judgement significance audit financial statement current period include significant assess risk material misstatement fraud identify matter include great effect overall audit strategy allocation resource audit direct effort engagement team matter address context audit financial statement form opinion financial statement provide separate opinion matter key audit matter description scope audit respond key audit matter valuation viiv healthcare shionogi contingent audit procedure perform consideration liability perform follow audit procedure group complete number significant transaction relate sale forecast result recognition material contingent obtain group assessment key input consideration liability key source estimation assumption forecast evaluate uncertainty significant liability appropriateness include enquiry key individual viiv healthcare shionogi contingent consideration liability senior leadership team commercial strategy team viiv ccl key personnel involve budgeting forecasting process group complete acquisition remain inspection support evidence interest shionogiviiv healthcare joint venture challenge volume assumption group completion group recognise contingent estimate sale forecast involve benchmarking forecast consideration liability fair value expect future market share datum external datum total payment shionogi december prescription volume new patient prescription volume liability value million order assess source contradictory evidence identify viiv ccl key audit matter evaluate reasonableness pricing assumption significant management estimate assumption relate group compare forecast return rebate rate sale forecast valuing viiv ccl product current rate assess forecast sensitivity valuation input significant return rebate comparable product relate sale forecast united states expect change payer policy certain product treatment portfolio forecast base assessment expect launch date consider result clinical study undertake year ability shift market practice prescriber behaviour group key competitor order assess longacte injectable treatment drug regimen corroborative contradictory assumption continue impact covid relate restriction hiv product portfolio sale forecast prescription subsequent sale volume pricing benchmarke group sale forecast forecast require significant audit effort perform include report analyst consider sale appropriate audit procedure challenge evaluate forecast total viiv basis individual product reasonableness forecast basis assess identify contradictory datum set note post balance sheet event group inspect agreement gilead evaluate financial statement agreement reach gilead management approach ensure meet relevant accounting settle global patent infringement litigation relate standard requirement input estimate commercialisation gilead biktarvy increase future impact fair value viiv ccl consistent consideration payable shionogi impact fair agreement external data value viiv ccl result audit assess management estimate impact test control key input assumption valuation contingent consideration liability include contingent consideration liability include viiv ccl review control sale forecast treatment product disclose key source estimation uncertainty note portfolio value viiv ccl group financial statement disclosure provide note matter discuss key observation communicate audit risk committee audit risk committee report corporate sale forecast valuation reasonable line governance section annual report relevant support information satisfy sale forecast reasonable appropriately reflect trend overall hiv treatment market include change competitive environment shift longacte injectable treatment drug regimen approach value viiv ccl consistent prior period overall satisfied valuation liability reasonable consistent ifrsindependent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter valuation return rebate rar accrual audit procedure perform group sell customer commercial perform follow audit procedure government mandate contract reimbursement relate estimate rar accrual arrangement include rebate chargeback right challenge assumption selection utilisation rate return certain pharmaceutical product revenue focus certain product conclude accrual recognition reflect grosstonet sale adjustment sensitive assumption challenge include adjustment know return rebate rar comparison historical utilisation rate consideration accrual source significant estimation uncertainty historical accuracy driver market change material impact report revenue impact ongoing generic competition macroeconomic pharmaceutical business million impact covid pandemic rar deduction gross revenue million supplement substantive analytical procedure result net revenue million balance sheet develop independent expectation accrual balance accrual december combine key segment base historical claim receive pharmaceutical vaccine business amount adjusted reflect market change period include million assessment time lag initial point sale significant payer channel refer claim receipt compare independent buying group rar accrual relate manage expectation record evaluate appropriateness healthcare organisation medicaid ryan white medicare year end accrual position consider historical accuracy estimate evaluate main cause significant estimation uncertainty forecast assumption appropriately update selection case actual rebate claim differed utilisation rate portion total sale accrue payer channel estimate group recording accrual utilisation assumption challenge appropriateness completeness challenge key assumption derive accrual periodend adjustment liability give influence market demand factor ongoing review estimate accrual outside control group test key control estimation rar accrual time lag point sale point include control associate forecasting exact rebate amount know group receipt utilisation rate process monthend accrual review claim payer channel long time lag result control great accrue period great level key observation communicate audit risk committee estimation uncertainty estimate period end accrual satisfied estimate liability rar accrual level estimation uncertainty impact significant yearend appropriate observe level prudence shift channel mix drive change competitive estimate assess independent landscape include competitor generic product launch expectation accordance requirement ifrs macroeconomic factor focus revenue contract customer limit risk utilisation assumption product deem significant reversal revenue level estimation uncertainty significant furthermore auditing standard presume significant fraud risk exist revenue recognition line presumption focus periodend adjustment rar accrual adjustment reflect update initial assumption include forecasted rar rate view present great opportunity fraud revenue recognition notwithstanding existence internal control pharmaceutical return rebate disclose key source estimation uncertainty note group financial statement disclosure provide note matter discuss audit risk committee report corporate governance section annual report gsk annual report gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter valuation intangible asset audit procedure perform december group hold million perform follow audit procedure intangible asset include licence patent trademark relate future sale growth likelihood successful new brand name exclude goodwill computer product innovation profit margin level assessment software recoverable intangible intangible asset impairment asset rely certain assumption estimate future meet key individual senior leadership team trading performance create estimation uncertainty product category lead key personnel involve asset risk material impairment identify forecasting process discuss evaluate group sensitivity analysis key assumption review evidence support future sale growth rate profitability potential trigger event indicative assumption impairment carrying value associate asset evaluate group risk assessment impact climate result analysis perform additional audit procedure change long term forecast focus large certain indefinite life consumer healthcare intangible asset product material carry value headroom key assumption apply determine recoverable compare external data point include future sale growth rate profit margin level evaluate business assumption apply estimate sale likelihood successful new product innovation gross profit margin forecast include benchmarke change assumption lead impairment forecast external market datum actual trading carrying value intangible asset performance cost include independent market research identify valuation intangible asset key expect category growth assessment source audit matter inherent judgement involve contradictory evidence estimate future cash flow year compare forecast sale gross profit margin increase uncertainty bring covid plan datum asset asset internal forecast approve pandemic associate lockdown auditing estimate gsk leadership team board director require extensive audit effort challenge evaluate reasonableness forecast assess historical accuracy forecast include consumption datum estimate new sale innovation disclosure relate intangible asset include note group financial statement matter consider event transaction occurred discuss audit risk committee report balance sheet date reporting date affect corporate governance section annual report conclusion reach carry value asset associate disclosure test review control key input assumption valuation intangible asset control encompass review valuation model contain number assumption revenue growth rate profit margin key observation communicate audit risk committee audit challenge future forecast performance consumer healthcare product conclude assumption underpin impairment review intangible asset reasonable accordance ifrsindependent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter valuation uncertain tax position include transfer audit procedure perform pricing support tax specialist assess group operate numerous jurisdiction appropriateness uncertain tax provision perform open tax transfer pricing matter exposure uk follow audit procedure overseas tax authority rise uncertain tax assess challenge provision uncertain tax position position wide range possible outcome evaluation possible outcome procedure provision contingency certain judgement respect focused jurisdiction group estimate tax exposure contingency require great potential exposure high level order assess adequacy tax provision judgement require complex result consideration require multiple tax law regulation assess assumption judgement require determine range possible outcome recognition december group record provision measurement uncertain tax position compliance million respect uncertain tax position requirement ifric valuation uncertain tax position disclose key source involve transfer pricing specialist evaluate transfer estimation uncertainty note group financial pricing methodology group associate approach statement disclosure include note provision recognition measurement matter discuss audit risk committee report corporate governance section annual report consider evidence actual result recent tax authority audits enquiry thirdparty tax advice obtain group tax specialist knowledge market practice relevant jurisdiction test key control preparation review report judgmental tax balance transaction include provision uncertain tax provision key observation communicate audit risk committee satisfied estimate relation uncertain tax position relate disclosure accordance ifrs work conclude consistent approach apply estimate uncertain tax provision whilst continue prudent require ifric appropriate supportable gsk annual report gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter system impact financial reporting audit procedure perform system group form critical component audit scope drive level reliance place group financial reporting activity impact account technology obtain sufficient audit evidence business balance process technology deem relevant audit base financial datum system configure automate control andor key identify system impact financial reporting financial report reside specialist key audit matter support evaluation risk associate technology pervasive reliance complex technology integral testing design operation control operation key business process financial testing technology deem relevant audit include reporting follow area reliance technology continue increase line general control include user access change business strategy increase use management control automation group key financial report system configure automate control importance control maintain effective control environment key interdependency exist control provide assurance completeness ability rely control ability rely accuracy relevant data migration financial datum system configure automate control test remediation previously identify deficiency system report risk assessment procedure include assessment continue remediation control support impact unremediated control deficiency determine application system relevant group financial impact audit plan relevant audit plan reporting activity adjust include test additional manual business implementation application system key business process control mitigate unaddresse risk area year key observation communicate audit risk committee system impact financial reporting discuss satisfied control impact group financial audit risk committee report corporate reporting activity design operate effectively control governance section annual report deficiency identify remediate year end mitigate compensating control significant progress year remediate control deficiency relate user access change management group layer business process control mitigate risk associate remain control deficienciesindependent auditor report continue report audit financial statement continue information information comprise information include annual report financial statement auditor report thereon director responsible information contain annual report opinion financial statement cover information extent explicitly state report express form assurance conclusion thereon responsibility read information consider information materially inconsistent financial statement knowledge obtain course audit appear materially misstate identify material inconsistency apparent material misstatement require determine give rise material misstatement financial statement base work perform conclude material misstatement information require report fact summarise work relation area information include area specifically require report matter specifically require report responsibility report principal risk viability statement review confirmation description light knowledge set corporate governance statement gather audit consider director section material report add draw process support statement challenging key judgement attention respect matter estimate consideration historical forecasting accuracy evaluate macroeconomic assumption consider statement align relevant provision code director remuneration report report director remuneration report audit set opinion matter prescribe properly prepare disclosure specify company act company act section opinion director remuneration report audit prepared accordance company act strategic report director report report consistent audit financial statement set opinion matter prescribe prepared accordance applicable legal requirement company act section opinion base work undertake course audit report identify material misstatement report information report consistent light knowledge understanding group parent audit financial statement prepare company environment obtain course audit accordance applicable legal requirement gsk annual report gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue report information responsibility report alternative performance measure apm apm measure define generally accept accounting opinion practice gaap typically include financial use calculation disclosure apm statement annual report group use apm adjust consistent group publish definition profit free cash flow constant currency growth rate report policy financial performance use apm group report result review assess calculation report consistent guideline produce esma metric assess consistency group publish definition frc policy item appropriate balance use consider assess use apm statutory metric apm clear group report result consistent guideline produce definition reconciliation apm financial regulator european security market authority esma report guideline use apm frc alternative performance measure thematic review publish october consider appropriate balance use statutory metric apm addition clear definition reconciliation apm financial reporting provide dividend distribution policy consider dividend policy transparent dividend pay opinion dividend policy appropriately consistent policy outline strategic report disclose dividend pay consistent policy responsibility director auditor responsibility audit financial statement explain fully director responsibilitie statement director responsible preparation objective obtain reasonable assurance financial statement satisfy financial statement free true fair view internal control director material misstatement fraud error determine necessary enable preparation financial issue auditor report include opinion reasonable statement free material misstatement assurance high level assurance guarantee fraud error audit conduct accordance isa uk detect material misstatement exist prepare financial statement director misstatement arise fraud error consider responsible assess group parent material individually aggregate reasonably companys ability continue go concern disclose expect influence economic decision user take applicable matter related going concern basis financial statement go concern basis accounting director intend liquidate group parent company cease description responsibility audit operation realistic alternative financial statement locate frc website wwwfrcorgukauditorsresponsibilitie description form auditor reportindependent auditor report continue report audit financial statement continue audit response risk identify extent audit consider result perform identify valuation capable detecting irregularity include return rebate accrual key audit matter fraud relate potential risk fraud key audit matter irregularity include fraud instance noncompliance section report explain matter detail law regulation design procedure line describe specific procedure response key audit responsibility outline detect material matter common audits isas uk misstatement respect irregularity include fraud require perform specific procedure respond risk extent procedure capable detect management override irregularity include fraud detail addition procedure respond risk identify include follow identify assess potential risk relate irregularity review financial statement disclosure test identify assess risk material misstatement support documentation assess compliance respect irregularity include fraud noncompliance provision relevant law regulation describe law regulation consider follow direct effect financial statement nature industry sector control environment enquire senior leadership team audit risk business performance include design group committee inhouse external legal counsel remuneration policy key driver director remuneration concern actual potential litigation claim bonus level performance target perform analytical procedure identify unusual result enquirie senior leadership team internal unexpected relationship indicate risk material audit audit risk committee include obtain misstatement fraud review support documentation concern read minute meeting charge group policy procedure relate governance review internal audit report identify evaluate comply law correspondence regulator regulation aware instance address risk fraud management override noncompliance control test appropriateness journal entry detect respond risk fraud adjustment assess judgement knowledge actual suspect alleged make accounting estimate indicative potential fraud bias evaluate business rationale significant transaction unusual outside normal course internal control establish mitigate risk relate business fraud noncompliance law regulation communicate relevant identify law regulation matter discuss engagement team include potential fraud risk engagement team member significant component audit team involve relevant significant component audit team remain alert internal specialist include tax valuation pension indication fraud noncompliance law industry specialist fraud regulation audit occur financial statement potential indicator fraud report legal regulatory requirement obtain understand legal regulatory framework group operate focus provision opinion matter prescribed law regulation direct effect company act determination material amount disclosure financial statement key law regulation opinion director remuneration report consider context include provision uk audit properly prepare accordance company act pension legislation tax legislation company act consider key law regulation opinion base work undertake course fundamental effect operation group include audit good clinical practice fda regulations general datum protection requirement antibribery corruption policy information give strategic report director foreign corrupt practice act report financial year financial statement prepare consistent financial statement strategic report director report prepared accordance applicable legal requirement gsk annual report gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue light knowledge understanding group director remuneration parent company environment obtain company act require report course audit identify material opinion certain disclosure director remuneration misstatement strategic report director report director remuneration report audit agreement account corporate governance statement record return list rule require review director statement report respect matter relation go concern longerterm viability corporate governance statement relate group matter require compliance provision uk corporate address governance code specify review auditor tenure base work undertake audit follow recommendation audit risk committee conclude follow element corporate effect january appoint governance statement materially consistent financial board director audit financial statement year statement knowledge obtain audit end december subsequent financial period director statement regard appropriateness period total uninterrupted engagement firm adopt go concern basis accounting year material uncertainty identify set consistency audit report additional report director explanation assessment group audit risk committee prospect period assessment cover audit opinion consistent additional report period appropriate set audit risk committee require provide director statement fair balanced understandable accordance isa uk annual report set use report board confirmation carry robust assessment emerge principal risk set report solely parent company member page body accordance chapter company act audit work undertake section annual report describe review state parent company member effectiveness risk management internal control matter require state auditor report system set page purpose full extent permit law section describe work audit risk accept assume responsibility committee set page parent company parent company member body audit work report opinion matter require report form exception course require financial conduct authority adequacy explanation receive accounting record fca disclosure guidance transparency rule dtr company act require report r financial statement form opinion european single electronic format esefprepare annual financial report file national storage mechanism receive information explanation uk fca accordance esef regulatory technical require audit standard esef rts auditor report provide adequate accounting record keep assurance annual financial report parent company return adequate audit prepare single electronic format specify receive branch visit esef rts parent company financial statement agreement parent company pass resolution accordance accounting record return section company act senior statutory auditor state report respect matter deloitte llp statutory auditor london united kingdom february consolidated income statement year end december note turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit finance income finance expense share tax profit associate joint venture loss disposal interest associates profit taxation taxation profit taxation year profit attributable noncontrolle interest profit attributable shareholder basic earning share penny p p p dilute earning share penny p p p consolidate statement comprehensive income year end december note profit year comprehensive incomeexpense year item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal overseas subsidiary associate fair value movement cash flow hedge tax fair value movement cash flow hedge reclassification cash flow hedge income statement item reclassify income statement exchange movement overseas net asset noncontrolle interest fair value movement equity investment tax fair value movement equity investment remeasurement gainslosse define benefit plan tax remeasurement define benefit plan comprehensive expenseincome year total comprehensive income year total comprehensive income year attributable shareholder noncontrolle interest total comprehensive income year gsk annual report gsk annual report strategic report governance remuneration financial statement investor information consolidate balance sheet december note noncurrent asset property plant equipment right use asset goodwill intangible asset investment associate joint venture investment defer tax asset derivative financial instrument noncurrent asset total noncurrent asset current asset inventory current tax recoverable trade receivables derivative financial instrument liquid investment cash cash equivalent asset hold sale total current asset total asset current liability shortterm borrowing contingent consideration liability trade payable derivative financial instrument current tax payable shortterm provision total current liability noncurrent liability longterm borrowing corporation tax payable deferred tax liability pension postemployment benefit provision derivative financial instrument contingent consideration liability noncurrent liability total noncurrent liability total liability net asset equity share capital share premium account retain earning reserve shareholder equity noncontrolle interest total equity financial statement page approve board february sign behalf sir jonathan symonds chairmanconsolidate statement change equity year end december shareholder equity share share retain noncontrolle total capital premium earning reserve total interest equity december revise implementation ifrs december adjust profit year comprehensive expenseincome year total comprehensive income year distribution noncontrolle interest change noncontrolle interest dividend shareholder recognition interest consumer healthcare jv realise loss disposal equity investment share issue share acquire esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december profit year comprehensive expenseincome year total comprehensive income year distribution noncontrolle interest contribution noncontrolle interest change noncontrolle interest dividend shareholder share issue realise profit disposal equity investment share associates joint venture realise profit disposal equity investment share acquire esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december profit year comprehensive expenseincome year total comprehensive income year distribution noncontrolle interest contribution noncontrolle interest dividend shareholder realise profit disposal equity investment share associates joint venture realise profit disposal equity investment share issue writedown share hold esop trust sharebase incentive plan transaction noncontrolle interest tax sharebase incentive plan december analysis reserve present note movement equity gsk annual report gsk annual report strategic report governance remuneration financial statement investor information consolidated cash flow statement year end december note cash flow operating activity profit taxation year adjustment reconcile profit tax operating cash flow cash generate operation taxation pay net cash inflow operating activity cash flow investing activity purchase property plant equipment proceed sale property plant equipment purchase intangible asset proceed sale intangible asset purchase equity investment proceed sale equity investment contingent consideration pay purchase business net cash acquire disposal business net cash dispose investment associate joint venture increasedecrease liquid investment interest receive proceed disposal associate joint venture dividend associate joint venture equity investment net cash inflowoutflow investing activity cash flow financing activity issue share capital purchase noncontrolle interest increase longterm loan repayment shortterm note repayment ofincrease shortterm loan repayment lease liability interest pay dividend pay shareholder distribution noncontrolle interest contribution noncontrolle interest finance cash flow net cash outflow financing activity decreaseincrease cash bank overdraft cash bank overdraft begin year exchange adjustment decreaseincrease cash bank overdraft cash bank overdraft end year cash bank overdraft end year comprise cash cash equivalent cash cash equivalent report asset hold sale overdraft note financial statement presentation financial statement description business financial period gsk major global healthcare group engage financial statement cover financial year creation discovery development manufacture january december comparative figure market pharmaceutical product vaccine overthe financial year january december counter otc medicine healthrelate consumer appropriate january december product gsk principal pharmaceutical product include accounting principle policie medicine follow therapeutic area respiratory hiv immunoinflammation oncology metabolic financial statement prepare antibacterial dermatology historical cost convention modify revaluation certain item state accounting policy go compliance applicable law ifrs concern basis financial statement prepare accordance financial statement prepare accordance international accounting standard conformity group accounting policy approve board requirement company act international describe note accounting principle policy financial reporting standard issue iasb information application accounting policy include area estimation judgement give note composition financial statement critical accounting judgement key source estimation consolidated financial statement draw sterling uncertainty functional currency glaxosmithkline plc accordance ifrs accounting presentation financial preparation financial statement conformity statement comprise generally accept accounting principle require management estimate assumption affect report consolidated income statement amount asset liability disclosure contingent consolidate statement comprehensive income asset liability date financial statement consolidate balance sheet report amount revenue expense report period actual result differ estimate consolidated statement change equity parent company financial statement consolidate cash flow statement financial statement parent company note financial statement glaxosmithkline plc prepare accordance composition group uk gaap uk accounting presentation company list subsidiary associate opinion balance sheet present accounting director principally affect profit net policy give page asset group give note principal group company accounting principle policy consolidation group ability exercise joint control consolidated financial statement include right net asset entity entity account joint venture group ability asset liability result cash flow exercise joint control arrangement right company subsidiary include esop trust specify asset obligation specify liability group share result net asset associate arrangement arrangement account joint joint venture operation group ability exercise significant influence entity account group share asset liability revenue expense associate result asset liability associate joint operation joint venture incorporate consolidated financial statement entity consolidate financial statement equity method accounting december year group right asset liabilitie revenue expense entity group power direct joint operation include consolidated financial relevant activity affect return group statement accordance right obligation generally control financial operating interest acquire entity consolidated date policy account subsidiary group acquire control interest sell deconsolidate date control cease gsk annual report gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue accounting principle policy continue transaction balance subsidiary eliminate exchange adjustment arise open net asset profit tax take sale subsidiary profit year retain overseas subsidiary product sell customer outside group associate joint venture translate sterling relevant proportion profit transaction joint exchange difference arise related foreign currency venture joint operation associate defer borrowing hedge group net investment product sell party transaction non operation take separate component equity control interest record directly equity defer retain earning tax relief unrealise intragroup profit account translate sterling asset liability result extent consider recoverable cash flow overseas subsidiary associate joint business combination venture report currency hyperinflationary economy adjustment material reflect business combination account acquisition current price level loss net monetary asset charge accounting method identifiable asset liability contingent consolidated income statement liability acquire measure fair value acquisition date consideration transfer measure fair value revenue include fair value contingent consideration turnover fair value contingent consideration liability group receive revenue supply good external reassess balance sheet date change customer order receive majority contract recognise income statement payment contingent gsk enter relate sale order contain single consideration reduce balance sheet liability result performance obligation delivery pharmaceutical record income statement vaccine consumer healthcare product average payment relate original estimate duration sale order month fair value contingent consideration acquisition product revenue recognise control good report investing activity cash flow statement pass customer point control pass payment relate increase liability determine customer arrangement generally occur acquisition date report operate cash flow delivery customer consideration transfer non product revenue represent net invoice value include fix control interest exceed fair value net asset variable consideration variable consideration arise sale liability contingent liability acquire excess good result discount allowance give accrual record goodwill cost effecting acquisition estimate future return rebate revenue charge income statement period recognise highly probable significant reversal incur cumulative revenue recognise occur goodwill capitalise separate item case methodology assumption estimate rebate subsidiary cost investment case return monitor adjust regularly light joint ventures associate goodwill denominate contractual legal obligation historical trend past experience currency operation acquire project market condition estimate associate return rebate revisit reporting date cost acquisition fair value net resolve revenue adjust accordingly refer asset acquire difference recognise directly note detail rebate discount allowance income statement group enter collaborative agreement typically equity subsidiary acquire pharmaceutical biotechnology company noncontrolle interest recognise fair value develop produce market drug candidate vaccine noncontrolle interest share net asset subsidiary qualify joint arrangement gsk control casebycase basis change group ownership commercialisation activity group recognise turnover percentage subsidiary account equity cost sale gross basis profit sharing amount foreign currency translation royalty counterparty record cost sale foreign currency transaction book functional cost sale include profit sharing cost million currency group company exchange rate ruling million million counterparty control date transaction foreign currency monetary asset commercialisation activity record sale group liability retranslate functional currency deem principal customer contract instead record rate exchange rule balance sheet date exchange share gross profit copromotion income net basis difference include income statement turnover nature copromotion activity group record cost sale pharmaceutical turnover consolidation asset liability include related include copromotion revenue million million goodwill overseas subsidiary associate joint million reimbursement counterparty venture translate sterling rate exchange collaboration sell general administration rule balance sheet date result cash flow research development cost record net overseas subsidiary associate joint venture respective line consolidate income statement translate sterling average rate exchangenote financial statement continue accounting principle policy continue operate income royalty income liability include group portion total cost gsk enter development marketing collaboration portion potentially responsible party cost outlicence group compound product probable able satisfy party contract rise fix variable respective share cleanup obligation recovery consideration upfront payment development milestone reimbursement record asset virtually certain salesbased milestone royalty legal dispute income dependent achievement development provision anticipate settlement cost legal milestone recognise highly probable dispute group outflow resource significant reversal cumulative revenue consider probable reliable estimate recognise occur usually relate event likely outcome respect product liability claim relate occur salesbase milestone income recognise certain product provision sufficient highly probable sale threshold reach history claim settlement enable management salesbase royalty licence intellectual property reliable estimate provision require cover recognise relevant product sale occur unasserted claim revenue time recognition revenue certain case incur report ibnr actuarial payment customer expect technique determine estimate addition year impact material consideration provision legal expense arise discount appropriate discount rate claim receive dispute value add tax sale taxis exclude revenue group involved legal proceeding respect possible meaningfully assess expenditure outcome result probable outflow expenditure recognise respect good service quantify reliably estimate liability case receive supply accordance contractual term appropriate disclosure case include provision obligation exist future liability provision respect past event cost associate claim group obligation reliably estimate manufacturing startup party charge income statement incur cost validation achievement normal production expense incur pension postemployment benefit advertising promotion expenditure charge income cost provide pension define benefit scheme statement incur calculate project unit credit method spread period benefit expect derive shipment cost intercompany transfer charge cost employee service consistent advice qualified sale distribution cost sale customer include actuary sell general administrative expenditure pension obligation measure present value restructuring cost recognise provide estimate future cash flow discount rate reflect appropriate respect direct expenditure business yield highquality corporate bond pension scheme asset reorganisation plan sufficiently detail measure fair value balance sheet date advance appropriate communication affect undertaken cost postemployment liability calculate similar way define benefit pension scheme spread research development period benefit expect derive research development expenditure charge employee service accordance advice income statement period incur qualified actuary service cost provide retirement development expenditure capitalise criterion benefit employee year cost recognise asset meet usually regulatory filing curtailment charge operating profit year major market approval consider actuarial gain loss effect change actuarial highly probable property plant equipment assumption recognise statement comprehensive research development capitalise depreciated income year arise accordance group policy group contribution define contribution plan environmental expenditure charge income statement incur environmental expenditure relate exist condition result past current operation employee share plan current future benefit discernible charge income incentive form share provide employee statement group recognise liability sitebysite share option share award scheme basis reliably estimate fair value option award calculate grant date blackschole option pricing model charge income statement relevant vesting period gsk annual report gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue accounting principle policy continue group provide finance esop trust purchase nonlease component account separately company share meet obligation provide share lease component plant equipment lease employee exercise option award cost run separately account land building vehicle lease esop trust charge income statement modification reassessment lease obligation occur share hold esop trust deduct lease liability right use asset remeasure reserve transfer reserve retain right use asset title expect pass gsk earning vest period relate share option point future depreciate basis consistent award reflect ultimate proceed receivable similar own asset case right use asset employee exercise depreciate short useful life asset property plant equipment lease term property plant equipment ppe state cost goodwill purchase construction provision depreciation goodwill state cost impairment goodwill impairment financing cost capitalise cost deem indefinite useful life test qualify asset construction impairment annually depreciation calculate write cost residual fair value interest acquire entitys value ppe exclude freehold land straightline asset liability contingent liability exceed basis expect useful life residual value live consideration pay excess recognise immediately review appropriate adjust annually normal gain income statement expect useful life major category ppe intangible asset freehold building year intangible asset state cost provision leasehold land building lease term year amortisation impairment plant machinery year equipment vehicle year licence patent knowhow marketing right separately acquire acquire business combination disposal ppe cost relate accumulate amortise estimate useful life generally depreciation impairment remove financial exceeding year straightline basis statement net proceed take time available use estimate useful life income statement determine amortisation charge account patent lease live exclusivity period applicable value group recognise right use asset lease obtain period nonexclusivity pharmaceutical arrangement lessee shortterm intangible asset depend characteristic competitive lease define lease lease term month environment estimate longterm profit asset lease low value asset right use asset book value amortise own party lease agreement capitalise exclusivity period straightline basis remain inception lease recognise consolidated book value amortise nonexclusivity period balance sheet year straightline basis vaccine intangible asset cost usually amortise exclusivity period plus correspond liability lessor recognise lease year year exclusivity period grant obligation short longterm borrowing carry straightline basis asset life review subsequently increase reflect interest appropriate adjust annually lease liability reduce lease payment contingent milestone payment recognise point calculate discount lease liability lease annual contingent event probable development payment million implicit rate lease cost incur group associate acquire available incremental borrowing rate licence patent knowhow marketing right write lease specific adjustment available income statement incur criterion lease annual payment million recognition internallygenerate intangible asset meet incremental borrowing rate incremental borrowing usually regulatory filing major market rate calculate rate interest gsk approval consider highly probable able borrow similar term similar security fund necessary obtain similar asset similar market acquire brand value independently fair value business acquire party brand finance cost charge income statement value substantial longterm brand produce constant periodic rate charge remain contractual legal nature sell separately balance obligation accounting period rest business acquire brand amortise variable rent lease liability right use estimate useful life year asset payment charge income statement straightline basis consider useful incur shortterm lowvalue lease capitalise economic life indefinite lease rental charge income statement incurrednote financial statement continue accounting principle policy continue cost acquire develop computer software expect credit loss recognise income statement internal use internet site external use capitalise financial asset measure amortise cost fair value intangible fix asset software site support comprehensive income apart equity significant business system expenditure lead investment creation durable asset erp system software amortise investment seven year computer software investment comprise equity investment year straightline basis investment limited life fund group elect impairment noncurrent asset designate majority equity investment measure carry value noncurrent asset review fvtoci initially record fair value plus transaction impairment standalone basis large cost remeasure subsequent reporting date cash generating unit indication asset fair value unrealise gain loss recognise impair additionally goodwill intangible asset comprehensive income indefinite useful live intangible asset disposal equity investment gain loss available use test impairment annually defer comprehensive income transfer provision impairment charge income statement directly retain earning investment limited life fund year concern measure fvtpl initially record fair value impairment goodwill reverse impairment loss remeasure subsequent reporting date fair value noncurrent asset reverse unrealised gain loss recognise income change estimate determine recoverable amount statement extent revise recoverable amount dividend equity investment distribution fund exceed carry value exist net recognise income statement group right depreciation amortisation impairment receive payment establish recognise purchase sale investment account investment associate joint venture joint trade date operation trade receivables investment associate joint venture carry trade receivable measure accordance consolidated balance sheet group share net business model portfolio trade receivables asset date acquisition postacquisition hold group portfolio business retain profit loss comprehensive income model ifrs collect contractual cash flow goodwill arise acquisition group factoring agreement place measure recognise right asset liability revenue expense amortise cost sell contractual cash flow joint operation trade receivable sell factoring agreement inventory measure fvtpl collect sell inventory include financial statement low contractual cash flow trade receivable sell cost include raw material direct labour direct cost factor arrangement measure fvtoci trade relate production overhead net realisable value receivables measure amortise cost carry cost generally determine basis original invoice allowance expect credit prelaunch inventory hold asset high loss probability regulatory approval product expect credit loss calculate accordance point provision carrying value simplify approach permit ifrs provision matrix recoverable provision reverse point apply lifetime historical credit loss experience trade high probability regulatory approval determine receivable expect credit loss rate vary depend extent settlement trade financial instrument receivables overdue adjust appropriate financial asset reflect current economic condition estimate future financial asset measure amortise cost fair value condition purpose determine credit loss rate comprehensive income fvtoci fair value customer classify grouping similar loss profit loss fvtpl measurement basis pattern key driver loss rate nature determine reference business model business unit location type customer manage financial asset contractual cash flow trade receivable determine reasonable characteristic financial asset financial asset expectation recovery write firstly trade receivables month expect credit loss expect credit loss allowance available ecl allowance record initial recognition income statement subsequent evidence significant increase credit risk asset allowance increase reflect lifetime subsequent recovery amounts previously provide ecl realistic prospect recovery asset write credit income statement longterm write receivable discount effect material gsk annual report gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue accounting principle policy continue cash cash equivalent change fair value derivative designate fair value cash hold deposit account measure amortise cost hedge record income statement investment money market fund hold fair value change fair value hedge asset liability profit loss fund fail solely payment taxation principal interest sppi test current tax provide amount expect pay borrowing apply tax rate enact substantively borrowing initially record proceed enact balance sheet date receive net transaction cost borrowing subsequently defer tax provide temporary difference arise carry amortise cost difference tax basis asset liability carry proceed net transaction cost amount financial statement defer tax asset redemption recognise charge income recognise extent probable future taxable statement period relevant borrowing profit available temporary difference derivative financial instrument utilise defer tax provide temporary derivative financial instrument manage exposure difference arise investment subsidiary associate market risk principal derivative instrument joint venture time reversal gsk foreign currency swap interest rate swap foreign temporary difference control probable exchange forward contract option group temporary difference reverse foreseeable hold issue derivative financial instrument trade future defer tax provide rate tax speculative purpose enact substantively enact balance sheet date derivative financial asset liability include derivative uncertain tax position identify management embed host contract separate judgement probable outcome host contract classify heldfortrading assume relevant tax authority knowledge measure fair value change fair value derivative situation assess economic outflow instrument qualify hedge accounting probable arise provision good estimate recognise immediately income statement liability estimate liability gsk apply riskbased approach take account appropriate hedge accounting probability group able obtain derivative designate hedge instrument classify compensatory adjustment international tax treaty inception hedge relationship cash flow hedge net estimate account specific circumstance investment hedge fair value hedge dispute relevant external advice change fair value derivative designate cash flow discount hedge recognise comprehensive income time value money material balance extent hedge effective ineffective portion discount current value appropriate discount rate recognise profit loss immediately amount defer unwind discount record finance income comprehensive income reclassify income finance expense statement hedge item affect profit loss net investment hedge account similar way cash flow hedge critical accounting judgement key source estimation uncertainty prepare financial statement management require estimate judgement item gross turnover reduce rebate discount allowance recognise financial statement estimate product return give expect give assumption affect amount asset liability vary product arrangement buy group revenue expense report financial statement arrangement purchase organisation dependent actual amount result differ estimate submission claim time initial follow consider critical accounting recognition sale accrual time sale judgement key source estimation uncertainty estimate rebate discount allowance payable return base available market information turnover historical experience report group turnover million millionnote financial statement continue critical accounting judgement key source estimation uncertainty continue pharmaceuticals business large estimate complex arrangement rebate discount allowance group open tax issue number revenue pharmaceutical turnover million authority management make judgement million recording deduction sufficient information able reliable estimate million million rebate discount outcome dispute insufficient information available allowance return balance sheet accrual rebate provision discount allowance return pharmaceutical sufficient information available estimate potential tax vaccine business manage combined basis liability gsk apply riskbased approach take december total accrual amount account appropriate probability group million million nature able obtain compensatory adjustment international accrual practicable meaningful tax treaty estimate account specific sensitivity estimate large volume variable circumstance dispute relevant external advice contribute overall rebate chargeback return inherently judgemental change substantially revenue accrual time dispute progress new fact emerge significant variability final outcome december group recognise provision group apply constraint measure variable element million respect uncertain tax position revenue revenue recognise suitably million number uncertain tax position hold cautious objective constraint ensure number jurisdiction relate highly probable significant reversal revenue practicable meaningful sensitivity estimate occur uncertainty resolve constraint uncertain tax position individually significant group apply make suitably cautious estimate input assumption estimate variable consideration factor affect tax charge future year set amount estimate fully reflect note taxation gsk continue believe final outcome amount subject change adequate provision liability likely arise open dependent thing type buy assessment open issue exist ultimate liability group product sale mix constraint apply matter vary amount provide recognise revenue mean risk material downward dependent outcome negotiation relevant adjustment revenue financial year low tax authority necessary litigation proceeding level accrual rebate return review legal dispute adjust regularly light contractual legal legal cost year million million obligation historical trend past experience project december provision legal dispute market condition market condition evaluate amount million million wholesaler thirdparty analysis market research datum internallygenerate information reasonably possible estimate significant adjustment management make judgement sufficient month recognise additional revenue actual outcome information able reliable estimate likely well cautious constrain estimate revenue outcome dispute legal expense arise recognise highly probable significant claim group insufficient information reversal cumulative revenue recognise available provision disclosure claim occur turnover recognise year give performance obligation satisfy previous period set estimate provision account specific note turnover segment information circumstance dispute relevant external advice indication level sensitivity estimate inherently judgemental change substantially time future event cause assumption dispute progress new fact emerge detail accrual base change materially affect status uncertainty involve significant future result group unresolve dispute set note legal proceeding company director take legal advice taxation establish provision take account relevant tax charge year million fact circumstance matter accordance million december current tax payable accounting requirement respect product liability claim million million noncurrent corporation relate certain product sufficient history claim tax payable million million current settlement enable management reliable tax recoverable million million estimate provision require cover unasserted claim gsk annual report gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue critical accounting judgement key source estimation uncertainty continued group involved legal proceeding respect pension postemployment benefit possible meaningfully assess judgement outcome result probable outflow quantify reliably surplus define benefit scheme arise estimate liability case appropriate disclosure potential surplus arise commit future case provide provision contribution right trustee prevent group contingent liability quantify obtain refund surplus future consider ultimate liability legal claim vary amount determine necessary restrict provide dependent outcome litigation surplus recognise uk scheme surplus proceeding investigation possible settlement negotiation combine surplus million december position change time million recognise pension surplus assurance loss result outcome totalling million spread country legal proceeding exceed provision million country gsk judgement report group financial statement material amount meet requirement recoverability contingent consideration estimate income statement charge contingent cost provide pension postemployment consideration million million benefit assess basis assumption select management assumption include future earning december liability contingent consideration pension increase discount rate expect longterm rate amount million million return asset mortality rate disclose note million million relate pension postemployment benefit acquisition shionogiviiv healthcare joint venture discount rate derive aa rate corporate bond yield country deep market corporate estimate bond government bond yield sensitivity contingent consideration include consideration analysis provide note pension post payable business combination record fair value employment benefit reduction discount rate date acquisition fair value generally base lead increase net pension deficit riskadjuste future cash flow discount appropriate approximately million increase annual pension posttax discount rate fair value review cost approximately million similarly increase regular basis annually change reflect discount rate lead decrease net pension income statement note contingent consideration deficit approximately million decrease annual liability pension cost approximately million selection different assumption affect future result group new accounting requirement group previously account saas software year group implement interest rate service configuration customisation cost intangible benchmark reform phase amendment ifrs ias asset follow ifrs ic interpretation committee ifrs ifrs ifrs issue august agenda decision saas april group adopt adopt uk endorsement board january treatment set ifrs ic agenda decision amendment address issue arise implementation expense configuration customisation cost reform include replacement benchmark entity control software configure alternative practical expedient provide impact change impairment million change contractual cash flow financial asset previously capitalise intangible asset increase liability include lease liability account expense million present sell general prospectively revise effective interest rate addition administration research development hedge accounting discontinue solely ibor reform information provide note retirement benefit employee entitle cap specify number consecutive year group certain new accounting standard amendment account previously account employee benefit standard interpretation publish employment commencement date follow ifrs ic mandatory december reporting period agenda decision attribute benefit period service early adopt group standard group adopt treatment set amendment interpretation expect ifrs ic agenda decision account employee benefit material impact group current future reporting specify number year employee period earn benefit impact change reduction expense million present cost sale sell general administration research developmentnote financial statement continue exchange rate group use average exchange rate prevail period translate result cash flow overseas subsidiary joint venture associate sterling period end rate translate net asset entity currency influence translation relevant exchange rate average rate period end rate euro euro yen yen turnover segment information operating segment report base financial information provide chief executive officer responsibility gsk leadership team glt gsk report result segment pharmaceutical pharmaceutical rd vaccine consumer healthcare individual member glt responsible segment group management reporting process allocate intragroup profit product sale market sale record profit analysis present basis corporate unallocated turnover cost include result certain consumer healthcare product hold sale number market order meet antitrust approval requirement cost corporate function revenue recognise year performance obligation satisfy previous period total million million include million million impacting turnover arise change prior year estimate rar return rebate accrual million million milestone income million million royalty income recognise current year turnover segment pharmaceutical vaccine consumer healthcare segment turnover corporate unallocated turnover gsk review presentation pharmaceutical product january move sale arnuity ellipta incruse ellipta relvarbreo ellipta respiratory therapeutic area establish pharmaceutical therapeutic area comparative information revise consistent basis revise revise pharmaceutical turnover therapeutic area respiratory hiv immunoinflammation oncology pandemic new specialty establish pharmaceutical vaccine turnover category meningitis influenza shingle establish vaccine pandemic vaccine gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information turnover segment information continue operation pharmaceutical vaccine business sale wholesaler million million million million million million million million million respectively allocate finalcustomer discount wholesaler consumer healthcare turnover category oral health pain relief vitamin mineral supplement respiratory health digestive health brand divestedunder review segment profit pharmaceutical pharmaceutical rd pharmaceutical include rd vaccine consumer healthcare segment profit corporate unallocated cost reconcile item segment profit operating profit operating profit finance income finance cost loss disposal interest associate share aftertax profit associate joint ventures profit taxation taxation profit taxation year reconcile item segment profit operating profit comprise item specifically allocate segment profit include impairment amortisation intangible asset major restructuring cost include impairment tangible asset computer software transactionrelate adjustment relate significant acquisition proceed cost disposal associate product business significant legal charge expense settlement litigation government investigation operate income royalty income item separation cost refer detail reconcile item segment profit operating profit analysis adjust item group financial review depreciation amortisation segment pharmaceutical pharmaceutical rd pharmaceutical include rd vaccine consumer healthcare segment depreciation amortisation corporate unallocated depreciation amortisation reconcile item segment depreciation amortisation total depreciation amortisation total depreciation amortisation note financial statement continue turnover segment information continue ppe intangible asset goodwill impairment segment pharmaceutical pharmaceutical rd pharmaceutical include rd vaccine consumer healthcare segment impairment corporate unallocated impairment reconcile item segment impairment total impairment total impairment ppe intangible asset impairment reversal segment pharmaceutical pharmaceutical rd pharmaceutical include rd vaccine consumer healthcare segment impairment reversal corporate unallocated impairment reversal reconcile item segment impairment reversal total impairment reversal total impairment reversal net operating asset segment pharmaceutical pharmaceutical rd pharmaceutical include rd vaccine consumer healthcare segment net operating asset corporate unallocated net operating asset net operating asset net debt investment associate joint venture derivative financial instrument current defer taxation asset hold sale exclude cash cash equivalent net asset pharmaceutical segment include shionogiviiv healthcare contingent consideration liability million million pfizer option million million gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information turnover segment information continue geographical information uk regard group country domicile turnover location customer uk rest world external turnover revise noncurrent asset location subsidiary uk belgium switzerland rest world noncurrent asset noncurrent asset location exclude amount relate investment defer tax asset derivative financial instrument pension asset amount receivable insurance contract certain noncurrent receivables country individually material external revenue noncurrent asset gsk revise presentation noncurrent asset location include belgium switzerland independently rest world operating incomeexpense fair value remeasurement equity investment disposal business asset fair value remeasurement contingent consideration recognise business combination remeasurement viiv healthcare option liability preferential dividend fair value adjustment derivative financial instrument income disposal business asset include net gain disposal right royalty stream cabozantinib net gain disposal cephalosporin antibiotic brand sandoz disposal business asset include net profit disposal horlick consumer healthcare nutritional brand subsidiary india bangladesh million reflect reversal million embed derivative gain value share take prior year partly offset related million loss share hindustan unilever limit include fair value remeasurement loss acquisition consideration divestment gsk consumer healthcare limited india subsequent disposal operating income include increase profit milestone income number asset disposal fair value remeasurement contingent consideration recognise business combination include million related acquisition shionogiviiv healthcare joint venture million payable novartis relate vaccine acquisition fair value movement relate hedging contractsnote financial statement continue operating profit follow item include operate profit employee cost note advertising distribution cost depreciation property plant equipment impairment property plant equipment net reversal depreciation right use asset impairment right use asset amortisation intangible asset impairment intangible asset net reversal impairment property plant equipment hold sale net reversal impairment intangible asset hold sale net reversal impairment goodwill allocate disposal group net reversal net foreign exchange gainslosse inventory cost inventory include cost sale writedown inventory reversal prior year writedown inventory shortterm lease charge lowvalue lease charge variable lease payment fees payable company auditor associate relation group reversal prior year writedown inventory principally arise reassessment usage demand expectation prior inventory expiration net foreign exchange gainslosse include net gain million million loss million gain arise recycling exchange liquidation disposal overseas subsidiary recycle exchange disposal overseas associate loss million nil report loss disposal interest associate include operate profit major restructuring charge million million million note major restructuring cost fee payable company auditor associate audit parent company consolidate financial statement include attestation sarbanesoxley act audit company subsidiary total audit service audit relate assurance service service total auditrelated nonaudit service assurance service provide auditor relate agree procedure assurance service outside statutory audit requirement addition fee pay auditor respect gsk pension scheme audit service material fee pay auditor respect audits certain company subsidiary acquire year million million audit fee include million relation incremental audit work perform audit opinion issue compliant pcaob auditing standard preparation consumer healthcare demerger audit relate assurance service include million report accountant work perform preparation consumer healthcare demerger gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information employee cost wage salary social security cost pension postemployment cost include augmentation note cost sharebase incentive plan severance cost integration restructuring activity group provide benefit employee commensurate local practice individual country include market healthcare insurance subsidise car scheme personal life assurance cost sharebase incentive plan analyse follow share value plan performance share plan share option plan cash settle plan average monthly number person employ group include director year number number number manufacturing sell general administration research development average monthly number group employee exclude temporary contract staff number group employee end financial year give financial record compensation director senior management member glt aggregate follow wage salary social security cost pension postemployment cost cost sharebase incentive plan information remuneration director give section annual report remuneration label audit page note financial statement continue major restructuring cost pharmaceutical sector highly regulate manufacture operation supply chain long lifecycle business mean restructure programme particularly involve rationalisation closure manufacturing rd site likely year complete major restructuring cost relate specific boardapprove major restructuring programme include integration cost follow material acquisition structural significant scale cost individual relate project exceed million exist combined restructure integration programme incorporate previous major change programme pharmaceutical restructure programme restructure integration programme follow novartis transaction programme substantially complete july board approve major restructure programme design significantly improve competitiveness efficiency group cost base saving deliver primarily supply chain optimisation reduction administrative cost programme substantially complete february board approve major restructuring plan generate synergies integration pfizer consumer healthcare business gsk consumer healthcare business january board approve twoyear separation preparation programme prepare separation gsk company total restructuring cost million incur follow area restructure cost prepare separation gsk company restructure follow integration pfizer consumer healthcare business gsk consumer healthcare continue implementation restructure programme start july simplify operating model improve resource allocation pharmaceutical consumer healthcare supply chain continue transformation central function include gsk technology platform interface deliver great digital synergy simplification application staff reduction analysis cost charge operating profit programme follow increase provision major restructuring programme note provision reverse unused note impairment loss recognise noncash charge cash cost provision reversal million million million reflect provision release mainly separation preparation programme major restructure programme asset impairment million noncash charge million principally comprise fix asset writedown manufacturing facility accelerate depreciation asset life shorten supply chain manufacturing network result major restructuring programme charge settle cash include site closure cost consultancy project management cost analysis major restructuring charge programme follow cash noncash total separation preparation programme consumer healthcare joint venture integration programme major restructuring programme include tesaro combine restructure integration programme cash noncash total separation preparation programme consumer healthcare joint venture integration programme major restructuring programme include tesaro combine restructure integration programme gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information major restructuring cost continue analysis major restructuring charge income statement line follow cost sale sell general administration research development operate expense finance income finance income arise financial asset measure amortise cost financial asset measure fair value profit loss net gain arise forward element forward contract net investment hedge relationship finance income finance expense finance expense arise financial liability amortise cost derivative fair value profit loss net loss arise financial instrument mandatorily measure fair value profit loss retranslation loan reclassification hedge comprehensive income unwind discount provision finance expense arise lease liability finance expense finance expense arise derivative fair value profit loss relate swap interest expensenote financial statement continue associate joint venture group share aftertax profit loss associate joint venture set share aftertax profit associate share aftertax loss joint venture follow disposal innoviva inc detail note december group hold significant individual associate december group hold significant associate innoviva inc summarise income statement information respect innoviva set group share aftertax profit associate comprehensive income include profit million comprehensive income nil respect innoviva result innoviva include summarise income statement information represent estimate earning innoviva relevant period base publicly available information balance sheet date figure include share innovivas turnover profit total comprehensive income date disposal turnover profit taxation total comprehensive income aggregate financial information respect gsk share associate undertaking joint venture set share turnover share aftertax loss share comprehensive income share total comprehensive incomeexpense group sale associate joint venture nil nil million refer balance sheet information associate joint venture note gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information taxation group tax charge sum total current defer tax expense taxation charge base profit year uk current year charge rest world current year charge chargecredit respect prior period current taxation defer taxation gsk payment million uk corporation tax hmrc amount uk corporation tax include business taxis bear uk gsk year defer tax credit period reflect origination current year expense offset taxable profit future period probable relate primarily unwind defer tax liability intangible asset recognition current year tax loss reversal temporary difference defer tax credit reflect impact revaluation defer tax asset liability follow enactment increase headline rate uk corporation tax significant prior year credit reflect impact settlement number open issue tax authority follow table reconcile tax charge calculate uk statutory rate group profit tax actual tax charge year reconciliation taxation group profit profit tax uk statutory rate taxation difference overseas taxation rate benefit intellectual property incentive rd credit fair value remeasurement nontaxable option tax loss benefit recognise permanent difference disposal acquisition transfer permanent difference reassessment prior year estimate change tax rate tax chargetax rate global healthcare company substantial business employment presence country world impact difference overseas taxation rate arise profit earn country tax rate high uk statutory rate significant belgium germany italy japan adverse impact partly offset benefit intellectual property incentive uk patent box belgian patent income deduction regime provide reduce rate corporation tax profit earn qualifying patent claim incentive manner intend relevant statutory regulatory framework change tax rate include credit relation enactment increase headline rate uk corporation tax effective change tax rate include credit relation uk previously propose reduction corporation tax rate cancel india tax treatment dividend change effect april uk credit partly reverse expense future benefit provide enact corporation tax rate permanent difference disposal acquisition transfer reflect tax credit arise transfer intellectual property group reflect tax impact disposal horlick consumer healthcare brand subsequent disposal share receive hindustan unilever group tax rate influence closure open issue tax authority jurisdiction reassessment prior year estimate include current defer tax future tax charge effective tax rate affect factor acquisition disposal restructuring location research development activity tax regime reform resolution open matter continue bring tax affair date world continue focus tax reform expect future year drive oecds project address tax challenge arise digitalisation economy result significant change establish tax principle increase tax authority dispute turn adversely affect gsk effective tax rate result high cash tax liabilitiesnote financial statement continue taxation continue tax item charge equity statement comprehensive income current taxation sharebase payment define benefit plan fair value movement cash flow hedge fair value movement equity investment defer taxation sharebase payment define benefit plan fair value movement cash flow hedge fair value movement equity investment total credit equity statement comprehensive income item charge statement comprehensive income tax sharebase payment issue relate taxation integrate nature group worldwide operation involve significant investment research strategic manufacture limited number location consequential crossborder supply route numerous endmarket line current oecd guideline base transfer pricing policy arm length principle support transfer price economic analysis report different tax authority seek attribute profit activity undertake jurisdiction potentially result double taxation group open item jurisdiction concern matter deductibility particular expense tax treatment certain business transaction gsk apply risk base approach determine transaction likely subject challenge probability group able obtain compensatory adjustment international tax treaty calculation group total tax charge necessarily involve degree estimation judgement respect certain item tax treatment finally determine resolution reach relevant tax authority appropriate formal legal process december group recognise provision million respect uncertain tax position million present current tax payable reductions current tax recoverable asset net increase recognise provision drive reassessment estimate utilisation provision uncertain tax position follow settlement number open issue tax authority jurisdiction whilst ultimate liability matter vary amount provide dependent outcome agreement relevant tax authority litigation appropriate group continue consider appropriate provision period open agree tax authority provision defer tax liability million december million respect taxation payable remittance profit certain overseas subsidiary whilst aggregate unremitte profit balance sheet date approximately billion billion majority unremitted profit subject tax include withhold tax repatriation uk legislation relate company distribution provide exemption tax overseas profit subject certain exception defer tax provide temporary difference million million arise unremitted profit management ability control future reversal consider reversal probable gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information taxation continue movement defer tax asset liability pension share accelerate post option net capital intangible contingent intragroup employment tax award temporary allowance asset consideration profit benefit loss scheme difference total january exchange adjustment creditcharge income statement creditcharge statement comprehensive income acquisition disposal rd credit utilisation december exchange adjustment creditcharge income statement creditcharge statement comprehensive income acquisition disposal rd credit utilisation december defer tax liability provide relation intangible asset predominately relate temporary difference arise asset liability acquire historic business combination group continue recognise defer tax asset future obligation respect contingent consideration amount payable minority shareholder payment tax deductible point time payment deferred tax asset recognise intragroup profit arise intercompany inventory eliminate consolidated account intragroup profit eliminate individual entity tax return temporary difference arise reverse point time inventory sell externally defer tax asset recognise tax loss million million relate trading loss defer tax asset recognise probable future taxable profit available utilise loss support product level forecast net temporary difference include accrue expense tax deduction available pay basis defer tax asset liability recognise balance sheet follow defer tax asset defer tax liability unrecognised unrecognised defer tax defer tax tax loss asset tax loss asset unrecognised tax loss trading loss expire year year available indefinitely december capital loss expire available indefinitely december defer tax asset recognise probable future taxable profit available utilise lossesnote financial statement continue earning share pence pence pence basic earning share dilute earning share basic earning share calculate divide profit attributable shareholder weight average number share issue period deduct share hold esop trust treasury share trustee waive right dividend share hold esop trust diluted earning share calculate adjust weight average number share basic calculation assume conversion potentially dilutive share potentially dilutive share form employee share scheme exercise price average market price gsk share period performance condition attach scheme meet balance sheet date number share calculate basic diluted earning share reconcile weight average number share issue million million million basic dilution share option award dilute dividend dividend total dividend total dividend total share dividend share dividend share dividend paidpayable penny pay penny pay pence interim july july july second interim october october october interim january january january fourth interim april april april total estimate fourth interim dividend disclose annual report account million million dividend ultimately pay ifrs interim dividend recognise financial statement pay declare gsk normally pay dividend quarter quarter relate quarter declare financial statement recognise dividend pay fourth interim dividend second interim dividend amount recognise year follow dividend shareholder gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information property plant equipment plant land equipment asset building vehicle construction total cost january exchange adjustment addition business combination addition capitalise borrowing cost disposal writeoff reclassification transfer asset hold sale cost december exchange adjustment addition capitalise borrowing cost disposal writeoff reclassification transfer asset hold sale cost december depreciation january exchange adjustment charge year disposal writeoff transfer asset hold sale depreciation december exchange adjustment charge year disposal writeoff transfer asset hold sale depreciation december impairment january exchange adjustment disposal writeoff impairment loss reversal impairment transfer asset hold sale impairment december exchange adjustment disposal writeoff impairment loss reversal impairment impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december note financial statement continue property plant equipment continue weight average interest rate capitalise borrowing cost year disposal writeoff year include number asset nil net book value long use business impairment loss principally arise decision rationalise facility calculate base fair value cost disposal fair value cost disposal valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy calculation determine net present value project riskadjuste posttax cash flow relevant asset cash generating unit apply discount rate group posttax weight average cost capital wacc adjust appropriate specific segment country currency risk asset continue group generally assess associate cash generating unit value use basis value use calculation posttax cash flow include impact future uncommitted restructuring plan improvement impairment indicate pretax cash flow calculation expect materially different result test reperforme pretax cash flow pretax discount rate group wacc equivalent pretax discount rate approximately net impairment loss charge cost sale million million rd million million sga million million include million million arise major restructuring programme reversal impairment arise subsequent review impaired asset condition gave rise original impairment deem long apply reversal credit cost sale million million computer software reclassify asset construction intangible asset ready use assess qualitative quantitative impact climate relate risk asset recoverable amount conclude impact cause material impairment right use asset land plant building equipment vehicle total net book value january exchange adjustment addition depreciation disposal impairment reclassification net book value december exchange adjustment addition depreciation disposal impairment net book value december total cash outflow lease amount million group enter lease contract commence nominal value estimate future lease payment lease contract approximate million december contract mainly concern relocation corporate headquarters lease period analysis lease liability set note net debt gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information goodwill cost january exchange adjustment addition business combination note movement transfer asset hold sale cost december net book value january net book value december million increase goodwill correspond immaterial payment pension liability consumer healthcare subgroup require sale purchase agreement increase noncontrolle interest subgroup result transaction goodwill allocate group segment follow pharmaceutical vaccine consumer healthcare net book value december recoverable amount cash generating unit assess fair value cost disposal model fair value cost disposal calculate discount cash flow approach posttax discount rate apply project riskadjuste posttax cash flow terminal value discount rate base group wacc cash generating unit integrate operation large part group discount rate adjust appropriate specific segment country currency risk valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy detail relate discount cash flow model impairment test pharmaceutical vaccine consumer healthcare cash generating unit follow valuation basis fair value cost disposal key assumption sale growth rate profit margin terminal growth rate discount rate taxation rate determination assumption growth rate internal forecast base internal external market information margin reflect past experience adjust expect change terminal growth rate base management estimate future longterm average growth rate discount rate base group wacc adjust appropriate taxation rate base appropriate rate jurisdiction period specific project cash flow year terminal growth rate discount rate terminal growth rate discount rate pharmaceutical pa pa pa vaccines pa pa pa consumer healthcare pa pa pa terminal growth rate exceed longterm project growth rate relevant market reflect impact future generic competition account new product launch goodwill monitor impairment segmental level case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment relate goodwill consumer healthcare cash generating unit comprise collection small cash generating unit include brand indefinite live carry value billion billion detail indefinite life brand give note intangible asset assess qualitative quantitative impact climate relate risk asset recoverable amount conclude impact cause material impairmentsnote financial statement continue intangible asset licence patent computer amortise indefinite life software brand etc brand total cost january exchange adjustment capitalise development cost addition business combination addition disposal asset writeoff transfer asset hold sale reclassification cost december exchange adjustment capitalise development cost addition disposal asset writeoff transfer asset hold sale reclassification cost december amortisation january exchange adjustment charge year disposal asset writeoff transfer asset hold sale amortisation december exchange adjustment charge year disposal asset writeoff transfer asset hold sale amortisation december impairment january exchange adjustment impairment loss reversal impairment disposal asset writeoff transfer asset hold sale reclassification impairment december exchange adjustment impairment loss reversal impairment disposal asset writeoff impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december weight average interest rate capitalise borrowing cost year net book value computer software include million million internally generate cost carry value december intangible asset impairment charge year follow impairment million million carrying value december intangible asset impairment reversal charge year follow impairment reversal million million patent expiry date group significant asset relevant set page refer note group accounting policy estimate useful life intangible asset exclusivity nonexclusivity period gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information intangible asset continue amortisation impairment loss net reversal charge income statement follow amortisation net impairment loss cost sale sell general administration research development licence patent amortise brand etc include large number acquire licence patent knowhow agreement marketing right market use development note acquisition disposal give detail addition business combination year book value large individual item follow tesaro asset meningitis portfolio dolutegravir benlysta alector asset iteo asset lamisil merck asset vir asset bms asset fluarixflulaval okairos curevac asset stiefel trade july gsk sign agreement global codevelopment cocommercialisation collaboration immunoneurology alector clinical stage firstinclass monoclonal antibodie neurodegenerative disease total upfront payment recognise intangible asset million total million pay total million pay june gsk sign codevelopment cocommercialisation collaboration iteo therapeutic eos antitigit monoclonal antibody recognise intangible asset million tesaro asset comprise zejula jemperli combination therapie meningitis portfolio include menveo bexsero man abcwy menjugate lamisil move licence patent amortise brand etc follow decision start amortisation gsk divest breathe right brand indefinite life brand comprise portfolio consumer healthcare product primarily acquire acquisition sterling winthrop inc block drug company inc novartis consumer healthcare business pfizer consumer healthcare business book value major brand follow advil voltaren centrum caltrate otrivin preparation h robitussin nexium fenistil chapstick emergenc theraflu panadol sensodyne note financial statement continue intangible asset continue brand consider indefinite life give strength durability brand level marketing support brand relatively similar stable profitable market sector similar risk profile size diversification market share mean risk marketrelated factor cause reduction live brand consider relatively low group aware material legal regulatory contractual competitive economic factor limit useful life accordingly amortise brand test annually impairment amortise intangible asset test indicator impairment arise testing apply fair value cost disposal methodology generally year posttax cash flow forecast terminal value calculation discount rate equal group posttax wacc adjust appropriate specific segment country currency risk valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy main assumption include future sale price volume growth product contribution future expenditure require maintain product marketability registration relevant jurisdiction exchange rate assumption base past experience review management budget strategic planning cycle change market condition sale erosion competition terminal growth rate apply management estimate future longterm average growth rate relevant market year end december robitussin preparation h affect low cold flu incidence result covid social distancing measure supply chain issue respectively result reduce level headroom group perform sensitivity analysis base change key assumption consider reasonably possible management leave assumption unchanged sensitivity analysis year end december identify brand sensitive reasonably possible change key assumption order recoverable equal carry value robitussin preparation h discount rate increase operating margin decrease long term growth rate decrease respectively group consider change key assumption magnitude reasonably possible current environment describe group consider reasonably possible change key assumption cause fair value cost sale brand disclose fall carry value assess qualitative quantitative impact climate relate risk asset recoverable amount conclude impact cause material impairment investment associate joint venture joint joint ventures associates total ventures associates total january exchange adjustment addition disposal distribution receive net fair value movement comprehensive income impairment interest associate profitloss tax recognise consolidated income statement december group hold significant associate december innoviva inc december group own million share innoviva biopharmaceutical company list nasdaq innoviva partner gsk development longacte beta agonist vilanterol currently receive royalty income sale product contain component relvarbreo ellipta anoro ellipta economic interest royalty pay gsk sale trelegy ellipta remain economic interest royalty hold theravance biopharma inc group hold investment note group agreed innoviva inc sell share innoviva innoviva million follow settlement transaction gsk long hold innoviva stock loss million include million recycling exchange difference innoviva present loss disposal interest associate consolidate income statement transaction include change innovivas commercial interest royalty pay gsk loss disposal interest associate include million gain disposal immaterial associate refer income statement information associate joint venture note gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information investment associate joint venture continue disposal include book value innoviva million million investment gsk receive noncash consideration summarise balance sheet information december respect innoviva set december noncurrent asset current asset current liability noncurrent liability net asset carry value group investment innoviva analyse follow interest net asset associate goodwill fair value adjustment carry value december investment innoviva market value million december investment investment investment designate investment designate investment measure measured measured measured fvtoci fvtpl fvtoci fvtpl january addition net fair value movement comprehensive income net fair value movement profit loss disposal settlement december investment comprise noncurrent equity investment record fair value balance sheet date investment trade active market fair value determine reference relevant stock exchange quote bid price investment fair value estimate management reference relevant available information include current market value similar instrument recent financing round discount cash flow underlie net asset net fair value movement include impact exchange gain million comprehensive income million profit loss loss million nil respectively investment include list investment million million gsk elect designate majority equity investment measure fair value comprehensive income fvtoci significant investment hold december curevac ag group hold vir biotechnology group hold investment fair value december million million million million respectively investment include equity stake company gsk research collaboration company provide access biotechnology development potential interest june gsk issue note exchangeable option note holder time maturity note june share hold gsk theravance biopharma inc note exchange gsk expect deliver share option certain circumstance deliver cash combination theravance biopharma shares cash theravance biopharma share measure fvtoci fair value december million million disposal equity investment measure fvtoci accumulate fair value movement reclassify fair value reserve retain earning investment fair value million million dispose year cumulative gain investment tax million million certain investment investment fund limited live investment acquire intention sell measure fair value profit loss fvtpl addition disposal investment measure fvtpl include acquisition share hindustan unilever limited merger gsk indian list consumer healthcare entity hindustan unilever subsequent divestment sharesnote financial statement continue noncurrent asset amount receivable insurance contract pension scheme surplus receivables amount receivable insurance contact hold cash surrender value movement profit loss receivables million million million million classified financial asset million million classify fair value profit loss remain balance million million expect credit loss allowance immaterial december inventory raw material consumable work progress finish good trade receivable trade receivables net loss allowance accrue income prepayment interest receivable employee loan advance receivables trade receivables include nil nil associate joint ventures receivables include nil nil associate joint venture loss allowance trade receivables january exchange adjustment charge year subsequent recovery amount provide utilise december total trade receivables balance million million consider credit impair million million expect credit loss allowance apply purchase originated credit impair receivables million million million million classified financial asset nil nil classify fair value profit loss remain balance million million expect credit loss allowance million million recognise december charge report profit loss year discussion credit risk practice refer note gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information cash cash equivalent cash bank hand shortterm deposit cash cash equivalent include billion billion available general use restriction apply subsidiary hold restriction include exchange control taxis repatriation asset hold sale property plant equipment intangible inventory noncurrent asset disposal group transfer asset hold sale expect carry amount recover principally disposal sale consider highly probable hold low carrying fair value cost sell inventory write fair value cost sell include asset hold sale million valuation methodology significant input base observable market datum valuation classify level fair value hierarchy intangible asset million transfer intangible year million intangible asset hold sale impairment exchange movement asset divest year remain december millionnote financial statement continue trade payable trade payable wage salary social security viiv healthcare option payable defer income customer return rebate accrual accrual trade payable include nil million associate joint ventures group provide limited supplier financing arrangement certain customer amount involve december material revenue recognise year include deferred income january million million customer return rebate accrual provide group point sale respect estimate rebate discount allowance payable customer include million million respect pharmaceutical vaccine fully describe group financial review accrual time sale actual amount pay base claim time initial recognition sale amount estimate fully reflect final outcome subject change dependent thing type buy group product sale mix level accrual review adjust quarterly light historical experience actual amount pay change arrangement future event cause assumption accrual base change affect future result group pfizer option shareholding viiv healthcare currently exercisable pfizer request ipo viiv healthcare time gsk consent ipo offering complete month pfizer require gsk acquire shareholding liability option hold gross redemption basis derive internal valuation viiv healthcare business utilise discount forecast future cash flow multiplesbase methodology table show indicative basis income statement balance sheet sensitivity pfizer option reasonably possible change key assumption increasedecrease financial liability lossgain income statement increase sale forecast decrease sale forecast basis point increase discount rate basis point decrease discount rate cent appreciation dollar cent depreciation dollar cent appreciation euro cent depreciation euro sale forecast viiv healthcare sale respect viiv healthcare option explanation accounting viiv healthcare set gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information net debt list exchange current asset liquid investment cash cash equivalent shortterm borrowing commercial paper bank loan overdraft libor medium term note new york stock exchange euribor euro medium term note london stock exchange euro medium term note london stock exchange medium term note new york stock exchange medium term note new york stock exchange lease liability longterm borrowing medium term note new york stock exchange medium term note new york stock exchange medium term note new york stock exchange euro medium term note london stock exchange exchangeable medium term note new york stock exchange medium term note new york stock exchange euro medium term note london stock exchange medium term note new york stock exchange medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange medium term note new york stock exchange euro medium term note london stock exchange medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange medium term note london stock exchange euro medium term note london stock exchange medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange medium term note new york stock exchange euro medium term note london stock exchange longterm borrowing lease liability net debt note financial statement continue net debt continue current asset liquid investment classify financial asset amortise cost december include treasury note government bond effective interest rate liquid investment december approximately approximately liquid investment balance december earn interest float rate million million liquid investment balance december earn interest fix rate million nil balance report cash cash equivalent original maturity month effective interest rate cash cash equivalent december approximately approximately cash cash equivalent december earn interest float fix rate amount million million respectively million million noninterest bearing holding amount million million gsk policy credit quality cash cash equivalent set note financial instrument relate disclosure shortterm borrowing gsk billion billion commercial paper programme nil issue december million million gsk billion euro commercial paper programme million million issue december nil gsk billion threeyear commit facility billion billion day commit facility threeyear commit facility agree september extend year september extend year august day commit facility agree august facility undrawn december preparation separation consumer healthcare business february gsk cancel replace year day facility new revolve credit facility equivalent size agree maturity september september weight average interest rate commercial paper borrowing december weight average interest rate current bank loan overdraft december average effective preswap interest rate note classify shortterm december rate reflect maturity libor coupon note zero coupon euribor note september longterm borrowing yearend gsk longterm borrowing billion billion billion billion fall year average effective preswap interest rate note issue december approximately approximately longterm borrowing repayable year carry interest effective rate repayment date range pledge asset group hold pledge investment treasury note par value million million million million security irrevocable letter credit issue group behalf respect group selfinsurance activity provision respect selfinsurance include provision legal dispute discuss note provision lease liability maturity analysis discount lease liability recognise group balance sheet follow rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total lease liability gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information pension postemployment benefit pension postemployment cost uk pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme analyse fund define benefithybrid pension scheme unfunded define benefit pension scheme unfunded postretirement healthcare scheme define benefit scheme define contribution pension scheme cost define benefit pension postretirement healthcare scheme charge income statement follow cost sale sell general administration research development gsk entity operate pension arrangement cover group material obligation provide pension retire employee arrangement develop accordance local practice country concern pension benefit provide state scheme define contribution scheme retirement benefit determine value fund arise contribution pay respect employee define benefit scheme retirement benefit base employee pensionable remuneration length service pension cost define benefit scheme accounting purpose calculate project unit credit method certain country pension benefit provide unfunded basis administer trustee company formal independent actuarial valuation group main plan undertake regularly normally year remeasurement movement year recognise statement comprehensive income discount rate derive aa rate corporate bond yield country deep market corporate bond government bond yield discount rate select reflect term expect benefit payment project inflation rate pension increase longterm prediction base yield gap longterm indexlinke fix interest gilt uk mortality rate determine adjust sap standard mortality table reflect recent scheme experience rate project reflect improvement life expectancy line cmi projection longterm rate improvement year male female mortality rate calculate pri white collar table adjust reflect recent experience rate project mp allow future improvement life expectancynote financial statement continue pension postemployment benefit continue average life expectancy assume individual age project apply individual age follow uk male female male female year year year year current project asset fund scheme generally hold separately administer trust specific asset proportion general fund insurance contract asset invest different class order maintain balance risk return investment diversify limit financial effect failure individual investment physical asset allocation strategy uk plan returnseeke asset liabilitymatche assets buyin insurance contract purchase cover substantially obligation uk plan december value insurance contract million million asset allocation plan currently set returnseeke asset liabilitymatche asset pension plan expose risk arise estimate market value plan asset decline investment return reduce estimate value plan liability increase line agree mix returnseeke asset generate future return liabilitymatche asset well match future pension obligation group define overall longterm investment strategy plan investment broad range asset main market risk asset hedge portfolio credit risk interest rate longterm inflation equitie property currency bank counterparty risk plan liability series future cash flow relatively long duration ias basis cash flow sensitive change expect longterm inflation rate discount rate aa corporate bond yield curve increase longterm inflation correspond increase liability increase discount rate correspond decrease liabilitie interest rate risk credit rate risk partially hedge target base accounting measure plan liability uk plan interest rate inflation hedge strategy place target base economic measure plan liability furthermore plan currently hedge portion equity exposure stagger maturity profile uk define benefit pension scheme operate benefit glaxo wellcome employee smithkline beecham employee remain separate scheme close new entrant subsequent uk employee entitle join define contribution scheme addition group operate number postretirement healthcare scheme principal follow period consultation impact employee announce december uk define benefit plan closed future accrual effective march result post closure accrue benefit active participant revalue line inflation rpi legacy glaxo wellcome plan cpi legacy smithkline beecham plan subject relevant cap arrangement cap pay increase addition define benefit plan participant active april receive define pension contribution effect closure define contribution enhancement result oneoff cost million announce september cash balance pension plan closed future accrual january change result credit million june september amendment retiree healthcare plan result credit million group apply follow financial assumption assess define benefit liability uk rest world pa pa pa pa pa pa pa pa pa rate increase future earning na na discount rate expect pension increase na na na cash balance creditconversion rate na na na inflation rate sensitivity analysis detail effect change assumption provide analysis provide reflect assumption change material impact result group gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information pension postemployment benefit continue amount record income statement statement comprehensive income year end december relation define benefit pension postretirement healthcare scheme follow postretirement pension benefit uk rest world group group amount charge operating profit current service cost past service cost net interest cost gain settlement expense remeasurement gainslosse record statement comprehensive income postretirement pension benefit uk rest world group group amount charge operating profit current service cost past service costcredit net interest incomecost gain settlement expense remeasurement gainslosse record statement comprehensive income postretirement pension benefit uk rest world group group amount charge operating profit current service cost past service costcredit net interest incomecost gain settlement expense remeasurement loss record statement comprehensive income amount include past service cost uk include million million million augmentation cost arise major restructuring programme charge nil million relation impact closure define benefit scheme future accrual past service credit million reflect closure cash balance pension plan january amendments retiree healthcare plan result credit million past service cost postretirement benefit note financial statement continue pension postemployment benefit continue summarise balance sheet presentation group define benefit pension scheme postretirement benefit set table recognise noncurrent asset pension scheme surplus recognise asset hold sale postretirement benefit recognise pension postemployment benefit pension scheme deficit postretirement benefit event plan windup gsk believe uk pension scheme rule provide company right refund surplus asset follow settlement plan liability result net surplus uk define benefit pension scheme recognise fair value asset liability uk define benefit pension scheme aggregate datum define benefit pension scheme group follow uk rest world group december equity list unlisted multiasset fund property list unlisted corporate bond list unlisted government bond list insurance contract liabilitiesasset fair value asset asset ceiling restriction present value scheme obligation net surplusobligation include noncurrent asset include pension postemployment benefit actual return plan asset multiasset fund comprise investment pool investment vehicle invest range asset class increase diversification growth portfolio value fund asset class quote market price million million liabilitiesasset category comprise cash mark market value derivative position indexlinke gilt hold uk repo programme include government bond relate loan million december million million deduct asset gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information pension postemployment benefit continue uk rest world group december equity list unlisted multiasset fund property list unlisted corporate bond list unlisted government bond list insurance contract liabilitiesasset fair value asset present value scheme obligation net surplusobligation include noncurrent asset include pension postemployment benefit actual return plan asset uk rest world group december equity list unlisted multiasset fund property list unlisted corporate bond list unlisted government bond list insurance contract liabilitiesasset fair value asset present value scheme obligation net surplusobligation include noncurrent asset include pension postemployment benefit actual return plan asset note financial statement continue pension postemployment benefit continue postretirement pension benefit uk rest world group group movement fair value asset asset january exchange adjustment addition business combination interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution benefit pay asset december exchange adjustment interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution benefit pay asset december exchange adjustment interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution benefit pay asset december group additional funding contribution uk pension scheme million million million nil nil nil scheme gsk reach revise agreement trustee uk pension scheme additional contribution eliminate pension deficit identify scheme december actuarial funding valuation base funding agreement additional contribution eliminate pension deficit expect million include note commitment fund commitment supersede previous agreement contribution base government bond yield curve approach select discount rate rate choose include allowance expect investment return reflect asset mix scheme employer contribution include special funding contribution estimate approximately million respect define benefit pension scheme million respect postretirement benefit gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information pension postemployment benefit continue postretirement pension benefit uk rest world group group movement define benefit obligation obligation january exchange adjustment addition business combination service cost past service cost interest cost settlement curtailment remeasurement scheme participant contribution benefit pay obligation december exchange adjustment disposal service cost past service cost interest cost settlement curtailment remeasurement scheme participant contribution benefit pay obligation december exchange adjustment service cost past service cost interest cost settlement curtailment remeasurement scheme participant contribution benefit pay obligation december define benefit pension obligation analyse follow fund unfunded liability postretirement healthcare scheme assess assumption pension scheme assumption future medical inflation grade december postretirement healthcare scheme obligation million million million postretirement benefit unfundednote financial statement continue pension postemployment benefit continue movement net define benefit liability follow january exchange adjustment addition business combination service cost past service cost interest cost settlement curtailment remeasurement return plan asset exclude amount include interest lossgain change demographic assumption gainloss change financial assumption experience lossgain employer contribution expense december remeasurement include postretirement benefit detailed gain change demographic assumption gainloss change financial assumption experience gain define benefit pension obligation analyse membership category follow active retire defer postretirement benefit obligation analyse membership category follow active retired defer weight average duration define benefit obligation follow year year year pension benefit postretirement benefit gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information pension postemployment benefit continue sensitivity analysis effect change assumption benefit obligation annual define benefit pension postretirement cost detailed information determine take account duration liability overall profile plan membership increase decrease discount rate decreaseincrease annual pension cost increasedecrease annual postretirement benefit cost decreaseincrease pension obligation decreaseincrease postretirement benefit obligation increase decrease decreaseincrease annual pension cost increasedecrease annual postretirement benefit cost decreaseincrease pension obligation decreaseincrease postretirement benefit obligation increase decrease inflation rate increasedecrease annual pension cost increasedecrease pension obligation year increase life expectancy increase annual pension cost increase annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation increase rate future healthcare inflation increase annual postretirement benefit cost increase postretirement benefit obligation note financial statement continue provision legal major employee restructure relate dispute programme provision provision total january exchange adjustment charge year reverse unused unwind discount utilise reclassification movement transfer pension obligation december settle year settle year december legal dispute major restructuring programme group involve substantial number legal group major restructuring dispute include notification possible claim set programme progress combined restructuring note legal proceeding provision legal integration programme major restructuring dispute include amount relate product liability antitrust programme substantially complete government investigation contract termination self consumer healthcare joint venture integration programme insurance separation preparation programme programme focus primarily simplify supply chain process net charge year million include reversal rationalise group manufacture network restructure estimate insurance recovery primarily relate pharmaceutical commercial operation integrate provision product liability case commercial dispute pfizer consumer healthcare business prepare government investigation separation gsk new company discount provision nil increase restructuring provision primarily include severance cost million discount calculate riskadjuste management formal decision eliminate project cash flow riskfree rate return certain position communicate respect product liability claim relate certain product group employee affect appropriate consultation provision sufficient history claim procedure complete appropriate provision settlement enable management reliable staff severance payment pay immediately estimate provision require cover unasserted claim discount provision increase million ultimate liability matter vary amount increase million provide dependent outcome litigation proceeding investigation possible settlement pension augmentation include million relate negotiation define benefit plan arise staff redundancy show note pension postemployment benefit nature group business number matter subject negotiation litigation employee relate provision year litigation proceeding include employee relate provision include obligation certain appeal procedure year reach resolution medical benefit disabled employee spouse outofcourt settlement discussion december provision benefit protract indemnify dispute result provision amount million million employee charge correspond receivable benefit reflect variety provision severance cost group potential settlement discussion number jubilee awards longservice benefit dispute amount provide give nature provision amount likely base current assessment progress settle year dispute estimate million provide december settle year provision december expect million include provision provision onerous million provision legal contract insurance provision number dispute reimburse party discussion provision include vehicle insurance regulatory matter legal issue note legal proceeding gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information contingent consideration liability consideration certain acquisition include amount contingent future event development milestone sale performance group provide fair value contingent consideration follow shionogi viiv novartis healthcare vaccine total january remeasurement income statement cash payment operate cash flow cash payment invest activity movement december remeasurement income statement cash payment operate cash flow cash payment invest activity december remeasurement income statement cash payment operate cash flow cash payment invest activity december contingent consideration payable december million million expect pay year consideration payable acquisition shionogiviiv healthcare joint venture novartis vaccine business expect pay number year result total estimate liability discount present value show shionogiviiv healthcare contingent consideration liability discount novartis vaccine contingent consideration liability discount commercialise product pipeline asset shionogiviiv healthcare novartis vaccine contingent consideration liability calculate principally base forecast sale performance specify product live product table show indicative basis income statement balance sheet sensitivity reasonably possible change key input valuation contingent consideration liability shionogi shionogi viiv novartis viiv novartis healthcare vaccine healthcare vaccine increasedecrease financial liability lossgain income statement increase sale forecast decrease sale forecast increase discount rate decrease discount rate cent appreciation dollar cent depreciation dollar cent appreciation euro cent depreciation euro sale forecast viiv healthcare sale respect shionogiviiv healthcare contingent consideration explanation accounting viiv healthcare set note financial statement continue noncurrent liability accrual defer income payable payable include number employeerelate liability include employee saving plan contingent liability december contingent liability gsk present obligation result past event comprise guarantee item arise normal course business amount million million contingent liability arise group present obligation arise past event december million million financial asset pledge collateral contingent liability provision outcome tax legal dispute probable group suffer outflow fund possible reliable estimate outflow december dispute provision possible meaningfully assess outcome result probable outflow quantify reliably estimate liability provision record description significant legal dispute group party set note legal proceeding commitment contractual obligation commitment contract provide financial statement intangible asset property plant equipment investment purchase commitment pension interest loan future finance charge lease commitment related intangible asset include milestone payment dependent successful clinical development meeting specify sale target represent maximum pay milestone unlikely achieve amount riskadjuste discount net decrease intangible asset commitment mainly attributable termination number agreement include termination agreement bintrafusp alfa merck kgaa darmstadt germany offset increase number new rd collaboration include alector iteo therapeutic lifemine therapeutic gsk reach agreement trustee uk pension scheme additional contribution eliminate pension deficit identify december actuarial funding valuation payment million table include commitment exclude normal ongoing annual funding requirement uk approximately million group commitment principally relate revenue payment licence alliance commitment respect future interest payable loan disclose take account effect interest rate swap gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information share capital share premium account share ordinary share p premium number share capital issue fully pay january issue employee share scheme ordinary share acquire esop trust december issue employee share scheme ordinary share acquire esop trust december issue employee share scheme ordinary share acquire esop trust december december december number share issuable employee share scheme number unissue share option december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme movement equity retain earning reserve amount million december million million million million million relate associate joint venture cumulative translation exchange equity follow net translation exchange include non total retain fair value control translation earning reserve interests exchange january exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal overseas subsidiary december exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal overseas subsidiary december exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal overseas subsidiary associate december note financial statement continue movement equity continue analysis comprehensive income equity category follow non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal overseas subsidiary associate fair value movement cash flow hedge reclassification cash flow hedge income expense tax fair value movement cash flow hedge item reclassify income statement exchange movement overseas net asset noncontrolle interest fair value movement equity investment tax fair value movement equity investment remeasurement loss define benefit plan tax remeasurement loss define benefit plan comprehensive expenseincome year non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal overseas subsidiary fair value movement cash flow hedge reclassification cash flow hedge income expense tax fair value movement cash flow hedge item reclassify income statement exchange movement overseas net asset noncontrolle interest fair value movement equity investment tax fair value movement equity investment remeasurement loss define benefit plan tax remeasurement loss define benefit plan comprehensive expenseincome year non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal overseas subsidiary fair value movement cash flow hedge reclassification cash flow hedge income expense tax fair value movement cash flow hedge item reclassify income statement exchange movement overseas net asset noncontrolle interest fair value movement equity investment tax fair value movement equity investment remeasurement gain define benefit plan tax remeasurement gain define benefit plan comprehensive expenseincome year information net investment hedge provide note financial instrument relate disclosure gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information movement equity continue analysis reserve follow esop trust fair value cash flow share reserve hedge reserve reserves total january exchange adjustment transfer retain earning year disposal equity investment net fair value movement year ordinary share acquire esop trust writedown share hold esop trust december exchange adjustment transfer retain earning year disposal equity investment net fair value movement year ordinary share acquire esop trust writedown share hold esop trust december exchange adjustment transfer retain earning year disposal equity investment net fair value movement year transfer income expense year impairment equity investment december reserve include nondistributable merger premerger reserve amount million december million million reserve include capital redemption reserve create result share buyback programme amount million december million million noncontrolling interest total noncontrolle interest includes follow individually material noncontrolle interest noncontrolle interest individually material viiv healthcare gsk hold viiv healthcare subgroup give rise material noncontrolle interest summarise financial information respect viiv healthcare subgroup follow turnover profit taxation comprehensive incomeexpense total comprehensive income noncurrent asset current asset total asset current liability noncurrent liability total liability net liability net cash inflow operating activity net cash outflow investing activity net cash outflow financing activity decreaseincrease cash bank overdraft year note financial statement continue noncontrolle interest continue financial information relate viiv healthcare group standalone basis impact grouprelate adjustment primarily relate recognition preferential dividend profit taxation million million million state charge preferential dividend payable gsk shionogi pfizer charge million million million remeasurement contingent consideration payable consideration expect pay number year follow amount attributable viiv healthcare group include gsk financial statement share profit year attributable noncontrolle interest dividend pay noncontrolle interest noncontrolle interest consolidate balance sheet consumer healthcare joint venture gsk hold consumer healthcare subgroup give rise material noncontrolle interest summarise financial information respect consumer healthcare subgroup follow turnover profit taxation comprehensive expense total comprehensive incomeexpense noncurrent asset current asset total asset current liability noncurrent liability total liability net asset net cash inflow operating activity net cash inflowoutflow investing activity net cash outflow financing activity increase cash bank overdraft yearperiod financial information relate consumer healthcare joint venture standalone basis period formation july december impact grouprelate adjustment classification cash pooling account group company outside consumer healthcare joint venture major restructuring charge follow amount attributable consumer healthcare joint venture include gsk financial statement share profit yearperiod attributable noncontrolle interest dividend pay noncontrolle interest noncontrolle interest consolidate balance sheet gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information relate party transaction year group dispose interest innoviva inc note detail disposal royalty gsk innoviva year date disposal million million loan million million medicxi venture lp remain gsk december gsk increase investment kurma biofund ii fcpr million medicxi venture lp million joint venture agreement qura therapeutics llc group obligation fund joint venture april gsk joint venture partner commit financial support million december outstanding liability qura million cash distribution receive investment medicxi venture lp million longwood founder fund lp million apollo therapeutic llp million aggregate compensation director glt give note employee cost acquisition disposal detail acquisition disposal significant subsidiary associate joint venture business give business acquisition gsk complete material business acquisition business disposal gsk number business disposal net cash consideration receive year million profit disposal business year million calculate follow total consideration cash consideration include currency forwards purchase adjustment defer consideration total net asset sell property plant equipment cash cash equivalent net asset total cost deal cost reclassification exchange comprehensive income gain disposal associate joint venture gsk agree innoviva inc innoviva sell approximately million share common stock innoviva innoviva price share raise gross proceed approximately million follow settlement transaction gsk long hold innoviva stock detail note investment associate joint venture cash flow associate joint business venture disposal disposal cash consideration receive net defer consideration pay transaction cost cash cash equivalent divestedacquire cash outflowinflow note financial statement continue acquisition disposal continue business acquisition gsk complete small business acquisition acquire pfizer biotech corporation taiwan pfizer consumer healthcare business previously recognise consumer healthcare joint venture september non cash consideration million represent goodwill million cash million asset acquire million noncontrolling interest million net liability million total net asset acquire intangible asset property plant equipment inventory trade receivables cash cash equivalent trade payable noncontrolle interest goodwill noncash consideration settlement promissory note total consideration business disposal april gsk complete divestment horlick consumer healthcare nutrition product india number country exclude bangladesh unilever merger gsk indian list consumer healthcare entity hindustan unilever indian list public company gsk receive equity stake hindustan unilever million cash gsk dispose equity stake hindustan unilever divestment bangladesh closed june total cash consideration receive million cash divest disposal india bangladesh consumer healthcare entity million profit disposal business year million calculate follows horlick divestment total consideration cash consideration receivable include currency forward purchase adjustment equity investment hindustan unilever limited total net asset dispose goodwill intangible asset property plant equipment inventory cash cash equivalent net liabilitiesasset total cost transaction cost derivative reclassification exchange comprehensive income total gain disposal gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information acquisition disposal continue exposure share price movement embed agreement merge gsk indian list consumer healthcare entity hindustan unilever limited divestment horlick nutrition product india number country recognise derivative signing agreement completion transaction million record cost table derecognition derivative asset largely reflect fair value gain recognise income statement prior period associates joint ventures year gsk investment associate million million pay cash cash flow associate joint business business venture acquisition disposal investment cash consideration receivedpaid net defer consideration transaction cost cash cash equivalent acquireddiveste cash inflowoutflow business acquisition pfizer consumer healthcare business acquisition pfizer consumer healthcare business complete july gsk pfizer contribute respective consumer healthcare business new consumer healthcare joint venture noncash transaction gsk acquire pfizer consumer healthcare business return share joint venture gsk equity interest majority control joint venture pfizer equity interest group control consumer healthcare joint venture consolidate group financial statement number territory legal completion acquisition occur regulatory constraint consumer healthcare joint venture obtain control majority business territory july consolidate net asset business date case entitle benefit trading business delay territory noncontrolle interest consumer healthcare joint venture calculate apply proportionate goodwill method represent pfizer share net asset joint venture exclude goodwill goodwill billion expect deductible tax purpose recognise goodwill represent potential synergy arise combine acquire business gsk exist business value workforce acquire total transaction cost recognise acquisition amount million acquisition july sale billion arise pfizer consumer healthcare business include group turnover business acquire beginning year estimate group turnover approximately billion high business integrate group exist activity practicable identify impact group profit period tesaro inc january gsk acquire tesaro inc oncology focus biopharmaceutical company cash consideration billion billion order strengthen group pharmaceutical pipeline transaction cost amount million goodwill billion expect taxdeductible recognise goodwill represent potential synergy arise combine acquire business gsk exist business value workforce acquire acquisition january december sale billion arise tesaro business include group turnover business integrate group exist activity practicable identify impact group profit periodnote financial statement continue acquisition disposal continue fair value asset acquire business combination include goodwill set table amount relate pfizer consumer healthcare business acquisition provisional subject change pfizer consumer healthcare business tesaro net asset acquire intangible asset property plant equipment right use asset inventory trade receivables asset include cash cash equivalent trade payable net defer tax liability liabilitie term loan noncontrolle interest goodwill total consideration settle share gsk consumer healthcare joint venture cash consideration pay fair value investment joint venture convert subsidiary total consideration noncontrolle interest million represent pfizer share fair value pfizer consumer healthcare business exclude goodwill total noncontrolle interest initially recognise consolidated statement change equity million include pfizer share book value gsk consumer healthcare business disposal gsk number business disposal net cash consideration receive year million profit disposal business year million calculate follow total cash consideration receivable net subsidy payable net asset dispose goodwill intangible asset property plant equipment inventory cash cash equivalent net asset transaction cost reclassification exchange comprehensive income noncontrolle interest divest transaction sign complete gain embed derivative transaction sign complete transaction cost total profit disposal gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information acquisition disposal continue transaction sign complete december december gsk agree divest horlick consumer healthcare nutrition brand unilever plc form merger glaxosmithkline consumer healthcare limit hindustan unilever limited total consideration value approximately billion glaxosmithkline consumer healthcare limited public company list national stock exchange nse bombay stock exchange bse gsk hold stake follow merger glaxosmithkline consumer healthcare limit hindustan unilever limited public company list nse bse gsk million hindustan unilever limited share group enter forward foreign exchange contract relation transaction contract value billion designate cash flow hedge foreign exposure arise transaction contract value billion designate net investment hedge inr eur asset addition exposure share price movement forward purchase share hindustan unilever limited recognise embed derivative embed derivative asset position fair value million december million associate joint venture year gsk investment million associate joint venture million pay cash cash flow associate joint business business venture acquisition disposal investment cash consideration paidreceive net defer consideration receive transaction cost cash cash equivalent acquireddiveste cash outflowinflow adjustment reconcile profit tax operating cash flow profit tax tax profit share aftertax profit associate joint venture finance expense net finance income depreciation amortisation intangible asset impairment asset write profit sale business profit sale intangible asset loss sale investment associate profit sale equity investment business acquisition cost change work capital decrease inventory increase trade receivables increase trade payable increase receivables contingent consideration pay note noncash increase contingent consideration liability increase payables increasedecrease pension provision sharebase incentive plan fair value adjustment cash generate operation note financial statement continue reconciliation net cash flow movement net debt net debt previously report implementation ifrs net debt begin year adjust increase cash bank overdraft increasedecrease liquid investment increase longterm loan repayment shortterm note repayment ofincrease shortterm loan repayment lease liability debt subsidiary undertaking acquire exchange adjustment noncash movement movement net debt net debt end year january interest change reclass december exchange expense fair value ification cash flow analysis change net debt liquid investment cash cash equivalent overdraft debt year commercial paper europeanu mtn bank facility lease liability debt year europeanu mtn bank facility lease liability net debt interest payable derivative financial instrument total liability finance activity exclude cash cash equivalent overdraft liquid investment gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information adjustment net cash flow movement net debt continue january interest change reclass december exchange expense fair value ification cash flow analysis change net debt liquid investment cash cash equivalent cash cash equivalent ahfs overdraft debt year commercial paper europeanu mtn bank facility lease liability debt year europeanu mtn bank facility lease liability net debt interest payable derivative financial instrument total liability finance activity exclude cash cash equivalent overdraft liquid investment information significant change net debt note net debtnote financial statement continue financial instrument relate disclosure objective gsk treasury activity minimise gsk access shortterm finance billion posttax net cost financial operation reduce volatility billion commercial paper programme nil nil benefit earning cash flow gsk use variety issue december million financial instrument finance operation derivative million gsk access shortterm finance financial instrument manage market risk billion euro commercial paper programme million operation derivative principally comprise foreign exchange million issue december nil forward contract swap swap december gsk billion threeyear commit borrowing liquid asset currency require group facility billion billion day commit purpose interest rate swap facility threeyear commit facility agree manage exposure financial risk change interest september extend year september rate financial instrument reduce uncertainty extend year august foreign currency transaction interest payment day commit facility agree august derivative exclusively hedge purpose commit facility undrawn december relation underlie business activity trading gsk consider level committed facility speculative instrument adequate give current liquidity requirement preparation separation consumer healthcare capital management business february gsk cancel replace gsk financial strategy support group strategic year day facility new revolve credit facility priority regularly review board gsk manage equivalent size agree maturity september capital structure group appropriate mix september debt equity gsk billion euro medium term note programme capital structure group consist net debt december billion note issue billion note net debt total equity include programme group billion item relate noncontrolle interest billion billion note issue december consolidate statement change equity shelf registration gsk borrowing mature date total capital include provide noncontrolle interest billion option own pfizer viiv healthcare group continue manage financial policy credit exercisable review liquidity requirement gsk consider profile particularly target shortterm credit rating sufficient financing option available p maintain single longterm rating consistent option exercise target group longterm credit rating standard poor stable outlook moodys market risk investor service moodys stable outlook interest rate risk management group shortterm credit rating p standard objective gsk treasury activity minimise poor moodys respectively effective net interest cost balance mix debt fix liquidity risk management float rate time gsk policy borrow centrally order meet anticipate group main interest rate risk arise borrowing funding requirement strategy diversify liquidity investment float rate refinance mature fix source range facility maintain broad access rate debt change interest rate affect future financial market day sweep cash cash flow fair value financial instrument policy number global subsidiary central treasury account interest rate risk management limit net liquidity management purpose gsk utilise physical float rate debt specific cap review agree notional cash pool arrangement appropriate location annually board currency notional cash pool liquidity draw majority debt issue fix interest rate foreign currency balance provide local funding change float rate interest significantly central liquidity require balance actively manage affect group net interest charge include maintain appropriate level balance notional borrowing interest rate swap place pool arrangement settle currency gross remove impact associate periodic reprice cash overdraft balance report shortterm borrowing include bank facility expose december gsk billion borrowing risk future change market interest rate repayable year hold billion cash majority cash liquid investment cash equivalent liquid investment billion hold centrally gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue interest rate benchmark reform order reduce foreign currency translation exposure interest rate benchmark reform amendment ifrs ias group seek denominate borrowing currency ifrs ifrs ifrs phase phase ii principal asset cash flow primarily issue iasb september august denominate dollar euro sterling borrowing adopt uk endorsement board january swap currency require phase amendment modify specific hedge accounting borrowing denominate swap foreign requirement allow hedge accounting continue currency match investment overseas group asset affect hedge period uncertainty treat hedge relevant asset forward hedge item hedge instrument affect current contract major currency reduce exposure interest rate benchmark amend result group investment overseas asset net ongoing interest rate benchmark reform phase ii provide investment hedge section note detail financial instrument measure amortise cost measurement change basis determine credit risk contractual cash flow require interest rate benchmark credit risk risk counterparty default reform reflect adjust effective interest contractual obligation result financial loss group rate immediate gain loss recognise arise cash cash equivalent favourable group closely monitor market output derivative financial instrument hold bank financial industry work group manage institution credit exposure wholesale retail transition new benchmark interest rate include customer include outstanding receivables announcement libor regulator include group consider maximum credit risk december financial conduct authority fca commodity million december future trading commission transition away million total group financial asset libor include gbp libor usd libor exception investment comprise equity euribor sterling overnight index average rate investment bear equity risk credit risk sonia secure overnight financing rate sofr detail group total financial asset euro shortterm rate str respectively december gsk great concentration december group directly expose credit risk billion wholesaler interest rate benchmark reform hold interest rate billion legal general investment derivative float rate debt reference libor management class gbp liquidity fund aaaaaa group transition material derivative float rate information group credit debt new index instrument reference risk exposure respect large wholesaler libor mature december customer foreign exchange risk management change estimation technique group objective minimise exposure overseas significant assumption current reporting operating subsidiary transaction risk match local period assess loss allowance financial asset currency income local currency cost possible amortise cost fvtoci adoption ifrs foreign currency transaction exposure arise external start report period internal trade flow selectively hedge gsk internal treasuryrelate credit risk trading transaction match centrally intercompany gsk set global counterparty limit gsk banking payment term manage reduce foreign currency risk investment counterpartie base longterm credit possible gsk manage cash surplus rating moodys standard poor usage borrowing requirement subsidiary company centrally limit actively monitor forward contract hedge future repayment originate currency gsk actively manage exposure credit risk reduce surplus cash balance possible gsk strategy regionalise cash management concentrate cash centrally possible table set credit exposure counterpartie rate liquid investment cash cash equivalent derivative gross asset position derivative contract consider purpose table isda agreement risk net position counterparty table e set group financial asset liability offset basisnote financial statement continue financial instrument relate disclosure continue december million million cash categorise hold unrated subinvestment grade rate counterpartie low bbbbaa million million cash transit remain exposure concentrate overseas bank local cash management investment purpose include million nigeria hold united bank africa zenith bank access bank stanbic ibtc bank million halk bank uk million btv austria million argentina hold banco de la nacion banco de la provincia million j trust royal bank cambodia million produbanco ecuador million banco central de honduras honduras million bac san jos panama million banco popular puerto rico million bank balance deposit hold bbbbaa rate counterpartie million hold bbbbaa rate counterpartie include balance deposit million hdfc bank india bank local investment purpose gsk measure expect credit loss cash cash equivalent function individual counterparty credit rating associate month default rate expect credit loss cash cash equivalent thirdparty financial derivative deem immaterial loss experience credit rating assign standard poor moodys respectively opinion rating agency differ gsk assign low rating counterparty local rating agency fitch datum source available rating convert global rating equivalent standard poor moodys publish conversion table credit rating form basis assessment expect credit loss treasuryrelate balance hold amortise cost bank balance deposit government security bbba aaaaaa aaaa aa bbbbaa unrated total bank balance deposit treasury treasury repo money market fund liquidity fund government security rd party financial derivative total bbba aaaaaa aaaa aa bbbbaa unrated total bank balance deposit treasury treasury repo money market fund liquidity fund government security rd party financial derivative total gsk centrally manage cash reserve amount december group trade receivable billion december available wholesaler total million month include billion cash manage total trade receivables million group viiv healthcare own subsidiary group expose concentration credit risk respect billion cash manage group gsk consumer wholesaler encounter healthcare own subsidiary group invest financial difficulty materially adversely affect centrally manage liquid asset bank deposit aaaaaa group financial result rate treasury treasury repo money market fund group credit risk monitoring activity relate aaaaaa rate liquidity fund wholesaler include review quarterly financial wholesale retail credit risk information standard poor credit rating development outside customer account gsk internal risk rating establishment periodic group trade receivable balance review credit limit line pharmaceutical company new customer subject credit vetting process group sell product small number wholesaler exist customer subject review annually addition hospital pharmacie physician vetting process subsequent review involve obtain group sale large wholesaler amount information include customer status government approximately sale private sector entity audit financial statement credit bureau pharmaceutical vaccine business report debt rating agency eg moodys standard poor report payment performance history trade reference industry credit group bank reference gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue trade receivables consist amount large number fair value financial asset liability exclude customer spread diverse industry lease liability geographical area ongoing credit evaluation perform table present carry amount financial condition account receivable fair value group financial asset liability appropriate credit insurance purchase factoring exclude lease liability december arrangement place december information obtain proportional level fair value financial asset liability include exposure consider information evaluate price receive sell asset pay quantitatively ie credit score qualitatively ie judgement transfer liability orderly transaction market conjunction customer credit requirement participant measurement date determine credit limit follow method assumption measure trade receivables group customer segment fair value significant financial instrument carry fair similar loss pattern assess credit risk value balance sheet receivables financial asset assess individually investment equity investment trade active historical forwardlooking information consider market determine reference relevant stock determine appropriate expect credit loss allowance exchange quote bid price equity investment group believe credit risk provision determine reference current market value similar require excess allowance expect credit loss instrument recent financing round discount cash note trade receivables flow underlie net asset credit enhancement trade receivables carry fair value base invoice group use credit enhancement include factoring credit insurance minimise credit risk trade receivables group december million interest rate swap foreign exchange forward contract million trade receivables insure swap option base present value order protect receivables loss credit risk contractual cash flow option valuation model default insolvency bankruptcy market source datum exchange rate interest rate balance sheet date group entity assess credit risk private customer determine credit insurance require cash cash equivalent carry fair value base net asset value fund factoring arrangement manage locally entity mitigate risk arise large credit risk contingent consideration business acquisition concentration factor arrangement nonrecourse divestment base present value expect future cash flow follow method assumption estimate fair value significant financial instrument measure fair value balance sheet receivables payable include option carry amortise cost approximate carry liquid investment approximate carry cash cash equivalent carry amortise cost approximate carry longterm loan base quote market price level fair value measurement case european medium term note approximate carry case fix rate borrowing float rate bank loan shortterm loan overdraft commercial paper approximate carry short maturity instrumentsnote financial statement continue financial instrument relate disclosure continue carry fair carry fair value value value value note financial asset measure amortise cost noncurrent asset b trade receivables b liquid investment cash cash equivalent financial asset measure fair value comprehensive income fvtoci investment designate fvtoci trade receivables ab financial asset mandatorily measure fair value profit loss fvtpl investment noncurrent assets ab trade receivables ab hold trading derivative designate effective hedge relationship ade cash cash equivalent derivative designate effective hedging instrument fair value movement comprehensive income ade total financial asset financial liability measure amortise cost borrowing exclude obligation lease liability bond designate hedge relationship bond bank loan overdraft commercial paper borrowing total borrowing exclude lease liability f trade payable c provision c noncurrent liability c financial liability mandatorily measure fair value profit loss fvtpl contingent consideration liability ac hold trading derivative designate effective hedge relationship ade derivative designate effective hedging instrument fair value movement comprehensive income ade total financial liability exclude lease liability net financial asset financial liability exclude lease liability valuation methodology measure fair value table describe categorise trade receivables noncurrent asset trade payable provision contingent consideration liability noncurrent liability reconcile relevant note page gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue fair value investment gsk share december employee share ownership plan esop trust hold gsk share carry value million million market value million million base quote market price share hold esop trust satisfy future exercise option award employee incentive scheme carry value low cost expect proceed share recognise deduction reserve december gsk hold treasury share cost million million deduct retain earning financial instrument hold fair value follow table categorise group financial asset liability hold fair value valuation methodology apply determine fair value possible quote price active market level price available asset liability classify level provide significant input valuation model base observable market datum significant input valuation model base observable market datum instrument classified level investment classify level table comprise equity investment unlisted entity group enter research collaboration investment emerge life science company level level level total december financial asset fair value financial asset measure fair value comprehensive income fvtoci investment designate fvtoci trade receivables financial asset mandatorily measure fair value profit loss fvtpl investment noncurrent asset trade receivable hold trading derivative designate effective hedge relationship cash cash equivalent derivative designate effective hedging instrument fair value movement oci financial liability fair value financial liability mandatorily measure fair value profit loss fvtpl contingent consideration liability hold trading derivative designate effective hedging relationship derivative designate effective hedging instrument fair value movement oci level level level total december financial asset fair value financial asset measure fair value comprehensive income fvtoci investment designate fvtoci trade receivables financial asset mandatorily measure fair value profit loss fvtpl investment noncurrent asset trade receivable hold trading derivative designate effective hedge relationship cash cash equivalent derivative designate effective hedging instrument fair value movement oci financial liability fair value financial liability mandatorily measure fair value profit loss fvtpl contingent consideration liability hold trading derivative designate effective hedging relationship derivative designate effective hedging instrument fair value movement oci note financial statement continue financial instrument relate disclosure continue movement year financial instrument measure level valuation method present january net loss recognise income statement net gain recognise comprehensive income settlement contingent consideration liability addition disposal settlement transfer level december net loss million million attributable level financial instrument recognise income statement respect financial instrument hold end year report operate income charge million million arise remeasurement contingent consideration payable acquisition shionogiviiv healthcare joint venture million million arise remeasurement contingent consideration payable acquisition novartis vaccine business net gain million net gain million attributable level financial instrument report comprehensive income fair value movement equity investment arise prior transfer level equity investment transfer level valuation methodology result list recognise stock exchange year net gain loss include impact exchange movement financial liability measure level valuation method december include million million respect contingent consideration payable acquisition shionogiviiv healthcare joint venture consideration expect pay number year vary line future performance specify product movement certain foreign currency include million million respect contingent consideration acquisition novartis vaccine business consideration expect pay number year vary line future performance specify product achievement certain milestone target movement certain foreign currency sensitivity analysis balance provide note contingent consideration liability b trade receivables noncurrent asset scope ifrs follow table reconcile financial instrument trade receivables noncurrent asset fall scope ifrs relevant balance sheet amount financial asset predominantly noninterest earn nonfinancial instrument include tax receivables pension surplus balance prepayment outside scope ifrs non non amortise financial financial amortise financial financial fvtpl fvtoci cost instrument instrument total fvtpl fvtoci cost instrument instrument total trade receivable note noncurrent asset note trade receivables include trade receivables million million group portfolio business model ifrs million million measure fvtpl hold sell contractual cash flow receivable sell factoring arrangement million million measure fvtoci hold collect sell contractual cash flow receivables sell factoring agreement million million measure amortise cost hold collect contractual cash flow factor agreement place gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue c trade payable provision contingent consideration liability noncurrent liability scope ifrs follow table reconcile financial instrument trade payable provision contingent consideration liability noncurrent liability fall scope ifrs relevant balance sheet amount financial liability predominantly noninterest bear nonfinancial instrument include payment account tax social security payable provision arise contractual obligation deliver cash financial asset outside scope ifrs non non amortise financial financial amortise financial financial fvtpl cost instrument instrument total fvtpl cost instrument instrument total trade payable note provision note contingent consideration liability note noncurrent liability note derivative financial instrument hedge programme derivative economic hedging purpose speculative investment classify hold trading designate effective hedging instrument present current asset liability expected settle month end reporting period classified noncurrent group follow derivative financial instrument fair value fair value asset liability asset liabilitie noncurrent cash flow hedge interest rate swap contract principal million nil current cash flow hedge interest rate swap contract principal nil million net investment hedge cross currency swap principal nil million cash flow hedge foreign exchange contract principal million million net investment hedge foreign exchange contract principal million million derivative designate effective hedging instrument noncurrent embed derivative current foreign exchange contract principal million million embed derivative derivative classify hold trading total derivative instrument fair value hedge december december group designate fair value hedgesnote financial statement continue financial instrument relate disclosure continue net investment hedge december certain foreign exchange contract designate net investment hedge respect foreign currency translation risk arise consolidation group net investment european euro japanese jpy foreign operation show table carry value bond include million million designate hedging instrument net investment hedge cash flow hedge group enter forward foreign exchange contract designate cash flow hedge enter hedge foreign exchange exposure arise cash flow euro denominate coupon payment relate note issue group european medium term note programme buyout novartis noncontrolle interest consumer healthcare joint venture divestment horlick nutrition brand take place refinance exist debt maturity group manage cash flow interest rate risk floatingtofixed interest rate swap addition group carry balance reserve arise prehedge fluctuation longterm interest rate pricing bond issue prior year current year future balance reclassify finance cost life bond foreign exchange risk current year group designate certain foreign exchange forward contract swap cash flow net investment hedge foreign exchange derivative financial asset liability present line derivative financial instrument asset liability consolidate balance sheet follow table detail foreign exchange forward contract swap outstanding end report period information relate hedge item hedge effectiveness determined inception hedge relationship periodic prospective effectiveness assessment ensure economic relationship exist hedge item hedging instrument group enter hedge relationship critical term hedge instrument match exactly term hedge item qualitative assessment effectiveness perform change circumstance affect term hedge item critical term long match exactly critical term hedge instrument group use hypothetical derivative method assess effectiveness main source hedge ineffectiveness hedging relationship effect counterparty group credit risk fair value foreign exchange forward contract swap reflect fair value hedge item attributable change foreign exchange rate ineffectiveness roll cash flow hedge divestment mention source ineffectiveness emerge hedging relationship ineffectiveness record cash flow hedge amount nil gain million ineffectiveness record net investment hedge nil include table borrowing bond notional value million swap fix interest rate eur debt cross currency interest rate swap periodic change value calculate average foreign notional carry hedge exchange rate currency value value ineffectiveness hedge instrument cash flow hedge foreign exchange contract buy foreign currency month usd month eur month eur gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue periodic change value calculate average foreign notional carry hedge exchange rate currency value value ineffectiveness hedging instrument net investment hedge foreign exchange contract sell foreign currency month eur sgd jpy borrowing month eur month eur cumulative balance cash periodic change value flow hedge reserveforeign calculate hedge currency translation reserve ineffectiveness continue hedge hedge item cash flow hedge variability cash flow foreign exchange exposure arise euro denominate coupon payment relate debt issue net investment hedge net investment foreign operation periodic change value calculate average foreign notional carry hedge exchange rate currency value value ineffectiveness hedge instrument cash flow hedge foreign exchange contract buy foreign currency month eur periodic change value calculate average foreign notional carry hedge exchange rate currency value value ineffectiveness hedging instrument net investment hedge foreign exchange contract sell foreign currency month eur month sgd month jpy borrowing include cross currency interest rate swap month eur month eur note financial statement continue financial instrument relate disclosure continue cumulative balance cash periodic change value flow hedge reserveforeign calculate hedge currency translation reserve ineffectiveness continue hedge hedge item cash flow hedge variability cash flow highly probable forecast transaction variability cash flow foreign exchange exposure arise euro denominate coupon payment relate debt issue net investment hedge net investment foreign operation million million balances cash flow hedge reserve arise hedging relationships hedge accounting long apply follow table detail effectiveness hedge relationship amount reclassify hedging reserve profit loss reclassify profit loss line item hedge hedge profit future cash line item hedge ineffectiveness loss flow gainslosse gainslosse hedge long hedge reclassification recognise recognise ineffectiveness expect item affect adjustment reserve profit loss include occur profit loss include cash flow hedge variability cash flow highly probable forecast transaction operate operate income income expense expense variability cash flow foreign exchange exposure arise finance finance euro denominate coupon payment relate debt issue income income expense expense net investment hedge net investment foreign operation finance finance income income expense expense follow table detail effectiveness hedge relationship amount reclassify hedging reserve profit loss reclassify profit loss line item hedge hedge profit future cash line item hedge ineffectiveness loss flow gainslosse gainslosse hedge long hedge reclassification recognise recognise ineffectiveness expect item affect adjustment reserve profit loss include occur profit loss include cash flow hedge variability cash flow highly probable forecast transaction operate operate income income expense expense variability cash flow foreign exchange exposure arise finance finance euro denominate coupon payment relate debt issue income income expense expense net investment hedge net investment foreign operation finance finance income income expense expense gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue interest rate risk group manage cash flow interest rate risk floatingtofixed interest rate swap quarterly interval difference fix contract rate float rate interest amount calculate reference agree notional principal amount exchange swap outstanding december interest rate risk element future debt issuance manage enter forward start interest rate swap effectively lock interest rate debt advance close time issue debt result gain loss hold oci recycle income statement interest payment debt impact income statement forward start interest rate swap forward start interest rate contract exchange float interest fix interest designate cash flow hedge hedge interest variability interest cash flow associate future fix rate debt interest rate swap interest rate swap contract exchange float rate interest fix interest designate cash flow hedge hedge variability interest cash flow associate float rate debt relate note issue group european medium term note programme interest rate swap interest payment loan occur simultaneously accumulate equity reclassify profit loss period float rate interest payment affect profit loss critical term interest rate swap forward start interest rate swap contract correspond hedge item materially qualitative assessment effectiveness perform expect value interest rate swap contract value correspond hedge item systematically change opposite direction response movement underlie interest rate main source ineffectiveness hedge relationship effect group credit risk fair value interest rate swap contract reflect fair value hedge item attributable change interest rate material source ineffectiveness emerge hedging relationship follow table provide information interest rate swap forward start interest rate swap contract outstanding related hedge item december december interest rate swap contract asset liability present line derivative financial instrument asset liability consolidate balance sheet change fair value average notional recognise fair value contract fix principal hedge asset rate value ineffectiveness liability hedge instrument year year year balance cash change value flow hedge reserve calculate continue hedge hedge ineffectiveness tax hedge item prehedge longterm interest rate million million balance cash flow hedge reserve arise hedge relationships hedge accounting long apply change fair value average notional recognise fair value contract fix principal hedge asset rate value ineffectiveness liability hedge instrument year year balance cash change value flow hedge reserve calculate continue hedge hedge ineffectiveness tax hedge item variable rate borrowing note financial statement continue financial instrument relate disclosure continue follow table detail effectiveness hedge relationship amount reclassify hedging reserve profit loss reclassify profit loss line item hedge profit future cash line item hedge hedge loss flow gainslosse ineffectiveness hedge long hedge reclassification recognise recognise ineffectiveness expect item affect adjustment reserve profit loss include occur profit loss include cash flow hedge variability cash flow finance finance income income expense expense prehedge longterm interest rate mature past finance finance year income income expense expense year year reclassify profit loss line item hedge profit future cash line item hedge hedge loss flow gainslosse ineffectiveness hedge long hedge reclassification recognise recognise ineffectiveness expect item affect adjustment reserve profit loss include occur profit loss include cash flow hedge variability cash flow finance finance income income expense expense prehedge longterm interest rate finance finance income income expense expense e offset financial asset liability financial asset liability offset net report balance sheet legally enforceable right offset recognise amount intention settle net basis realise asset settle liability simultaneously arrangement meet criterion offset allow related amount offset certain circumstance bankruptcy termination contract follow table set financial asset liability offset subject enforceable master netting arrangement similar agreement offset december december column net show impact group balance sheet offset right exercise gross financial financial liability net financial relate asset asset asset amount net liability offset liability offset december financial asset trade receivables derivative financial instrument financial liability trade payable derivative financial instrument gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue gross financial financial liability net financial relate asset asset asset amount net liability offset liability offset balance december financial asset trade receivables derivative financial instrument financial liability trade payable derivative financial instrument amount meet criterion offset balance sheet settle net certain circumstance principally relate derivative transaction isda international swap derivative association agreement party option settle amount net basis event default party presently legally enforceable right offset amount offset balance sheet present separately table f debt interest rate repricing table follow table set exposure group interest rate debt include commercial paper maturity analysis fix rate debt state contractual maturity float rate debt interest rate repricing date purpose table debt define class borrowing lease liability total debt total float fix rate debt year year year year year year great year total original issuance profile fix rate interest float rate interest addition forward start interest rate swap enter affect pricing debt raise future section interest rate risk detailsnote financial statement continue financial instrument relate disclosure continue g sensitivity analysis table illustrate estimate impact income statement equity result hypothetical market movement foreign exchange interest rate relation group financial instrument range variable choose sensitivity analysis reflect management view change reasonably possible oneyear period foreign exchange sensitivity group operate internationally primarily expose foreign exchange risk relation sterling movement dollar euro japanese yen foreign exchange risk arise translation financial asset liability functional currency entity hold base group net financial asset liability december weaken strengthen sterling currency variable hold constant illustrate table table exclude financial instrument expose group foreign exchange risk risk fully hedge financial instrument increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposure cent appreciation dollar cent appreciation euro yen appreciation yen increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposure cent depreciation dollar cent depreciation euro yen depreciation yen equity impact show foreign exchange sensitivity relate derivative nonderivative financial instrument hedge group net investment european euro foreign operation cash flow hedge foreign exchange exposure arise euro denominate coupon payment relate note issue group european medium term note programme increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposure cent appreciation euro increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposure cent depreciation euro gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information financial instrument relate disclosure continue table present group sensitivity weakening strengthen sterle relevant currency base composition net debt show note adjust effect foreign exchange derivative net debt affect future foreign currency cash flow increasedecrease increasedecrease net debt net debt impact foreign exchange movement net debt cent appreciation dollar cent appreciation euro yen appreciation yen increasedecrease increasedecrease net debt net debt impact foreign exchange movement net debt cent depreciation dollar cent depreciation euro yen depreciation yen interest rate sensitivity group expose interest rate risk outstanding borrowing investment change interest rate affect future cash flow fair value financial instrument majority debt issue fix interest rate change float rate interest significantly affect group net interest charge majority cash liquid investment earn float rate interest table hypothetically show group sensitivity change interest rate relation sterling dollar euro float rate financial asset liabilitie interest rate applicable float rate financial asset liability increase basis point assume variable remain constant estimate group finance income decrease approximately million million increase basis point movement usd interest rate cause increase million equity nil basis point movement interest rate eur sterling deem material effect equity increasedecrease increasedecrease income income income statement impact interest rate movement basis point increase sterling interest rate basis point increase dollar interest rate basis point increase euro interest rate note financial statement continue financial instrument relate disclosure continue h contractual cash flow nonderivative financial liability derivative instrument follow table provide analysis anticipate contractual cash flow include interest payable group non derivative financial liability undiscounte basis purpose table debt define class borrowing lease liability interest calculate base debt hold december take account future issuance float rate interest estimate prevail interest rate balance sheet date cash flow foreign currency translate spot rate december finance trade payable charge interest lease lease liability debt debt liability liabilitie net debt total december year year year year year year great year gross contractual cash flow finance trade payable charge interest lease lease liability debt debt liability liabilitie net debt total december year year year year year year great year gross contractual cash flow table provide analysis anticipate contractual cash flow group derivative instrument exclude equity option rise cash flow embed derivative material undiscounted cash flow cash flow foreign currency translate spot rate december gross cash flow foreign exchange contract present purpose table practice group use standard settlement arrangement reduce liquidity requirement instrument gross cash inflow gross cash ouflow gross cash inflow gross cash outflow foreign foreign foreign foreign forward exchange forward exchange cross exchange cross exchange start forward start forward currency forward currency forward interest rate contract interest rate contract interest rate contract interest rate contract swap swap swap swap swap swap swap swap year year year year year great year gross contractual cash flow gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information employee share scheme gsk operate employee share scheme include share value plan award grant employee acquire share ad glaxosmithkline plc cost threeyear vest period performance share plan award grant employee acquire share ad glaxosmithkline plc cost subject achievement group specify performance target grant restrict share award replace grant option employee cost scheme readily equate potential gain employee group operate saving relate share option scheme option grant employee acquire share glaxosmithkline plc discount price grant restrict share award normally exercisable end threeyear vest performance period award normally grant employee acquire share ad glaxosmithkline plc circumstance settle cash grant savingsrelate share option scheme normally exercisable year save accordance uk practice majority option savingsrelate share option scheme grant price market price ruling date grant option historical share option scheme grant market price ruling date grant total charge sharebase incentive plan million million million million million million arise share value plan note employee cost detail glaxosmithkline share award scheme share value plan share value plan share award grant certain employee cost award vest half year performance criterion attach fair value award determine base closing share price day grant deduct expect future dividend yield duration award share weight ad weight number share ad issuable number fair value number fair value january award grant award exercise award cancel december award grant award exercise award cancel december award grant award exercise award cancel december performance share plan performance share plan share award grant director senior executive cost percentage award vest base performance group define measurement period dividend reinveste period award grant performance condition base equally weight measure threeyear performance period adjust free cash flow tsr rd new product performance award grant performance condition base measure threeyear performance period adjust free cash flow tsr rd new product performance pipeline progress fair value award determine base closing share price day grant tsr performance element adjust likelihood condition meet assess time grant award million share weight fair value million ad weight fair value december outstanding award million share million adsnote financial statement continue employee share scheme continue share option savingsrelate option purpose value savingsrelated option arrive sharebased payment charge blackschole option pricing model assumption model follow grant grant grant riskfree interest rate dividend yield volatility expect life year year year savingsrelate option grant price include discount savingsrelate option outstanding share option scheme weight number exercise price december range exercise price option outstanding year end weight average market price exercise year weight average remain contractual life year option million share grant year savingsrelate share option scheme weight average fair value december million savingsrelate share option exercisable change effective exercise price outstanding option year employee share ownership plan trust group sponsor employee share ownership plan esop trust acquire hold share glaxosmithkline plc satisfy award employee incentive plan option grant employee share option scheme trustee esop trust purchase share finance provide group way loan contribution cost run esop trust charge income statement share hold esop trust deduct reserve amortise value proceed receivable employee exercise transfer retain earning trustee waive right dividend share hold esop trust february million treasury share transfer esop trust trust hold million share exercise share option share reward share hold share award scheme number share nominal value carry value market value share hold share option scheme number share nominal value carry value market value gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information principal group company follow represent principal subsidiary country incorporation group december equity share capital entity show percentage column company incorporate principal country operation state england glaxo group limited alacer corp glaxo operation uk limited block drug company inc glaxosmithkline capital plc corixa corporation glaxosmithkline consumer healthcare holdings limited glaxosmithkline capital inc glaxosmithkline consumer healthcare uk trading limited glaxosmithkline consumer healthcare holding llc glaxosmithkline consumer trading services limit glaxosmithkline consumer healthcare lp glaxosmithkline export limited glaxosmithkline holdings americas inc glaxosmithkline finance plc glaxosmithkline llc glaxosmithkline holdings limit human genome sciences inc glaxosmithkline research development limited gsk consumer health inc glaxosmithkline service unlimited gsk equity investment limited glaxosmithkline uk limited stiefel laboratories inc glaxosmithkline trading limit tesaro inc glaxo wellcome uk limited viiv healthcare company setfirst limited smithkline beecham limited viiv healthcare finance limit viiv healthcare limited viiv healthcare uk limited europe glaxosmithkline biological sa belgium glaxosmithkline australia pty ltd australia glaxosmithkline sant grand public france glaxosmithkline consumer healthcare australia pty ltd australia laboratoire glaxosmithkline france glaxosmithkline brasil limitada brazil viiv healthcare sas france glaxosmithkline consumer healthcare ulcglaxosmithkline soin glaxosmithkline consumer healthcare gmbh co kg germany de sante aux consommateurs sri canada glaxosmithkline gmbh co kg germany glaxosmithkline inc canada gsk vaccines gmbh germany d biomedical corporation quebec canada glaxosmithkline consumer healthcare srl italy pf consumer healthcare canada ulcpf soin de sante glaxosmithkline spa italy sri canada gsk vaccines srl italy glaxosmithkline limited china hong kong viiv healthcare srl italy sinoamerican tianjin smith kline french laboratories ltd china pfizer consumer manufacturing italy srl italy wyeth pharmaceutical co ltd china gsk service sp z oo poland glaxosmithkline asia private limited india glaxosmithkline trading services limited republic ireland glaxosmithkline pharmaceuticals limited india glaxosmithkline healthcare ao russia glaxosmithkline consumer healthcare japan kk japan jsc glaxosmithkline trading russia glaxosmithkline kk japan glaxosmithkline sa spain glaxosmithkline pakistan limited pakistan laboratorios viiv healthcare sl spain glaxo wellcome manufacturing pte ltd singapore gsk consumer healthcare sarl switzerland glaxosmithkline korea limited republic korea directly hold whollyowne subsidiary glaxosmithkline plc head office england subsidiary associate list principally affect figure group financial statement glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline llc whollyowne finance subsidiary company company fully unconditionally guarantee security issue glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline llc page complete list subsidiary undertaking associate joint venture form financial statementsnote financial statement continue legal proceeding group involve significant legal administrative dolutegravir proceeding proceeding principally product liability intellectual property tivicaytriumeq tax antitrust consumer fraud governmental investigation viiv healthcare receive patent challenge letter significant matter tax matter hatchwaxman act cipla dr reddys labs apotex describe group make provision triumeq tivicay letter lupin mylan triumeq proceeding regular basis summarise note letter sandoz tivicay viiv healthcare list accounting principle policy note patent fda orange book tivicay triumeq provision note describe disclosure patent cover molecule dolutegravir expire proceeding provision legal expense october second patent claim crystal form incur provision relate legal claim charge dolutegravir expire december letter sell general administration cost group challenge laterexpire crystal form patent believe information seek plaintiff generic company allege crystal form patent know meaningful respect invalid claim crystal form patent invalid legal proceeding number factor include infringe propose product viiv limited stage proceeding entitlement healthcare file patent infringement suit generic party appeal decision clarity theory liability company settlement reach litigation damage govern law september viiv healthcare receive paragraph iv december group aggregate provision legal letter lupin relate tivicay mg dosage oral dispute include tax matter describe note suspension challenging crystal form patent taxation million assurance november viiv healthcare file suit lupin loss result outcome legal proceeding district court district delaware trial date exceed material provision set report group financial statement dovato happen material adverse impact result september viiv healthcare receive paragraph iv operation group report period letter cipla relate dovato challenge judgement incur settlement enter crystal form patent november viiv healthcare file intellectual property suit cipla district court district delaware trial date set intellectual property claim include challenge validity enforceability group patent product juluca process assertion noninfringement january viiv healthcare receive paragraph iv letter patent loss case result loss lupin relate juluca challenging crystal form patent protection product issue consequence patent patent relate combination loss significant decrease sale dolutegravir rilpivirine expire january product materially affect future result operation february viiv healthcare file suit lupin group patent additionally june cipla send viiv healthcare paragraph iv letter relate juluca july coreg viiv healthcare file suit cipla federal court gsk initiate suit teva induce delaware court set trial date matter infringement patent relate use carvedilol coreg decrease mortality cause congestive heart litigation gilead sciences inc failure june case proceed jury trial february viiv healthcare file patent infringement district court district delaware jury return litigation bictegravir gilead sciences inc verdict gsk favour award gsk lose profit gilead district court district delaware reasonable royalty total award million canadian federal court viiv healthcare allege march trial judge rule posttrial motion file gilead triple combination hiv drug contain hiv teva find substantial evidence trial support integrase inhibitor bictegravir infringe viiv healthcare patent jurys find induce infringement overturning jury cover dolutegravir compound include award gsk appeal october divide panel dolutegravir unique chemical scaffold viiv healthcare court appeal federal circuit reverse commence action uk france germany japan ireland district court rule reinstate jury award gsk south korea australia gilead allege gilead favour december teva file petition rehear biktarvy infringe certain viiv healthcare hiv integrase en banc court grant tevas petition inhibitor patent viiv healthcare agree settle global rehearing threemember panel issue original patent infringement litigation gsk shionogi decision august original panel issue shareholder viiv healthcare gilead concern viiv rehear opinion majority reinstate jurys healthcare patent relate dolutegravir detail damage award million gsk favour teva global settlement licensing agreement find file petition rehear en banc reject note post balance sheet event court appeal federal circuit february gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information legal proceeding continue product liability group name defendant approximately group currently defendant number product personal injury claim numerous unfiled claim liability lawsuit register census require court preside zantac multidistrict litigation mdl proceeding class action avandia allege economic injury thirdparty payer class action pende class action bring thirdparty file federal court outside payer assert claim racketeer influence class action pende group canada corrupt organization act rico state consumer class action israel state court case protection law december circuit court naming group bellwether trial california appeals reverse summary judgement grant favour currently schedule begin october trial group remand thirdparty payer case schedule madison county illinois proceed district court discovery underway district court august trial date set possible class certification hearing hold early february product liability litigation assign mdl status southern district florida ppi litigation group file round motion dismiss certain member group defendant ongoing mdl result follow position court rule proton pump inhibitor ppi litigation plaintiffs allege favour group motion innovator liability issue use ppis cause bodily injury include appeal court rule favour defendant acute kidney injury chronic kidney disease endstage respect party payor class action plaintiff opt renal failure january approximately replead action issue appeal prevacid hr personal injury lawsuit approximately court dismiss rico claim economic loss nexium hr case pende group nearly class action allow class forward plaintiff pende multidistrict litigation mdl misbranding theory medical monitoring proceeding district new jersey manufacturers economic loss class action allow forward ppi include prescription otc product generic retailer packager dismiss name codefendant mdl group file case motion dismiss case mdl court rule motion ppi bellwether mdl plaintiff require identify type trial delay ongoing covid pandemic cancer wish pursue identify different set october involve group type november plaintiff withdraw consideration addition mdl case small number case breast cancer kidney cancer reduce number type pende state court cancer january plaintiff withdraw consideration colorectal prostate lung procee zantac follow type cancer bladder group contact regulatory esophageal gastric liver pancreatic authority detection nnitrosodimethylamine ndma zantac ranitidine product base information addition class action litigation march available time correspondence regulator department justice doj send group notice civil group decision suspend release distribution investigation open allegation false claim act supply dose form zantac market pende violation group relate zantac june outcome ongoing test investigation doj serve civil investigative demand group precautionary action group decision initiate formalizing request document day voluntary pharmacyretail level recall zantac product new mexico attorney general file lawsuit multiple globally defendant include group allege violation state consumer protection false advertising statute april european medicine agency ema claim recommend suspension ranitidine medicine follow publication emas recommendation company communicate decision reenter market fda request manufacturer withdraw ranitidine product marketnote financial statement continue legal proceeding continue zofran antitrustcompetition group defendant product liability case certain governmental action private lawsuit involve zofran pende multidistrict litigation mdl bring group allege violation competition proceed district massachusetts case allege antitrust law child suffer birth defect mother uk competition market authority investigation ingestion zofran andor generic ondansetron pregnancy february uk competition market relate nausea vomit plaintiff assert group authority cma issue decision fine group sell zofran know unsafe pregnant woman fail million infringement competition act connection warn risk illegally market zofran offlabel agreement settle patent dispute group enter use pregnant woman potential supplier generic june mdl court grant group motion paroxetine formulation summary judgment federal preemption ground court group appeal competition appeal tribunal cat find fda fully inform relevant safety deliver initial judgement march information zofran repeatedly rejected refer certain question law european union court attempt add birth defect warning label court justice ecj january ecj issue grant judgment group case pende mdl judgement endorse general approach undertake closed mdl proceeding july plaintiff file cma original decision cat appeal preemption decision united states deliver final judgement hold gsk infringe court appeal circuit appeal pende applicable competition law reduce fine impose group defendant state court case group million million litigation propose class action canada close sale marketing regulation lamictal purport class direct purchaser file suit group marketing promotion pharmaceutical district court district new jersey allege vaccine product subject certain governmental group teva pharmaceuticals unlawfully conspire delay investigation private lawsuit bring litigant generic competition lamictal result overcharge theory law purchaser enter allegedly anticompetitive gsk korea proceeding fair trade law reverse payment settlement resolve patent infringement august gsk korea indict koreas litigation separate count accuse group monopolising monopoly regulation fair trade law relation market government tender hpv cervarix pcv synflorix december trial judge grant plaintiff class vaccine prosecutor allege certification motion certify class direct purchaser gsk korea action group file rule f motion court appeal employee interfere tender process circuit challenging class certification decision national immunisation programme straw bidder april court appeal vacate low court employee charge individual capacity grant class certification remand issue prosecutor relation matter low court analysis number wholesaler codefendant proceeding october district court hear argument korea fair trade commission commence plaintiff renew motion class certification remand investigation gsk korea matter gsk april district court deny plaintiffs motion korea cooperate authority matter class certification putative direct purchaser class leave proceeding ongoing potential class brandonly purchaser plaintiff move supplement expert report seek additional discovery support addition certain generic purchaser january district court deny plaintiff motion supplement expert report seek additional discovery hold issue generic purchaser decided deny court rule decertification party briefing class certification remain brandonly purchaser gsk annual report note financial statement continue gsk annual report strategic report governance remuneration financial statement investor information post balance sheet event february viiv healthcare reach agreement gilead settle global patent infringement litigation relate commercialisation gilead biktarvy concern viiv healthcare patent relate dolutegravir antiretroviral medication medicine treat human immunodeficiency virus hiv term global settlement licensing agreement gilead upfront payment billion viiv healthcare february addition gilead pay royalty future sale biktarvy respect bictegravir component future bictegravircontaine product sell royalty payable gilead viiv healthcare february expiry viiv healthcare patent october gilead obligation pay royalty extend period regulatory paediatric exclusivity award settlement result remeasurement exist liability contingent consideration pfizer option year end upfront payment contingent asset balance sheet date receipt consider virtually certain date recognise q operating income result settlement patent infringement case uk france ireland germany japan south korea australia canada discontinue company balance sheet uk gaap include frs reduce disclosure framework december note fix asset investment e current asset trade receivables f cash bank total current asset trade payable g total current liability net current asset total asset current liability provision liability h noncurrent liability net asset capital reserve share capital j share premium account j reserve k retain earning january profitloss year change retain earning k equity shareholder fund financial statement page approve board february sign behalf sir jonathan symonds chairman glaxosmithkline plc register number company statement change equity year end december share share premium retain total capital account reserve earning equity january profit total comprehensive income attributable shareholder dividend shareholder share issue employee share scheme treasury share transfer esop trust december profit total comprehensive income attributable shareholder dividend shareholder share issue employee share scheme december gsk annual report gsk annual report strategic report governance remuneration financial statement investor information note company balance sheet uk gaap include frs reduce disclosure framework presentation financial statement balance sheet prepare accordance company accounting policy approve board description business describe note b policy consistently glaxosmithkline plc parent company gsk major apply state global healthcare group engage creation discovery development manufacture marketing key accounting judgement estimate pharmaceutical product include vaccine overthecounter key accounting judgement estimate require otc medicine healthrelate consumer product current year preparation financial statement b accounting policy financial statement prepare foreign currency transaction historical cost convention modify include revaluation certain financial instrument go concern basis foreign currency transaction record exchange prepare accordance financial reporting standard rate ruling date transaction foreign currency asset reduce disclosure framework uk accounting liability translate rate exchange rule presentation company act december balance sheet date comparative figure december dividend pay receive permit section company act dividend pay receive include financial income statement company present statement period relate dividend annual report actually pay receive expenditure company include group financial statement glaxosmithkline plc publicly available expenditure recognise respect good service receive supply accordance contractual term follow exemption requirement ifrs provision obligation exist future liability apply preparation financial statement respect past event accordance frs obligation reliably estimate paragraph b ifrs sharebase investment subsidiary company payment investment subsidiary company hold cost ifrs financial instrument disclosure provision impairment include capital contribution relation movement contingent consideration paragraph ifrs fair value measurement impairment investment paragraph ias presentation financial statement carry value investment review impairment comparative information requirement respect indication investment paragraph iv ia impair assessment method compare paragraph f b carry value investment share ia presentation financial net asset value investment share statement valuation subsidiary base expect discount cash ias statement cash flow flow total investment evaluate group valuation basis overall market paragraph ias accounting policy change capitalisation impairment charge recognise accounting estimate error income statement year concern paragraph ias relate party disclosure sharebase payment requirement ia disclose related party issuance company subsidiary grant transaction enter member company share represent additional capital group contribution company subsidiarie additional accounting convention standard investment subsidiary result correspond increase balance sheet prepare historical shareholder equity additional capital contribution cost convention complie applicable uk accounting base fair value grant issue allocate standard underlie grant vest period accounting principle policy preparation balance sheet conformity generally accept accounting principle require management estimate assumption affect report amount asset liability disclosure contingent asset liability date balance sheet actual amount differ estimatesnote company balance sheet uk gaap include frs reduce disclosure framework continue taxation financial guarantee current tax provide amount expect pay liability relate guarantee issue company apply tax rate enact substantively behalf subsidiary initially recognise fair value enact balance sheet date amortise life guarantee defer tax provide liability method c perate profit temporary difference arise tax basis asset fee relate audit liability carry amount financial company charge operate profit statement defer tax asset recognise extent consider recoverable future dividend taxable profit director declare interim dividend result defer tax measure average tax rate dividend year penny line dividend expect apply period temporary detail note group financial difference expect realise settle defer statement dividend tax liability asset discount e fix asset investment share glaxosmithkline service unlimited share glaxosmithkline holding limited share glaxosmithkline holdings limited share glaxosmithkline consumer healthcare holdings limited shares glaxosmithkline mercury limited capital contribution relate sharebased payment contribution relate contingent consideration f trade receivables amount year uk corporation tax recoverable amount owe group undertaking amount year amount owe group undertaking movement amount owe group undertaking period reflect note primarily reflect receipt dividend income subsidiary utilisation company current account fund payment fourth interim dividend second interim dividend gsk annual report gsk annual report strategic report governance remuneration financial statement investor information note company balance sheet uk gaap include frs reduce disclosure framework continue g trade payable amount year creditor contingent consideration payable amount owe group undertaking company guarantee debt issue subsidiary company receive fee aggregate company outstanding guarantee billion debt instrument billion amount subsidiary company relation guarantee fee recover life bond disclose trade receivable note f h provision liability january charge year utilise december provision relate number legal dispute company currently involve noncurrent liability contingent consideration payable contingent consideration relate payable acquisition novartis vaccine portfolio current year liability include trade payable detail note group financial statement contingent consideration liabilitiesnote company balance sheet uk gaap include frs reduce disclosure framework continue j share capital share premium account share premium ordinary share p account number share capital issue fully pay january issue employee share scheme ordinary share acquire esop trust december issue employee share scheme december december december number share issuable employee share scheme number unissue share option december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme february million treasury share transfer esop trust trust hold million share exercise share option share reward k retain earning reserve profit glaxosmithkline plc year million million profit dividend pay million million effect nil treasury share transfer subsidiary company million retain earning december stand million million million unrealise million dividend shareholder pay realise profit company december amount million million reserve include capital redemption reserve reserve reflect historical contribution share company issue satisfy share option award grant employee subsidiary company l group company page complete list subsidiary associate joint venture significant shareholding form financial statement gsk annual report gsk annual report strategic report governance remuneration financial statement investor information investor information section quarterly trend pharmaceutical turnover vaccine turnover year record product development pipeline product competition intellectual property principal risk uncertainty share capital control dividend financial calendar annual general meeting tax information shareholder shareholder service contact law regulation group company glossary term gsk annual report strategic report governance remuneration financial statement investor informationfinancial record quarterly trend unaudite analysis group result provide quarter sterle financial year income statement total month q q q q report report report report report cer cer cer cer cer turnover pharmaceutical vaccine consumer healthcare total turnover cost sale sell general administration research development royalty income operating incomeexpense operating profit net finance cost loss disposal interest associate share aftertax profitslosse associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder basic earning share penny p p p p p dilute earning share penny p p p p p income statement adjust total turnover cost sale sell general administration research development royalty income operating profit net finance cost share aftertax profitslosse associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder adjust earning share penny p p p p p calculation adjust result describe gsk annual report gsk annual report strategic report governance remuneration financial statement investor information financial record continue quarterly trend continue quarterly trend unaudite analysis group result provide quarter sterle financial year income statement total month q q q q report report report report report cer cer cer cer cer turnover pharmaceutical vaccine consumer healthcare total turnover cost sale sell general administration research development royalty income operating incomeexpense operating profit net finance cost loss disposal interest associate share aftertax profitslosse associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder basic earning share penny p p p p p dilute earning share penny p p p p p income statement adjust total turnover cost sale sell general administration research development royalty income operating profit net finance cost share aftertax profitslosse associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder adjust earning share penny p p p p p calculation adjust result describe financial record continue pharmaceutical turnover therapeutic area total europe international growth growth growth growth therapeutic areamajor product cer cer cer cer respiratory anoro ellipta trelegy ellipta nucala hiv dolutegravir product tivicay triumeq juluca dovato rukobia cabenuva immunoinflammation benlysta oncology zejula blenrep jemperli pandemic xevudy new specialty pharmaceutical establish pharmaceutical establish respiratory arnuity ellipta avamysveramyst flixotideflovent incruse ellipta relvarbreo ellipta seretideadvair ventolin respiratory dermatology augmentin avodart imigranimitrex lamictal seroxatpaxil valtrex pharmaceuticals gsk annual report gsk annual report strategic report governance remuneration financial statement investor information financial record continue pharmaceutical turnover therapeutic area total europe international growth growth growth growth therapeutic areamajor product cer cer cer cer respiratory anoro ellipta trelegy ellipta nucala hiv dolutegravir product tivicay triumeq juluca dovato rukobia cabenuva immunoinflammation benlysta oncology zejula blenrep new specialty pharmaceutical establish pharmaceutical establish respiratory arnuity ellipta avamysveramyst flixotideflovent incruse ellipta relvarbreo ellipta seretideadvair ventolin respiratory dermatology augmentin avodart imigranimitrex lamictal seroxatpaxil valtrex pharmaceuticals financial record continue vaccine turnover total europe international growth growth growth growth major product cer cer cer cer meningitis bexsero menveo influenza fluarix flulaval shingle shingrix establish vaccine infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix vaccine exclude pandemic pandemic vaccine pandemic adjuvant total vaccine represent growth actual exchange rate cer represent growth constant exchange rate vaccine turnover total europe international growth growth growth growth major product cer cer cer cer meningitis bexsero menveo influenza fluarix flulaval shingle shingrix establish vaccine infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix total vaccine represent growth actual exchange rate cer represent growth constant exchange rate gsk annual report gsk annual report strategic report governance remuneration financial statement investor information financial record continue year record record financial performance provide analysed accordance current reporting practice information include year record prepare accordance ifrs adopt european union ifrs issue international accounting standard board group turnover geographic region europe international group turnover segment pharmaceutical vaccine consumer healthcare segment turnover corporate unallocated turnover revise revise revise revise pharmaceutical turnover respiratory hiv immunoinflammation oncology pandemic new specialty establish pharmaceutical vaccine turnover meningitis influenza shingle establish vaccine pandemic vaccine consumer healthcare turnover oral health pain relief vitamin mineral supplement respiratory health digestive health subtotal brand divestedunder review financial record continue year record continue financial result total turnover operate profit profit taxation profit taxation pence pence pence pence pence basic earning share dilute earning share million million million million million weight average number share issue basic diluted financial result adjust turnover operate profit profit taxation profit taxation pence pence pence pence pence adjust earning share return capital employ return capital employ calculated total profit taxation percentage average net asset year gsk annual report gsk annual report strategic report governance remuneration financial statement investor information financial record continue year record continue balance sheet noncurrent asset current asset total asset current liability noncurrent liability total liability net asset shareholder equity noncontrolle interest total equity number employee europe international manufacturing sell administration research development geographic distribution employee table base location gsk subsidiary company number employee number permanent employ staff end financial period exclude employee employ manage gsk contract basis exchange rate guide holder ad follow table set period indicate information exchange rate dollar sterling report bank england pm buy rate average rate year calculate average pm buy rate day year average feb jan dec nov oct sep high low pm buying rate february usfinancial record continue year record continue divestment intangible intangible significant adjust result reconciliation total asset asset major transaction legal separation adjust result amortisation impairment restructure relate item cost result december turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost loss disposal interest associate share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share p p p p p p p p weight average number share million divestment intangible intangible significant adjust result reconciliation total asset asset major transaction legal separation adjust result amortisation impairment restructure relate item cost result december turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share p p p p p p p p weight average number share million gsk annual report gsk annual report strategic report governance remuneration financial statement investor information financial record continue year record continue divestment intangible intangible significant adjust result reconciliation total asset asset major transaction legal adjust result amortisation impairment restructure relate item result december turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share p p p p p p p weight average number share million divestment intangible intangible significant adjust result reconciliation total asset asset major transaction legal adjust result amortisation impairment restructure relate item result december turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost profit disposal associate share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share p p p p p p p weight average number share million financial record continue year record continue divestment intangible intangible significant adjust result reconciliation total asset asset major transaction legal tax adjust result amortisation impairment restructure relate item reform result december turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost profit disposal associate share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share p p p p p p p p weight average number share million gsk annual report gsk annual report strategic report governance remuneration financial statement investor information pipeline product competition pharmaceutical vaccine product development pipeline key nlicense alliance relationship party eua emergency use authorisation v iiv healthcare global specialist hiv company phase e valuation clinical pharmacology usually conduct gsk pfizer inc shionogi limited shareholder volunteer responsible developing deliver hiv medicine phase ii etermination dose initial evaluation efficacy bla biological licence application conduct small number patient maa marketing authorisation application europe phase iii l arge comparative study compound versus placebo nda new drug application andor establish treatment patient establish approve clinical benefit safety submit maa ndabla regulatory review milestone show table achieve future filing date include list achieve regulatory review milestone compound mechanism actionvaccine type indication phase maa ndabla oncology jemperli antiprogramme cell death protein receptor l dmmrmsih endometrial cancer approve jun apr dostarlimab pd antibody l dmmr solid tumour approve aug l endometrial cancer iii l endometrial cancer combination niraparib iii nonsmall cell lung cancer ii zejula poly adpribose polymerase parp inhibitor l maintenance ovarian cancer combination iii niraparib dostarlimab l maintenance non small cell lung cancer iii nsclc combination pembrolizumab premetastatic select biomarker population iii breast cancer blenrep adc target bcell maturation antigen l multiple myeloma iii belantamab l multiple myeloma combination pomalyst iii mafodotin dexamethasone l multiple myeloma combination velcade iii dexamethasone multiple myeloma combination anticancer ii treatments platform study l multiple myeloma combination velcade revlimid dexamethasone letetresgene engineer tcr tcell target nyeso l synovial sarcoma myxoidround cell ii pivotal autoleucel liposarcoma l nonsmall cell lung cancer ii cobolimab antitcell immunoglobulin mucin domain nonsmall cell lung cancer combination ii tim antibody jemperli dostarlimab docetaxel antilymphocyte activation gene lag cancer antibody sting cytosolic dna pathway agonist cancer cd antagonist cancer engineer tcr tcells coexpresse cda cancer cell surface receptor target nyeso engineer tcr tcell coexpresse cancer dntgfrii cell surface receptor target nyeso methionine adenosyltransferase mata cancer inhibitor tigit antagonist cancer eos footnote nonregistrational transition activity underway enable progression partner gsk exclusive option codevelop post ph ph trial patient progranulin gene mutation gsk contribute pandemic adjuvant covid vaccine collaboration submit canada enrolment vaccination stop february analysis well understand safety datum trial ongoingpipeline product competition continue pharmaceutical vaccine product development pipeline continue achieve regulatory review milestone compound mechanism actionvaccine type indication phase maa ndabla hiv apretude hiv integrase strand transfer inhibitor hiv preexposure prophylaxis approve dec cabotegravir longacte hiv mgml formulation hiv maturation inhibitor hiv infection ii hiv broadly neutralise antibody hiv infection ii hiv maturation inhibitor hiv infection hiv capsid protein inhibitor hiv infection infectious disease xevudy sotrovimab antispike protein antibody covid approve adec eua gepotidacin triazaacenaphthylene bacterial type ii uncomplicated urinary tract infection uuti iii topoisomerase inhibitor gonorrhea gc leucyl trna synthetase inhibitor tuberculosis ii bepirovirsen hbv antisense hepatitis b ii fimh antagonist uncomplicated urinary tract infection uuti crk inhibitor visceral leishmaniasis proteasome inhibitor visceral leishmaniasis mtb cholesterol dependent inhibitor tuberculosis bvlgsk ethionamide booster tuberculosis vir antispike protein antibody covid vir neutralize monoclonal antibody influenza pik beta inhibitor viral copd exacerbation priorix mmr vaccine live attenuate measle mump rubella prophylaxis registration jun menveo vaccine conjugatedliquid formulation meningococcal acw disease prophylaxis registration sep adolescent rotarix vaccine live attenuate pcv porcine circovirus rotavirus prophylaxis registration dec free bexsero vaccine recombinant protein meningococcal b disease prophylaxis infant iii man abcwy vaccine recombinant protein conjugate meningococcal abcw disease prophylaxis iii adolescent rsv vaccine recombinant protein respiratory syncytial virus prophylaxis pregnant iii woman population prevent respiratory syncitial virus low respiratory tract illness infant month life transfer maternal antibodie recombinant protein adjuvante respiratory syncytial virus prophylaxis old adult iii population covid plant recombinant proteinadjuvante vaccine covid registration derive viruslike particle vaccine medicago covid vaccine recombinant proteinadjuvante vaccine covid iii sanofi covid vaccine recombinant protein nanoparticle covid iii sk bioscience adjuvante vaccine sam vaccine selfamplifye mrna vaccine covid covid model footnote nonregistrational transition activity underway enable progression partner gsk exclusive option codevelop post ph ph trial patient progranulin gene mutation gsk contribute pandemic adjuvant covid vaccine collaboration submit canada enrolment vaccination stop february analysis well understand safety datum trial ongoing gsk annual report gsk annual report strategic report governance remuneration financial statement investor information pipeline product competition continue pharmaceutical vaccine product development pipeline continue achieve regulatory review milestone compound mechanism actionvaccine type indication phase maa ndabla infectious disease continue malaria recombinant protein adjuvante malaria prophylaxis plasmodium falciparum ii generation vaccine vaccine fractional dose shigella vaccine bioconjugate tetravalent vaccine shigella diarrhea prophylaxis ii therapeutic hbv primeboost viral vector vaccine treatment chronic hepatitis b infection aim ii vaccine co sequentially administrate functional cure controlling resolving adjuvante recombinant protein infection reduce need treatment aureus vaccine recombinant protein bioconjugate active immunization prevention primary ii adjuvanted vaccine recurrent softskintissue infection cause aureus man abcwy recombinant protein conjugate meningococcal b c wy disease prophylaxis ii vaccine nd gen vaccine adolescent infant varicella new strain live attenuate vaccine active immunization prevention varicella ii individual month age old c difficile vaccine recombinant protein adjuvanted vaccine active immunization prevention primary c diff disease prevention recurrence sam vaccine selfamplifye mrna rabie prophylaxis rabie model klebsiella recombinant protein bioconjugate klebsiella pneumoniae prophylaxis pneumoniae adjuvante vaccine cmv recombinant subunit adjuvante cytomegalovirus cmv infection prophylaxis vaccine female year age immunology respiratory nucala interleukin il antagonist hypereosinophilic syndrome approve nov mepolizumab nasal polyposis approve nov jul egpa approve nov copd iii otilimab granulocyte macrophage colony rheumatoid arthritis iii stimulate factor inhibitor depemokimab interleukin il antagonist longacte asthma iii al antisortilin monoclonal antibody frontotemporal dementia ftd iii amyotrophic lateral sclerosis al ii anticcl antibody osteoarthritis pain transglutaminase tg inhibitor celiac disease al antisortilin monoclonal antibody neurodegenerative disease antiil antibody atopic dermatitis antiil antibody multiple sclerosis ms hsdb silencer nonalcoholic steatohepatitis nash opportunity drive daprodustat hif prolyl hydroxylase inhibitor anaemia chronic kidney disease iii row linerixibat ileal bile acid transporter ibat inhibitor cholestatic pruritus pbc primary biliary cholangitis iii trpv channel blocker diabetic macular edema dme novel mechanism heart failure brand name appear italic trade mark own license gsk group company footnote nonregistrational transition activity underway enable progression partner gsk exclusive option codevelop post ph ph trial patient progranulin gene mutation gsk contribute pandemic adjuvant covid vaccine collaboration submit canada enrolment vaccination stop february analysis well understand safety datum trial ongoingpipeline product competition continue pharmaceutical product competition intellectual property major patent expiry date product compound indication competitor brand eu respiratory anoro ellipta umeclidinium bromide copd stiolto respimat vilanterol trifenatate utibronultibro nce nce breezhaler duaklir genuair device device bevespi aerosphere brimica genuair arnuity ellipta fluticasone furoate asthma beclazone pulmicort budesonide gx nce nce asmanex alvesco device device avamysveramyst fluticasone furoate rhinitis dymista xhance nasonex expire fluticasone gx flixotideflovent fluticasone propionate asthmacopd beclazone pulmicort expire expire budesonide gx diskus device diskus device asmanex alvesco expire hfadevice hfadevice incruse ellipta umeclidinium bromide copd spiriva handihaler respimat yupelri nce nce braltus seebri breezhaler bretaris device device genuair nucala mepolizumab severe eosinophilic asthma egpa xolair cinqair expire expire hypereosinophilic syndrome chronic fasenra dupixent rhinosinusitis nasal polyp relvarbreo ellipta fluticasone furoate asthmacopd symbicort foster vilanterol trifenatate budesonideformetrol gx nce nce sirdupla dulera device device seretideadvair salmeterol xinafoate asthmacopd symbicort foster expire expire fluticasone propionate budesonideformetrol gx diskus device diskus device sirdupla dulera expire hfadevice hfadevice trelegy ellipta fluticasone furoate copd trimbow vilanterol trifenatate breztri aerosphere nce nce umeclidinium bromide trixeo aerosphere enerzair breezhaler device device ventolin hfa albuterol sulphate asthmacopd generic company expire hfadevice hfadevice xevudy sotrovimab early treatment covid regencov na bamlanivimabetesevimab nbe evusheld antiviral valtrex valaciclovir genital herpe coldsore shingles prevymis valacyclovir gx expire expired valcyte central nervous system lamictal lamotrigine epilepsy bipolar disorder vimpat trokendi xr expire expire inovelon imigranimitrex sumatriptan migraine zomig maxalt relpax expire expire seroxatpaxil paroxetine depression anxiety trintellix aplenzin viibryd expire expire disorder zoloft cardiovascular urogenital avodart dutasteride benign prostatic hyperplasia harnal vesomni urorec expire expire antibacterials augmentin amoxicillinclavulanate common bacterial generic product na expire potassium infection include supplementary protection certificate grant multiple country eu include uk patent term extension grant data exclusivity expire eu gsk annual report gsk annual report strategic report governance remuneration financial statement investor information pipeline product competition continue pharmaceutical product competition intellectual property continue major patent expiry date product compound indication competitor brand eu oncology zejula niraparib ovarian cancer lynparza rubraca nce nce blenrep belantamab mafodotin relapsedrefractory multiple sarclisa xpovio myeloma jemperli dostarlimab dmmr recurrent advanced keytruda endometrial cancer solid tumour nbe nbe immunoinflammation benlysta benlysta belimumab systemic lupus erythematosus lupkynis saphnelo sc iv lupus nephritis hiv apretude cabotegravir hiv prevention descovy truvada nce nce cabenuvavocabria cabotegravir rilpivirine hivaids descovy genvoya rekamby odefsey biktarvy nce nce rukobia fostemsavir hivaids trogarzo nce nce dovato dolutegravir lamivudine hivaids descovy genvoya odefsey biktarvy nce nce juluca dolutegravir rilpivirine hivaids descovy genvoya odefsey biktarvy nce nce triumeq dolutegravir lamivudine hivaids descovy genvoya abacavir odefsey biktarvy nce nce tivicay dolutegravir hivaid isentress prezista symtuza reyataz nce nce biktarvy vaccine product competition intellectual property major patent expiry date product compound indication competitor brand eu bexsero meningococcal groupb vaccine meningitis group b prevention trumenba boostrix diphtheria tetanus acellular diphtheria tetanus acellular adacel expire expire pertussis pertussis booster vaccination infanrix hexapediarix diphtheria tetanus pertussis prophylaxis diphtheria pentacel pediacel expire expired polio hepatitis b haemophilus tetanus pertussis polio pentaxim pentavac influenzae type b eu hepatitis b haemophilus hexaxim hexyon influenzae type b eu vaxeli cervarix hpv virus like human papilloma virus gardasil silgard particle vlp type adjuvant mpl aluminium hydroxide fluarix tetra split inactivated influenza seasonal influenza prophylaxis intenza flumist qiv antigens virus subtype vaxigrip qiv subtype b fluzone qiv fluzone high dose flulaval split inactivated influenza seasonal influenza prophylaxis vaxigrip mutagrip antigen virus subtype fluzone influvac subtype b aggripal fluad intenza flumist menveo meningococcal group c w meningitis group c w nimenrix menactra conjugate vaccine prophylaxis priorix priorix tetraab live attenuate measle mump measle mump rubella mmr ii mmrvaxpro expire expire varilrixb rubella varicella vaccine chickenpox prophylaxis proquad varivax rotarix human rotavirus rix strain rotavirus prophylaxis rotateq synflorix conjugate pneumococcal prophylaxis invasive prevenar prevnar na polysaccharide disease pneumonia acute otitis medium shingrix zoster vaccine herpe zoster zostavax recombinant adjuvante shingle note financial statement legal proceeding include supplementary protection certificate grant multiple country eu include uk patent term extension grant relate compoundsindication measle mump rubella vaccineprophylaxisb b relate compound varicella vaccinepipeline product competition continue consumer healthcare product competition brand product application market competition oral health sensodyne toothpaste toothbrushe relief dentinal hypersensitivity global colgate sensitive prorelief pronamel mouth rinse pronamel additionally protect colgatepalmolive acid erosion elmex colgatepalmolive oral b procter gamble parodontax toothpaste dailymedicate help stop prevent global colgate total gum health corsodyl mouthwash gel spray bleed gum treat colgatepalmolive prevent gingivitis oral b gum enamel repair crest gum detoxify procter gamble polident denture adhesive denture improve retention comfort global fixodent kukident poligrip cleanser wipe denture clean denture procter gamble corega steradent reckitt benckiser aquafresh toothpastes toothbrushes aids prevention dental cavity global colgate colgatepalmolive mouthwash maintain healthy tooth gum crest procter gamble fresh breath oralb procter gamble pain relief panadol tablet caplet infant paracetamolbase treatment global aspirin bayer syrup headache joint pain fever cold tylenol johnson johnson symptoms nurofen reckitt benckiser voltaren topical gel diclofenac nonsteroidal diclofenac base global salonpa hisamitsu tablet patch antiinflammatory aspirin bayer tylenol johnson johnson nurofen reckitt benckiser icy hot sanofi advil tablet caplet gel caplet ibuprofen base treatment canada brazil tylenol tylenol pm tylenol children nonrespiratory liquid fill suspension headache toothache backache colombia mexico motrin motrin childrens johnson range drop children menstrual cramp muscular johnson aleve aleve pm bayer pain minor pain arthritis vitamin mineral supplement centrum tablet gummie vitamin supplement global nutralite infinitus cheongkwanjung capsule chewables byhealth nature herbalife swisse caltrate tablet gummie calcium supplement global citracal bayer oscal nature soft chew private label emergenc powder gummie immune support dietary canada airborne reckitt benckiser supplement zicam church dwight nature pharmavite sambucol healthcare brand international esterc american health respiratory health otrivin nasal spray nasal decongestant germany netherlands afrin bayer nasivin proctor gamble norway russia sweden tyzine johnson johnson theraflu hot liquids tablet syrup cold flu relief russia poland tylenol cold flu johnson johnson mucinex reckitt benckiser lemsip reckitt benckiser advil respiratory tablet allergy relief cold flu tylenol cold flu johnson johnson cold flu advil relief lemsip mucinex reckit benckiser respiratory allergy flixonaseflonase nasal spray tablet allergy relief china uk ireland claritin bayer allegra sanofi piriton zyrtec johnson johnson robitussin syrup tablet coughcold canada singapore mucinex reckitt benckiser philippines australia dimetapp foundation consumer healthcare digestive health nexium hr capsule clear mini treatment frequent heartburn canada australia prilosec prevacid tablet day week adult year old zovirax topical cream lip care treat prevent global compeed johnson johnson abreva nonmedicate patch onset cold sore carmex carma labs blistex blistex incorporate retail label chapstick lip balm protect moisturise prevent global blistex burt bee carmex carma labs soothe chap lip eos nivea beiersdorf vaseline unilever eno effervescent immediate relief antacid global estomazil hypermarca gelusil tums chewable tablet immediate relief antacid alkaseltzer bayer gaviscon reckitt benckiser rolaids sanofi nicorette lozenge gum treatment nicotine withdrawal global nicorette johnson johnson nicoderm nicotinell transdermal patch aid smoking reduction niquitin perrigo ex australia cessation gsk annual report gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertainty outline principal risk uncertaintie relevant similarly global business expose litigation gsk business financial condition operation government investigation include product liability litigation affect performance ability achieve objective patent antitrust litigation sale marketing litigation risk believe cause actual litigation government investigation relate result differ materially expect historical result provision unfavourable outcome increase related cost insurance premium operate pharmaceutical sector carry inherent materially adversely affect financial result risk uncertainty affect business detail status uncertainty comply broad range law regulation significant unresolved dispute potential litigation set apply research development manufacture note legal proceeding test approval distribution sale marketing pharmaceutical vaccine consumer healthcare product detail risk management framework affect cost product development time require identify principal risk find page reach market likelihood successfully uninterrupted basis uk regulation require description principal risk rule regulation change government interpretation uncertainty explanation manage evolve business activity develop nature mitigate description principal risk particular risk alter change regulatory regime summary activity manage substantial alteration failure comply risk business list order applicable law regulation materially adversely significance consistent principal risk detail affect financial result page patient safety risk definition balance routine pharmacovigilance activity potential failure appropriately collect review follow variety business change initiative support report human safety information hsi include adverse event current product portfolio optimise perform potential source act relevant finding pharmacovigilance prepare deliver future timely manner strategy include increase focus oncology vaccine specialty medicine successful separation risk impact consumer healthcare business gsk zero tolerance unfavourable benefittorisk ratio collect information safety efficacy patient use product collect review follow product human clinical development gain report human safety information potential source comprehensive information realworld use product use conduct robust timely safety signal market addition safety surveillance detection appropriate measure safeguard activity external party analyse publiclyavailable clinical trial patient consumer effectively manage risk result data new external initiative use realworld patient safety activity repercussion evidence source accessible gsk harm patient compliant regulatory agency supplement validate pharmacovigilance drug safety regulation globally evidence use support safety efficacy consequence include inspection finding regulatory product scrutiny civil criminal sanction temporary permanent loss product marketing authorisation ineffective extensive news social medium coverage safety management patient safety risk lead efficacy covid vaccine therapy increase reputational damage loss trust patient healthcare public recognition importance pharmacovigilance provider productrelate litigation loss shareholder drug development process product marketing confidence phase rise misinformation lead distrust vaccine hesitancy environment undermine regulatory context governmental public trust medicine treat fully accountable safeguarding patient covid negatively influence healthcare licence operate depend compliance increasingly decision disease lead reputational damage complex variable global regulatory requirement product liability lawsuit include pharmacovigilance regulation stringent privacy protection information security consideration compliance depend employee party act behalf manage human safety information accordance internal processesprincipal risk uncertainty continue patient safety continue mitigate activity action discuss regulatory chief medical officer accountable patient safety authority include update prescribing information enterprise risk human safety matter collaboration communicate healthcare provider restrict product head global safety crossenterprise safety governance prescribingavailability help assure safe use carry board oversee implementation control framework clinical trial certain case appropriate include risk management global safety board ensure stop clinical trial withdraw product specific batch address human safety proactively product market lifecycle global policy management human safety reinforce requirement human safety information require employee immediately report issue information management gsk range relate safety product thirdparty oversight communication effort include improve internal mechanism framework ensure party encounter human adverse event report launch initiative safety information identify train appropriately automate adverse event case intake processing reporting manage safety information product source consolidate governance pharmacovigilance process compliance global regulation information allow relate activity board single governance detect safety signal product timely action forum launch pilot optimise delivery oversight information change product riskbenefit profile patient safety activity globally target core patient safety process simplification andor optimisation product quality risk definition increasingly new technology enhance failure gsk contractor supplier ensure manufacture testing product example use new electronic documentation system advance appropriate control governance quality product laboratory information management tool development significant change take place gsk implement compliance good manufacturing practice good new strategy structure quality organisation distribution practice regulation commercial clinical trial assess change sure quality procedure manufacture distribution activity governance facilitate strategy ensure compliance term gsk product licence unintended consequence increase product quality risk support regulatory activity industry experience increase regulatory onsite inspection presence resume onset pandemic risk impact take step ensure inspection readiness failure ensure product quality farreache implication patient consumer safety cause product mitigating activity launch delay drug shortage product recall align extensive global network quality compliance regulatory legal financial consequence professional sitelevel senior management materially adversely affect gsk reputation financial business unit provide oversight assist delivery result quality performance operational compliance deliver management oversight hierarchy quality context council independent chief product quality officer external environment product quality remain global product quality office oversee product quality risk challenge affect misinformation fuel vaccine company hesitancy increase cyberattack datum breach develop implement single quality industry cyberattack remain key risk management system define quality standard integrity product quality datum audit trail system business associate pharmaceutical prepare meet european medicine vaccine consumer healthcare product clinical agency ema requirement license medical device trial material system broad scope applicable continue prepare vitro diagnostic medical product lifecycle rd mature device regulation effective commercial supply consolidation regulatory requirement continue plan implementation new annex market world augment system guidance manufacture sterile medicinal product mean meet external expectation product quality half market supply system base internationally recognise principle ich q pharmaceutical quality system framework gsk annual report gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertaintie continue product quality continue routinely update quality management system qms establish complaint process ensure respond keep pace evolve external regulatory environment appropriately product quality issue raise patient new scientific understanding product customer independent function review triage allegation process policy procedure noncompliance misconduct receive formal simple understand implement adopt innovative informal speak channel global disciplinary tool userfriendly regularly train staff enforcement procedure apply breach regulatory expectation learning inspection standard initiate appropriate follow exist procedure maintain current good investigation use key risk indicator support risk manufacturing practice standard management activity provide gsk leadership team risk oversight compliance council implement riskbase approach assess integrate assessment product quality performance manage party supplier provide material finished product expect contract manufacturer complete initial review manufacturing product comply gsk standard regularly process product identify potential risk conduct audits provide assurance associate nitrosamine impurity complete work accordance health authority regulatory timeline product incident committee process place continue product evaluation investigate product issue recommendation necessary risk mitigation step remediation activity include necessary recall product protect patient consumer financial control report risk definition treasury group deal daily high value transaction failure comply current tax law incur significant foreign exchange cash management transaction loss treasury activity failure report accurate transaction involve market volatility counterparty risk financial information compliance accounting standard group effective tax rate reflect location applicable legislation activity value generate determine jurisdiction profit arise applicable tax rate risk impact higher low uk statutory rate noncompliance exist new financial reporting reflect regime encourage innovation investment disclosure requirement change recognition income rd provide tax incentive change expense expose gsk litigation regulatory affect gsk tax rate addition worldwide nature action materially adversely affect financial operation mean crossborder supply route result current global pandemic significant necessary ensure supply medicine result change short notice failure comply change conflict claim tax authority profit substance application law govern transfer pricing tax individual country lead double taxation dividend tax credit intellectual property profit tax country complexity materially adversely affect financial result tax regulation mean occasionally disagree inconsistent application treasury policy transactional tax authority technical interpretation particular settlement error counterparty default lead area tax law tax charge include financial significant loss statement well estimate tax liability pende audits tax authority context expect continue focus tax reform drive require law jurisdiction publicly initiative oecd ec address tax disclose financial result event materially challenge arise digitalisation economy affect group financial result regulator routinely review domestic initiative world result financial statement list company compliance significant change establish tax principle new revise exist accounting regulatory increase tax authority dispute regardless merit requirement believe comply appropriate outcome costly divert management attention regulatory requirement concern financial statement adversely impact reputation relationship key disclosure material information include stakeholder transaction relate business restructuring acquisition divestiture subject investigation potential noncompliance accounting disclosure requirement lead restatement previously report result significant penaltiesprincipal risk uncertainty continue financial control report continue mitigate activity counterparty exposure subject define limit approve financial result review approve regional board credit rating individual counterpartie management review gsk group financial middle office treasury monitor management controller chief financial officer cfo allow counterparty risk line agree policy oversight financial controller cfo assess evolution corporate compliance officer operate independently business time evaluate performance plan treasury detail mitigation treasury risk significant judgement review confirm senior find page management integrate technical organisational manage tax risk robust internal policy process transformation newly acquire activity external risk train compliance programme maintain open covid pandemic risk assessment constructive relationship tax authority worldwide apply appropriate control review monitor government debate tax policy key jurisdiction maintain control environment design identify material understand potential future change tax error financial reporting disclosure design law share inform point view relevant operating effectiveness key financial reporting control provide pragmatic constructive business input tax policy regularly review management test external maker directly industry trade body party minimum standard control set place include advocate reform support economic growth finance location irrespective size review job creation need patient key management monitor independently give stakeholder submit significant tax decision tax assurance control key financial reporting governance board meet quarterly comprise senior disclosure process operate effectively global gsk finance colleague finance risk management control frmc group tax affair manage global basis team tax provide extra support significant transformation professional lead global head tax work closely system deployment managementstructural business daytoday basis global tax team reorganisation add operational resource adapt suitably qualified role perform support programme timeline ensure process control training need provide date technical maintain significant change advice line responsibility disclosure committee reporting board review submit tax return accord statutory time limit gsk quarterly result annual report year engage proactively tax authority ensure tax affair consultation legal advisor disclosure committee current enter continuous audit programme determine necessary disclose publicly advance pricing agreement appropriate information group stock exchange arrangement provide longterm certainty tax announcement date late authority gsk tax treatment business development financial reporting requirement work base disclosure relevant fact seek resolve external auditor legal advisor difference interpretation tax legislation tax treasury management group tmg meet regularly authority cooperative manner exceptional case ensure liquidity interest rate counterparty foreign resolve dispute formal proceeding currency transaction foreign currency translation risk manage line prudent approach detailed risk strategy policy adopt board gsk annual report gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertainty continue antibribery corruption abac risk definition appropriate control place transaction bribery corruption risk failure gsk employee payment party train awareness consultant party comply antibribery raise strong monitoring plan continue pre corruption abac principle standard posttransaction abac diligence increase applicable legislation capabilitie business monitoring oversight red flag resolution party review control risk impact accountabilitie government official continue assess failure mitigate risk expose group understand money launder risk exposure associate person governmental investigation regulatory mitigate exist risk action civil criminal liability compromise code conduct value expectation group ability supply product certain government commitment zero tolerance bribery corruption contract addition failure prevent bribery corruption integral mitigate risk light complexity substantial implication gsk reputation geographic breadth risk constantly evolve credibility senior leader erode investor confidence oversight activity datum reinforce workforce governance risk management lead gsk clear expectation acceptable behaviour legal financial penalty maintain regular communication centre local context market overall environment abac continue challenge build abac programme base good class country hold individual corporation principle subject ongoing review development accountable increase employer duty care provide basis seek manage divergence legislation increase political protectionism risk example social inequality pricing pressure make compliance programme include toplevel commitment board hard society hold corporation high standard leadership datum analytic programme create technology provide rapid anonymous avenue embe local key risk indicator enable target intervention dissemination previously confidential information risk management activity damage false report global abac policy write standard control enforcement action penalty continue globe address business activity rise abac focus use thirdparty intermediary propose risk underpin programme addition programme eu legislation require business conduct mandate enhance control interaction government diligence potential human right relate environmental official business development transaction impact operation supply chain impose legal control abac policy establish diligence standard care addition ongoing impact covid requirement engagement party increase risk bribery corruption dedicated team responsible implementation supportive aspect external environment include evolution abac programme abac team increase transparency collaboration enforcement continually work group enterprise authority aim reduce bribery corruption address improve control monitoring requirement globally advance technology use datum analytic audit assurance independent business monitoring team provide well platform streamline process complement team work provide add assurance detect potential issue use issue find oversight assurance exercise investigation identify area specific intervention mitigating activity market drive continuous improvement enterprise wide abac programme design programme ensure compliance abac policy mitigate risk regularly provide mandatory abac training employee bribery corruption build business standard relevant party accordance role culture form comprehensive practical approach responsibility risk face compliance flexible evolve nature business benchmark abac programme gsk abac governance board oversee provide large multinational company use external expertise programme governance enterprise risk management internal insight drive improvement include representation key functional area formal informal speak channel available report misconduct noncompliance central investigation team review triage allegation noncompliance allocate investigation appropriateprincipal risk uncertainty continue commercial practice risk definition approve medicine vaccine failure engage commercial activity consistent obligation provide important information healthcare letter spirit law industry regulation community way responsible legal group requirement relate sale promotion ethical manner appropriate product promotion ensure hcp medicine vaccine appropriate interaction access information need patient healthcare professional organisation patient legitimate consumer fact medicine vaccine transparent transfer value competition antitrust require prescribe recommend regulation commercial practice include trade channel manner provide healthcare benefit activity tender business commit ethical responsible commercialisation product support purpose risk impact improve quality human life enable people failure engage activity consistent feel well live long letter spirit law industry regulation group requirement relate sale promotion medicine mitigate activity vaccine appropriate interaction healthcare achieve strategic objective meet price professional hcp organisation patient expectation payer hcp consumer community legitimate transparent transfer value pricing value behaviour provide guide lead competition antitrust regulation commercial decision constantly strive right thing practice include trade channel activity business deliver quality medicine vaccine sustain reliable tendering materially adversely affect ability supply meet customer need seek ensure deliver strategy longterm priority additionally action reflect gsk value behaviour purpose result incomplete awareness riskbenefit profile understand impact datum industry strive product possibly suboptimal treatment patient organisation make datadriven decision consumer governmental investigation regulatory action approach align effort agile legal proceeding bring group governmental work pace gsk act enhance improve private plaintiff result government policy standard application datum analytic sanction criminal andor financial penalty practice channel activity develop policy support find misaligned value expectation strong growth consumer healthcare internet channel result reputational harm dilute trust digital marketing activity artificial intelligence establish external stakeholder power tool improve oversight context gsk website operate highly regulated extremely competitive evolve policy standard stepwise approach biopharma consumer industry peer ensure commercial activity undertake significant product innovation technical advance conduct behalf execute established intensify price competition additional external factor impact governance train employee relevant information business operation include ongoing covid global focus interactive learn element behavioural pandemic access limitation customer macroeconomic science commercial activity worldwide conform inflationary dynamic pricing pressure market high ethical regulatory industry standard local achieve strategic objective continue standard differ global one apply develop commercially viable new product deliver stringent standard acquire company joint additional use exist product address need venture partner differ global standard remediate patient consumer hcp payer financially new legacy policy implement revision align productsindication carry uncertainty consumer healthcare business harmonise policy regard future success product development costly procedure guide regional global commercial timely uncertain carry potential failure practice process clarify applicable standard stage successful product development operation market operate face challenge launch competitor implement specific control framework export product pricing strategy render asset hub embed promotional code china enable competitive support effort product innovation responsible business growth employee behaviour continue focus create omnichannel way engagement continue focus patient gsk annual report gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertainty continue commercial practice continue gsk pharmaceutical consumer healthcare vaccine implement phase thoughtful approach business continue use internal control framework support comprehensive training control monitor support assessment management risk business framework ensure alignment gsk valuesbase unit risk management compliance board manage approach hcp engagement risk global incountry business activity oversee allow fair market value payment gsk commercial activity monitor programme expert practitioner speak innovative medicine recent combination legal compliance function vaccine restrict period product lifecycle team result strong cohesive support global endtoend process system currently set function business begin deployment q improve promotional material activity review execution activity strengthen control approve accord policy standard automation use datum permit conduct accordance local law regulation report payment individual hcp commitment requirement seek ensure material activity transparency responsible disclosure fairly represent group product service consumer consumer healthcare key driver development healthcare deploy new copy approval tool improve ethical code global selfcare federation setting control important promotional activity necessary principle promotion healthcare practitioner event misconduct discipline employee pharmacy staff include termination contract claw remuneration senior management gsk commit comply applicable sanction law regulation deploy programme enable continue evolve incentive programme management sanction risk programme lead gsk pharmaceutical vaccine sale representative well finance system control include recognise reward individual effort mature market limited policy procedure training cap variable pay element representative compensation awareness screen monitor risk reporting evaluate basis individual sale target nonpromotional engagement risk definition context failure engage nonpromotional activity nonpromotional engagement diverse activity direct consistent local law regulation guidance industry healthcare professional patient payer code internal gsk policy standard control external stakeholder engagement conduct gsk value include communication hcpohs improve patient care exchange provision nonhcp relate medicine andor associate disease knowledge use product relate disease areas ii appropriate conduct nonpromotional interaction nonpromotional engagement external stakeholder group iii legitimacy transparency nonpromotional vital gsk researchbase healthcare company interaction necessary scientific medical advance expect nonpromotional activity scientifically sound risk impact accurate conduct ethically transparently compliant control place risk result real applicable code law regulation non perceive disguised promotion include offlabel promotional engagement largely unregulated priorauthorisation promotion real perceive provision measure risktake root sound value principle medical advice turn lead criminal investigation base decisionmake training communication penalty civil litigation competitor complaint monitor activity key manage risk time engage fully appropriately enable appropriate engagement result patient harm failure advance science innovation reputational damage financial loss mitigating activity consequence reduce trust public patient chief medical officer cmo oversee nonpromotional healthcare professional payer regulator government engagement enterprise risk owner gsk code practice key internal policy nonpromotional engagement activity activity include scientific interaction support medical education advice seek gathering insight unmet need patient scientific communication research disease awarenessprincipal risk uncertainty continue nonpromotional engagement continue pandemic see continue increase enhance internal network foster collaboration virtual engagement eg external expert advisory good practice share risk management network board patient advocacy patient engagement scientific identify emerge risk associate nonpromotional congress develop modernised digital activity early support staff conduct activity approach hcp insightgathere applied compliance gsk value policy local law internal principle policy rapidly change regulation continue build effective management grow environment monitor system apply key risk indicator manage nonpromotional engagement privacy risk definition country datum privacy law require appointment failure collect secure use share destroy personal datum protection officer dpo gsk appoint single dpo information pi accordance datum privacy law lead eu represent support specific country harm individual eg financial stress prejudice gsk country privacy advisor eg fine operational financial reputational general counsel gsk enterprise risk owner ero ero appoint delegate risk owner global risk impact privacy officer gpo daytoday accountability noncompliance datum privacy law globally lead design implement control framework gpo harm individual gsk damage trust colead crossfunctional privacy centre excellence gsk individual community business partner global privacy counsel privacy officer government authority country increase privacy counsel multiple country privacy advisor enforcement power datum protection authority familiar local privacy regulation support group allow impose significant fine impact crossborder datum flow temporarily ban datum process new gsk evolve initial control framework implement country law individual right bring collective eu general data protection regulation legal action company like gsk failure follow comprehensive privacy control framework base global datum privacy law privacy principle common global privacy landscape global framework deploy country show need context comprehensive framework base factor like robust datum privacy legislation diverse limited harmonisation local privacy legislation establish datum protection authority simplification challenge multinational gsk footprint country deploy standardise approach compliance datum privacy proportionate control framework set minimum privacy law government enforce compliance datum privacy standard irrespective applicable legislation law rigorously focus ethical use personal privacy centre excellence responsible information grow compliance datum privacy law increase volume datum operate improve centralised global privacy control process advance technology framework workforce protection effective privacy control research continuously assess provide relevant covid pandemic create unique challenge proportionate control aid nondeploye market additionally new datum privacy law personal monitor new change law adapt privacy information protection law pipl china court decision framework accordingly like court justice european union ruling deploy comprehensive training programme drive schrem ii invalidating establish international datum great awareness accountability manage personal transfer mechanism international company rely information entire organisation increase trend datum sovereignty affect ability drive medical innovation effectively operate certify key gsk privacy network role accredit internationally international privacy association mitigating activity continuously improve process issue identification report handle monitor general counsel chair privacy privacy centre excellence engage new business governance board oversee gsk overall datum privacy development opportunity early stage ensure operating model gsk business area appoint risk perform appropriate diligence right step take owner accountable overseeing privacy risk support onboarde splitting business unit privacy leader business gsk annual report gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertainty continue research practice risk definition use wide variety biological material discovery research practice risk failure adequately conduct research development asset ethical sound preclinical clinical research addition convention biological diversity cbd nagoya failure engage scientific activity protocol international community establish global consistent letter spirit law industry framework regulate access use genetic resource group requirement comprise follow subrisk nonhuman origin research development datum governance laboratory research human subject support principle access benefitshare research genetic resource outline cbd nagoya protocol recognise importance appropriate risk impact effective proportionate implementation measure potential impact risk include harm human subject national regional level reputational damage failure obtain necessary regulatory mitigating activity approval product governmental investigation legal proceeding bring gsk governmental research practice risk oversee enterprise private plaintiff product liability suit claim damage framework seeks strengthen governance rd loss revenue inadequate patent protection inability pharmaceutical vaccine consumer healthcare supply product regulatory action fine business penaltie loss product authorisation poor datum integrity leadership research practice enterprise risk governance compromise gsk rd effort owner management risk take pragmatic approach negatively impact reputation materially information sharing streamline risk identification adversely affect financial result damage trust escalation ensure ownership risk mitigation stay patient customer business context establish office animal welfare ethic research involve animal raise ethical concern strategy risk oawesr lead chief veterinary case research animal way officer support humane responsible care investigate effect potential new medicine living animal carry ethical review independent scientific body human animal research provide critical review animal study share knowledge advocate information cause mechanism disease application nonanimal alternative oawesr remain vital research continually provide framework animal welfare governance define seek way minimise use animal provide oversight training animal care promote research development testing comply replacement refinement reduction animal research regulatory requirement reduce impact conduct quality assessment manage programme animal external animal diligence develop deploy strategy human subject research critical assess reproduce experiment translate human demonstrating safety efficacy investigational clinical end point product evaluate product ensure implement maintain proper data governance approve research include clinical trial healthy control remain important priority especially volunteer patient follow regulation high ethical scientific strategy evolve advantage breath medical scientific standard disclose result datum example genomics artificial intelligence research externally regardless reflect machine learn focus build datum integrity positively negatively product scientific privacy usage control internal control framework community learn outcome research quality assurance team conduct audits provide independent work human biological sample business monitor internal control fundamental discovery development safety rd organisation maintain control prepublication monitoring product commit managing procedure guard public disclosure patent human biological sample accordance relevant law application file addition lack datum regulation ethical principle manner integrity prepare patent application datum information respect interest sample donor lead loss patent protection legal expert collaborate datum pivotal rd strategy maximise rd support review process new patent use datum serve patient govern datum accordance application rd organisation collaborate relevant law regulation contractual obligation legal expert development asset expectation culture privacy information account relevant thirdparty patent right security datum integrity essentialprincipal risk uncertainty continue environment health safety risk definition mitigate activity failure management global leadership team responsible ehs governance risk oversight ensure effective execution hazardous activity control framework inplace inuse manage ehs gsk physical asset infrastructure risk impact legal compliance issue handle process hazardous chemical business unit include assign responsibility senior biological agent manager provide maintain control ensure tiere monitoring governance process control release substance harmful environment place business unit function leader ensure short longterm ehs control framework implement effectively lead incident disrupt rd supply respective business area compliant applicable activity harm employee harm community harm law regulation adequately resource local environment operate maintain communicate monitor employee qualified contractor acting behalf gsk personally risk impact responsible ensuring follow applicable local failure manage ehs risk lead significant harm standard operating procedure people environment community riskbase proactive approach articulate operate fine inability meet stakeholder expectation global ehs policy detailed global ehs standard regulatory requirement litigation regulatory action audit operation ensure compliance damage company reputation materially ensure hazards appropriately control adversely affect financial result design facility equipment system rigorous context procedure apply correctly effective barrier gsk subject health safety environmental law place protect employee health safety jurisdiction law impose duty protect late create safety improvement plan people environment community strengthen corporate safety programme focus operate life save rule safety leadership warehouse safety significant milestone programme deliver overall number significant incident occur year reduce environmental sustainability risk definition risk impact failure management recognise way respond climate change manage environmental risk affect ability supply physical climate environmental risk product patient consumer lead harm current future regulatory requirement environmental environment reputation failure meet fastevolve policy taxis regulatory requirement stakeholder expectation delivery performance management environmental result litigation regulatory action objective material adverse impact financial result long term loss trust undermine credibility company lead reduce supply chain resilience product life cycle management issue loss trustreputation employee context investor customer regulator stakeholder increasingly understand interconnect effect increase cost loss sale market access negative climate change nature loss societys impact impact environment influence human health internal external expectation company address impact environment increase effect climate change operational resilience regard access energy water natural resource product potential cost increase regulatory change environmental taxis gsk annual report gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertainty continue environmental sustainability continue mitigate activity ensure delivery reduction carbon emission energy november gsk announce new commitment water waste operation mature net zero climate impact net nature positive programme manage performance improvement goal build longterm ambition set site include sustainability consideration design reduce impact environment product packaging strengthen engagement supplier target key intervention gsk leadership team glt responsible support need environmental sustainability governance risk oversight ensure effective framework place use continue monitor control antibiotic emission manage risk business manufacture effluent gsk facility deliver commitment glt responsibility include supplier follow good operational practice meeting appoint dedicated senior leader resource provide emission limit define amr alliance manufacturing maintain risk control ensure governance framework assess impact environment process establish effective business continuously reassess business resilience climate dedicate environmental sustainability enterprise risk plan change task force climaterelate financial place support dedicated programme team disclosure tcfd framework guideline governance framework manage transformation activity information security risk definition covid pandemic continue significant risk information security gsk characterise external factor affect manage information security unauthorised disclosure theft unavailability corruption gsk covidrelated threat include increase gsk information key information system lead ransomware attack healthcare sector hacker harm patient workforce customer disruption continue use opportunity disrupt critical healthcare business andor loss commercial strategic advantage operation case seize healthcare research regulatory sanction damage reputation relate covid vaccine treatment operate highly connect information network risk impact hold confidential research development manufacturing failure adequately protect information key information commercial workforce financial datum mean system cause harm patient workforce system information continue customer disruption business andor loss commercial target cyberattack continue consolidate information strategic advantage regulatory sanction damage system reduce attack point enable focused reputation control gsk strategic approach digital analytic context increase dependency digital asset distribute datum continue analysis assessment overall information security environment challenge critical data asset threat asset difficulty keep pace increasingly require continuous reevaluation emerge risk gsk sophisticated cyber threat factor mitigate action define area include include complexity large regulate organisation secure deployment operation resource highrisk wellresource nature hack activity increase market risk pose gsk datum cloud demand accountability datum handle company potential complexity result agile businessle additionally gsk separation period significant development enterprise change increase risk require additional vigilance continue reassess reliance interconnectivity party contractor partner suppliersprincipal risk uncertainty continue information security continue mitigate activity optimise security architecture mitigate risk datum dedicated team program activity support loss intentionally unintentionally implement cloud global information security policy accompany security strategy ensure new solution development standard process gsk technology security include security design continue risk function provide strategy direction oversight remediate improve control environment privilege mirror function new ch readiness elevate user right system separation include active monitoring cybersecurity transfer party risk management manage enhance global information security capability service partner organisation process critical ongoing programme investment continue sensitive information support solution enable significant investment mitigation activity party access resource continue advance come year remotely secure environment modernise cyber operation consistent evaluation enable business performance high risk market security solution deployment good class cyber assess datum information originate flow security technology ensure timely detection international market local law norm represent response information security incident particular heighten risk confidentiality integrity availability focus ransomware preparation awareness operational system modernise cyber security manufacture rd site address age complexity global footprint environment supply continuity risk definition complex endtoend supply chain involve party failure deliver continuous supply compliant finished supplier active pharmaceutical ingredient api product inability respond effectively crisis incident manufacturer raw material supplier party timely manner recover sustain critical operation logistic provider contract engineering firm embed integrate risk management source day day risk impact business process alongside thirdparty oversight recognise important continuity supply programme product patient consumer rely covid exemplar event external environment supply disruption lead result unforeseen significant supply challenge include staffing shortage essential manufacturing product shortage product recall operation critical raw material supply pressure eg glass regulatory intervention vial plastic tubing interruption distribution reputational harm cybersecurity remain significant threat supply chain lose sale revenue operation global cyber threat increase global pandemic remain hypervigilant datum security consequently need sophisticated endtoend supply chain breach operational technology risk management robust crisis management business continuity plan place respond mitigating activity risk management context supply chain set ensure sustainable supply run supply chain continually evolve highly gsk portfolio pharmaceutical vaccine regulated environment single set global consumer healthcare product gsk internal control regulation govern manufacture distribution framework drive approach risk management design medicine adhere requirement identify emerge new risk support clear decision market licence sell manufacture product make rely internal quality management system internal control framework ensure continue preserve licence operate gsk annual report gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertainty continue supply continuity continue supply chain manage risk oversight business continuity hierarchy risk management compliance board crisis management business continuity plan place assure risk mitigation include identify new emerge pharmaceutical vaccine consumer healthcare threat include authorise response recovery strategy key area responsibility clear communication route supply inventory management chain regularly use business continuity plan manage supply chain governance committee business potential supply disruption manufacturing site crisis unit closely monitor inventory status delivery management plan place test annually product occurrence deployment ensure maintenance skill core commercial cycle link supply chain forecasting crisis management commercial ambition design reduce risk demand fluctuation manage temporary shortage supply periodically review node supply chain ensure hold adequate safety stock whilst balance work capital particular emphasis mitigate supply risk associate medically critical highrevenue product new product launch eg dual source key product apis use monthly performance management process supply chain monitor business activity highlight adverse trend supply operation budget workforce capability transformation separation risk definition mitigate activity failure deliver plan successful transformation future ready office fro establish fourth separation gsk new lead company quarter accountable monitoring progress biopharma consumer healthcare performance risk associate create new company report monthly gsk leadership team risk impact glt ensure enterprise oversight plan failure manage macro level risk covid key performance risk indicator track programme highly competitive labour market relation delivery resource programme delivery talent retention recruitment separation plan materially adversely affect onboarde address covid labour market ability deliver gsk strategy longterm priority challenge addition gsk chief executive officer ceo chief financial officer chief strategy officer head fro context meet leader consumer healthcare gather input february gsk announce new future ready approval key design choice new company overall programme prepare separation company balance transformation separation uphold new gsk pharma company rd approach focus clear governance joint coordination new gsk science relate immune system use genetic consumer healthcare rigorous progress track new technology new leader consumer set clear parameter healthcare gsk increase investment rd new product launch twoyear separation programme aim gsk board regularly inform future ready drive common approach innovation improve capital programme lead indicator ceo board report allocation align improve capability efficiency board meeting board level transformation global support function support new gsk separation committee support advise management optimise supply chain portfolio include divest work transform separate group committee noncore asset prepare consumer healthcare chair gsk chairman include senior operate standalone company complete outlook independent director chair audit risk company fundamentally strengthen remuneration corporate responsibility committee make efficient modern automate skill capability serve futuresharehold information share capital control detail issue share capital number share interest voting right hold treasury december found state far aware note financial statement share capital share person significant direct indirect holding premium account company information provide company pursuant ordinary share list london stock exchange financial conduct authoritys disclosure guidance lse quote new york stock exchange transparency rule dtr publish regulatory nyse form american depositary share ad information service company website ad represent ordinary share detail list debt wwwgskcom list refer note financial statement company receive notification accordance net debt dtr follow notifiable interest voting right holder ordinary share ad entitle receive company issue share capital dividend declare company annual report december february entitle attend speak appoint proxy percentage percentage exercise voting right general meeting company total voting total voting voting right right voting right right restriction transfer limitation blackrock inc hold ordinary share ad requirement dodge cox obtain approval prior transfer ordinary share p ercentage total voting right date notification company ad carry special right regard control c omprise indirect interest ordinary share company restriction vote right major holding qualify financial instrument contract shareholder voting right share difference shareholder know arrangement c omprise indirect interest ordinary share financial right hold person holder american depositary share share know agreement restriction share company acquire disposed interest transfer vote right share period review share acquire group employee share plan rank equally share issue special share buyback programme right trustee employee share ownership plan board authorise issue allot ordinary trust waive right dividend share hold share article company article association trust power article authority company purchase share subject shareholder exchange control limitation authority seek annual basis annual affect holder general meeting agm share purchase certain economic sanction company cancel hold treasury share force time time currently applicable law satisfy share option grant group decree regulation force uk restrict import employee share plan export capital restrict remittance dividend programme cover purchase share cancellation payment holder company share hold treasury share accordance nonresident uk similarly certain economic authority renew shareholders agm sanction force time time company authorise purchase maximum limitation relate nonresident uk english million share detail share purchase law company article association right cancel hold treasury share subsequently holder vote respect company share transfer treasury satisfy awards group employee share plan disclose note financial statement share capital share premium account determine specific share repurchase level company consider development free cash flow year share purchase company confirm currently intend market purchase company review potential future share buyback line usual annual cycle subject return rating criterion gsk annual report gsk annual report strategic report governance remuneration financial statement investor information shareholder information continue share capital control continue market capitalisation share price trend year end market capitalisation base share issue exclude december treasury share gsk december billion date gsk th large company market uk capitalisation ftse index share price january december increasedecrease high year low year table set middle market closing price companys share price increase compares increase ftse index year middle market closing share price february uk share price uk ad price nature trading market follow table set period indicate high low middle market closing price company ordinary share lse ad nyse ordinary share ad uk share share high low high low february january december november october september quarter end december quarter end september quarter end june quarter end march quarter end december quarter end september quarter end june quarter end march year end december year end december year end december year end december february shareholder information continue analysis shareholding december number total total number account account share share hold share hold institutional corporate holder individual corporate body guaranty nominee limit hold treasury share glaxosmithkline jp morgan chase bank na depositary company american depository receipt adr programme company ad list nyse ordinary share represent company adr programme manage depositary register guaranty nominee limit february guaranty nominee limit hold ordinary share represent issue share capital exclude treasury share date february number holder ordinary share holding ordinary share number register holder ad holding ad certain ordinary share ad hold broker nominee result number holder record register holder representative number beneficial holder residence beneficial holder dividend company pay dividend quarterly continue return june new gsk investor update gsk cash shareholder dividend policy dividend set progressive dividend policy remain essential component total shareholder return implement new gsk dividend policy total gsk recognise importance dividend shareholder expect cash distribution respective dividend payout company aim distribute regular dividend payment ratio new gsk new consumer healthcare remain determined primarily reference free cash flow unchanged gsk expect declare p share dividend generate business funding investment payable current group half comprise necessary support group future growth penny share new gsk penny share represent consumer healthcare half whilst dividend share group second half new gsk table set dividend share ad continue expect declare p share dividend year dividend ad translate previously communicate new gsk expect declare dollar applicable exchange rate dividend penny share follow separation dividend policy new consumer year penny healthcare company responsibility board director expect guide cent payout ratio basis expect secondhalf dividend new consumer healthcare company equivalent payout penny share subject board decision intrayear phase dividend q ordinary dividend receivable ad holder calculate base payment expect distribution share second exchange rate april annual fee ad half year adjust highlight ad quarter charge depository cumulative dividend receivable ad holder q q q gsk investor update june reflect total number share circa billion share new consumer healthcare company expect issue demerger june planning assumption investor update reflect gsk share issue time circa billion share gsk annual report gsk annual report strategic report governance remuneration financial statement investor information shareholder information continue dividend continue aggregate represent year basis dividend calendar equivalent group dividend p share quarter exdividend date record date payment date dividend payable consumer healthcare q february february april receivable shareholder remain invest consumer q july healthcare postseparation appropriate record date q august august october detail dividend declare amount payment q november november january date give note financial statement q february february april dividend financial calendar result announcement event date quarter result announcement april result announcement issue lse available annual general meeting news service send security quarter result announcement july exchange commission sec nyse issue quarter result announcement november media available website preliminaryquarter result announcement february financial report annual report publication februarymarch annual report distribution march company publish annual report available website date publication information company include share ad shareholder elect receive notification email price available website wwwgskcom information publication annual report register available website constitute wwwshareviewcouk elect receive annual report print copy annual report contact registrar equiniti limited copy previous annual report available website print copy obtain registrar contact detail annual general meeting annual general meeting agm hold pm ad holder wish attend meet electronically uk time wednesday sofitel london refer agm notice detail request proxy heathrow terminal london heathrow airport tw gd appointment depositary jp morgan chase bank na broadcast live join electronically enable attend ask question vote electronically business transact meeting agm company principal forum communication ad holder remind instruct private shareholder addition formal agm depositary way share represent business presentation ceo ad vote complete return performance group future development voting card provide depositary share opportunity question ask board vote chair board committee workforce engagement director available question document display relate role article association company director detail access agm electronically service contract applicable letter appointment attend person ask question vote find director company subsidiary notice annual general meeting agm notice letter relate severance term pension available website wwwgskcom arrangement available inspection company investor hold share nominee service register office available inspection arrange nominee service appoint agm proxy respect shareholding order attend vote meeting electronicallyshareholder information continue tax information shareholder summary certain uk tax federal income tax inheritance tax consequence holder share ad citizen individual ukdomicile shareholder uk set complete liable uk inheritance tax transfer share ad analysis possible tax consequence purchase tax charge value ownership sale security intend shareholder estate reduce result transfer general guide holder advise consult adviser way lifetime gift disposal market respect tax consequence purchase ownership value case bequest death tax charge sale share ad consequence state value share date shareholder death local tax law implication current gift disposal subject uk ukus tax convention inheritance tax estate gift tax estate gift tax holder ad generally treat owner convention generally provide tax pay underlie share purpose current ukus credit tax payable uk double taxation convention relate income gain stamp duty stamp duty reserve tax income tax convention estate gift taxis estate gift tax convention purpose internal revenue uk stamp duty andor stamp duty reserve tax sdrt code amend subject certain exemption payable transfer share rate round near uk shareholders case stamp duty consideration transfer notwithstanding provide instrument execute summary apply uk resident shareholder pursuance agreement give rise charge hold share capital asset sdrt instrument stamp year agreement include stamp exempt sdrt taxation dividend charge cancel sdrt uk tax year uk resident individual entitle pay repay dividend tax allowance dividend receive tax year free tax shareholder dividend excess allowance tax basic rate taxpayer high rate taxpayer summary apply shareholder citizen additional rate taxpayer note april tax resident domestic corporation person dividend income increase help support subject federal income tax net income nhs social care basis respect share ad hold share ad capital asset resident uk uk tax purpose uk resident shareholder corporation taxpayer hold share purpose trade profession note dividend payable ordinary share generally vocation carry uk branch entitle exemption corporation tax agency taxation capital gain summary address tax treatment holder subject special tax rule bank uk resident shareholder liable uk tax gain taxexempt entity insurance company dealer security disposal share ad currency person hold share ad disposal individual uk tax year integrate investment include straddle comprise taxable capital gain accrue disposal share ad share ad position person tax basic rate taxpayer directly indirectly constructively allowable deduction individual taxable income company stock vote value address tax year exceed basic rate income tax banding note treatment applicable result international follow use exemption available individual income tax treaty taxpayer annual exempt corporation taxpayer entitle indexation allowance apply reduce capital gain extent gain arise inflation indexation allowance reduce chargeable gain create allowable loss asset acquire january legislation finance act freeze level indexation allowance give calculate company chargeable gain value apply disposal asset december asset acquire january onwards legislation finance act remove indexation allowance disposal gsk annual report gsk annual report strategic report governance remuneration financial statement investor information shareholder information continue tax information shareholder continue taxation dividend taxation capital gain gross dividend receive treat foreign generally holder subject uk capital gain source dividend income tax purpose eligible tax subject tax capital gain realise dividend receive deduction allow corporation sale disposal share ad gain dividend ad payable dollar dividend longterm capital gain subject reduce rate taxation ordinary share payable sterling dividend pay individual holder share ad hold sterling include income dollar year date share vestedrelease calculate reference exchange rate day shortterm capital gain subject taxation rate dividend receive holder subject certain longterm capital gain subject exception shortterm hedge position individual rate state local tax rate capital gain eligible holder subject taxation maximum apply federal rate plus applicable state local tax respect qualified dividend qualified dividend define information report backup withhold internal revenue service irs dividend dividend payment proceed sale share meet follow criterion ad pay certain usrelated financial ust issue corporation corporation intermediary subject information reporting incorporated possession corporation subject backup withholding holder eligible benefit comprehensive income tax treaty corporation exempt recipient provide taxpayer deem satisfactory publish irs identification number certifie loss exemption occur nonus holder generally subject dividend type list irs dividend information report backup withholding qualify require provide certification nonus status require dividend hold period meet connection payment receive amount withhold share own day allow refund credit holder federal hold period define day income tax liability provide require information furnish period begin day exdividend date irs day stock trade dividend price example stock exdividend date october estate gift taxis share hold day period estate gift tax convention shareholder august november year order generally subject uk inheritance tax count qualified dividend holder subject federal estate gift tax dividend qualified subject taxation stamp duty federal graduate tax rate maximum rate type dividend automatically exclude uk stamp duty andor sdrt subject certain exemption qualified dividend meet requirement payable transfer share ad custodian include limited depository rate consideration provide transfer sale value transfer capital gain distribution consideration dividend bank deposit stamp duty sdrt payable ividend hold corporation employee stock transfer agreement transfer ad ownership plan esop dividend pay taxexempt corporation state local tax rate qualify nonqualified dividend vary assess addition federal tax rate communicate aboveother statutory disclosure shareholder service contact registrar company registrar equiniti limited aspect house spencer road lance bn da wwwshareviewcouk tel uk tel outside uk equiniti provide range service shareholder service offer participate dividend reinvestment plan alternative receive cash dividend choose drip election form download drip reinvest dividend buy gsk share wwwshareviewcouk request contact equiniti dividend payment direct bank dividend pay directly bank building society dividend bank mandate form account bank mandate account receive cash dividend provide download wwwshareviewcouk equiniti bank building society account detail request contact equiniti quick secure method payment dividend payment direct bank equiniti convert dividend local currency detail service cost account overseas shareholder send direct local bank account service available involve contact equiniti country worldwide electronic communication shareholder elect receive electronic notification register wwwshareviewcouk company communication include annual report dividend payment dividend confirmation availability online vote general meeting time gsk publish shareholder document receive email contain link document relevant website shareview portfolio service enable create free online portfolio view register wwwshareviewcouk share balance movement update address dividend payment instruction register vote general meeting deduplication publication mailing receive duplicate copy mailing contact equiniti account contact equiniti arrange account merge convenience avoid waste unnecessary cost share deal service shareholder trade share hold certificate online transaction log note market trading hour form corporate sponsor nominee online wwwshareviewcoukdeale pm uk time telephone postal dealing service provide equiniti telephone transaction monday friday exclude public financial service limit uk holiday england wale outside uk line open pm uk time monday friday exclude uk public holiday postal transaction request deal form corporate sponsor nominee account convenient way manage share require application form request share certificate service provide facility hold wwwshareviewcouk share nominee account sponsor company contact equiniti continue receive dividend payment attend vote company general meeting shareholder name appear publicly available share register service free join individual saving account isas company arrange equiniti financial service detail available wwwshareviewcouk limited provide gsk corporate isa hold gsk share request telephone equiniti line open pm deal pm enquiry monday friday exclude public holiday england wale line open pm monday friday exclude public holiday england wale provision share deal detail intend invitation inducement engage investment activity advice share dealing obtain stockbroker independent financial adviser gsk annual report gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue shareholder service contact continue ad depositary contact adr programme administer jp morgan investor relation chase bank na investor relation contact follow regular correspondence uk eq shareowner services great west road po box brentford middlesex tw gs st paul mn tel delivery stock certificate overnight mail eq shareowner services crescent drive centre point curve suite philadelphia pa mendota heights mn tel toll free wwwshareowneronlinecom tel outside general gsk response center outside tel toll free depository provide global invest direct direct share scam alert ad purchasesale dividend reinvestment plan ad receive unsolicited telephone offering sell buy holder detail enrol visit wwwadrcom share extra care caller helpline number obtain enrolment pack highly organise financial scam donate share save child uk shareholder contact financial gsk embark ambitious global partnership conduct authority wwwfcaorgukconsumer save child share expertise resource consumer helpline aim help save live million child tel uk shareholder small number share value tel outside uk make uneconomical sell wish consider donate save child donate share aggregate line open pm uk time monday friday uk public holidays pm saturdays sell save child use fund raise help reach goal obtain share donation form contact registrar equiniti manage donation sale uk share save child free charge provision share deal detail intend invitation inducement engage investment activity advice share dealing obtain stockbroker independent financial adviser stock exchange announcement notification provide shareholder service receive automatic email notification publish stock exchange announcement receive email notification sign announcement wwwgskcom investor sectionother statutory disclosure continue law regulation number provision law regulation apply section corporate responsibility company share quote nyse financial report form ad sarbanesoxley require ceo cfo complete formal certification confirm nyse rule review annual report form f general nyse rules permit company follow uk corporate governance practice instead apply base knowledge annual report form f provide explain significant variation contain material misstatement omission explanation contain form f base knowledge financial statement access sec edgar database website financial information fairly present material respect nyse rule require file annual interim write financial condition result operation cash flow affirmation concern audit risk committee arc date period present annual report statement significant difference corporate form f governance responsible establish maintain sarbanesoxley act disclosure control procedure ensure material information know evaluated follow number corporate accounting scandal effectiveness control procedure year congress pass sarbanesoxley act end result evaluation contain sarbanesoxley wideranging piece legislation annual report form f concern largely financial report corporate governance responsible establish maintain internal control financial reporting provide reasonable recommend sec company establish assurance reliability financial reporting disclosure committee committee report ceo preparation financial statement external purpose cfo arc chair company secretary accordance generally accept accounting principle member consist senior manager finance legal corporate communication investor relation disclose annual report form f external legal counsel external auditor internal expert change internal control financial reporting invite attend disclosure committee meeting period cover annual report form f periodically committee responsibility consider materially affect reasonably likely affect materially materiality information timely basis determine company internal control financial reporting disclosure information responsibility disclose base recent evaluation timely filing report sec formal review internal control financial report external auditor annual report form f committee meet arc significant deficiency material time weaknesse design operation internal control sarbanesoxley require annual report form f financial reporting reasonably likely affect contain statement member arc adversely company ability record process audit committee financial expert define rule summarise report financial information fraud sarbanesoxley statement relevant member regardless materiality involve person arc charles bancroft include board significant role company internal control financial committee information area corporate governance reporting report biography additional group carry evaluation supervision disclosure requirement arise section section participation management include ceo sarbanesoxley respect disclosure control cfo effectiveness design operation procedure internal control financial reporting group disclosure control procedure december inherent limitation effectiveness system disclosure control procedure include possibility human error circumvention override control procedure accordingly effective disclosure control procedure provide reasonable assurance achieve control objective gsk annual report gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue law regulation continue ceo cfo expect complete certification group export certain pharmaceutical vaccine report conclusion effectiveness disclosure consumer product iran sale nonus entity control procedure march follow subsidiary entity privately hold iranian certification file sec group distributor form f group regularly receive information identity distributor downstream customer section management annual report internal intermediary iran possible party control financial reporting include entity governmentowne hospital accordance requirement section pharmacy own directly indirectly iranian sarbanesoxley follow report provide government person entity sanction connection management respect company internal control terrorism proliferation activity financial report define rule af df group regularly receive information securities exchange act amend identity distributor downstream customer exchange act establish proportion gross revenue sale management responsible establish maintain potentially attributable entity affiliate iranian adequate internal control financial reporting government party sanction disclosable activity group internal control financial reporting design result group report entire gross revenue provide reasonable assurance reliability million net profit million group financial reporting preparation financial statement sale iran external purpose accordance ifrs group aware hospital medical management conduct evaluation effectiveness facility lebanon affiliated control internal control financial reporting base hezbollah group designate united framework internal control integrate framework state pursuant executive order group issue committee sponsor organisation deal directly hospital facility treadway commission coso instead sell distributor group unable change group internal control establish proportion gross revenue sale potentially financial reporting materially attributable reportable activity result group affect reasonably likely materially affect report entire gross revenue million net group internal control financial reporting profit million group sale lebanon management assess effectiveness internal note group intend continue activity control financial reporting december describe conclusion file group form addition section r exchange act law f generally restrict dealing person dealing deloitte llp audit consolidated financial subject jurisdiction certain country statement group year end december territory subject comprehensive sanction currently assess effectiveness group crimea cuba donetsk people republic iran luhansk internal control financial reporting audit people republic north korea syria standard public company accounting oversight government venezuela country board united states audit report file venezuela group business nonus group form f entities own control entity certain jurisdiction believe group complie section r exchange act applicable sanction material respect law complex continue evolve rapidly section r exchange act require issuer specific disclosure annual report certain type dealing iran control transaction dealing governmentowne entity dealing entity sanction activity relate terrorism proliferation weapon mass destruction activity prohibit law involve personsother statutory disclosure continue donation political organisation political expenditure ensure consistent approach political contribution result definition cover legitimate business group global policy introduce activity ordinary sense consider political voluntarily stop corporate political contribution donation political expenditure design support political party independent election candidate period january december group political donation eu notwithstanding policy noneu organisation intend donation eu political party organisation incur eu political expenditure notwithstanding introduction policy accordance annually seek shareholder authorisation inadvertent federal election campaign act continue expenditure support employeeoperate political action committee pac facilitate voluntary political donation eligible authority precautionary measure ensure gsk employee company subsidiary inadvertently breach legislation pac control gsk decision amount recipient contribution govern pac board authorisation process expenditure director contribution pac participate year date agm hold follow eligible employee exercise legal right pool introduction political party election resource political contribution subject referendum act authority strict limitation law total renew annually donate political organisation gsk employee pac english law require prior shareholder approval political contribution eu political party independent election candidate eu political expenditure definition political donation political expenditure political organisation legislation broad particular definition eu political organisation extend body concern policy review law reform representation business community special interest group concern environment company subsidiary wish support gsk annual report gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company accordance section company act list subsidiary associate joint venture joint arrangement address register office effective percentage equity own december disclose state share capital disclose comprise ordinary share indirectly hold glaxosmithkline plc percentage hold class share state state subsidiary company register office tax resident country incorporation security register address wholly own subsidiary alberta ulc common nd street sw calgary ab tp j canada action potential venture capital limit ordinary great west road brentford middlesex tw gs england adechsa gmbh ii ordinary co prv provide treuhandgesellschaft ag dorfstrasse baar switzerland allen hanburys limited ii ordinary great west road brentford middlesex tw gs england allen hanburys pharmaceutical nigeria limited ordinary abimbola way ilasamaja isolo lagos nigeria allen farmaceutica sa ordinary severo ochoa parque tecnolgico de madrid tres cantos madrid spain allen pharmazeutika gesellschaft mbh ordinary wagenseilgasse euro plaza gebude stock vienna austria beecham group plc p shares b great west road brentford middlesex tw gs england p share beecham pharmaceutical pte limited ordinary quality road jurong industrial estate jurong singapore beecham portuguesaprodutos farmacuticos e qumico lda ordinary quota rua dr antonio loureiro borge arquiparque miraflore alge portugal beecham sa ii ordinary avenue fleming wavre belgium biovesta ilalari ltd sti ii nominative bykdere caddesi levent plaza b blok levent istanbul turkey cascan gmbh co kg partnership capital prinzregentenplatz munich germany castleton investment ltd liquidation ordinary co dtos cybercity th floor standard charter tower ebene mauritius cellzome gmbh ordinary meyerhofstrasse heidelberg germany cellzome limited liquidation year end ordinary baker street london wu eu united kingdom charles midgley limited liquidation year end cumulative preference baker street london wu eu united kingdom ordinary clarge pharmaceutical limited liquidation year end ordinary baker street london wu eu united kingdom preference clarge pharmaceutical trustee limited ii iv ordinary great west road brentford middlesex tw gs england colleen corporation common corporation service company little fall drive wilmington de united states corixa corporation common corporation service company little fall drive wilmington de united states dealcyber limited ordinary great west road brentford middlesex tw gs england desarrollo energa solar alternativa sl ordinary severo ochoa parque tecnolgico de madrid tres cantos madrid spain duncan flockhart australia pty limited ii iv ordinary mountain highway boronia victoria vic australia duncan pharmaceuticals philippines inc common rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines etex farmaceutica ltda social capital avenue andre bello piso las conde santiago cp chile genelabs technologies inc common corporation service company gateway oak drive suite n sacramento united states glaxo group limit ordinary great west road brentford middlesex tw gs england glaxo kabushiki kaisha ii ordinary akasaka minatoku tokyo japan glaxo laboratories nigeria limited ii ordinary marine road apapa lagos nigeria glaxo laboratory limit liquidation ordinary baker street london wu eu united kingdom glaxo new zealand pension plan trustee limited ordinary level e generator gridakl madden street wynyard quarter auckland new zealand glaxo operation uk limit ordinary great west road brentford middlesex tw gs england glaxo property bv ordinary van asch van wijckstraat h lp amersfoort netherlands glaxo trustees limited ii liquidation ordinary baker street london wu eu united kingdom glaxo verwaltung gmbh ordinary prinzregentenplatz munich germany glaxo wellcome australia pty ltd ii iv ordinary mountain highway boronia victoria vic australia glaxo wellcome farmacutica limitada ordinary quota rua dr antonio loureiro borge arquiparque miraflore alge portugal glaxo wellcome international bv ii iii ordinary huis ter heideweg lz zeist netherlands glaxo wellcome manufacturing pte ltd ordinary pioneer sector jurong industrial estate jurong singapore glaxo wellcome production ordinary rue franois jacob rueilmalmaison france glaxo wellcome vidhyasom limited ii ordinary th floor wave place wireless road lumpini pathumwan bangkok thailandother statutory disclosure continue group company continue security register address wholly own subsidiary continue glaxo wellcome sa ordinary poligono industrial allendeduero avenida de extremadura aranda de duero burgo spain glaxo sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxoallenburys nigeria limited ii ordinary creek road apapa lago pmb nigeria glaxochem pte ltd iii ordinary rochester park singapore glaxosmithkline produtos farmacuticos limitada ordinary quota rua dr antonio loureiro borge arquiparque miraflore alge portugal glaxosmithkline cambodia co ltd liquidation ordinary th floor dksh building preah monivong boulevard co sangkat phsar deum thakov khan chamkarmon phnom penh cambodia glaxosmithkline china investment co ltd ordinary room unit floor mid th east ring road chaoyang district beijing china glaxosmithkline china rd company limited equity f building huanke road pilot free trade zone shanghai china glaxosmithkline cyprus limited ordinary arch makariou iii capital center th floor nicosia pc cyprus glaxosmithkline gsk srl ordinary costache negri street opera center th th floor zone district bucharest romania glaxosmithkline ireland limit ordinary riverwalk citywest business campus dublin ireland glaxosmithkline israel ltd ordinary basel street po box petachtikva israel glaxosmithkline malta limit ordinary floor de la cruz avenue qormi qrm malta glaxosmithkline private limited ii ordinary unit anthony road msasa harare zimbabwe glaxosmithkline thailand limited ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline ab ordinary hemvarnsg solna sweden glaxosmithkline ag ordinary talstrasse muenchenbuchsee switzerland glaxosmithkline angola unipessoal limitada iv quota luanda bairro petrangol estrada de cacuaco n angola glaxosmithkline argentina sa ordinary tucumn piso buenos aire caaa argentina glaxosmithkline ordinary drammensveien oslo norway glaxosmithkline asia private limited equity patiala road nabha dist patiala punjab india glaxosmithkline australia pty ltd ordinary mountain highway boronia victoria vic australia glaxosmithkline bv ordinary van asch van wijckstraat h lp amersfoort netherlands netherlands glaxosmithkline beteiligung gmbh ordinary prinzregentenplatz munchen germany glaxosmithkline biological shanghai ltd ordinary niudun road pilot free trade zone shanhai china glaxosmithkline biological kft ordinary gdll homoki nagy istvn utca hungary glaxosmithkline biological sas ordinary rue des aulnois saintamand les eaux france glaxosmithkline biological sa ordinary rue de b rixensart belgium preference glaxosmithkline brasil limitada quotas estrada do banderiantes rio de janeiro brazil glaxosmithkline capital inc common wilmington trust sp services inc north market street suite wilmington de united states glaxosmithkline capital plc ordinary great west road brentford middlesex tw gs england glaxosmithkline caribbean limited ordinary great west road brentford middlesex tw gs england glaxosmithkline chile farmaceutica limitada social capital avenue andre bello piso las conde santiago cp chile glaxosmithkline colombia sa ordinary avenida el dorado bpiso bogot colombia glaxosmithkline consumer healthcare holding limit ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer hold bv ii ordinary van asch van wijckstraat h lp amersfoort netherlands glaxosmithkline doo quota zmja od bosne broj sarajevo bosnia herzegovina glaxosmithkline doo equity capital ulica damira tomljanovica gavrana zagreb croatia glaxosmithkline doo beograd ordinary omladinskih brigada new belgrade city belgrade serbia glaxosmithkline ecuador sa ordinary av de agosto n naciones unidas edificio electroectuatoriana piso quito ecuador glaxosmithkline eesti ou ordinary ltsa tallinn estonia glaxosmithkline el salvador sa de cv ordinary municipio de san salvador departamento de san salvador el salvador glaxosmithkline eood ordinary g tsarigradsko shose blvd floor mladost region sofia bulgaria glaxosmithkline export limit ordinary great west road brentford middlesex tw gs england glaxosmithkline export panama sa ordinary panama city republic panama panama glaxosmithkline far east bv ordinary van asch van wijckstraat h lp amersfoort netherlands glaxosmithkline finance plc ordinary great west road brentford middlesex tw gs england glaxosmithkline gmbh co kg partnership capital prinzregentenplatz munchen germany glaxosmithkline guatemala sa ordinary ra av zona torre citibank nivel guatemala city guatemala gsk annual report gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company continue security register address wholly own subsidiary continue glaxosmithkline hold ordinary drammensveien oslo norway glaxosmithkline holdings americas inc common wilmington trust sp services inc north market street suite wilmington de united states glaxosmithkline holding limited ordinary great west road brentford middlesex tw gs england glaxosmithkline holding limit ordinary great west road brentford middlesex tw gs england glaxosmithkline holdings pty ltd ordinary mountain highway boronia victoria vic australia glaxosmithkline honduras sa ordinary tegucigalpa mdc honduras glaxosmithkline ihc limit ordinary great west road brentford middlesex tw gs england glaxosmithkline ilaclari sanayi ticaret nominative bykdere caddesi levent plaza b blok levent istanbul turkey glaxosmithkline inc class common mississauga road north mississauga ontario ln l canada class c preference glaxosmithkline insurance ltd ordinary parlaville road hamilton hm bermuda glaxosmithkline intellectual property limit ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property development limit ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property holding limit ordinary great west road brentford middlesex tw gs england b ordinary glaxosmithkline intellectual property limit defer great west road brentford middlesex tw gs england ordinary glaxosmithkline intellectual property management limit ordinary great west road brentford middlesex tw gs england glaxosmithkline investigacin desarrollo sl ordinary severo ochoa parque tecnolgico de madrid tres cantos madrid spain glaxosmithkline investment holdings limit liquidation ordinary baker street london wu eu united kingdom glaxosmithkline investment service limit liquidation ordinary baker street london wu eu united kingdom glaxosmithkline investment pty ltd ordinary mountain highway boronia victoria vic australia glaxosmithkline kk ordinary akasaka minatoku tokyo japan glaxosmithkline korea limited ordinary f ls yongsan tower hangangdaero yongsangu seoul korea republic glaxosmithkline latin america sa ordinary panama city republic panama panama glaxosmithkline latvia sia ordinary dunte iela riga latvia glaxosmithkline lietuva uab ordinary ukmerge st vilnius lt lithuania glaxosmithkline limit ordinary f tower gateway canton road tsimshatsui kowloon hong kong glaxosmithkline llc llc interest corporation service company little fall drive wilmington de united states glaxosmithkline manufacture spa ordinary viale dellagricoltura verona italy glaxosmithkline maroc sa ordinary angle bd rachidi et abou ham el glaza casablanca morocco glaxosmithkline medical healthcare product limit ordinary h csorsz utca budapest hungary glaxosmithkline mercury limit ordinary great west road brentford middlesex tw gs england glaxosmithkline mexico sa de cv ordinary calzada mexicoxochimilco colonia san lorenzo huipulco ordinary b delegacion tlalpan mexico glaxosmithkline nz limit ordinary level e generator gridakl madden street wynyard quarter auckland new zealand glaxosmithkline oy ordinary piispansilta po box espoo fin finland glaxosmithkline peru sa ordinary av javier prado oeste san isidro lima peru glaxosmithkline pharma ordinary nykaer dk brondby denmark glaxosmithkline pharma gmbh ordinary wagenseilgasse euro plaza gebude stock wien glaxosmithkline pharmaceutical kenya limit ordinary likoni road nairobi kenya glaxosmithkline pharmaceutical nigeria limited ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline pharmaceutical sdn bhd ordinary level quill jalan prof khoo kay kim petale jaya selangor malaysia glaxosmithkline pharmaceuticals pvt ltd ordinary galle road kaldemulla moratuwa sri lanka glaxosmithkline pharmaceuticals costa rica sa ordinary autopista florencia del castillo kilmetro siete oficentro terracampus edificio uno cuarto piso san diego cartago costa rica glaxosmithkline pharmaceuticals sa ordinary ul grunwaldzka poznan poland ordinary b ordinary c ordinary glaxosmithkline pharmaceutical sa ordinary site apollo avenue pascal wavre belgium glaxosmithkline pharmaceutical ukraine llc charter capital pavla tychyny avenue v kiev ukraine glaxosmithkline philippines inc ordinary rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines glaxosmithkline pte ltd ordinary rochester park singapore glaxosmithkline puerto rico inc common prenticehall corporation system puerto rico inc co fast solution llc ponce de leon avenue floor san juan puerto ricoother statutory disclosure continue group company continue security register address wholly own subsidiary continue glaxosmithkline republica dominicana sa ordinary blue mall tower floor ave winston churchill santo domingo dominican republic glaxosmithkline research development limit ordinary great west road brentford middlesex tw gs england glaxosmithkline sa ordinary severo ochoa parque tecnolgico de madrid tres cantos madrid spain glaxosmithkline spa ordinary viale dellagricoltura verona italy glaxosmithkline sro ordinary hvezdova c prague czech republic glaxosmithkline services gmbh co kg partnership capital prinzregentenplatz munchen germany glaxosmithkline service unlimite ordinary great west road brentford middlesex tw gs england glaxosmithkline single member aebe ordinary kifissias avenue halandri athens greece glaxosmithkline sl llc llc interest corporation service company little fall drive wilmington de united states glaxosmithkline sl lp ii viii partnership great west road brentford middlesex tw gs england glaxosmithkline slovakia sro ordinary galvaniho bratislava slovakia glaxosmithkline south africa pty limited ordinary flush meadow build campus sloane street bryanston south africa glaxosmithkline trading services limit iii ordinary riverwalk citywest business campus dublin ireland glaxosmithkline tunisia sarl ordinary immeuble regus lot b centre urbain nord tunis tunisia glaxosmithkline uk limit ordinary great west road brentford middlesex tw gs england glaxosmithkline uruguay sa register provisory stock salto cp montevideo uruguay glaxosmithkline trading limit ordinary great west road brentford middlesex tw gs england glaxosmithkline venezuela ordinary urbanizacion la trinidad calle luis de camoems edif apatado posta caracas venezuela bolivarian republic glaxosmithkline vietnam limited liability company ii iv equity capital metropolitan dong khoi street district th floor unit ho chi minh city vietnam glycovaxyn ag iv common grabenstrasse schlieren switzerland prefer preferred b prefer c groupe glaxosmithkline ordinary rue franois jacob rueilmalmaison france gsk australia nvd pty ltd ii iv ordinary mountain highway boronia victoria vic australia gsk bangladesh private limited ordinary sweden tower harinnachala konabari gazipur bangladesh gsk biopharma argentina sa nominative non endorseable ordinary tucumn piso buenos aire caaa argentina gsk business service centre sdn bhd ordinary level quill jalan prof khoo kay kim petale jaya selangor malaysia gsk capital bv iii v ordinary great west road brentford middlesex tw gs england gsk capital kk ordinary akasaka minatoku tokyo japan gsk commercial sp z oo ordinary ul rzymowskiego warsaw poland gsk doo ljubljana ordinary amerika ulica ljubljana slovenia gsk enterprise management co ltd ordinary floor lane huanke road zhongke road shanghai china gsk equity investment limited unit corporation service company interstate drive suite harrisburg pa united states gsk finance limit ordinary great west road brentford middlesex tw gs england gsk finance plc ordinary great west road brentford middlesex tw gs england gsk india global services private limited equity level luxor north tower bagmane capital business park outer ring road bangalore karnataka india gsk international hold finance bv ordinary van asch van wijckstraat h lp amersfoort netherlands gsk kazakhstan llp participation interest furmanov street almaty medeu district kazakhstan gsk limit ordinary great west road brentford middlesex tw gs england gsk pharma vietnam company limited charter capital unit th floor metropolitan tower dong khoi street ben nghe ward district ho chi minh vietnam gsk pharmaceutical trading sa ii iv ordinary buchar costache negri street opera center th floor discussion room district romania gsk psc poland sp z oo equal indivisible share ul grunwaldzka pozna pol gsk service sp z oo ordinary ul grunwaldzka poznan poland gsk vaccine bv ordinary hullenbergweg cl amsterdam netherlands gsk vaccine gmbh ordinary emilvonbehringstr marburg germany gsk vaccines institute global health srl quota fiorentina siena italy gsk vaccines srl quota fiorentina siena italy gsk vaccines vertriebs gmbh ii ordinary rudolfdieselre holzkirchen germany hgs france sarl ii iv ordinary rue de la belle feuille boulognebillancourt france human genome sciences inc common corporation service company little fall drive wilmington de united states d biomedical corporation quebec common boul du parc technologique qubec qubec gp r canada gsk annual report gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company continue security register address wholly own subsidiary continue instituto luso farmaco limitada ii quotas rua dr antonio loureiro borges arquiparque miraflore algs portugal interpharma dienstleistungen gmbh ii quotas wagenseilgasse euro plaza gebude stock vienna austria jj technologies lc llc interest corporation service company shockoe slip nd floor richmond va united states jsc glaxosmithkline trading ordinary leningradskiy prospect build floor premise xv room moscow russian federation laboratoire glaxosmithkline ordinary rue franois jacob rueilmalmaison france laboratoire pharmaceutique algrien lpa production spa ordinary zone industrielle est boudouaou boumerde algeria laboratoire pharmaceutique algrien spa ordinary zone industrielle est boudouaou boumerde algeria laboratoires paucourt ii ordinary rue franois jacob rueilmalmaison france laboratoire saintgermain ii ordinary rue franois jacob rueilmalmaison france laboratorios dermatologico darier sa de cv ordinary calzada mexico xochimilco san lorenzo huipulco district federal ordinary b mexico mexico laboratrios farmaceuticos stiefel portugal ltda ii ordinary rua dr antonio loureiro borges arquiparque miraflore algs portugal laboratorios stiefel de venezuela sa ordinary calle luis de camoens edificio glaxosmithkline urb la trinidad caracas venezuela bolivarian republic laboratorios stiefel ltda ordinary rua professor joao cavalheiro salem bairro de bonsucesso municipality guarulhos sao paulo cep brazil laboratorios wellcome de portugal limitada ii quota rua dr antonio loureiro borge arquiparque miraflore alge portugal mixis genetic limit liquidation ordinary bdo llp temple square temple street liverpool l rh montrose pharma company limited ii iv ordinary quota h csorsz utca budapest hungary penn labs inc ii common corporation service company little fall drive wilmington de united states setfirst limit ordinary great west road brentford middlesex tw gs england sitari pharma inc common stock corporation service company little fall drive wilmington de united states smith kline french portuguesaprodutos farmaceutico ordinary rua dr antonio loureiro borges arquiparque miraflore lda ii alge portugal smithkline beecham bangladesh private limited ii ordinary housea roadgulshan dhaka bangladesh smithkline beecham cork limit ordinary riverwalk citywest business campus dublin ireland smithkline beecham manufacturing limit liquidation ordinary bdo beax lane house mercer street low dh dublin dh ireland smithkline beecham swg limited liquidation ordinary bdo llp temple square temple street liverpool l rh smithkline beecham egypt llc quotas amoun street el salam city cairo egypt smithkline beecham farma sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain smithkline beecham limit ordinary great west road brentford middlesex tw gs england smithkline beecham pension plan trustee limited ii ordinary great west road brentford middlesex tw gs england smithkline beecham pension trustee limit liquidation ordinary baker street london wu eu united kingdom smithkline beecham pharma gmbh co kg partnership capital prinzregentenplatz munchen germany smithkline beecham pharma verwaltung gmbh ordinary prinzregentenplatz munchen germany smithkline beecham pharmaceuticals pty limited ii iv ordinary flush meadow build campus sloane street bryanston south africa smithkline beecham pharmaceutical co common corporation service company little fall drive wilmington de united states smithkline beecham port louis limited liquidation ordinary co cim corporate services ltd les cascade build edith cavell street port louis mauritius smithkline beecham senior executive pension plan trustee ordinary great west road brentford middlesex tw gs england limited ii stiefel dominicana srl ii iv ordinary ave lope de vega torre novocentro local santo domingo dominican republic stiefel farma sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain stiefel gmbh co kg partnership capital prinzregentenplatz munchen germany stiefel india private limited equity battery house bhulabhai desai raod mumbai maharashtra india stiefel laboratory maidenhead ltd liquidation ordinary bdo llp temple square temple street liverpool l rh stiefel laboratory legacy ireland limited ordinary unit build avenue cork airport business park cork ireland stiefel laboratory limit liquidation year end ordinary baker street london wu eu united kingdom stiefel laboratory pte limited ordinary pioneer sector singaporeother statutory disclosure continue group company continue security register address wholly own subsidiary continue stiefel laboratory inc common corporation service company little fall drive wilmington de united states stiefel maroc sarl ii iv ordinary boulevard zerktouni casablanca morocco stiefel research australia holdings pty ltd ordinary mountain highway boronia victoria vic australia stiefel research australia pty ltd ordinary mountain highway boronia victoria vic australia stiefel west coast llc llc interest corporation service company little fall drive wilmington de united states strebor inc common corporation service company little fall drive wilmington de united states tesaro bio gmbh liquidation ordinary poststrasse zug switzerland tesaro bio netherlands bv ordinary joop geesinkweg ab amsterdamduivendrecht netherland tesaro bio sweden ab common co bdo malardalen ab skatt box stockholm sweden tesaro development ltd ordinary clarendon house church street hamilton hm bermuda tesaro inc common corporation service company little fall drive wilmington de united states sydney ross co ii ordinary corporation service company princeton south corporate center suite charle ewing blvd ewe nj united states ucb pharma asia pacific sdn bhd ii ordinary th floor menara symphony jalan prof khoo kay kim seksyen petale jaya malaysia wellcome consumer healthcare limited ii ordinary great west road brentford middlesex tw gs england wellcome consumer product limit liquidation ordinary bdo llp temple square temple street liverpool l rh year end wellcome developments pty ltd ii iv ordinary mountain highway boronia victoria vic australia wellcome limited ordinary great west road brentford middlesex tw gs england wellcome operations pty ltd ii iv ordinary mountain highway boronia victoria vic australia effective security ownership register address subsidiary effective interest alacer corp common corporate service company dba csc lawyer incorporate service gateway oak drive suite n sacramento california united states amoun pharmaceutical industry co sae new monetary share el salam city po box cairo egypt beecham enterprises inc ii common corporation service company little fall drive wilmington de united states biddle sawyer limited equity dr annie besant road mumbai india block drug company inc common corporation service company princeton south corporate center suite charle ewing blvd ewe nj united states block drug corporation ii common corporation service company princeton south corporate center suite charle ewing blvd ewe nj united states british pharma group limited capital great west road brentford middlesex tw gs england consumer healthcare holding limit ordinary great west road brentford middlesex tw gs england consumer healthcare intermediate holding limit ordinary great west road brentford middlesex tw gs england duncan consumer healthcare philippines inc common rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines exlax inc common prentice hall corporation system puerto rico inc co citi tower ponce de leon avenue floor san juan puerto rico ferrosan aps share delta park vallensbk strand denmark b share ferrosan international aps ordinary delta park vallensbk strand denmark ferrosan srl register capital c calea turzii clujnapoca cluj county romania galvani bioelectronics inc common corporation service company little fall drive wilmington de united states galvani bioelectronic limit ordinary great west road brentford middlesex tw gs england b ordinary glaxo saudi arabia limit ordinary po box area warehouse city stage al khomrah jeddah saudi arabia glaxo wellcome ceylon limit ordinary galle road kaldemulla moratuwa sri lanka ordinary b glaxosmithkline suzhou trading co ltd register capital gangpu road wusongjiang science technology industrial park wuzhong economic technical development zone suzhou china glaxosmithkline tianjin co ltd ordinary fifth avenue tai feng industrial park tianjin economic technolog tianjin china glaxosmithkline algrie spa ordinary zone industrielle est boudouaou wilaya de boumerdes algeria glaxosmithkline brasil produtos para consumo quotas av das america th floor room rio de janeiro rj e saude ltda brazil gsk annual report gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company continue effective security ownership register address subsidiary effective interest continued glaxosmithkline consumer healthcare china co ltd ordinary room shengang boulevard lingang special area china pilot free trade z shanghai shanghai china glaxosmithkline consumer healthcare hong kong limit ordinary f tower gateway canton road tsimshatsui kowloon hong kong glaxosmithkline consumer healthcare ireland limit ordinary riverwalk citywest business campus dublin ireland glaxosmithkline consumer healthcare overseas limit ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare thailand limited ordinary th floor unit wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline consumer healthcare uk ip limit iv ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare uk trading limit ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare ip llc llc interest corporation service company little fall drive wilmington de united states glaxosmithkline consumer healthcare ab ordinary hemvrnsgatan po box solna sweden glaxosmithkline consumer healthcare aps ordinary delta park vallensbk strand denmark glaxosmithkline consumer healthcare australia pty ltd ordinary hughes avenue ermington new south wale nsw australia glaxosmithkline consumer healthcare bv ordinary van asch van wijckstraat g lp amersfoort netherlands glaxosmithkline consumer healthcare colombia sa ordinary carrera piso colombia glaxosmithkline consumer healthcare czech republic sro ordinary hvezdova c prague czech republic glaxosmithkline consumer healthcare finance limit ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare finance limit ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare finland oy ordinary piispansilta fin espoo finland glaxosmithkline consumer healthcare gmbh ordinary wagenseilgasse euro plaza gebude stock vienna austria glaxosmithkline consumer healthcare gmbh co kg partnership capital barthstr mnchen germany glaxosmithkline consumer healthcare hellas single ordinary kifissias avenue halandri athens greece member societe anonyme glaxosmithkline consumer healthcare holding great west road brentford middlesex tw gs england limited b preference glaxosmithkline consumer healthcare holding llc llc interest corporation service company little fall drive wilmington de united states glaxosmithkline consumer healthcare investment ordinary knockbrack dungarvan co waterford x ry ireland ireland limited iii liquidation glaxosmithkline consumer healthcare investment ordinary knockbrack dungarvan co waterford x ry ireland ireland unlimited company iii liquidation glaxosmithkline consumer healthcare japan kk ordinary akasaka minatoku tokyo japan glaxosmithkline consumer healthcare korea co ltd ordinary f ls yongsan tower hangangdaero yongsangu seoul korea republic glaxosmithkline consumer healthcare llc llc interest corporation service company interstate drive suite harrisburg pa united states glaxosmithkline consumer healthcare mexico de rl ordinary boulevard adolfo ruiz cortine torre piso colonia de cv jardines del pedregal alcalda alvaro obregn ciudad de mxico cp mexico glaxosmithkline consumer healthcare new zealand ulc ordinary level e madden street auckland central auckland new zealand glaxosmithkline consumer healthcare norway ordinary drammensveien lysaker norway glaxosmithkline consumer healthcare pakistan limit ordinary syke building dockyard road west wharf karachi pakistan glaxosmithkline consumer healthcare philippines inc common rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines glaxosmithkline consumer healthcare pte ltd ordinary rochester park singapore glaxosmithkline consumer healthcare sa ordinary site apollo avenue pascal wavre belgium glaxosmithkline consumer healthcare sa ordinary severo ochoa parque tecnolgico de madrid tres cantos madrid spain glaxosmithkline consumer healthcare srl ordinary zambeletti snc baranzate milan italy glaxosmithkline consumer healthcare saudi limited ordinary salamah tower th floor madinah road alsalamah district jeddah saudi arabia glaxosmithkline consumer healthcare sdn bhd ordinary lot jalan enggang ampang hulu kelang industrial estate selangor darul ehsan ampang malaysia glaxosmithkline consumer healthcare slovakia r ownership interest galvaniho bratislava slovakia glaxosmithkline consumer healthcare south africa pty ordinary flush meadow build campus sloane street bryanston ltd south africa glaxosmithkline consumer healthcare spzoo ordinary ul grunwaldzka poznan poland glaxosmithkline consumer healthcare srl ordinary costache negri street opera center th floor zone district buchar romaniaother statutory disclosure continue group company continue effective security ownership register address subsidiary effective interest continued glaxosmithkline consumer healthcare ulc class preference burrard street suite bentall centre po box glaxosmithkline soin de sante aux consommateurs sri common vancouver bc vx l canada glaxosmithkline consumer healthcare vietnam company charter capital floor metropolitan dong khoi ben nghe ward district ho limited ii chi minh city vietnam glaxosmithkline consumer healthcare lp partnership capital corporation service company little fall drive wilmington de united states glaxosmithkline consumer healthcare produto para ordinary quota rua dr antonio loureiro borges arquiparque miraflore saude e higiene lda algs portugal glaxosmithkline consumer nigeria plc vi ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline consumer private limited equity patiala road nabha dist patiala punjab india glaxosmithkline consumer trading service limit ordinary great west road brentford middlesex tw gs england glaxosmithkline costa rica sa ordinary san jos este de la rotonda betania carretera sabanilla costa rica glaxosmithkline dungarvan limit ordinary knockbrack dungarvan co waterford x ry ireland glaxosmithkline healthcare ao ordinary premise iii room floor presnenskaya nab moscow russian federation glaxosmithkline healthcare gmbh ordinary barthstr mnchen germany glaxosmithkline healthcare ukraine ooo ownership interest pavla tychyny avenue v kiev ukraine glaxosmithkline limited cumulative redeemable likoni road po box nairobi kenya preference ordinary glaxosmithkline pakistan limit ordinary syke building dockyard road west wharf karachi pakistan glaxosmithkline panama sa nonqualified preference urbanizacion industrial juan calles b republic panama share panama ordinary glaxosmithkline paraguay sa ordinary oficial gilberto aranda planta alta casi salvador del mundo asuncin paraguay glaxosmithkline pharmaceuticals limited equity dr annie besant road mumbai india glaxosmithkline sae ordinary boomerang office building land zone j st district town center th tagammoe new cairo city egypt glaxosmithkline sant grand public ordinary rue franois jacob rueilmalmaison france glaxosmithkline technology taizhou co ltd ordinary room building phase ii new drug innovation base taizhou jiangsu province china glaxosmithkline tuketici sagligi anonim sirketi nominative bykdere caddesi levent plaza b blok levent istanbul turkey glaxosmithklineconsumer kft membership h csorsz utca budapest hungary gsk canada hold company limit ordinary great west road brentford middlesex tw gs england gsk ch caricam sociedad de responsabilidad participation urbanizacion industrial juan calles b republic panama limitada ii panama gsk ch kazakhstan llp charter capital manasa str bostandyk district almaty kazakhstan gsk consumer health inc common corporation service company little fall drive wilmington de united states gsk consumer healthcare capital nl bv iii v share great west road brentford middlesex tw gs england gsk consumer healthcare capital llc llc interest corporation service company little fall drive wilmington de united states gsk consumer healthcare chile spa clp interests av andrs bello n th floor las condes chile gsk consumer healthcare egypt limit ordinary north th street boomerang build th district cairo egypt gsk consumer healthcare egypt llc quota north th street boomerang build th district cairo egypt gsk consumer healthcare export limit ordinary great west road brentford middlesex tw gs england gsk consumer healthcare holding limited nonvoting preference great west road brentford middlesex tw gs england share ordinary gsk consumer healthcare holding limited nonvoting preference great west road brentford middlesex tw gs england share ordinary gsk consumer healthcare holding limit ordinary great west road brentford middlesex tw gs england gsk consumer healthcare holding limit ordinary great west road brentford middlesex tw gs england gsk consumer healthcare holding limit ordinary great west road brentford middlesex tw gs england gsk consumer healthcare holding inc common corporation service company little fall drive wilmington de preference stock united states gsk annual report gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company continue effective security ownership register address subsidiary effective interest continued gsk consumer healthcare holdings llc iii unit corporation service company little fall drive wilmington de united states gsk consumer healthcare insurance limit ordinary dorey court admiral park st peter port gy guernsey gsk consumer healthcare israel ltd iv ordinary basel street petech tikva israel gsk consumer healthcare levice sro ordinary priemyselny park gena ul e sachsa levice slovakia gsk consumer healthcare peru srl ordinary av jorge basadre piso san isidro lima w peru gsk consumer healthcare sarl ordinary route de prangin switzerland gsk consumer healthcare schweiz ag ordinary suurstoffi rotkreuz switzerland gsk consumer healthcare services inc common corporation service company little fall drive wilmington de united states gsk consumer healthcare singapore pte ltd ordinary rochester park singapore gsk consumer healthcare trinidad tobago limited ordinary th floor algico plaza st vincent street port spain trinidad preference tobago gskgebro consumer healthcare gmbh ordinary bahnhofbichl fieberbrunn kitzbhel austria iodosan spa ordinary zambeletti snc baranzate milan italy kuhs gmbh ordinary barthstr mnchen germany laboratorios viiv healthcare sl ordinary severo ochoa parque tecnolgico de madrid tres cantos madrid spain modern pharma trading company llc quotas amoun street po box el salam city cairo egypt nch nutrition consumer health ltd ii ordinary hamephalsim st petach tikva israel pt smithkline beecham pharmaceutical ordinary jl pulobuaran raya kav iii dd kawasan industri pulogadung ordinary b jakarta indonesia pt sterling product indonesia share graha paramita build th f jalan denpasar raya blok jakarta b share indonesia panadol gmbh ordinary barthstr mnchen germany pf consumer healthcare llc membership interest corporation service company little fall drive wilmington de united states pf consumer healthcare bv class van asch van wijckstraat g lp amersfoort netherlands class b pf consumer healthcare brazil importadora e distribuidora quota barueri avenida ceci block iii tambore district de medicamentos ltda paulo brazil pf consumer healthcare canada ulcpf soin de sante common burrard street suite bentall centre po box sri prefer vancouver bc vx l canada pf consumer healthcare hold bv ordinary van asch van wijckstraat g lp amersfoort netherlands pf consumer healthcare uk limit liquidation ordinary great west road brentford middlesex tw gs england pf consumer ireland company limit liquidation ordinary bdo beax lane house mercer street low dh dublin dh ireland pf consumer taiwan llc interest corporation trust company corporation trust center orange street wilmington de united states pfizer biotech corporation ordinary f sec zhong xiao w rd taipei taiwan pfizer consumer healthcare ab ordinary vetenskapsvagen se sollentuna sweden pfizer consumer healthcare gmbh ordinary linkstrasse berlin germany pfizer consumer manufacturing italy srl quota stock nettunese aprilia prov di latin italy pfizer laboratory pfe pty ltd common flush meadow build campus sloane street bryanston south africa pfizer pfe colombia sas common carrera piso colombia phivco llc llc interest corporation service company little fall drive wilmington de united states phivco llc llc interest corporation service company little fall drive wilmington de united states prism pch limited nonvoting share great west road brentford middlesex tw gs england voting share pt glaxo wellcome indonesia class jl pulobuaran raya kaviiidd kws industri pulogadung class b jatinegara cakung jakarta timur indonesia pt gsk consumer healthcare indonesia ordinary graha paramita build th f jalan denpasar raya blok kuningan jakarta selatan indonesia pt bina dentalindo liquidation ordinary gedung graha ganesha lantai jl raya bekasi km jakarta timur indonesia shionogiviiv healthcare llc ii common interest corporation service company little fall drive wilmington de united states sinoamerican tianjin smith kline french laboratory ordinary cheng lin zhuang industrial zone dong li district tianjin ltd china smithkline beecham private limited ordinary world trade center level west tower echelon square colombo sri lankaother statutory disclosure continue group company continue effective security ownership register address subsidiary effective interest continued smithkline beecham research limit ordinary great west road brentford middlesex tw gs england smithkline beecham sa ordinary ctra de ajalvir km alcala de henares madrid spain smithkline beechambiome ooo participation interest leningradskiy prospect build floor premise xiv room moscow russian federation staffordmiller ireland limit ordinary clocherane youghal road dungarvan co waterford ireland staffordmiller limit liquidation ordinary clocherane youghal road dungarvan co waterford dungarvan noncumulative non waterford ireland redeemable preference sterling drug malaya sdn berhad ordinary lot jalan enggang ampanghulu kelang industrial estate selangor darul ehsan ampang malaysia sterling products international incorporate ii common corporation service company little fall drive wilmington de united states stiefel consumer healthcare uk limit ordinary great west road brentford middlesex tw gs england stiefel egypt llc ii quotas amoun street po box el salam city cairo egypt stiefel laboratories ireland limited liquidation ordinary bdo beax lane house mercer street low dh dublin dh ireland treerly health co ltd capital contribution unit room east zhujiang road tianhe district guangzhou city prc china viiv healthcare south africa proprietary limited ii iv ordinary flush meadow build campus sloane street bryanston south africa viiv healthcare bv ordinary van asch van wijckstraat h lp amersfoort netherlands netherlands viiv healthcare company common corporation service company little fall drive wilmington de united states viiv healthcare finance limit liquidation ordinary baker street london wu eu united kingdom viiv healthcare finance limit ordinary great west road brentford middlesex tw gs england viiv healthcare finance limit ordinary great west road brentford middlesex tw gs england redeemable preference viiv healthcare gmbh ordinary prinzregentenplatz munchen germany viiv healthcare gmbh ordinary talstrasse muenchenbuchsee switzerland viiv healthcare hong kong limited ii ordinary f tower gateway canton road harbour city tsimshatsui kowloon hong kong viiv healthcare kk ordinary akasaka minatoku tokyo japan viiv healthcare limited class great west road brentford middlesex tw gs england class b class c class class defer class e cumulative preference viiv healthcare pty ltd ordinary mountain highway boronia victoria vic australia viiv healthcare puerto rico llc llc interest centro international de mercadeo carr torre suite guaynabo puerto rico viiv healthcare srl quota viale dellagricoltura verona italy viiv healthcare sas ordinary rue franois jacob rueilmalmaison france viiv healthcare sprl ordinary site apollo avenue pascal wavre belgium viiv healthcare trading llc ii participation interest leningradskiy prospect build floor premise xiv room moscow russian federation viiv healthcare trading service uk limit ordinary great west road brentford middlesex tw gs england viiv healthcare uk limit ordinary great west road brentford middlesex tw gs england viiv healthcare uk limit ordinary great west road brentford middlesex tw gs england viiv healthcare uk limit ordinary great west road brentford middlesex tw gs england viiv healthcare uk limit ordinary great west road brentford middlesex tw gs england viiv healthcare uk limit ordinary great west road brentford middlesex tw gs england viiv healthcare uk limit ordinary great west road brentford middlesex tw gs england viiv healthcare ulc common nd street sw calgary ab tp j canada viiv healthcare venture llc llc interest corporation service company little fall drive wilmington de united states viivhiv healthcare unipessoal lda quota rua dr antonio loureiro borges arquiparque miraflore algs portugal vog au pty ltd ii ordinary hughe avenue ermington new south wale nsw australia redeemable preference winster pharmaceutical limited ii ordinary association avenue ilupeju industrial estate lago po box nigeria wyeth pharmaceutical co ltd register capital baodai west road suzhou jiangsu province china wyeth pharmaceutical company vii partnership register address require puerto rico general partnership contact entity contact questions puerto rico gsk annual report gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company continue effective security ownership register address associate glaxosmithkline landholde company inc common rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines index ventures life vi jersey lp partnership interest esplanade st helier jersey je wg channel islands kurma biofund ii fcpr partnership interest rue royale paris france longwood fund lp partnership interest prudential tower suite boylston street boston medicxi ventures lp partnership interest esplanade st helier jersey je wg channel island joint ventures chiron panacea vaccines private limit equity share th floor wing sagar tech plaza saki naka andheri east mumbai maharashtra india qualivax pte limit ordinary robinson road singapore qura therapeutics llc unit corporation service company little fall drive wilmington de united states significant holding axon therapy inc common series west th street new york delaware usa preference global farm sa share cazadore de coquimbo piso munro argentina b shares c share share e share f shares longwood fund ii lp partnership interest prudential tower suite boylston street boston sanderle ventures vii lp partnership interest el camino real suite san mateo sr capital fund ib lp partnership interest corporation service company little fall drive city wilmington county new castle delaware follow uk subsidiary advantage audit exemption set section company act period end december state undertaking list own directly indirectly glaxosmithkline plc effective company security ownership register address number uk register subsidiary exempt audit burrough wellcome international limited ordinary great west road brentford middlesex tw gs england domantis limit ordinary great west road brentford middlesex tw gs england edinburgh pharmaceutical industry limited ii ordinary shewalton road irvine ayrshire ka ap united kingdom sc preference eskaylab limit ordinary great west road brentford middlesex tw gs england glaxo wellcome uk limit ordinary great west road brentford middlesex tw gs england glaxochem uk unlimite ordinary great west road brentford middlesex tw gs england ordinary b ordinary c glaxosmithkline consumer healthcare uk ordinary great west road brentford middlesex tw gs england limited glaxosmithkline consumer healthcare sri lanka ordinary great west road brentford middlesex tw gs england holdings limited glaxosmithkline intellectual property limit ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limit ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limit ordinary great west road brentford middlesex tw gs england glaxosmithkline international limited ordinary great west road brentford middlesex tw gs england gsk consumer healthcare capital uk plc ordinary great west road brentford middlesex tw gs england gsk consumer healthcare holding limit ordinary great west road brentford middlesex tw gs england gsk consumer healthcare holding limit ordinary great west road brentford middlesex tw gs england gsk new zealand hold company limit ordinary great west road brentford middlesex tw gs england montrose fine chemical company ltd ordinary shewalton road irvine ayrshire ka ap united kingdom sc phivco uk ii limited ordinary great west road brentford middlesex tw gs england phivco uk limit ordinary great west road brentford middlesex tw gs england smith kline french laboratory limit iv ordinary great west road brentford middlesex tw gs england smithkline beecham export limit ordinary great west road brentford middlesex tw gs england smithkline beecham h limited noncumulative great west road brentford middlesex tw gs england nonredeemable ordinaryother statutory disclosure continue group company continue effective company security ownership register address number uk register subsidiary exempt audit continue smithkline beecham investment limit ordinary great west road brentford middlesex tw gs england smithkline beecham legacy h limited ordinary great west road brentford middlesex tw gs england smithkline beecham marketing technical ordinary great west road brentford middlesex tw gs england services limited smithkline beecham nominee limit ordinary great west road brentford middlesex tw gs england smithkline beecham overseas limit ordinary great west road brentford middlesex tw gs england stiefel laboratory uk ltd ordinary great west road brentford middlesex tw gs england tesaro uk limit ordinary great west road brentford middlesex tw gs england wellcome foundation limit ordinary great west road brentford middlesex tw gs england viiv healthcare overseas limited ordinary great west road brentford middlesex tw gs england accordance section c company act company guarantee debt liability uk subsidiary undertaking december total sum debt liabilitie million million key directly own glaxosmithkline plc ii ormant entity iii ax resident uk iv entity expect disposed remove v incorporate netherlands vi consolidated subsidiary accordance section company act ground dominant influence vii principal business address puerto rico viii exempt provision regulation partnership account regulation accordance exemption note regulation regulation gsk annual report gsk annual report strategic report governance remuneration financial statement investor information glossary term term annual report equivalent brief description accelerate capital allowance tax allowance excess depreciation arise purchase fix asset delay charge payment tax equivalent tax depreciation american depositary receipt adr r eceipt evidencing title ad gsk adr represent ordinary share american depositary share ad list new york stock exchange represent ordinary share basic earning share basic income share call share capital ordinary share issue fully pay cer growth growth constant exchange rate company glaxosmithkline plc currency swap exchange currency couple subsequent reexchange currency agree exchange rate date define benefit plan pension plan specific employee benefit call final salary scheme define contribution plan pension plan specific contribution level pension dependent growth pension fund derivative financial instrument financial instrument derives value price rate underlie item dilute earning share diluted income share employee share ownership plan trust trust establish group satisfy sharebase employee incentive plan equity shareholder fund shareholder equity finance lease capital lease freehold ownership absolute right perpetuity group glaxosmithkline plc subsidiary undertakings gsk glaxosmithkline plc subsidiary undertaking hedging reduction risk normally relation foreign currency interest rate movement make offset commitment intangible fix asset asset physical substance computer software brand licence patent knowhow marketing right purchase outside party ordinary share fully pay ordinary share capital company profit income profit attributable shareholder net income share capital ordinary share capital stock common stock issue fully pay share option stock option share premium account additional paidup capital paidin surplus distributable share issue number share outstanding subsidiary entity gsk exercise control treasury share treasury stock turnover revenue uk corporate governance code require uk list authority company disclose annual report apply good practice corporate governance provision financial reporting council uk corporate governance codeindex remuneration policy summary investor relation accounting principle policy key performance indicator acquisition disposal legal proceeding adjustment reconcile profit tax operate major restructuring cost cash flow modern employer affordability availability movement equity annual general meeting net debt approach tax new accounting requirement asset hold sale nomination committee report associate joint venture noncontrolle interest audit risk committee report noncontrolle interest viiv healthcare responsible business nonexecutive director fee business model nonfinancial information statement cash cash equivalent note financial statement cash generation conversion operating profit ceo statement intangible asset chairman statement investment chairmans governance statement noncurrent asset chairman remuneration annual statement noncurrent liability climaterelate financial disclosure operating incomeexpense commitment provision consolidate balance sheet culture consolidated cash flow statement external environment consolidated income statement longterm priority consolidate statement change equity pension postemployment benefit consolidate statement comprehensive income performance consumer healthcare pharmaceutical consumer healthcare product competition pharmaceutical product competition contingent consideration liability intellectual property contingent liability pipeline corporate governance post balance sheet event corporate responsibility committee report presentation financial statement critical accounting judgement key source principal group company estimation uncertainty principal risk uncertaintie critical accounting policy property plant equipment datum engagement quarterly trend director senior management reconciliation net cash flow movement net debt director interest share registrar director report related party transaction director statement responsibilitie reliable supply dividend remuneration governance donation political organisation remuneration report political expenditure reporting framework earning share right use asset employee cost risk management employee share scheme science technology environment science committee report ethic value section statement exchange rate share capital control finance expense share capital share premium account finance income shareholder information financial calendar shareholder service contact financial instrument relate disclosure stakeholder engagement financial performance task force climaterelate financial disclosure financial position resource taxation financial statement glaxosmithkline plc prepare tax information shareholder uk gaap board year record trade payable glossary term trade receivables goodwill transformation separation committee report group company treasury policy group financial review trust gsk leadership team turnover segment information independent auditor report law regulation innovation vaccine inventory vaccine product competition intellectual property investment associate joint venture viability statement gsk annual report strategic report governance remuneration financial statement investor information gsk glaxosmithkline plc incorporate english brand name brand name appear italic report public limited company december trade mark own andor license gsk associate company trade mark form merger glaxo wellcome plc property respective owner smithkline beecham plc gsk acquire acknowledgement print english company december print sustainably uk pureprint carbonneutral company fsc chain custody iso merger arrangement certify environmental management system recycle dry waste share list london stock exchange paper print innovation premium fsc certify paper new york stock exchange pulp totally chlorine free manufacturing mill iso environmental management certification mill energy produce biomass fuel source local forestry read wwwgskcom fossil fuel carbon emission measure offset world land trust carbon balanced scheme download pdfs nnual report f orm f cautionary statement number nonifrs measure report group guidance assume successful delivery forwardlooke statement performance business measure define group integration restructuring plan group report file furnish page reconciliation adjust assume separation programme deliver securities exchange commission sec include result total result set demerger consumer healthcare business r f f g f bou uh e yivt ti rl e u uw e ha r r ae et es ho r e b ed e fc ad vy u g cel nr te tr hk uo n pr g ba ts nl h e sn c eih td nua ya vt ra l dee fn e sm oomy n f e ne n orn eht h tct xe se p ra eg r nem f lw c ar ia ttr rd eaui ewt te p not siae tt r rt nm fdo csi ttl oh loy hf yo r e e c tr fk ospm oi e nu rn ha e tb g c si tlo si ta ac n ts e r tn ce aom eh lf ne e ot n rs g e p p cn ofh e elf g ne r f fx sar oi tgt r r ro sf uo es ar inm e dn ni tl c cal ha n e et k si ro l c nan n n p e ot ni hn r tni p oe hn ol fiv r ih c n ti tii gns boa fo v ertd ie ni r ao er e tnnc ct h lu aiit ien som se dv tanb ie utu nan pay ntt oco ud n anho iv l ae rtr ss r ie e e n p gi not pu u r c tc se en htm ote ot ui n lfu dt u te bo u e ra e n n bh fe pe e afew e sl cti iv ie co sse p x tn i p se de n d c sn b u tac tu h hc ei dl ec gn e u gs r tn uo ig oc iu df nhu v p aae el l ns ly n cd pa eagn p ia ai sevt ee r l gdinnr ri ia vt ed l h e ntc e nh h ep rs nv ot es u e bf ctno l e oo itr ne noa vi nn skl e v tdf sm ae e ns c mav tt ye e c l b nr ue e e tp rn r mt e ii nn en ct n yt current fact use word anticipate outlook sale ambition estimate expect intend project plan assumption relate guidance dividend expectation read believe target word term similar outlining guidance group section basis preparation assumption mean connection discussion future certain assumption healthcare sector cautionary statement page stock operate financial performance particular different market group operate exchange announcement relate update investor include statement relate future action prospective delivery revenue financial benefit current date june outlook ambition statement product product approval future performance portfolio pipeline restructuring programme give constant currency basis use result current anticipate product sale effort group assume demerger consumer actual exchange rate base expense outcome contingency legal healthcare business deliver mid proceeding dividend payment financial result guidance relate new gsk notice limitation accordance legal regulatory director liability english law obligation include market abuse group planning assumption uk company act safe harbour limit regulation uk list rule disclosure healthcare system approach normality year liability director respect statement transparency rule financial conduct progress expect sale specialty medicine omission director report authority group undertake obligation update grow approximately cer sale general strategic report remuneration report forwardlooke statement result medicine slight decrease primarily reflect english law director liable new information future event reader increase genericisation establish respiratory company party consult additional disclosure product vaccine sale expect grow low report contain error result recklessness group document teen percentage cer year know misstatement dishonest concealment publish andor file sec reader government prioritisation covid vaccination material fact liable page locate note disclosure programme ongoing measure contain inclusive comprise accordingly assurance give pandemic expect result continue director report page inclusive comprise particular expectation meet investor disruption adult immunisation impact strategic report page inclusive comprise caution place undue reliance weight half shingrix despite potential remuneration report draw forwardlooke statement shortterm pandemic disruption continue expect present accordance reliance f fn ao h cr e tw ore ra snr h rl aio tko ask r ean ng bd es yuta ont nce dem r te han eint gt ia e rr ose u psu sb n cj ye c nt f rt will h l oic rs h pu r rm e el cp itt seio e tn os e rot xnr yp ln trg yo nd ii nogo cn u od b g mel eu iad frni og n mi ci n g e ao ex lw ss ett ih n ti tnga lecn mld ua edr r ne ek tc se ao ts nhrd dea na f liun ctn eugu nre ea l e bgs aea ra gnle p e re h fi etib c mia nas e l e nd e c limon ng itnl ais e tih c nc io n w np dia hn hl ta e rw ce ta orn e nd p h pre rts l vi sa ih db eil li dlt bes suf u bt ch j hee c lad w tir e tc ht eo rs estimate group caution investor number gilead announce february website important factor include document cause actual result differ materially plan assumption operate profit gsk website wwwgskcom give additional information express imply forwardlooke statement guidance dividend expectation assume material group notwithstanding reference interruption supply group product material annual report gsk website factor include limit merger acquisition disposal material litigation information available website constitute discuss principal risk uncertaintie investigation cost company save annual report shall deem page annual report impact recognise provision incorporate reference covid pandemic forwardlooking change group shareholding viiv statement behalf group speak healthcare assumption assume material date base change healthcare environment unexpected knowledge information available director significant change pricing result government date annual report competitor action guidance factor divestment product exit announce datefront cover image take short film gsk use human genetic advanced technology increase probability successful new medicine click gskadvancedtechcom watch search head office register office glaxosmithkline plc great west road brentford middlesex tw gs united kingdom tel register number wwwgskcom